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First, collections of conformationally flexible 𝛿-lactam and piperidine analogs 
were designed and synthesized following the discovery of a rigid indoloquinolizidine 
scaffold whose derivatives inhibit the growth of Trypanosoma brucei¸ the protozoan 
parasite that causes human African trypanosomiasis, via the inhibition of methionyl-
tRNA synthetase (TbMetRS). Many of 𝛿-lactam and piperidine analogs were found to be 
superior T. brucei growth inhibitors relative to the initial indoloquinolizidine compounds; 
however, it was also found that these flexible compound sets displayed greatly 
diminished activity against TbMetRS. Then, a diversity-oriented synthesis (DOS) of 
spirocyclic β-phenethylamines was realized via the development of an intramolecular 
aza-Hosomi-Sakurai reaction. Facile elaboration of these aza-spirocyclic scaffolds was 
demonstrated through a variety of means, and several derivatives were identified as 
potent Sigma-1 receptor (σ1R) ligands in a biochemical screen. Finally, a one-step 
biomimetic total synthesis of the cyclohepta[b]indole-coumarin natural products exotines 
 vii 
A and B was achieved via the development of an acid-catalyzed three-component 
cyclization reaction between indole, prenal, and trans-dehydoosthol. Some mechanistic 
aspects of this process are investigated, and evidence is obtained which supports the 
mechanism of a [4 + 2] cycloaddition followed by a 1,2-migration, in accordance with the 
original biosynthetic proposal of Jiang.   
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SYNTHESIS AND EVALUATION OF NOVEL ANTI-TRYPANOSOMAL 
COMPOUNDS 
Chapter 1. Human African Trypanosomiasis: Etiology, Current and 
Prospective Treatments   
1.1. HUMAN AFRICAN TRYPANOSOMIASIS 
Human African Trypanosomiasis (HAT)—also known as African sleeping sickness—is a 
deadly disease caused by the protozoan parasite Trypanosoma brucei (T. brucei). The disease has 
an at-risk population of 60 million people throughout sub-Saharan Africa, and is transmitted to 
humans via the tsetse fly, which resides over roughly 10 million kilometers of the African 
landmass.1 HAT is classified as a neglected tropical disease (NTD) by the World Health 
Organization (WHO) because it predominantly affects impoverished populations in developing 
(sub)tropical nations.2–4 There have been several incidences of HAT epidemics during the 20th 
century, the first around the turn of the century, another in 1920, and the most recent HAT 
epidemic lasted from 1970 until the late 1990s.2,4 These epidemics were brought under control 
initially via culling animal reservoirs of the disease and deforestation and later via management 
of the insect vector and proactive surveillance of populations for disease presence.1,2 As a result 
of these practices, the number of new cases of HAT dropped below 10,000 in 2009 for the first 
time in 50 years, and in 2015 there were only 2804 new cases reported, leading the WHO to 
project that elimination of the disease as a public health concern may be achievable in the near 
future.4 However, caution is warranted as HAT incidences are chronically under-reported due to 
its occurrence predominantly in rural communities and in regions lacking adequate health 
infrastructure.1,2 For instance, a study estimated that in 2007 there were 18,592 people in the 
Democratic Republic of Congo (DRC)—the country with the greatest incidence of the disease in 
modern times—with HAT, which is more than twice the amount reported to the WHO that year.1 
Indeed, examining of the history of HAT outbreaks shows that they often coincide with periods 
of war, famine, and economic instability that hamper or prevent adequate surveillance, diagnosis, 
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and treatment.1,2,4 These societal vagaries, along with the difficult treatment regimens required 
by current HAT chemotherapeutics and the emergence of drug-resistant strains of T. brucei, 
provide the impetus for continued research and the development of better methods for 
preventing, containing, and treating this deadly disease.1,2,5,6  
There are three subspecies of T. brucei: T b gambiense, which is responsible for 
approximately 97% of HAT cases, T b rhodesiense, a more virulent strain which is responsible 
for the remaining 3% of cases, and T b brucei, which infects animals and is used to study the 
parasite in vitro.1,2 The subspecies gambiense and rhodesiense occupy separate geographic 
regions in Africa, except for Uganda where both have been observed.1,2 Humans are the main 
reservoir of T b gambiense, while animals such as cattle act as the main reservoir for T b 
rhodesiense.1 After the blood-sucking tsetse fly bites a T. brucei reservoir, the parasite enters the 
midgut and undergoes morphological and biochemical changes to reach its mature, infective 
state upon migrating to the salivary glands of the tsetse fly.1 From here, the mature parasite can 
be spread to new human and animal hosts.   
Upon entering a human host, the progression of the disease is divided into two distinct 
stages, the haemolymphatic “early” stage and the meningo-encephalitic “late” stage. During the 
haemolymphatic stage the parasite resides in the bloodstream of the host, and the effects of the 
infection at this stage are diffuse. The spleen or liver may become enlarged, cardiac disorders 
may be observed, and various dysfunctions of the endocrine system may occur.1 Intermittent 
fever is common during the first stage as the body of the host mounts an immune response to the 
invading parasite. T. brucei has evolved sophisticated mechanisms for evading these immune 
responses. Roughly 10% of the T. brucei genome encodes for variant surface glycoproteins 
(VSGs) which are expressed on the parasite’s outer surface.1 The parasite achieves a high degree 
of antigenic variation by rapidly switching the expressed VSG, and only a single VSG is present 
on the cell surface at a given time; because of this, it is unlikely that we will see development of 
a vaccine for HAT.1,2 Having successfully evaded the immune response of the host, the parasite 
is free to proliferate and spread throughout the host, eventually crossing the blood-brain barrier 
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(BBB) and taking up residence in the central nervous system (CNS) in the late, meningo-
encephalitic stage of infection.1,2 During the late stage various neurological effects are present, 
with one of the most common being profound disturbances in the sleep/wake cycle of the host—
hence the disease’s common namesake of “sleeping sickness”.1,2 Psychiatric symptoms are 
frequently observed, along with motor disturbances, neuropathy, and meningoencephalitis or 
brain inflammation.1,2 The course of the disease varies with the infecting subspecies. With T b 
gambiense disease onset is slow and progression to the second stage usually occurs after several 
months. On the other hand, in T b rhodesiense infections progression to the second stage occurs 
rapidly, usually in a matter of weeks.1 Both forms of the disease are usually fatal if left untreated, 
although cases of spontaneous remission in T b gambiense infection have been observed.1 
1.1.1. Current Treatments for HAT 
There are five medicines currently used to treat HAT, and their use varies with the 
disease stage and with the T brucei subspecies responsible for the infection. Pentamidine (1.1) 
and suramin (1.2) are the first-line treatments for early-stage T b gambiense and T b rhodesiense 
infections, respectively (Figure 1.1). Late-stage disease treatment requires that the medicine 
cross the BBB, which the polyionic compounds 1.1 and 1.2 are unable to do. For late-stage 
treatment, eflornithine (1.3)—alone or in combination with nifurtimox (1.4)—and melarsoprol 
(1.5) are used against T b gambiense and T b rhodesiense infections, respectively (Figure 1.1). 
The currently available treatments are broadly considered to be unsatisfactory owing to their 





Figure 1.1. Medicines currently used to treat HAT 
Pentamidine (1.1), developed in the 1930’s, is the first-line treatment for early-stage T b 
gambiense infections.6 It is a diaryl diamidine that exists as a di-cation at physiological pH, 
thereby preventing pentamidine from being absorbed by the intestine. Hence, it is most 
commonly administered via intramuscular injetion.6 The drug is administered at a 4 mg/kg 
dosage in 24 h intervals for 7 days.2,5,6 Pentamidine is taken up into trypanosomes via the P2 
aminopurine permease transporter and the high-affinity pentamidine transporter 1 (HAPT1), 
leading to millimolar intra-trypanosomoal concentrations of pentamidine when the parasite is 
exposed to micromolar extracellular concentrations.5,6  The exact mechanism by which 
pentamidine kills trypanosomes remains unknown; however, it has been shown that pentamidine 
binds to DNA via ionic interactions with the phosphate backbone, and it appears that the 
mitochondrion is an important site of activity for the drug.5–7 In Leishmania tropica, a protozoan 
parasite closely related to trypanosomes, pentamidine was found to accumulate in the 
mitochondrion and bring about a disintegration of mitochondrial kinetoplast DNA.8 The most 
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common side effects of pentamidine treatment are pain at the site of injection, gastrointestinal 
(GI) distress and hypoglycemia.2 Pentamidine resistance has been induced in trypanosomes in 
vitro but is not a significant concern in the field, as resistance comes at the cost of greatly 
reduced virulence.5,6 Pentamidine is ineffective for the treatment of T b rhodesiense infections.6 
Suramin (1.2) is a polysulfonated naphthalene that is the first-line treatment against early-
stage T b rhodesiense infections.1,2 It has been used to treat T. brucei infections since 1922, 
giving it the distinction of being one of the oldest antimicrobial drugs still in use.5 Suramin is 
administered via slow intravenous injection in 20mg/kg dosage five times over the course of four 
weeks.2,6 Like pentamidine, the mechanism of action of suramin is not well understood.5,6 It is 
thought to enter the trypanosome via endocytosis, and it can bind to many different proteins via 
electrostatic interactions with its six sulfonate moieties. Its high affinity for serum proteins lead 
to a long half-life of 41–78 days.5,6 Some evidence points to glycolysis as being a likely site of 
activity as suramin has been shown to inhibit several glycolytic enzymes, and it is a hundred-fold 
less active against procyclic trypanosomes than against bloodstream trypanosomes that require 
glycolysis to survive.6 The most common side effects of suramin treatment are renal failure, 
peripheral neuropathy, and hypersensitivity reactions.1,2 Resistance to suramin in the field is rare 
but has been reported.6 
Nifurtimox/eflornithine combination therapy (NECT), which was approved in 2009,  is 
the first-line treatment for late-stage T b gambiense infections.1,9 Eflornithine (1.3), a fluorinated 
ornithine analog, is an ornithine decarboxylase (ODC) inhibitor developed in the 1970s. Before 
the advent of NCET, eflornithine monotherapy was the first-line treatment for late-stage T b 
gambiense infections.2,6 The ODC enzyme is an essential component of polyamine biosynthesis, 
and ODC turnover happens more slowly in trypanosomes than in mammalian cells making 
eflornithine less toxic to host cells than trypanosomes.5,6 While safer and more effective than 
melarsoprol (vide infra), eflornithine monotherapy also suffers from severe liabilities. 
Eflornithine has a half-life of only three hours, mid-micromolar GI50 values, and is not orally 
available. These combined factors result in an incredibly difficult dosage regimen of 100 mg/kg 
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intravenous injections every six hours for 14 days, roughly half of a kilogram of the drug in total 
for an average-sized individual.5,6 The main advantage of NCET is that it allows for a reduction 
in eflornithine dosage to a more manageable, but still severe, regimen of 200 mg/kg every 12 
hours for 7 days when nifurtimox (1.4)—a drug used to treat the related trypanosomal infection 
Chagas disease—is co-administered orally once per day.5,9 Eflornithine and NCET can have 
serious side effects including bone marrow toxicity, convulsions, alopecia, and GI disorders.2,6 
Resistance to eflornithine via loss of the TbAAT6 transporter has been demonstrated in vitro and 
observed in isolated incidences in the field; however, it is hoped that use of NCET will mitigate 
the threat of eflornithine-resistant trypanosomes.1,9 Eflornithine and NCET are ineffective 
against T b rhodesiense.1,9 
Melarsoprol (1.5), an organic arsenical introduced in 1949, is the only available treatment 
for late-stage T b rhodesiense infection, and is still used to treat T b gambiense infections in 
resource-poor and isolated settings where eflornithine and NCET are not accessible.1,2 It is 
administered intravenously, at 2.2  mg/kg dosage in 24 hour intervals for 10 days.2 Like 
pentamidine, melarsoprol is taken up in trypanosomes via the P2 transporter, whereupon it 
causes rapid lysing of trypanosomes, but the mechanism by which this happens is poorly 
understood.6 It is thought that the arsenic in melarsoprol interacts with the thiol group of 
trypanothiol, a small molecule that maintains the reducing environment in trypanosomes, thus 
rendering the trypanosome more sensitive to oxidative stress.6 Melarsoprol is highly toxic and 
has severe side effects, the most alarming of which is reactive encephalopathy or swelling of the 
brain, which results in death for 5.9% of patients undergoing melarsoprol treatment.1 Other side 
effects include agranulocytosis, peripheral neuropathy, cardiac arrythmias, rashes, and 
inflammation.1 Resistance to melarsoprol in the field has been documented, and treatment 
failures are increasingly common; however, it is not clear to what extent these failures are due to 
drug resistance.1,5  
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1.1.2. Emerging HAT Treatments 
There are currently two drug candidates in clinical trials for the treatment of HAT: the 
nitro-imidazole fexinidazole (1.6) and the oxaborole SCYX-7158 (1.7) (Figure 1.2).5 First 
synthesized in the 1970s and developed as a broad-spectrum antimicrobial agent that was never 
advanced beyond preclinical research, fexinidazole (1.6) was rediscovered via compound mining 
of >700 nitro-heterocycles as part of the Drugs for Neglected Diseases initiative (DNDi).10 
Fexinidazole and its sulfoxide and sulfone metabolites are active against both T b rhodesiense 
and T b gambiense in vitro, with IC50 values of 0.7–3.3 µM, values comparable to eflornithine 
(1.3) and nifurtimox (1.4) but significantly less potent than melarsoprol (1.5).10,11 Its mechanism 
of action has yet to be determined, but it is thought to involve reductive bio-activation of the 
drug via nitroreductase activity.10 Fexinidazole displays negligible cytotoxicity at its effective 
dosage, good oral bioavailability, and it was found to cure mouse models of both T b rhodesiense 
and T b gambiense infections.10,11 It has been advanced through phase 3 clinical trials, and in late 
2018 fexinidazole was recommended by the European Medicines Agency for treatment of late-
stage T b gambiense infections, with distribution of the drug in endemic countries expected to 
begin in 2019.12,13 
 
 
Figure 1.2. HAT drug candidates currently in clinical trials 
SCYX-7158 (1.7) is a unique benzoxaborole compound that is currently in phase II/III 
clinical trials for the treatment of late-stage T b gambiense infection. It was developed after 
screening of a library of boron-based compounds at Anacor Pharmaceuticles identified several 
benzoxaboroles with promising anti-trypanosomal activity.5,14 SCYX-7158 displays good 
pharmacokinetic properties, oral bioavailability, and it was successful in curing murine models 
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of T b brucei infection.5,14 Its mechanism of action is unknown, but a proteomic study found that 
SCYX-7158 interacts with 13 different trypanosome proteins that do not share any common 
cellular function, suggesting that SCYX-7158 displays polypharmacological activity, a property 
that may render it less susceptible to the emergence of drug resistance.15 The phase II/III clinical 
trial assessing the efficacy of SCYX-7158 for treatment of late-stage T b gambiense HAT is 
estimated to be completed in June 2020.  
1.2. AMINOACYL-TRNA SYNTHETASE INHIBITORS  
Aminoacyl-tRNA synthetases (AARS) are integral components of the cellular protein 
translation machinery, and they are responsible for charging tRNA molecules with their cognate 
amino acid via a two-step process.16,17 In the first step (Equation 1.1) the AARS catalyzes the 
esterification of its cognate amino acid (AA) with adenosine triphosphate (ATP) to form an 
aminoacyl-adenylate (AA-AMP) intermediate and pyrophosphate (PPi).16,17 In the second step 
(Equation 1.2), the AA-AMP intermediate is transesterified with its cognate tRNA to form an 
aminoacylated tRNA (AA-tRNA) and adenosine monophosphate (AMP).16,17 Thus charged, the 
AA-tRNA can participate in polypeptide and protein synthesis at the ribosome.16,17 In addition to 
this essential function, eukaryotic AARSs often serve as proofreaders ensuring translational 
fidelity via their editing domain, and they can be involved in transcription regulation, immune 
responses, and other cellular signaling pathways.17  
AA + ATP + AARS → AA-AMP·AARS + PPi   (1.1) 
AARS·AA-AMP + tRNA → AA-tRNA + AMP + AARS  (1.2) 
AARSs are attractive targets for chemotherapeutic development for several reasons. The 
inhibition of AARSs causes an interruption of chain elongation at the ribosome thus halting 
protein synthesis, leading to a downregulation of RNA and DNA polymerase activity and 
ultimately the inhibition of cellular growth and proliferation.16 Many parasites including T. 
brucei undergo continuous proliferation inside a host organism, making AARSs and other 
protein synthesis machinery good targets for chemotherapeutics because even in the absence of 
selectivity for parasite versus host enzymes, the chemotherapy will be more damaging to 
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parasites than host cells due to their higher rate of growth and proliferation.17 However, 
selectivity for parasite AARSs is often achievable in both microbial and eukaryotic targets, as 
there is often a high degree of evolutionary divergence between mammalian AARSs and their 
bacterial or protozoan counterparts that result in substantial differences in their active site 
structures.16,17 The utility of AARS inhibitors as anti-infective agents is borne out by the success 
of the topical antibiotic mupirocin (1.8, Figure 1.3), a selective bacterial isoleucyl-tRNA 
synthetase (IleRS) inhibitor commonly prescribed for the treatment of methicillin-resistant 
Staphylococcus aureus (MRSA) infections.16   
 
 
Figure 1.3. Mupirocin (1.8), an isoleucyl-tRNA synthetase inhibitor used for the treatment of 
MRSA 
1.2.1. T. brucei Leucyl-and-Isoleucyl-tRNA Synthetase Inhibitors  
Several classes of AARS inhibitors have been developed targeting T. brucei isoleucyl 
tRNA synthetase (TbIleRS) and leucyl-tRNA synthetase (TbLeuRS).17 Cestari and Stuart 
identified and screened a series of putative TbIleRS inhibitors obtained from the National Cancer 
Institute These compounds were identified based on their structural homology with the isoleucyl-
adenylate (Ile-AMP) intermediate, which is known to bind tightly (Kd = 10
–9 M) to IleRS.18 From 
this screen, adenosine diastereomer 1.9 (Figure 1.4) was identified as a promising lead displaying 
potent in vitro activity and ≈900-fold parasite selectivity, and it was successful in curing a 
murine model of T brucei infection.18 Ding and co-workers developed a series of TbLeuRS 
inhibitors inspired by the antifungal benzoxaborole tavaborole (1.10, Figure 1.4), which inhibits 
LeuRS by trapping tRNALeu in its editing site via the formation of a borate adduct with the 3’ 
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terminal ribose of tRNALeu.19,20 They built a homology model of the TbLeuRS editing site and 
used this structure to guide the design of a series of substituted benzoxaboroles. They thus 
identified C(6) as the optimal site of substitution and prepared analogs such as 1.11 (Figure 1.4), 
which displayed a TbLeuRS IC50 of 5 µM, T. brucei GI50 of 0.4 µM, and >100-fold parasite 
selectivity.20 Zhao and co-workers also developed TbLeuRS inhibitors using homology modeling 
of the TbLeuRS active site to screen compounds from the Specs database in silico.21 In this way, 
they identified several potential inhibitors with a 2-pyrrolidinone scaffold, and they subsequently 
synthesized and assayed a series of analogs, the best of which (1.12, Figure 1.4) displayed 
moderate (IC50 = 32 µM) activity against TbLeuRS.
21 Finally, Zhang and co-workers developed 
a series of thiourea compounds designed to inhibit TbLeuRS by mimicking the Leu-AMP 
intermediate, the most potent of which (1.13, Figure 1.4) displayed an IC50 of 1.1 µM..
22
 
Unfortunately, none of the compounds were active against T. brucei cell cultures at 
concentrations up to 100 µM, which the authors attribute to the poor membrane permeability of 




Figure 1.4. Adenosine-like TbIleRS inhibitor 1.9, fungal LeuRS inhibitor tavaborole (1.10), 
benzoxaborole TbLeuRS inhibitor 1.11, pyrrolidinone TbLeuRS inhibitor 1.12, thiourea 
TbLeuRS inhibitor 1.13  
1.2.2. T. brucei Methionyl-tRNA Synthetase Inhibitors  
The evolutionary and biochemical properties of T. brucei methionyl-tRNA synthetase 
(MetRS) make it an attractive target for chemotherapeutic development. Specifically, TbMetRS 
is a type 1 MetRS, a distinction based on sequence similarity and susceptibility to various 
inhibitors. Type 1 MetRSs are found in Gram-positive bacteria including S. aureus, whereas type 
2 MetRSs are usually found in archaea and eukaryotes, as well as some Gram-negative 
bacteria.23 Mammalian cells contain both types of MetRSs, with type 2 MetRS present in the 
cytoplasm and type 1 MetRS present in the mitochondria.23 Comparison of the sequence of 
TbMetRS with human cytoplasmic MetRS reveals substantial differences in active site 
residues.23,24 Selective type 1 MetRS inhibitors have been developed in the pharmaceutical 
industry as broad-spectrum antibiotics, culminating in the discovery of REP8839 (1.14, Figure 
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1.5), a diaryl diamine MetRS inhibitor that is currently in clinical trials for the treatment of S. 
aureus skin and wound infections.25,26 In addition to validating type 1 MetRSs as druggable 
targets, the development of REP8839 provided a chemotype that has served as the basis for 
development of TbMetRS inhibitors.  
 
Figure 1.5. The structure of REP8839 (1.14), a diaryl diamine MetRS inhibitor in clinical trials 
for treatment of topical S. aureus infections 
Seminal work on the development of selective and potent T. brucei methionyl-tRNA 
synthetase (TbMetRS) inhibitors was done by the research groups of Buckner, Fan, Verlinde, and 
Hol at the University of Washington—Seattle. In their preliminary studies they demonstrated via 
RNAi knockdown that TbMetRS is essential for T. brucei growth. They then prepared a series of 
aminoquinolone diaryl diamines inspired by REP8839 (1.14, Figure 1.5), from which meta-
dichlorinated analog 1.15 (Figure 1.6) emerged as their lead compound with a T. brucei 50% 
growth inhibition (GI50) value of 4 nM and >5000-fold parasite selectivity.
23 However the 
compounds displayed several liabilities, including poor oral bioavailability and membrane 
permeability, a plasma half-life of only 1 hour, and in a mouse model of T. brucei infection 1.15 
was only able to suppress parasitemia for 7-8 days.23,27 These undesirable properties were 
attributed to the aminoquinolone moiety, which was known from antibacterial drug development 
to have poor bioavailability.27   
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Figure 1.6. TbMetRS inhibitors 1.15–1.17 developed by the Fan, Buckner, Verlinde, and Hol 
labs 
A second series of urea-based diaryl diamines (e.g. 1.16, Figure 1.6) was then designed, 
based on the rationale that the aryl-urea moiety should be able to participate in the same 
hydrogen-bonding and π-stacking interactions (vide infra) as the aminoquinoline moiety while 
imparting more desirable pharmacological properties.27 Their lead compound 1.16 displayed 28 
nM TbMetRS IC50 and 220 nM T. brucei GI50 values, >50-fold parasite selectivity, and oral 
bioavailability and brain permeability in mice.27 However, 1.16 was found to be just as 
metabolically labile as 1.15 with a plasma half-life of roughly 1 hour, and ultimately it was not 
able to rescue a mouse model of T. brucei infection.27 Subsequent work found that incorporation 
of a halogenated aza-benzimidizole moiety (e.g. 1.17, Figure 1.6) resulted in improved potency 
(1.17 T. brucei GI50 = 0.4 nM), oral bioavailability and brain penetration, and 1.17 reproducibly 
cured a mouse model of early-stage T. brucei infection.28  
The development of the TbMetRS inhibitors exemplified by 1.15–1.17 was aided by 
extensive X-ray crystal structures of the inhibitors complexed with TbMetRS.24,29,30 These 
structures revealed the binding mode of the inhibitors, allowed for the identification of key 
interactions between the inhibitor and TbMetRS, and provided fundamental insights into the 
structural biochemistry of TbMetRS. Specifically, it was found that the N-benzyl moieties 
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occupy an enlarged methionine-binding pocket, with the chlorine atom of m-chlorinated analogs 
such as 1.15–1.17 occupying the same position as the sulfur atom of methionine.24,29,30 The 
heteroaromatic moieties of 1.15–1.17 occupy a mostly hydrophobic pocket that is occluded in 
the methionine-bound TbMetRS structure, dubbed the auxiliary pocket.24,29,30 Binding in the 
auxiliary pocket is facilitated by a key hydrogen-bonding interaction between the carboxylate 
group of Asp287 and the various heteroaromatic N-H groups and π-stacking interactions with 
Tyr250.
24,29,30 They also found that TbMetRS undergoes dramatic conformational changes upon 
binding with various substrates, as grossly different enzyme structures were observed in the 
methionine-bound, methionyl-AMP-bound, and inhibitor-bound complexes.24 Analysis of the 
various TbMetRS-substrate binding modes led the authors to conclude that their inhibitors bind 
to TbMetRS via a conformational selection mechanism, as opposed to an induced-fit 
mechanism.24 The insights gained from these studies informed the design of our TbMetRS 
inhibitors, which will be described further in Chapter 2.  
 
1.3. PREVIOUS WORK IN THE MARTIN LAB  
The Martin lab has a long-standing history in the twin fields of natural products synthesis 
and diversity-oriented synthesis (DOS) of targeted compound libraries via multi-component 
assembly processes (MCAPs).31 These two research arenas are frequently symbiotic, as new 
targets and strategies for total synthesis often inspire and inform the development of new MCAP 
methodologies and DOS applications.31 This relationship is nicely illustrated by the previous 
work in our lab, which led us to the discovery and development of novel TbMetRS inhibitors.  
1.3.1 Development of a Multi-Component Vinylogous Mannich Reaction for Indole 
Alkaloid Synthesis  
As part of an ongoing program in the synthesis of indole alkaloids, the Martin lab sought 
to develop a concise synthesis of the heteroyohimbinoid and coryantheoid alkaloids 
tetrahydroalstonine (1.18), cathenamine (1.19), and geissoschizine (1.20, Scheme 1.1) utilizing a 
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hetero-Diels-Alder reaction.32 To enable this strategy they sought an expeditious route for the 
synthesis of the hetero-Diels-Alder substrate 1.24. To that end, dihydro-β-carboline 1.21, which 
was prepared in two steps from tryptamine, was treated with trans-crotonyl chloride (1.22) in the 
presence of silyl dienol ether 1.23 at –78 ˚C, and upon warming the N-acyl-iminium intermediate 
underwent a vinylogous Mannich reaction to deliver 1.24 in 78% yield. Heating 1.24 in refluxing 
mesitylene brought about the desired hetero-Diels-Alder reaction to generate adduct 1.25 in 89% 
yield as a 9:1 mixture of diastereomers. Subsequent introduction of the E-ring carbomethoxy 
group was achieved via acylation with trichloroacetyl chloride followed by methanolysis to give 
key intermediate 1.26. Full reduction of the amide moiety of 1.26 with alane and sodium 
cyanoborohydride delivered tetrahydroalstonine (1.18) in 90% yield, while partial reduction with 
lithium diethoxyaluminum hydride furnished cathenamine (1.19) in 70% yield. Finally, opening 
of the dihydropyran ring of 1.26 followed by a challenging 1,2-reduction of the α,β-unsaturated 




Scheme 1.1. Martin lab synthesis of tetrahydroalstonine (1.18), cathenamine (1.19), and 
geissoschizine (1.20) 
The synthesis of 1.18–1.20 is remarkable for the brevity with which the A-E rings of the 
heteroyohimbinoid natural products were constructed, a mere two steps from known compound 
1.21. The obvious advantages of this approach led the Martin lab to apply the β-carboline 
vinylogous Mannich/(hetero)Diels-Alder reaction manifold to the synthesis of other indole 
alkaloids including oxogambirtanine (1.27), pteropodine (1.28), akuammicine (1.29), and 
strychnine (1.30, Figure 1.7).33–36 In addition to the dihydro-β-carboline-derived natural products 
1.27–1.30,  the VMR was also utilized in the synthesis of rugulovasines A & B (1.31a,b), 
setoclavine (1.32), pumiliotoxin 251D (1.33) and croomine (1.34, Figure 1.7).37–39 These 
syntheses expanded the scope of the VMR by pioneering the use of siloxyfurans as the dienic 
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component to form β-amino butenolides, which in the syntheses of setoclavine 1.32 and 
pumiliotoxin 1.33 underwent subsequent lactone-lactam rearrangements. 37–39 These and other 
studies demonstrated that the VMR was quite generalizable, tolerating a wide variety of imino 
groups, acylating agents, and π-nucleophiles.31,33 This generalizability enabled the development 
of a multi-component assembly process (MCAP), which was utilized to rapidly prepare diverse 
libraries of compounds inspired by bioactive natural products and medicines (see Chapter 3 for 
further discussion).31  
 
 
Figure 1.7. Other alkaloids synthesized in the Martin lab via the vinylogous Mannich reaction 
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1.3.2. Synthesis of Yohimbine and Corynanthe Alkaloid Analogs via a Multi-Component 
Assembly Process  
Alkaloids from the yohimbine and corynanthe families (e.g. 1.18, 1.20, Scheme 1.1) are 
known to display an array of useful biological activities, often mediated by action at the α-
adrenergic receptor.40,41 Accordingly, these natural product scaffolds make attractive templates 
for a diversity-oriented synthesis (DOS), which the Martin lab developed using a Mannich-type 
MCAP as a key diversity-introducing step. Dihydro-β-carbolines 1.21, 1.31, and 1.32 were 
treated with 1.22 in the presence of silyl enol ether 1.33 to generate aldehydes 1.34–1.36. 
Condensation of these aldehydes with N-methyl hydroxylamine in the presence of base lead to 
the formation of a nitrone in situ, which underwent a [3 + 2] dipolar cycloaddition upon heating 
with the pendant olefin to deliver isoxazolidines 1.37–1.39 in 38–60% yield over two steps 
(Scheme 1.2).41  
 
 
Scheme 1.2. Synthesis of isoxazolidines 1.37–1.39 
Intermediates 1.37–1.39 were subsequently carried through divergent synthetic sequences 
to deliver libraries of functionalized analogs with diverse chemotypes. Nor-bromo isoxazolidine 
1.37 was reduced with LiAlH4 to the amine 1.40, and both 1.37 and 1.40 underwent reductive 
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ring opening to deliver amino alcohols 1.41 and 1.42 (Scheme 1.3). The secondary amino group 
of 1.41 and 1.42 was then functionalized with an array of reagents to generate the tertiary 
amines, (sulfon)amides, (thio)ureas, and carbamates that comprise analog sets 1.43 and 1.44 
(Scheme 1.3).41 Brominated isoxazolidines 1.38 and 1.39 underwent Suzuki coupling with a 
range of electron-rich, neutral, and deficient boronic acids, furnishing biaryl lactams 1.45 and 
1.47 that were reduced with alane and lithium aluminum hydride, respectively, to deliver amino-
isoxazolidines 1.46 and 1.48 (Scheme 1.4). Reductive ring-opening of 1.45–1.48 followed by N-
functionalization delivered biaryl analog sets 1.53–1.56 (Scheme 1.4). In total, 180 analogs with 
diverse steric and electronic functionality were prepared via these synthetic sequences, enabling 
exploration of the structure-activity relationships (SAR) for any target biological receptor.41  
 
Scheme 1.3. Synthesis of amino- and amido- analog sets 1.43 and 1.44  
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Scheme 1.4. Synthesis of biaryl analog sets 1.53–1.56 
Screening of analog sets 1.43–1.44 and 1.53–1.56 was carried out by the National 
Institute of Health’s (NIH) Molecular Library Probe Production Center Network (MLPCN) and 
the National Institute of Mental Health’s Psychoactive Drug Screening Program (PDSP).41,42 The 
Molecular Libraries Initiative (MLI)—a component of the 2004 NIH Roadmap for Medical 
Research—was a far-reaching program that sought to leverage the then-recently-completed 
sequencing of the human genome and facilitate public-sector research into the development of 
new classes of biological tool compounds and therapeutic leads.42,43 These screening efforts 
identified several analogs in our molecular libraries as having promising biological activity, 
including several compounds that inhibited TbMetRS and T. brucei growth in vitro.41 These 
initial hits formed the basis of our efforts to develop novel HAT therapeutic leads, which will be 
discussed further in Chapter 2.  
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Chapter 2. Development of Novel Anti-Trypanosomal Compounds 
2.1 INITIAL HITS & DESIGN OF TARGET SCAFFOLDS 
Our work on the development of novel anti-trypanosomal compounds from the initial hits 
2.1–2.3 (Figure 2.1) identified by the NIH MLI began with an analysis of their SAR and a 
comparison of their structural features with the TbMetRS inhibitors developed by the the 
Buckner, Fan, Verlinde, and Hol labs (see section 1.2.2).23,24,27–30  
 
 
Figure 2.1. TbMetRS initial hits 2.1–2.3 and inactive analogs 2.4–2.5   
Comparison of our initial hits with the TbMetRS inhibitors synthesized by Fan and co-
workers revealed notable similarities and differences (see Figure 1.6). Both feature N-benzyl and 
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heteroaromatic moieties, but in our compounds these substituents are connected via a rigid 
quinolizinone core, whereas in the majority of the Fan compounds they are joined by a flexible 
diaminopropane linker.23,27,28,30  Our initial hits displayed the following TbMetRS IC50 values: 
2.1 IC50 = 0.6 µM, 2.2 IC50 = 0.3 µM, and 2.3 IC50 = 1 µM (Figure 2.1). Benzamide 2.4 and 
diamine 2.5 were both inactive against TbMetRS; this finding will prove to be significant during 
the later stages of our studies (vide infra).  This limited SAR was in accordance with that 
observed by Fan and co-workers. Namely, the increased activity of m-dichloro analogs relative 
to p-chloro analogs.23,27 While none of their compounds featured a N-piperonyl moiety, they did 
find that m-methoxy substitution seemed to improve activity, while p-methoxy substitution did 
not.27 These similarities lead us to hypothesize that our compounds might interact with TbMetRS 
in a similar fashion, with the N-benzyl moiety occupying the methionine-binding pocket and the 





Analysis of the X-ray structures of compounds such as 1.15 and 1.16 in complex with 
TbMetRS lead us to a rationale for the design of analogs of 2.1–2.3. The crystal structures of 
1.15 and 1.16 bound TbMetRS show that the inhibitors must adopt a bent conformation in order 
for the N-benzyl and heteroaromatic moieties to access their respective binding pockets while 
Figure 2.2. Crystal structures of aminoquinoline and urea inhibitors 1.15 (left) and 
1.16 (right) bound to TbMetRS (see Figure 1.6). PDB: 4EG5, 4MVW  
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avoiding the central ridge formed by Val473 (Figure 2.2).
23,27 Based on this observation, we 
reasoned that increasing the conformational flexibility of our analogs might enable them to adopt 
an optimal orientation while mitigating any steric clash with Val473, thus improving their binding 
affinity and anti-trypanosomal activity. To test this hypothesis, we envisioned severing the C(2)–
C(3) bond of our scaffold 2.6 to give a scaffold with the general structure 2.7 (Figure 2.3). In 
addition to increasing the flexibility of the scaffold, we reasoned that this would allow for a more 
modular synthesis with late-stage diversification of either the indole or N-benzyl substituents and 
variation of the linker connecting the heteroaromatic (indole) substituent to the scaffold core. At 
the outset of the project, we planned to prepare two distinct series of compounds, differentiated 
by the presence or absence of a R2 alkoxy motif on the lactam core of 2.7. The alkoxy-lactam 
compounds (X = O, R2 = CH(CH3)OH, CH2OH)  were prepared by Dr. Alan R. Meis, and their 
synthesis will not be discussed here.44 A third series of compounds with a piperidine core was 
also prepared, following the discovery of a piperidine analog that displayed potent T. brucei 
growth inhibition (vide infra).  
 
Figure 2.3. Design of conformationally flexible scaffold 2.7 from initial hit scaffold 2.6 
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2.2 SYNTHESIS OF LACTAM & PIPERIDINE ANALOG SETS 
2.2.1. Synthesis of δ-Lactam Analogs  
Our initial plan for the synthesis of δ-lactam analogs was to introduce the heteroaromatic 
moiety and alkyl linker in the final step via N-alkylation of a fully functionalized lactam ring 
(e.g. 2.14 → 2.16, Scheme 2.1). This route was attractive to us because it would enable late-stage 
introduction of both the N-benzyl and heteroaromatic moieties. The synthesis of 2.16 began with 
the partial hydrolysis of malonate 2.8 to generate carboxy-acid 2.9, which was then converted to 
an acyl chloride and treated with amine 2.10 in the presence of catalytic iodine to generate 
cyclization precursor 2.11 in 45% yield. Sodium hydride-promoted Dieckmann cyclization, 
followed by saponification and decarboxylation delivered keto-lactam 2.12 in 50% yield. 
Subsequent reductive amination with benzylamine 2.13 followed by deprotection with CF3CO2H 
(TFA) gave amino-lactam alkylation substrate 2.14. Unfortunately, attempts effect the alkylation 
of 2.14 with 2.15 using sodium hydride or sodium hexamethyldisilazide as the base in a variety 
of solvent and temperature regimes only resulted in the hydrolysis or elimination of alkyl 




Scheme 2.1. Failed synthesis of lactam analog 2.16 via amide N-alkylation 
For our revised synthesis of 2.16, we decided to include indole-ethyl moiety from the 
outset and thus avoid the problematic lactam alkylation. While this approach would not enable 
facile variation of the linker-heteroaromatic moiety, it would still allow us to readily introduce 
various N-benzyl groups. In the event, conjugate addition of tryptamine (2.17) into ethyl acrylate 
gave intermediate 2.18, which underwent N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 
(EDCI)-mediated acylation with 2.9 to generate 2.19 (Scheme 2.2). Cyclization and 
saponification/decarboxylation gave keto-lactam 2.20, which was reductively aminated with 2.13 
to deliver N-dichlorobenzyl lactam analog 2.16 in 10% yield, along with significant quantities of 




Scheme 2.2. Synthesis of δ-lactam analog 2.16 via a revised route 
Attempts were made to optimize the reductive amination of 2.20 with secondary 
benzylamines such as 2.13, but we invariably observed large quantities of vinylogous urea side-
products and thus concluded that an alternate approach was needed. We reasoned that the use of 
a primary amine instead of a secondary amine for the reductive amination of 2.20 might mitigate 
enamine (vinylogous urea) formation, and after some experimentation, we found that 2.20 
readily underwent reductive amination with methylamine to generate methylamino-lactam 2.22 
in 71% yield, with no trace of any vinylogous urea byproducts. Reductive alkylation of 2.22 with 





Scheme 2.3. Synthesis of δ-lactam analogs 2.16 and 2.23–2.29 via amino-lactam 2.22 
Drawing inspiration from the compounds prepared by Fan and co-workers (see Figure 
1.6), we also sought to prepare analogs with a secondary N-benzyl moiety. This was achieved via 
the treatment of keto-lactam 2.20 with excess ammonium acetate and sodium cyanoborohydride 
to generate primary amine 2.30 (Scheme 2.4). Subsequent imine formation followed by 




Scheme 2.4. Synthesis of N-H analogs 2.31 and 2.32 
Having thus secured an initial series of δ-lactam analogs designed to probe the SAR of 
the N-benzyl moiety and finding that several of these compounds did indeed inhibit T. brucei 
growth in vitro, we returned our attention to securing a route for the late-stage introduction of the 
heteroaromatic-linker moiety. During the course of these investigations we developed an 
improved synthesis of alkylation substrate 2.14, summarized in Equation 2.1. 
 
After discovering precedent for the use of potassium hydroxide in DMSO to effect N-
alkylation of a δ-lactam, we successfully utilized these conditions to alkylate 2.14 with bromo-
ethers 2.33 and 2.34, which was prepared in three steps from o-allylphenol, to generate phenyl-
ether and phenol analogs 2.36 and 2.37 in 44% and 33% yield, respectively.45 However, when 
we attempted to use these conditions to prepare 7-aza-indole analog 2.38 via alkylation with 
2.35, only returned starting material and uncharacterized degradation products were obtained.46  
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Scheme 2.5. Alkylation of 2.14 with 2.33–2.35 using KOH/DMSO conditions 
The low yields and limited substrate scope of these δ-lactam N-alkylation reactions 
prompted us to explore an alternate strategy for introducing the heteroaromatic moiety. We 
envisioned that incorporation of a pendant N-acetonitrile group on our δ-lactam core might allow 
for facile derivatization via Buchwald-Hartwig or Chan-Lam cross-coupling reactions of the 
masked amino moiety. To pursue this idea, we prepared 2.41 from β-alanine (2.39) via a three-
step esterification, N-alkylation, and N-acylation sequence. Unfortunately, subjecting 2.41 to our 
optimized Dieckmann conditions generated an intractable mixture of byproducts, and this 




Scheme 2.6. Attempted synthesis of δ-lactams with an N-CH2CN functional handle 
2.2.2. Synthesis of Piperidine Analogs 
We initially set out to prepare acyl-piperidines with the general structure 2.43 (Figure 
2.4) to test the effects of restricting a rotor on our heteroaromatic linker. In addition to this SAR 
insight, the piperidine scaffold 2.43 was attractive to us for its ease of derivatization at both the 
N-benzyl and heteroaromatic sites.  
 
 
Figure 2.4. Acyl-piperidine scaffold 2.43 
Preparation of acyl-piperidine analogs began with reductive amination of Boc-piperidone 
2.44 with methylamine to generate 2.45, which was then reductively alkylated and Boc-
deprotected to deliver diamines 2.46 and 2.47 (Scheme 2.7). The free N-H of 2.46 and 2.47 was 
then acylated with a series of indole carboxylic acids to deliver acyl-piperidine analogs 2.51–
2.54. Analogs 2.51 and 2.52 were designed for direct comparison with δ-lactam analogs 2.16 and 
2.24, while 5’MeO- derivative 2.53 was prepared because we had found that other 5'-MeO- 
analogs had shown increased potency in a T. brucei growth inhibition assay (vide infra). When 
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2.51–2.53 were found to be inactive against T. brucei, we prepared the indole-propionic acid 
derivative 2.54 to see if increasing the linker length would improve activity, but 2.54 likewise 
proved to be inactive. 
  
 
Scheme 2.7. Synthesis of acyl piperidines 2.51–2.54.  
Hoping to gain a new lead from our failed series of acyl-piperidines, we reduced 2.51 





We were initially hesitant to prepare piperidine diamines such as 2.55, due to finding such 
compounds to be inactive in the context of our initial tetracyclic scaffold (e.g. 2.5, Figure 2.1). 
Contrary to our expectations, 2.55 was an excellent T. brucei growth inhibitor, so we pivoted to 
the preparation of a small library of analogs built around a piperidine core.   
For our piperidine library, we sought to vary both the N-benzyl and heteroaromatic 
substituents. Thus, a series of N-benzyl variants 2.56–2.59 were prepared from 2.45, and 2.46 
was re-synthesized following this new procedure (Equation 2.3). While the reductive 
alkylation/Boc-deprotection sequence had previously been telescoped for the synthesis of 2.46 
and 2.47 (see Scheme 2.7), we found that this procedure suffered from reproducibility issues, and 
we thus opted for the two-step sequence shown in Equation 2.3.  
 
Derivatization of 2.46 and 2.56–2.59 via the introduction of heteroaromatic-linker 
moieties was achieved via divergent synthetic sequences dictated by the availability of the 
various N-functionalizing reagents and the compatibility of the amide (or keto-amide) reducing 
agents with the functional groups present on the molecule. For amido- compounds with aryl 
chloride substituents such as 2.51 and 2.60–2.62, we found that using the Lewis-acidic reducing 
(2.3) 
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agents alane and borane mitigated competitive dehalogenation during the preparation of 2.55 and 
2.63–2.65 (Scheme 2.8). Fluorinated derivative 2.67 required extra consideration, as we found 
that the use of acid during workup of the borane-mediated ketoamide reduction resulted in facile 
reduction of the electron-deficient indole ring to form a difficult-to-separate indoline byproduct. 
Thankfully, we were able to find conditions to lyse the diamine-borane adducts—cesium fluoride 
and sodium carbonate in refluxing ethanol—which did not result in any indoline formation, thus 
generating fluorinated analog 2.67. 47 The synthesis of 2.67 was developed in collaboration my 
undergraduate mentee Alexandra Pham.  
 
 
Scheme 2.8. Synthesis of piperidine analogs 2.55, 2.63–2.65, and 2.67. 
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To enable comparison of the N-benzyl substituent SAR on the piperidine scaffold with 
our other scaffolds, three additional 5'-MeO-indole analogs were prepared for direct comparison 
with 2.63 and 2.65 (see Scheme 2.8). Piperidine intermediates 2.57–2.59 (see Equation 2.3) were 
treated with ketoacyl chloride 2.68, and the resultant ketoamide was reduced with lithium 
aluminum hydride to deliver analogs 2.69 – 2.71 (Scheme 2.9).  
 
Scheme 2.9. Synthesis of piperidine analogs 2.69 – 2.71 
Aza-indole analog 2.72 and phenyl-urea analog 2.73 were prepared via alkylation or 
acylation of 2.46 with 2.35 (see Scheme 2.5) or phenyl isocyanate, respectively (Scheme 2.10).  
 
 
Scheme 2.10. Synthesis of piperidine analogs 2.72 and 2.73 
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Finally, analog 2.76 was prepared to assess the effect of a benzamide moiety on the 
piperidine scaffold. To this end, N-methylamino intermediate 2.45 (see Scheme 2.7) was 
acylated with mixed anhydride 2.74; Boc-deprotection and alkylation with 2.75  delivered 
benzamide analog 2.76. This synthetic sequence was developed and carried out by Alexandra 
Pham.   
 
 
Scheme 2.11. Synthesis of piperidine benzamide analog 2.76 
 
2.3 BIOLOGICAL EVALUATION OF INHIBITORS 
To assess the viability of our analogs as anti-trypanosomal compounds, we assayed their 
inhibition of T. brucei growth in vitro, their inhibition of recombinant TbMetRS in an 
aminoacylation assay, and their ability to stabilize TbMetRS via complexation in a thermal shift 
assay. The T. brucei growth inhibition assay was performed by our collaborators in the Mensa-
Wilmot Lab at The University of Georgia, whereas the aminoacylation and thermal shift assays 
were performed in our lab and will be discussed further in Section 2.3.2.  
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2.3.1. T. brucei Growth Inhibition 
Our initial series of lactam (2.16, 2.23–2.29) and hydroxylactam (2.77–2.84) analogs, 
shown in Table 2.1, were designed to probe the SAR around the N-benzyl substituent and to 
make direct comparisons between the two scaffold types. Analysis of their GI50 values appears to 
support our central hypothesis that scaffolds with increased flexibility would display improved 
anti-trypanosomal activity, as both 2.77 and 2.16 were five-fold more active against T. brucei 
than initial hit 2.1, which displayed a GI50 of 25.3 µM in this assay (Figure 2.5). We found the 
hydroxylactam scaffold to be superior to the lactam scaffold, as 2.77–2.84 were better growth 
inhibitors than their counterparts 2.16 and 2.23–2.29. This trend may be explained by the 
difference in solubility between the two scaffolds, as we found many lactam analogs were 
sparingly soluble in aqueous media, while the hydroxy-lactam analogs readily went into solution. 
Finally, our SAR trends appeared to be broadly in agreement with those observed by Fan and co-
workers. For example, the m-chloro analogs 2.16, 2.24, 2.26, 2.77, 2.79, and 2.81 were relatively 
potent while the m-diMeO analogs 2.25 and 2.80 and unsubstituted analogs 2.29 and 2.84 were 














Table 2.1. Growth inhibition (GI50) of T. brucei with hydroxylactam analogs 2.77–2.84 and 




Figure 2.5. T. brucei GI50 of initial hit 2.1, as determined by UGa collaborators 
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Lactam N-H analogs 2.31 and 2.32 and phenyl ether/phenol analogs 2.36 and 2.37 were 
all found to have T. brucei GI50 values ≥ 10 µM (Table 2.2). Because 8 of the 12 lactam analogs 
had GI50 values ≥ 10 µM, and so derivatives of this scaffold were not pursued any further.  
 
 
Figure 2.6. Growth inhibition (GI50) of T. brucei with lactam N-H analogs 2.31, 2.32 and phenyl 
ether/phenol analogs 2.36, 2.37. 
In the interest of further elucidating the SAR of our hydroxylactam scaffold, Dr. Alan 
Meis prepared analogs 2.85–2.91 (Table 2). These analogs were designed to probe the SAR of 
the indole-lactam linker length (2.85, 2.86), of substituents on the indole ring (2.87–2.90), and of 
the pendant hydroxyethyl moiety (2.91). Considering our hypothesized binding mode in which 
the heteroaromatic and N-benzyl moieties occupy two binding pockets separated in space, we 
were surprised to find that one-carbon and three-carbon analogs 2.85 and 2.86 were equipotent 
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with each other and with two-carbon analog 2.77 (GI50 = 4.3 µM, see Table 2.1). However, the 
introduction of substituents on the indole ring did have a substantial effect on the activity against 
T. brucei. The addition of a methoxy substituent at the 5'-position as in 2.87 resulted in a five-
fold increase in activity, making this our most potent analog to date; addition of a benzyloxy 
substituent at the 5'- or the 4'-positions as in 2.88 and 2.89 resulted in a two-fold increase in 
activity. This potentiating effect was not observed with the addition of a hydroxyl substituent, as 
5'-hydoxy analog 2.90 was equipotent with unsubstituted analog 2.77. We also wanted to 
determine what effect, if any, the methyl group of the pendant hydroxyethyl substituent has, 
because it was absent in initial hit 2.1, but present in 2.2 (see Figure 2.1). Comparing the nor-
methyl analog 2.91 with 2.77, we found the presence or absence of the methyl group had little 

















Table 2.2. Growth inhibition (GI50) of T. brucei with hydroxylactam analogs 2.85–2.91 
 
  
The piperidine analog series was notable for producing several potent T. brucei growth 
inhibitors and for demonstrating SAR trends that caused us to question the hypothesized binding 
mode of our compounds with TbMetRS. As mentioned previously, acyl-piperidines 2.51–2.54 
(see Scheme 2.7) have GI50 values ≥ 10 µM. However, N-alkyl piperidine 2.55 displayed a GI50 
value of 1.7 µM (Table 2.4), making it one of our most potent compounds, second only to the 5'-
MeO-indolyl hydroxylactam derivative 2.87 (see Table 2.3) at this stage of the project. Several 
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N-dichlorobenzyl piperidine derivatives were prepared to assess SAR of the heteroaromatic 
substituent on the piperidine nitrogen, the results of which are summarized in Table 2.4. Analysis 
of 5'-methoxyindolyl analog 2.63 was complicated by a discrepancy in results. In an initial 
screen 2.63 displayed a GI50 in the range of 1–5 µM, but in a follow-up assay the GI50 was 25 
µM. We tentatively suspect that this discrepancy is due to degradation of the compound and 
believe the initial measurement to be indicative of the correct GI50 value, based on the observed 
potency of other N-dichlorobenzyl and 5'-methoxyindolyl piperidine analogs. Despite this 
ambiguity, we can conclude that incorporation of a 5'-methoxyindolyl substituent on the 
piperidine scaffold did not have the same potentiating effect that was observed with the 
hydroxylactam scaffold, as 2.55 and 2.63 appear to be roughly equipotent. The introduction of an 
electron-deficient 6'-fluoroindolyl moiety in analog 2.67 likewise had little effect on activity. 
Replacement of the indolyl group of 2.55 with a benzimidazole moiety in analog 2.64 proved 
inconsequential, while introduction of a 7-azaindole moiety in 2.72 resulted in a four-fold 
reduction in activity. Finally, phenyl-urea analog 2.73 was found to have a GI50 value ≥ 10 µM, 













Table 2.3. Growth inhibition (GI50) of T. brucei with piperidine analogs 2.55, 2.63, 2.64, 2.67, 
2.72, and 2.73 
 
We also prepared a series of 5'-MeO-indolyl piperidine derivatives to probe the SAR of 
N-benzyl substituents, the results of which are summarized in Table 2.5. These SAR trends 
diverged considerably from those which were observed in the lactam and hydroxylactam analog 
series (see Table 2.1). Thioanisole derivative 2.70 was one of the most potent piperidine analogs 
with a GI50 of 1.6 µM, consistent with the observed potency of thioanisole hydroxylactam analog 
2.83 (Table 2.1). However, m-chloro and m-MeO-benzyl piperidine analogs 2.65 and 2.69 were 
equipotent (GI50 = 3.5–3.6 µM), which was inconsistent with the previous observation that m-
chloro analogs were consistently more potent than m-methoxy analogs in the lactam and 
hydroxylactam analog series (c.f. 2.26 and 2.81, 2.27 and 2.82, Table 2.1). Inconsistent SAR was 
also observed with unsubstituted N-benzyl analog 2.71, which displayed a GI50 value of 6.1 µM, 
wherease the unsubstituted N-benzyl lactam and hydroxylactam analogs 2.29 and 2.84 both had 
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GI50 values ≥ 10 µM. Finally, m-dichloro benzamide analog 2.76 displayed a GI50 value of 2.9 
µM, while in the initial tetracyclic series of compounds benzamide analogs (e.g. 2.4, Figure 2.1) 
were found to have GI50 values ≥ 10 µM. 
 
Table 2.4. Growth inhibition (GI50) of T. brucei with piperidine analogs 2.65, 2.69–2.71, 2.76: 
N-benzyl substituent SAR. 
 
 
 While the inconsistencies in SAR observed between scaffolds could be rationalized as the 
result of subtle stereoelectronic effects, the paucity of observable SAR within analogs of the 
same scaffold—most noticeable in the piperidine analog series—raised concerns regarding the 
hypothesized binding mode of our compounds to TbMetRS and the presumption that the 
observed inhibition of T. brucei growth was occurring via the inhibition of TbMetRS. To address 
these concerns, we decided to evaluate our compounds as inhibitors of TbMetRS in vitro. 
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2.3.2. Inhibition of T. brucei MetRS 
At the inception of our program to develop potent analogs of initial hits 2.1 and 2.2, we 
had intended to determine their ability to inhibit T. brucei growth, and to determine their binding 
energetics with TbMetRS using isothermal titration calorimetry (ITC). We also planned 
structural studies of selected complexes using X-ray crystallography. However, our efforts 
toward the latter were thwarted by low yields of recombinant TbMetRS obtained from 
expression in E. coli. Unfortunately, we were also not able to use the radiolabeled methionine 
TbMetRS aminoacylation inhibition assay developed by Buckner and co-workers, as our lab was 
not equipped or authorized to use radioactive materials.27 Ultimately we settled on the use of a 
colorimetric pyrophosphatase-coupled TbMetRS aminoacylation inhibition assay, adapted from 
the procedure developed by Cestari and Stuart for the analysis of TbIleRS inhibitors (see Section 
1.2.1).18,48 In this assay, the pyrophosphate (PPi) byproduct generated from aminoacyl-adenylate 
formation is converted to phosphate (Pi) by the enzyme pyrophosphatase. Pi concentration is then 
measured via its complexation with the malachite green reagent using visible-light 
spectrophotometry.49 To calibrate our assay we tested our initial hit 2.1, which we found to have 
an IC50 value of 4.9 ± 1.5 µM, as well as 2.92, a representative phenyl-urea inhibitor developed 
by Fan, which was found to have an IC50 value of 1.6 ± 0.3 µM (Figure 2.5). The discrepancy 
between the IC50 values determined by us for 2.1 and 2.92 and those determined by the MLPCN 
or the Buckner lab is not surprising, as IC50 values are assay-specific and vary with enzyme and 
substrate concentration. We were by necessity using higher concentrations of TbMetRS, ATP, 
methionine, and tRNA in our colorimetric assay than was used in their radiolabeled methionine 




Figure 2.7. TbMetRS IC50 and T. brucei GI50 values for positive controls 2.1 and 2.92. 
What was surprising, however, was the discovery that most of our analogs are inactive 
against TbMetRS at concentrations up to 200 µM. The handful of compounds that displayed 
>15% inhibition at 200 µM are shown in Table 2.5. Hydroxy-lactam analogs 2.77, 2.79, 2.84, 
and 2.90 were all weakly active. It is interesting that N-dichlorobenzyl analog 2.77 was active, 
but the N-piperonyl analog 2.78 and the nor-methyl N-dichlorobenzyl analog 2.87 were inactive, 
because these two compounds were the most direct analogs of our initial hits 2.1 and 2.2 (see 
Table 2.1 and 2.3). It is also noteworthy that the 5'-hydroxyindolyl analog 2.90 was one of the 
most potent TbMetRS inhibitors, while 5'-hydroxyindolyl analog 2.87, our most potent T. brucei 
growth inhibitor, was completely inactive against TbMetRS. The lactam series fared worse, with 
only the N-dichlorobenzyl analog 2.16 and N-H dichlorobenzyl analog 2.31 displaying any 
activity. Acyl-piperidine analog 2.52 was weakly active, and none of the piperidine analogs 
displayed any activity against TbMetRS. These results were corroborated via a thermal shift 
assay, in which all of our “flexible” analogs displayed negligible ΔTm values, but 2.1 showed a 
ΔTm of 2.4 ˚C.
51  Collectively, the results of our TbMetRS assays show that our strategy for 
improving our initial hits by increasing their conformational flexibility paradoxically abolished 
their activity against TbMetRS, while maintaining, and in many cases improving, their activity as 
T. brucei growth inhibitors.   
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Table 2.5. Percent inhibition (> 15%) of TbMetRS at 200 µM inhibitor concentration. 
 
  
2.3 INDOLOQUINOLIZIDINE ANALOG SYNTHESIS AND ANALYSIS 
For the final phase of the project, we set to apply the insights gained from our flexible 
analog sets to the indoloquinolizidine scaffold of our initial hits. Specifically, we targeted 
analogs with 5' substituents on the indole ring, because 5'-methoxy analog 2.87 was our most 
potent T. brucei growth inhibitor, and 5'-hydroxy analog 2.90 displayed relatively potent anti-
TbMetRS activity (see Tables 2.3 and 2.5).  
Synthesis of the 5'-methoxyindolyl analog 2.98 and the 5'-hydroxyindolyl analog 2.99 
was realized via the synthetic sequence developed by Granger and co-workers using 5-
methoxytryptamine 2.94, which was readily prepared from 5-methoxyindole (2.93), as our 
starting material (Scheme 2.12). A boron tribromide (BBr3)-mediated demethylation converted 




Scheme 2.12. Synthesis of indoloquinolizidine analogs 2.98 and 2.99 
Comparing the biological activity of 2.98 and 2.99 with 2.1 revealed that addition of the 
5'-indolyl substituents resulted in a decrease in TbMetRS inhibition that was 2–3-fold for 2.99 
and >20-fold for 2.98. Interestingly, both 2.98 and 2.99 showed a 2-to-3-fold increase in T. 
brucei growth inhibition relative to 2.1. This discrepancy suggests that the indoloquinolizidine 
analogs  act on other cellular targets in addition to TbMetRS to inhibit T. brucei growth. 
However even with this increase in potency, the indoloquinolizidine analogs were still inferior to 
most of our flexible analogs in terms of T. brucei growth inhibiton.  
 
 




2.4. SUMMARY & CONCLUSIONS 
 In the endeavor to synthesize and biochemically analyze novel leads for the treatment of 
HAT, we developed robust protocols for the synthesis of a library of hydroxylactam, lactam, and 
piperidine analogs of our initial hits 2.1 and 2.2. These analogs were assayed for inhibition of T. 
brucei growth in vitro by our collaborators at the University of Georgia, and we found that many 
of these compounds have GI50 values that are lower than our initial hit 2.1, with our most potent 
growth inhibitor 2.69 displaying a 25x increase in activity relative to 2.1. However, when we 
queried the ability of our analogs to inhibit TbMetRS in an aminoacylation assay, we found that 
they were all essentially inactive at biologically relevant concentrations. Finally, we prepared 
indoloquinolizidine analogs 2.98 and 2.99 to leverage the results of our SAR studies on a 
scaffold known to inhibit TbMetRS, and found that they were superior T. brucei growth 
inhibitors but inferior TbMetRS inhibitors relative to 2.1.  
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A clue as to why our flexible analogs do not inhibit TbMetRS may be found in the work 
of Fan and co-workers, which was published subsequent to our work, in which they prepared 
1,3-disubstituted piperidine 2.100 and its acyclic analog 2.101 and found them to be roughly 
equipotent in their binding and inhibition of TbMetRS (Figure 2.6).30 Furthermore, examination 
of the crystal structures of 2.100 and 2.101 bound to TbMetRS reveals that the orientation and 
position of the two molecules is nearly identical.30 This result suggests that the 1,3-disubstituted 
piperidine core preorganizes the two aromatic substituents into a bent orientation optimal for 
binding with TbMetRS, in contrast with our 1,4-disubstituted piperidine and lactam scaffolds 
which would disfavor such an orientation. Re-examining our initial hits 2.1 and 2.2 (see Figure 
2.1), we can see that the indoloquinolizidine motif likewise enforces a bent orientation between 
the two aromatic substituents, leading to the conclusion that severing the C(2)–C(3) bond of 2.1 
and 2.2 removed a key conformational constraint that preorganized the ligands into a favorable 
orientation for binding with TbMetRS.  
 
 
Figure 2.8. TbMetRS inhibitors 2.100 and 2.101 developed by Fan and co-workers  
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 DIVERSITY-ORIENTED SYNTHESIS OF SPIROCYCLIC BETA-
PHENETHYLAMINES 
Chapter 3. Multi-Component Assembly Processes for Diversity-Oriented 
Synthesis, Privileged Scaffolds, Aza-Spirocycles, and Intramolecular Aza-
Hosomi-Sakurai Reactions  
3.1 MULTI-COMPONENT ASSEMBLY PROCESSES FOR DIVERSITY-ORIENTED SYNTHESIS 
The utility of vinylogous Mannich reaction (VMR) as a generalizable tool for the rapid 
construction of N-heterocycles was first demonstrated by the expedient syntheses of structurally 
diverse alkaloid natural products (see Section 1.3.1).32,33,36–39,52 Generalization of this process led 
lead to the development and application of a VMR-based multi-component assembly process 
(MCAP) to the diversity-oriented synthesis (DOS) of novel compound libraries, many of which 
displayed useful biological activity.31  
3.1.1. Diversity-Oriented Synthesis  
Diversity-oriented synthesis (DOS) is concerned with the development of synthetic 
methods and strategies to prepare libraries of small molecules with high degrees of diversity and 
complexity.53–55 The main impetus for preparing such libraries is to identify new bioactive 
compounds for use in chemical genetics or drug discovery and to explore under-represented or 
unknown areas of chemical space.53–55 New bioactive compounds may be identified either by 
their activity toward a specific protein target or via a phenotypic screen.53,54 From this 
perspective, it is obvious why a high degree of structural diversity is desirable, as a more diverse 
set of molecules will have a greater probability of eliciting a desired biological responses than a 
more “focused” set of molecules, provided little is known in advance about the target 
pharmacophore.54 As a corollary, a structurally diverse compound library would be expected to 
elicit a broader range of biological activities than a focused library, and would thus be of greater 
utility in a chemical genetics sense, where chemical probes are used to explore biological 
systems and characterize the functional activity of proteins via their perturbation with small 
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molecules.53,54 Structural complexity is also an important feature of a DOS compound library, as 
it has been postulated that increasing molecular complexity engenders specificity for a given 
protein target and correlates with the likelihood of success of a molecule as a drug candidate, 
although the generality of these observations have been called into question.54–59  
The development of DOS strategies and tactics can be thought of as an extension or 
evolution of  combinatorial chemistry strategies.53 Combinatorial chemistry techniques emerged 
from the development of solid-phase synthesis of peptides and small molecules.60 These 
techniques often utilize solid-phase synthesis in a “split-pool” or “one bead, one compound” 
regime to rapidly generate a large library of compounds—differing primarily in their functional 
appendages—often in a highly automatable fashion.53,54,60 However, these libraries often display 
low degrees of scaffold diversity and thus are of limited utility for the identification of new 
therapeutic leads or in chemical genetics endeavors, where scaffold diversity is of paramount 
importance.53,54 It is this emphasis on scaffold diversity, in addition to stereochemical and 
functional group/appendage diversity, that distinguishes DOS methods from traditional 
combinatorial chemistry methods.53,54  
While there are many different approaches that may be utilized in the development of a 
DOS method, there are some general features and strategies that warrant discussion. In contrast 
with target-oriented synthesis, DOS sequences are not evaluated in a retrosynthetic fashion, but 
instead are developed in a forward synthetic fashion to generate branched, divergent synthesis 
pathways.55,61,62 DOS sequences often incorporate multi-component reactions (MCRs) or tandem 
reactions as a means of simultaneously introducing multiple functional handles that can 
subsequently serve as branch points for functionalization and cyclization reactions.53,55,61,63,64 
Cycloaddition reactions such as the Diels-Alder reaction and [3+2] dipolar cycloadditions are 
also frequently used in DOS due to their ability to generate multiple bonds and stereocenters in 
the course of a single reaction.31,53,61  For the introduction of appendage and functional group 
diversity, cross-coupling and heteroatom-functionalization reactions are often utilized, as is the 
case in classical combinatorial chemistry.53,54,61 A general strategy for DOS known as the “build-
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couple-pair” strategy described by Nielsen and Schreiber is illustrated in Scheme 3.2.62 Synthons 
with diverse stereochemical and functional motifs 3.2 are built from simple starting materials 3.1 
and then coupled to prepare functionalized templates 3.3, which are subsequently paired in an 
intramolecular fashion to generate a set of structurally diverse scaffolds (3.4, Scheme 3.2).54,62 
This general strategy has been used by numerous research groups to prepare libraries of 
structurally diverse, stereochemically rich compounds for a variety of applications, and is 
analogous to the strategies utilized in the Martin Lab’s application of the MCAP to DOS 
endeavors.54,62 
 
Scheme 3.1. An example of the “build-couple-pair” DOS strategy described by Nielsen and 
Schreiber62 
3.1.2. Development and Applications of the Martin Lab MCAP  
The general features of the Martin MCAP approach to preparing diverse collections of 
small molecules are outlined in Scheme 3.2: an aryl aldehyde 3.5 and a primary amine 3.6 are 
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condensed to form an imine 3.7 which is subsequently activated via treatment with an acylating 
agent 3.8 to undergo electrophilic addition with a nucleophile 3.9 to form amides with the 
general structure 3.10. Incorporation of appropriate functional groups in the reaction inputs 3.5–
3.8 allows for subsequent ring-forming and functionalization reactions of 3.10 to generate 
polycyclic scaffolds such as 3.11 with diverse skeletal structures and functionalities. The MCAP 
is conceptually similar to an MCR, in which three or more “building block” substrates are 
combined to form a single product; however, the MCAP often requires a sequential addition of 
reactants to avoid undesired side-reactions.31,63  
 
 
Scheme 3.2. General outline of the Martin Lab MCAP 
In pioneering studies carried out by Sunderhaus, Dockendorf, and Martin, various facets 
of the MCAP were explored.65,66 A key finding of these exploratory studies was the realization 
that the experimental procedure for the MCAP reaction could be altered to accommodate the  
differing reactivity of various substrates. For instance, the imine formed from condensation of 
the amine 3.6 and aldehyde 3.5 inputs could be isolated in a discreet step, or directly reacted with 
an acyl chloride 3.8 and nucleophile 3.9.65,66 The character of the nucleophile 3.9 has a 
significant influence on the experimental condition required to achieve the desired reactivity. For 
example, when 3.9 is a weak π-nucleophile such as a silyl enol ether, the imine must first be 
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activated via acylation with 3.8 before electrophilic addition can occur. Conversely, when 3.9 is 
a strong nucleophile such as a Grignard reagent, addition to the imine can be carried out in the 
absence of 3.8, and the resultant amine may be isolated or subjected to subsequent acylation with 
3.8 in a one-pot fashion.65,66 This procedural flexibility enabled the utilization of the MCAP with 
a variety of substrates, and some noteworthy and illustrative examples of which will be described 
in the following section.  
One key strategy for scaffold preparation that was developed in these exploratory studies 
was the combination of the MCAP with subsequent ring-closing metathesis (RCM) and 
intramolecular Heck cyclization reactions. An early example of this strategy is shown in Scheme 
3.3, in which indolic aldehyde 3.12 underwent a two-step MCAP where it was first condensed 
with allylamine, and then sequentially treated with allylmagnesium bromide and benzyl 
chloroformate to furnish 3.13.65,66 RCM of 3.13 in the presence Grubbs catalyst 3.14 formed the 
tetrahydropyridine ring, which was subjected to an intramolecular Heck cyclization to deliver the 
novel ergoline-like scaffold 3.15. While 3.15 itself was not found to display any noteworthy 
biological activity, the development of the MCAP/RCM/Heck reaction manifold and its 
attendant application to DOS compound libraries would result in the discovery of a family of 
compounds with potent biological activity and exciting therapeutic potential (vide infra). 
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Scheme 3.3. Synthesis of 3.15 via a MCAP/RCM/Heck reaction sequence 
Another key tactic that emerged from these exploratory studies was the combination of 
the MCAP and a [3 + 2] dipolar cycloaddition with an azomethine ylide, nitrone, or azide dipole, 
and this general strategy was extended to the synthesis of a variety of scaffolds (see also Section 
1.3.2).40,41,65–71 In the work of Hardy and Martin, this strategy was leveraged to prepare 
pyrrolidine and isoxazolidine-fused 2-arylpiperidine scaffolds, an example of which shown in 
Scheme 3.4.67 Cycloaddition precursor 3.16 was prepared via a two-step MCAP involving 
condensation of 3.17 with allylamine, followed by treatment with 3.18 and 3.19.67 Treatment of 
3.16 with sarcosine derivative 3.20 and heating generated an azomethine ylide that underwent a 
[3+2] dipolar cycloaddition to furnish 3.21. Removal of the N-pentenoyl group of 3.21 with 
molecular iodine and HCl revealed pyrrolidine-fused piperidine 3.22. The N-H and aryl bromide 
moieties of 3.22 were exploited for subsequent diversification via N-functionalization, cross-
coupling, and intramolecular cyclization reactions. Additionally,  MCAP products such as 3.16 
were also made to undergo nitrone [3 + 2] dipolar cycloadditions to furnish isoxazolidine-fused 
piperidines that were elaborated in an analogous fashion.67 In screening efforts undertaken by the 
NIH Molecular Library Probe Production Center Network (MLPCN) (see Section 1.3.2), 3.22 
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was found to inhibit RAD52 (IC50 = 4.6 µM), a therapeutic target for BRCA2-mediated breast 
cancer.31 
 
Scheme 3.4. Synthesis of pyrrolidine-fused 2-arylpiperidine 3.17 via a MCAP/azomethine ylide 
[3 + 2] dipolar cycloaddition sequence  
A fruitful application of the MCAP/dipolar cycloaddition reaction manifold was 
developed by Donald, Wood, and Martin in the synthesis of triazole-fused benzodiazepines via a 
Huisgen-type azide-alkyne [3 + 2] cycloaddition.68,70 An example of this strategy is shown in 
Scheme 3.5, in which azo-benzaldehyde 3.23 undergoes condensation with propargylamine to 
generate 3.24, which was activated with acetyl chloride to undergo Huisgen [3 + 2] cycloaddition 
to furnish N-acetyl benzodiazepine 3.25. Alternatively, 3.24 underwent a Huisgen [3 + 2] 
cycloaddition when heated, and the resultant N-H benzodiazepine scaffold could be N-
functionalized in a subsequent step to generate derivatives such as the p-methoxy benzamide 
3.26. The pendant nitrile group of 3.25 and 3.26 could be exploited for further elaboration. For 
example, deprotonation of the amino nitrile 3.25 with sodium hydride and subsequent capture of 
the anion with benzyl bromide furnished the alkylated derivative 3.27. Alternatively, treatment 
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of 3.26 with Schweizer’s reagent generated the pyrrole-fused analog 3.28. Screening of this 
compound set by the MLPCN identified several analogs with notable biological activity. For 
instance, 3.27 was found to inhibit 5-methyl-CpG-binding domain protein 2 (29% inh. at 4.4 
µM), which is involved in the epigenetic gene silencing that occurs as a result of DNA hyper-
methylation in cancerous cells, and 3.28 was found to inhibit the SWI/SNF chromatin 
remodeling complex (AC40 = 4.6 µM), which plays an essential role in the induction of 
pluripotency in stem cells and in tumor suppression.31,72,73  
 
 
Scheme 3.5. Synthesis of triazole-fused [1,4]-benzodiazepines 3.22 and 3.23 via a 
MCAP/Huisgen [3 + 2] dipolar cycloaddition sequence 
The MCAP/[3 + 2] dipolar cycloaddition reaction manifold was further extended by the 
work of Granger, Kaneda and Martin, in which they explored the use of bromo-
dihydroisoquinoline 3.29 as an MCAP input (Scheme 3.6).69,71 They found that 3.29 underwent a 
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one-pot MCAP/Huisgen [3 + 2] cycloaddition cascade vial sequential treatment with a metal 
acetylide and then with azido-benzoyl chloride 3.30 to furnish the fused tetrahydroisoquinoline-
benzodiazepines 3.31 and 3.32, which were subsequently derivatized via cross-coupling 
reactions with the aryl bromide moiety. Alternatively, 3.29 was treated with 3.18 and 3.33 to 
effect an N-acyl-iminium MCAP reaction, and the resultant aldehyde underwent condensation 
and nitrone [3 + 2] dipolar cycloaddition to furnish isoxazolidine 3.34, which was elaborated via 
a three-step cross coupling/ring opening/N-functionalization reaction sequence to furnish analogs 
such as 3.35 (see Section 1.3.2). MLPCN screening of this compound set identified 3.32 as an 
inhibitor of transactive response DNA-binding protein 43 (TDP-43) (AC50 = 35.5 µM). 
Aggregation of mutated TDP-43 in nerve cells is a marker for neurodegenerative diseases such 
as amylotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration, and compounds 
that inhibit TDP-43 may be useful tool compounds for studying these diseases.31,74 Urea 
derivative 3.35 was also found to display useful biological activity as an inhibitor of the hepatitis 
C virus (AC50
 = 2.0 µM).31 
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Scheme 3.6. Synthesis of tetrahydroisoquinoline derivatives 3.26, 3.27, and 3.30 via MCAP/[3 + 
2] dipolar cycloaddition sequences 
As mentioned previously, the MCAP/RCM/Heck reaction manifold proved to be one of 
the most fruitful extensions of the MCAP to DOS library generation. This strategy was 
developed by Sahn and Martin for the preparation of norbenzomorphans via reaction sequences 
such as the one depicted in Scheme 3.7.75–78 Benzaldehydes 3.36 and 3.37 underwent an N-acyl-
iminium-type MCAP to deliver 3.38 and 3.39, which were then cyclized via RCM and 
intramolecular Heck reactions to furnish norbenzomorphan scaffolds 3.40 and 3.41.76 
Subsequent ionic reduction of 3.40 and 3.41 gave 3.42 and 3.43, which were functionalized via a 
Buchwald-Hartwig amination with piperazine and reductive alkylation with propionaldehyde to 
deliver norbenzomorphan analogs 3.44 and 3.45.78 In this fashion, libraries of norbenzomorphan 
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derivatives were prepared and screened for their activity at various central nervous system (CNS) 
receptors by the Psychoactive Drug Screening Program (PDSP) at UNC Chapel Hill.  
 
 
Scheme 3.7. Synthesis of norbenzomorphans 3.44 and 3.45 via an MCAP/RCM/Heck reaction 
sequence 
Screening of 3.44, 3.45, and many other norbenzomorphan analogs by the PDSP revealed 
that these scaffolds display remarkable activity at the sigma 1 (σ1) and sigma 2 (σ2) receptors.78 
Sigma receptors are transmembrane proteins that reside primarily on the endoplasmic reticulum 
and are distributed throughout the central and peripheral nervous system.78,79 Broadly speaking, 
they are known to be involved in intracellular calcium regulation and neuronal survival or 
apoptosis.78,79 The σ1 receptor is well studied, having been cloned, sequenced and structurally 
characterized via X-ray crystallography, and compounds that target the σ1 receptor are currently 
in clinical trials for the treatment of Alzheimer’s disease, epilepsy and pain.78 The σ2 receptor is 
less well-studied, primarily due to the fact that, prior to our work in this field, it had never been 
cloned. However, σ2 ligands were known in the literature, and the σ2 receptor shows promise as 
a chemotherapeutic and diagnostic target for cancer as it is overexpressed in proliferating tumor 
cells.78 Our research found 3.44 and 3.45 to be potent and selective ligands for the σ1r and σ2r, 
respectively: 3.44 σ1 Ki = 8.7 nM, σ2 Ki = 29.3 nM; 3.45 σ1 Ki = 230 nM, σ2 Ki = 5.1 nM.
78 This 
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relationship between aryl substitution and σ receptor subtype selectivity appears to be general, 
with 4-substituted ligands preferring σ1 and 5-substituted ligands preferring σ2.78 This discovery 
of a new class of potent, selective σ2 receptor ligands has spurred a great deal of research in our 
group, including the investigation of norbenzomorphan σ2 ligands for the treatment of 
Alzheimer’s disease,80 neuropathic pain,81 traumatic brain injury,82 and alcohol use withdrawal.83 
We have also discovered other chemical scaffolds capable of potently inhibiting the  σ2 receptor 
such as isoindolines84 and aminotetralins, and the latter was used in work which led to the 
isolation and cloning of the σ2 receptor and its identification as transmembrane protein (TMEM) 
97.85  
Taken together, these examples illustrate the utility and generalizability of the MCAP 
procedure for the rapid synthesis of compound libraries built around unique, diverse scaffolds. 
Furthermore, many of these compounds were found to display promising biological activities, 
which lead to fruitful medicinal chemistry and chemical biology research programs focused on 
human African trypanosomiasis (see Chapter 2) and the σ2 receptor. Thus, we expect that future 
endeavors to expand the MCAP and apply it to DOS will likewise pay dividends in the arenas of 
chemical biology and drug discovery.  
 
3.2 PRIVILEGED STRUCTURES  
One of the most important considerations in developing a useful DOS procedure is the 
design of molecular scaffolds to be prepared and elaborated via the DOS method.86 This process 
can be daunting, as it is estimated that there are over 1060 possible configurations of carbon-
based small (< 500 daltons) molecules.87 DOS scaffold design may be driven by the desire to 
explore new or under-represented areas of this vast chemical space.55,61 However, it is often 
desirable to design DOS scaffolds that populate areas of chemical space that have been pre-
validated as biologically relevant.86  In this case, the scaffold design process is informed by the 
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structures (or substructures) of natural products or drugs with desirable (bio)chemical properties, 
which are commonly referred to as “privileged structures”.55,86  
3.2.1. Definition, History, and Examples of Privileged Structures 
The concept of a privileged structure was first introduced by Evans in 1988, which he 
defined as “a single molecular framework able to provide high-affinity ligands for more than one 
type of receptor.”88  This concept emerged from his work on the development of cholecystokinin 
(CCK) antagonists such as 3.46 (Figure 5) that contained a 1,4-benzodiazepine nucleus.88,89 The 
1,4-benzodiazepine scaffold forms the core of benzodiazepine class of drugs, of which diazepam 
(3.47, Figure 5)—trade name Valium—is a noteworthy example.90 Benzodiazepines are 
commonly prescribed for their anxiolytic and sleep-inducing effects, which are primarily induced 
via action  at γ-amino butyric acid (GABA) and  receptors in the CNS.90 By modifying 
substituents around the 1,4-benzodiazepine core, Evans and co-workers were able to produce 
compounds such as 3.46 that were potent CCK receptor antagonists (3.46 IC50 = 3.4 µM), but did 
not display any activity at benzodiazepine receptors.88,89 This ability of the benzodiazepine 
nucleus to produce ligands that bind with high affinity to different biological receptors lead 
Evans to designate it as a “privileged” scaffold.  
 
 
Figure 3.1. 1,4-benzodiazepines 3.46 and 3.47 which display divergent biological activities 
Since its initial conception, the designation of a privileged structure has been broadened 
to include scaffolds or substructures whose derivatives frequently display biological activity, 
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without the criterion that these activities must be mediated by different biological receptors.91,92 
Natural products provide numerous examples of privileged structures, which is not surprising 
given that the enzymatic machinery that produces natural products does so for a specific 
biochemical purpose.86,91,93 Natural product scaffolds and the enzymatic machinery that produce 
them are highly conserved throughout nature, and there are many examples of natural product 
classes whose individual family members display diverse biological activity.93 Analysis and 
hierarchical classification of the substructures found within and across natural product families, 
and the relationship between these substructures and the attendant biological activities of their 
derivatives (natural and unnatural) is one of the principal components of biology-oriented 
synthesis (BIOS), which seeks to use these analyses to guide the synthesis of compound libraries 
enriched in bioactivity.93  
Many medicines are either natural products themselves or are derived from natural 
products. So there are numerous examples of privileged scaffolds that are found in both natural 
products and drugs, some examples of which are shown in Figure 3.2.91,93 The steroid skeleton 
3.48 is ubiquitous in the worlds of natural products and medicinal chemistry, and its derivatives 
display widely divergent bioactivity. For instance, the aminosterol squalamine (3.49), isolated 
from the tissue of the spiny dogfish shark Squalaus acanthias, has both antimicrobial and 
antiangiogenic activity, while the synthetic testosterone derivative quinbolone (3.50) is an 
anabolic and androgenic steroid.94,95  
Many nitrogenous heterocycles are classified as privileged structures, of which 
tetrahydroisoquinoline (THIQ, 3.51) and tetrahydro-β-carboline (THBC, 3.54) are two 
noteworthy examples (Figure 3.2, see also Section 1.3.1 for additional examples of THBC 
natural products).96,97 The THIQ natural product erythravine (3.52), which is isolated from the 
Brazilian ornamental tree Erythrina mulungu and belongs to the large Erythrina family of 
alkaloids whose members frequently display CNS activity, is a potent nicotinic acetylcholine 
receptor antagonist with demonstrated anxiolytic and anticonvulsive activity.98–100 Apomorphine 
(3.53) is a semi-synthetic THIQ morphine derivative and dopamine receptor agonist.101 
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Apomorphine (3.48) is used for the relief of symptoms associated with Parkinson’s disease.101,102 
It is also a potent emetic and sedative, and it has been used historically for the treatment of a 
multitude of conditions including alcoholism, poisoning, and respiratory disorders.101,102 The 
THBC natural product reserpine (3.55), isolated from the Indian snake root Rauvolfia serpentina, 
likewise has a long, storied history of  medical use.52 Reserpine exhibits sympatholytic activity 
via the depletion of catecholamine and serotonin neurotransmitters, and was one of the first 
antipsychotic drugs.103,104 While today reserpine is rarely used as an antipsychotic, owing to its 
serious and sometimes irreversible side effects, it still finds use in the treatment of 
hypertension.103,104 Finally, tadalafil (3.56) is a synthetic THBC phosphodiesterase 5 inhibitor 




Figure 3.2. Privileged structures (left) and representative natural products (center) and synthetic 
medicines (right)  
3.2.2. β-Phenethylamine (PEA) as a Privileged Structure 
An especially well-known, occasionally notorious privileged structure is β-
phenethylamine (3.57, Figure 3.3). Unsubstituted β-phenethylamine (PEA, 3.57), which is 
formed from the decarboxylation of phenylalanine, is widely distributed throughout nature, 
having been identified in algae, fungi, bacteria, and numerous plant species, as well as in the 
brains of humans and other mammals.106 PEA is classified as a trace amine neurotransmitter 
because it is present in the nervous system at much lower concentrations than the biogenic amine 
neurotransmitters serotonin, dopamine, (nor)epinephrine, and histamine owing to its rapid 
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metabolism by monoamine oxidase B (MAO-B).106 The neurochemical effects of PEA are 
mediated by its activation of the G protein coupled-receptor (GPCR) trace amine-associated 
receptor 1 (TAAR1), which results in a downstream inhibition of serotonin, dopamine, and 
norepinephrine reuptake.107 This monoamine reuptake inhibition may confer the stimulatory and 
amphetamine(3.58)-like subjective and physiological effects of PEA that have led to its 
popularity as a nutritional supplement.106,107 
 
Figure 3.3. β-phenethylamine (PEA, 3.52) and noteworthy derivatives 
As mentioned previously, PEA is a somewhat notorious privileged structure, as it is 
found in psychostimulants such as amphetamine (3.58, Figure 3.3), which is used therapeutically 
for the treatment of attention deficit hyperactivity disorder (ADHD) and obesity, but it has a high 
potential for abuse and addiction.108 Substituted amphetamines such as N-methylamphetamine 
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(meth) and 3,4-methylenedioxymethamphetamine (MDMA, 3.59) are also well-known drugs of 
abuse, although in recent years there has been renewed clinical interest in the use of MDMA 
(3.59) as a psychotherapeutic tool, especially in the treatment of post-traumatic stress disorder 
(PTSD).109,110 The PEA scaffold can also be found in hallucinogenic drugs such as mescaline 
(3.60), the active ingredient in preparations of the peyote cactus that have been used by 
indigenous Americans for over 5700 years.110,111  
However, there are also many licit members of the PEA family of drugs. In fact, 25 of the 
200 most-prescribed medications in 2016 were phenethylamines.112 Many of these medicines act 
on the same monoamine neurotransmitter systems as PEA itself, such as the aforementioned 
amphetamine and methylphenidate (3.61), which both stimulate noradrenergic and dopaminergic 
neurotransmission and are primarily used for the treatment of ADHD.108 The antidepressants 
bupropion (3.62) and venlafaxine (3.63) likewise stimulate monoamine neurotransmission. 
Bupropion is a norepinephrine and dopamine reuptake inhibitor while venlafaxine is a serotonin 
and norepinephrine reuptake inhibitor.113 Albuterol (3.64) is a β-adrenergic (epinephrine) 
receptor agonist and bronchodilator used for the treatment of asthma symptoms.114 There are also 
examples of medicines containing the phenethylamine structure whose biological activity and 
therapeutic indication deviates considerably from that of “traditional” β-phenethylamines. For 
instance, the phenethylamino-acid baclofen (3.65) is a skeletal muscle relaxant and GABA 
receptor agonist, and levothyroxine (3.66) is a thyroid hormone used in the treatment of 
hypothyroidism.115,116 It is also found in the antidiabetic medications glipizide (3.67) and 
sitagliptin (3.68). Glipizide (3.67) stimulates the release of insulin from pancreatic β cells, while 
sitagliptin (3.68) helps to regulate blood glucose levels via the inhibition of dipeptidyl peptidase 
4.117,118 In conclusion, the PEA scaffold is a highly validated privileged structure with numerous 




Spirocyclic scaffolds having two ring systems are fused via a single carbon atom are 
found in numerous natural products, and these frameworks are increasingly being investigated 
for their use in drug discovery.119–122 Spirocyclic ring systems display several properties that 
make them attractive molecular scaffolds: They are inherently rigid and often contain multiple 
sp3-hybridized carbon atoms and chiral centers.56,57,122 Molecules with rigid scaffolds tend to be 
more selective for a given biological target than their flexible analogs, and a common tactic in 
drug development is the incorporation of rigidifying elements such as spirocyclic ring systems 
into a scaffold to impart greater selectivity and binding affinity. However the application of this 
tactic is not always straightforward, as shown by Martin’s research into the effects of 
conformational constraints on protein-ligand interactions.121,123 Three-dimensionality is an 
important feature for drug scaffolds because it enables them to better occupy protein binding 
sites and make multiple contacts with binding site residues.120–122 Spirocyclic scaffolds are often 
globular or capsule-shaped and can bear substituents that project with well-defined geometry into 
all three dimensions, making them attractive platforms for optimizing interactions within a target 
binding site.122 Attendant to this three-dimensionality is the degree of molecular complexity 
often found in spirocyclic molecules. Complexity, quantified via the fraction of sp3-hybridized 
carbon atoms and the number of chiral centers in a molecule, has been shown to correlate with 
target specificity, aqueous solubility, metabolic stability, and ultimately with success in the drug 
development process.56,57  
 
3.2.1. Aza-Spirocycles in Drug Discovery  
Aza-spirocycles are especially interesting scaffolds from a drug discovery perspective, as 
nitrogenous heterocycles are among the most common structural motifs found in 
pharmaceuticals.96 An elegant demonstration of the potential utility of aza-spirocyclic scaffolds 
can be found in the work of Burkhard and co-workers, who synthesized a series of 2,6-
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diazaspiro[3.3]heptanes 3.69 and compared their physiochemical and biochemical properties 
with an analogous series of piperazines 3.70 (Figure 3.4).124 They found that in most cases the 
spirocyclic compounds 3.69 displayed decreased lipophilicity, increased solubility in aqueous 
buffer, and were less susceptible to oxidative degradation by human liver microsomes than their 
non-spirocyclic analogs 3.70.124 
 
 
Figure 3.4. Comparison of 2,6-diazaspiro[3.3]heptane scaffold 3.69 with piperazine scaffold 
3.70 
A more medically relevant example of aza-spirocycle incorporation can be found in the 
work of Johansson and coworkers during lead optimization of melanin concentrating hormone 
receptor 1 (MCHr1) antagonists for the treatment of obesity.125 They found that substitution of 
the amino-oxetane moiety in analogs such as 3.71 with an 2-oxa-6-azaspiro[3.3]heptane moiety 
in their lead compound 3.72 dramatically slowed the metabolism of the molecule in a human 
liver microsome (HLM) assay and also resulted in diminished human ether-a-go-go (HERG) 
channel affinity without affecting potency of the compound at MCHr1. 
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Figure 3.5. Incorporation of an aza-spirocycle slows degradation by human liver microsomes 
(HLMs) 
Some examples of aza-spirocycles that are currently in clinical trials or are approved for 
medical use are shown in Figure 3.6. The spiro-piperidine 3.73 is an acetyl-CoA carboxylase 
inhibitor that has progressed through phase 1 clinical trials for the treatment of metabolic 
syndrome.122 Spiro-oxindole 3.74 is an antagonist of the calcitonin gene-related peptide which 
has completed phase 2 clinical trials for the treatment of migraine.122 Sigma-1 receptor agonist 
3.75 is used as a radioligand for cancer diagnostic positron emission tomography (PET) 
imaging.122 Finally, rolapitant (3.76) is a neurokinin 1 antagonist that was approved in 2015 for 
the treatment of chemotherapy-induced nausea.122 Interestingly, the molecular targets of 3.72 and 
3.74–3.76 are all GPCRs, and it has been suggested that spirocycles may be privileged scaffolds 




Figure 3.6. Aza-spirocycles currently in clinical trials, approved diagnostic tools and medicines  
3.2.2. Aza-Spirocycles in Natural Products   
Aza-spirocycles can also be found in the skeletons of numerous bioactive natural 
products.126 Here we will limit our discussion to natural products containing a 1-
azaspiro[5.5]undecane (3.76) or 1-azaspiro[4.5]decane (3.77) core, as these motifs will be the 
focus of our DOS methodology (Figure 3.7, see Chapter 4). However, it is worth mentioning that 
there are many examples of other aza-spirocyclic motifs in the spiro-oxindole and spiro-indoline 
classes of natural products, which display diverse bioactivity and have been the subject of 
numerous total syntheses and DOS methodologies.127–131   
The aza-undecane scaffold 3.76 is found throughout the Erythrina family of alkaloids 
(e.g. erythravine, 3.52), which are known for being potent NAChR inhibitors (Figure 3.7, see 
also Section 3.2.1).98–100 It is also present in histrionicotoxin (3.78) and its partially-to-fully 
saturated congeners, which are isolated from the skin of the Colombian poison arrow frog 
Dendrobates histrionicus and exhibit potent and highly subtype-selective NAChR inhibition, 
making them useful tool compounds for  the study of neurophysiology.132 Many members of the 
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Lycopodium  family of alkaloids contain the 3.76 motif, including the prototypical member 
lycopodine (3.79).133 Extracts of Lycopodium clubmosses have a long history of use in Chinese 
folk medicine, and members of this alkaloid family display wide-ranging bioactivity and are 
under continual investigation for the treatment of various cardiovascular, neuromuscular, and 
neurodegenerative diseases. Lycopodine (3.79) itself is cytotoxic and has shown promise as a 
chemotherapeutic agent.133,134 Finally the 3.76 subunit is present in the protoberberine alkaloid 
karachine (3.80), that was isolated from the root bark of Berberis aristate.135,136 Preparations of 
Berberis aristate are used in Unani medicine for the treatment of jaundice and other skin 
conditions, although it is unclear if karachine itself contributes to this therapeutic activity.135,136 
While not as frequently observed as 3.76, 1-azaspiro[4.5]decane (3.77) ring system can also be 
found in several natural products, including the Lycopodium alkaloid annotine (3.81), which has 
been shown to effect the maturation of dendritic cells, and methyl homodaphniphyllate (3.82), 
which is isolated from the Yuzuriha tree but does not have any known biological activity.137–139 
Many of these alkaloids and their congeners have been the subject of total synthesis, including 
erythravine (3.52),100,140 histrionicotoxin (3.78),132,141 lycopodine (3.79, see ref. 143 for 





Figure 3.7. Representative natural products containing 1-azaspiro[5.5]undecane (3.76) and 1-
azaspiro[4.5]decane (3.77) ring systems  
3.4. THE INTRAMOLECULAR AZA-HOSOMI-SAKURAI REACTION  
The Hosomi-Sakurai reaction, developed by Akira Hosomi and Hideki Sakurai, is a 
Lewis acid-catalyzed allylation of a carbonyl derivative 3.83 with an allylsilane (3.84) to 
generate homoallylic alcohols such as 3.85 (Equation 3.1).149,150 The observed reactivity is due to 
the β-effect of the silyl group, which stabilizes the intermediate carbocation 3.86 via  σ → π 
donation from the σ(Si-C) bond to the vacant p orbital on the adjacent carbon atom.150 As a 
result, the reaction is highly regioselective for electrophilic attack at the terminal allylic carbon 
atom, and when optically active allylsilanes are used, the reaction proceeds with varying degrees 
of stereoselectivity to give predominantly anti-SE` products.
150 In their initial work, Homosi and 
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Sakurai treated aliphatic and benzylic aldehydes and ketones with substituted allylsilanes in the 
presence of titanium (IV) chloride to provide homoallylic alcohols in good yields and 
stereoselectivities.149 Subsequent studies expanded the scope of the reaction to include acetals, 
α,β-unsaturated carbonyl compounds, acid halides, epoxides, allyl and alkyl halides, and 
iminium ions as electrophilic components in the reaction.150–156   
 
 
Seminal work on the use of iminium ions in the Hosomi-Sakurai reaction was performed 
by Grieco, Fobare and Larsen (Figure 3.8).157,158 They found that treatment of allylsilanes 3.87 
with benzylamine-TFA salt and formaldehyde in water triggered a domino reaction sequence in 
which electrophilic addition of 3.87 to N-benzylmethanimine leads to the formation of an 
intermediate homoallylamine, which subsequently undergoes a condensation/intramolecular  
aza-Prins cascade to deliver 4-hydroxypiperidines with the general structure 3.88 (Figure 
3.8a).158 Substitution at the R1 and R2 positions of 3.87 is tolerated, and when R1=R2=cycloalkyl 
they obtained cis-fused bicycles, while incorporation of a pendant alkoxy group at the R2 position 
resulted in the formation of spirocyclic oxacycles. In most instances, competitive 





Figure 3.8. Aza-Hosomi-Sakurai reactions for N-heterocycle synthesis developed by Grieco, 
Fobare, and Larsen. a) intermolecular reactions b) intramolecular reactions  
Grieco and Fobare later extended their methodology to intramolecular cyclizations with 
amino-allylsilanes, as shown in Figure 3.8b.157 Trans-disubstituted amino-allylsilanes 3.89 and 
3.90 participated in the reaction to deliver pyrrolidine and piperidine products 3.91 and 3.92 with 
pendant olefin groups. Use of gem-disubstituted amino-allylsilanes 3.93–3.96 was also 
investigated, and while 3.93 did not cyclize to give pyrrolidine 3.97, 3.94–3.96 readily 
underwent cyclization to generate piperidine, azepane and azocine products 3.98–3.100. Finally, 
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they found that substituted aldehydes could serve as substrates in the reaction, as 3.94 underwent 
condensation and cyclization with phenylacetaldehyde to form phenethylamino- piperidine 
3.101. This general strategy for the synthesis of N-heterocycles has since seen widespread 
application in natural products synthesis, and many methodological variants and extensions have 
been reported.159–167  
3.4.1. Cascade Aza-Hosomi-Sakurai Reactions for the Synthesis of Quinolizidines and 
Indolizidines 
The Martin Lab recently developed a cascade aza-Hosomi-Sakurai reaction sequence for 
the one-pot synthesis of natural products and derivatives of the quinolizidine and indolizidine 
scaffolds.168,169 The general features of the cascade sequence developed by Amorde and co-
workers are shown in Scheme 3.8. Briefly, an amino-allylsilane 3.102 and an acetal-aldehyde 
3.103 are condensed to form an imine 3.104 that is poised to undergo sequential acid-catalyzed 
cyclizations to form a hemiaminal species 3.105, which can then be intercepted with a 
nucleophile to deliver functionalized N-bicycles with the general structure 3.106.  
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Scheme 3.8. Cascade Aza-Hosomi-Sakurai reactions for the synthesis of amino-bicycles 3.106 
and 3.108 
The general applicability of this strategy was demonstrated by the reaction sequences 
shown in Scheme 3.9.168,169 Reaction of the amino-allylsilanes 3.102a (n = 0) or 3.102b (n = 1) 
with acetal-aldehydes 3.103a (n = 0) or 3.103b (n = 1) furnished amino-bicycles 3.109–3.111 as 
single diastereomers. The reaction proved to be most efficient for the synthesis of quinolizidines, 
as 3.109 was formed in 75% yield, whereas the indolizidines 3.110 and 3.111 were formed in 
36% and 45% yield, respectively. Ozonolysis of 3.109–3.111, followed by hydride reduction 
delivered the natural products (±)-epilupinine (3.112) and (±)-tashiromine (3.113) in 88% and 




Scheme 3.9. Synthesis of (±)-epilupinine (3.107), (±)-tashiromine (3.108), and indolizidine 
3.109 
The use of chiral amino-allylsilane 3.115 enabled the enantioselective synthesis of the 
quinolizidine natural product (–)-epimyrtrine (3.117).168,169 Treatment of 3.115 with 3.103b 
under standard cyclization conditions furnished intermediate 3.116 as an inconsequential mixture 
of diastereomers following interception of the quinolizidine iminium ion with sodium cyanide. 
Reduction of the α-aminonitrile moiety of 3.116 followed by ozonolysis delivered an inseparable 




Scheme 3.10. Synthesis of (–)-epimyrtrine (3.117) and (+)-myrtrine (3.118)  
Further studies were directed toward the synthesis of novel scaffolds via the cascade aza-
Hosomi-Sakurai reaction manifold.168,169 For instance, reaction of amino-allylsilane 3.119 with 
3.103b and sodium cyanide produced α-aminonitrile 3.120, which underwent α-alkylation with 
sulfonate 3.121 to generate 3.122 (Scheme 3.11, top). The pendant allylsilane moiety of 3.122 
underwent Lewis-acid-mediated cyclization to deliver the spiro-quinolizidine scaffold 3.123 in 
81% yield. The use of cyclohexanone acetal 3.124 as a cyclization substrate with 3.119 resulted 
in a diastereomeric mixture of spirocyclic tricycles (3.125) which were then reduced with sodium 
borohydride to deliver 3.126 and 3.127 as an inseparable mixture (1.1:1) in 60% yield. These 
studies laid the groundwork for our use of an intramolecular aza-Hosomi-Sakurai cyclization in 
the DOS of aza-spirocyclic compounds, which will be discussed further in Chapter 4.  
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Scheme 3.11. Synthesis of spiro- tricycles 3.118, 3.121, and 3.122 
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Chapter 4.  Diversity-Oriented Synthesis of Spirocyclic β-Phenethylamines 
Building on the Martin lab’s prior work in the development of diversity-oriented 
syntheses (DOSs) using multi-component assembly processes (MCAPs, see Section 3.1.2) and 
our use of intramolecular aza-Hosomi-Sakurai reactions for the synthesis of N-heterocycles (see 
Section 3.4.1), we endeavored to develop a new DOS methodology for the synthesis of aza-
spirocyclic scaffolds with the general structure 4.1 (Scheme 4.1). We anticipated that derivatives 
of 4.1 would display a high degree of biological relevance, as 4.1 combines the β-
phenethylamine motif discussed in Section 3.2.2 with the [6.6] and [6.5] aza-spirocyclic 
scaffolds discussed in Section 3.3.2, both of which appear in numerous CNS-active molecules. 
From a DOS standpoint, 4.1 possesses several functional handles that can serve as branch points 





Scheme 4.1. Synthesis of β-phenethylamine spirocyclic scaffold 4.1  
We envisioned synthesizing 4.1 via a tandem imine condensation/aza-Hosomi-Sakurai 
cyclization sequence between the known amino-allylsilane 4.2166 and β-aryl ketones with the 
general structure 4.3 (Scheme 4.1). We expected that the reaction would deliver 4.1 with a syn 
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stereochemical relationship between the amino and aryl groups due to a 1,2-stereoinduction 
effect from the β-aryl group during addition of the pendant allylsilane to the iminium ion. 
Preparation of the β-aryl ketone substrate 4.3 could be accomplished via the use of Hartwig’s 
[Pd]-catalyzed enolate arylation reaction between an aryl halide and cyclic ketone 4.4. 
Alternately, 4.3 could be prepared from cyclic epoxide 4.5 via a two-step nucleophilic addition, 
oxidation sequence (Scheme 4.1).170 
Elaboration of 4.1 could also be achieved through a variety of approaches. For instance, 
the piperidine nitrogen atoms could be alkylated or acylated to generate N-functionalized 
scaffolds such as 4.6, or the exocyclic olefin could be hydrated or ozonolyzed to introduce 
alcohol or ketone moieties as in 4.7 and 4.8, respectively. An appropriately substituted aryl group 
on 4.1 could participate in cross-coupling reactions to generate biaryl scaffolds such as 4.9, and 
finally, 4.1 could undergo an intramolecular Pictet-Spengler reaction to generate spirocyclic 






Scheme 4.2. Elaboration and diversification of 4.1 to generate functionalized scaffolds 4.6–4.11 
4.1 SYNTHESIS OF CYCLIC BETA-ARYL KETONE SUBSTRATES 
The first challenge to be met in reducing our new DOS method to practice was securing a 
robust, high-yielding protocol for the synthesis of the requisite cyclic β-aryl ketone substrates 4.3 
(see Scheme 1). To this end, we attempted to reproduce Kawatsura and Hartwig’s [Pd]-catalyzed 
enolate arylation protocol for the synthesis of phenyl cyclohexanone 4.13, which they obtained 
in 73% yield using condition set 1 in Figure 4.1a.170 Initial attempts gave 4.13 in <30% yield, 
along with large quantities of an arylation-aldol byproduct, which is tentatively assigned the 
structure of 4.14. We hypothesized that trace moisture present in the reaction may have been 
responsible for the unexpected low yield, but rigorous exclusion of water from the reactants and 
solvent provided only a modest increase in the yield of 4.13 to 44% (Entry 1, Figure 4.1a). 
Another marginal increase in yield was achieved through increasing the catalyst loading and 
switching to the more active [Pd0] catalyst Pd(tBu3P)2, which delivered 4.13 in 52% yield, along 
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with 22% of the difficult-to-separate byproduct 4.14 (Entry 2, Figure 4.1a). We reasoned that 
lowering the reaction temperature might suppress the aldol side reaction; however, we found that 
at room temperature the proportion of 4.14 formed relative to 4.13 was increased, although the 
overall conversion was very low (Entry 3, Figure 4.1a). We also evaluated other substrates in the 
reaction such as m-chloroanisole (4.15) and Boc-piperidone 4.17, and we found that these 
substrates likewise delivered their products 4.16 and 4.18 in low yields of 25% and 35% 
respectively, along with substantial quantities of uncharacterized byproducts.  
 
Figure 4.1. Synthesis of β-aryl ketones via [Pd] catalyzed enolate arylation. a) attempts to 
optimize reaction conditions. b) additional reaction substrates 4.15 and 4.17. 
The persistent problems encountered in our attempts to use a [Pd]-catalyzed enolate 
arylation led us to pursue the epoxide 4.5 addition-oxidation strategy that we had conceived as a 
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backup plan for the synthesis of β-aryl ketones 4.3 (see Scheme 4.1). This strategic pivot is 
analogous to the strategies used by Yang and co-workers in their work on the asymmetric 
fluorination of cyclic β-aryl ketones.171 They prepared their β-aryl ketone substrates primarily via 
a two-step procedure comprised of a BF3·OEt2-mediated reaction of an aryllithium reagent with 
cyclohexene oxide, followed by alcohol oxidation with Dess-Martin or Swern reagents (see 
Scheme 4.1).171,172  Only when this approach was not practical, such as in the synthesis of 
piperidone 4.18 (Figure 4.1) did they utilize [Pd]-enolate arylation chemistry, suggesting that 
they found the addition-oxidation sequence to be preferable, despite requiring an additional 
step.171  
In the event, we found that the addition of aryllithium reagents into cyclohexene or 
cyclopentene oxide (4.19, 4.20) in the presence of BF3·OEt2 readily delivered trans-β-aryl 
alcohols 4.21–4.27 (Figure 4.2a). The aryllithium reagents were generated from the 
corresponding aryl bromide and n-butyllithium (n-BuLi), although 2-lithiofuran (for 4.25) was 
prepared via C-H lithiation of furan with n-BuLi. We also investigated a modified procedure for 
lithium-halogen exchange to prepare 4.27 and found that the use of tert-BuLi instead of n-BuLi 
resulted in a marginally improved yield of 4.27 (54% → 64%). Finally, β-indolyl alcohol 4.28 
was prepared according to a literature procedure from indole (4.29) and cyclohexene oxide 
(4.19) via the generation of the indolyl-Grignard reagent (Figure 4.2b).173 
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Figure 4.2. Synthesis of β-aryl cyclohexanols and cyclopentanols; a) addition of Ar-[Li] reagents 
with BF3·OEt2;
172
 b) addition of an indolyl-Grignard reagent;
173 a) n = 2. b) n = 1; c) 
t-BuLi used for lithium-halogen exchange instead of n-BuLi  
With β-aryl alcohols 4.21–4.28 in hand, we turned our attention to the necessary 
oxidation (Figure 4.3). Pyridinium chlorochromate (PCC) reliably oxidized alcohols 4.21–4.23 to 
their respective ketones; however, the oxidation of heteroaromatic substrates 4.25 and 4.28 
produced complex mixtures containing degradation products, even when the reaction was cooled 
to 0 ˚C (Figure 4.3a). We next investigated the use of Dess-Martin periodinane for the oxidation 
of 4.25 and 4.28 and found that it delivered furyl- ketone 4.33 in 66% yield; however, indolyl- 
ketone 4.34 proved elusive because 4.28 rapidly degraded upon exposure to the reaction 
conditions (Figure 4.3b). Swern oxidation of 4.28 provided 4.34 in variable yields ranging from 
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20–70%, and this procedure was further complicated by the formation of α-oxidation byproduct 
4.35, which proved difficult to separate from 4.34 (Figure 4.3c).173 Gratifyingly, we found that 
treatment of  4.28 with 2-iodoxybenzoic acid (IBX) in refluxing ethyl acetate delivered 4.34 in 
>95% yield (Figure 4.3d).174 Additionally, these conditions proved to be effective for a variety of 
other substrates and, in this fashion, ketones 4.30–4.33 and 4.37–4.38 were prepared in >95% 
yield, while p-bromophenyl ketone 4.36 was generated in 87% yield (Figure 4.3d).    
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Figure 4.3. Oxidation of alcohols 4.21–4.28; a) oxidations with PCC; b) oxidations with DMP; 
c) Swern oxidation of 4.28; d) oxidations with IBX; α) yield of 4.36 = 87% 
4.2 DEVELOPMENT OF THE AZA-HOSOMI-SAKURAI SPIROCYCLIZATION REACTION 
Our initial effort to develop the cascade condensation/aza-Hosomi-Sakurai cyclization 
used conditions inspired by those used by Amorde and co-workers for their cascade cyclization 
reactions (Table 4.1, see Section 3.4.1).168,169 While we were pleased to find that the reaction of 
ketone 4.30 and amino-allylsilane 4.2 in the presence of trifluoroacetice acid (TFA)  delivered 
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the desired aza-spirocycle 4.39 as a single diastereomer (Entry 1, Table 4.1), the reaction was 
sluggish, taking roughly three days to go to completion gave only 50% yield. We reasoned that 
the addition of molecular sieves may accelerate the reaction by driving imine formation via the 
removal of water, but we found that they had only a modest effect on the reaction rate and yield 
(Entry 2). However, we found that heating to 50 °C substantially increased the reaction rate, 
leading to formation of 4.39 in 54–58% yield after 18–22 hours, along with significant quantities 
of protodesilylated 4.2 (Entries 3 and 4). In accord with our expectations that the formation of an 
iminium ion was necessary for cyclization to occur, we found that the reaction did not proceed in 
the absence of acid, even with heating over the course of four days (Entry 5). Finally, a 
promising result was obtained when we used acetic acid instead of TFA to promote the reaction: 
Compound 4.39 was obtained in 63% yield after only 24 hours (Entry 6). We also explored 
reaction conditions analogous to those used by Grieco and Fobare for intramolecular aza-
Hosomi-Sakurai cyclizations, but found that the reaction barely proceeded at room temperature, 
and upon heating generated a complex mixture of products from which no 4.39 was obtained 













Table 4.1. Optimization of aza-Hosomi-Sakurai cyclization: conditions in MeCN 
 
Entry Conditions Yield (%) 
1 TFA, MeCN, rt, 72 h 50 
2 TFA, MeCN, 3Å MS, rt, 66 h 58 
3 TFA, MeCN, 3Å MS, 50 °C, 22 h 54 
4 TFA, MeCN, 50 °C, 18 h 58 
5 MeCN, 3Å MS, 50 °C, 96 h 0 
6 AcOH, MeCN, 3Å MS, rt, 24 h 63 
7 TFA, H2O:THF (1:3), reflux 0 
 
To better understand and improve our cascade imine formation/cyclization reaction, we 
elected to optimize the individual steps separately, so we set out to identify conditions that would 
allow us to quantitatively form imine 4.40 (Table 4.2). Unfortunately, both magnesium sulfate in 
CH2Cl2 (Entry 1, Table 4.2) and molecular sieves in MeCN (Entry 2) produced marginal 
amounts of 4.40 relative to starting ketone 4.30 after extended reaction times, while the use of 
molecular sieves in a Soxhlet extractor with refluxing toluene (Entry 3) resulted in the formation 
of a complex mixture. To our surprise, the use of molecular sieves in methanol resulted in 
formation of cyclized product 4.39 and only trace amounts of 4.40 (Entry 4, c.f. Entry 5, Table 
4.1), as did use of the Lewis acid titanium (IV) isopropoxide (Ti(OiPr)4) in methanol (Entry 5). 
The results in Entries 4 and 5 suggest that quantitative imine formation may not be readily 
achieved, as it appears that while formation of the imine is sluggish, the subsequent attack of the 
pendant amino-allylsilane occurs rapidly under favorable conditions.  
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Table 4.2. Attempts to quantitatively form imine 4.40 
 
Entry Conditions Results 
1 MgSO4, CH2Cl2, rt, 96 h 5 : 1 4.30 : 4.40  
2 3Å MS, MeCN, 40 °C, 24 h 10 : 1 4.30 : 4.40 
3 3Å MS, PhMe, reflux 
(Soxhlet extractor) 
Decomposition 
4 3Å MS, MeOH, 18 h 4.39 observed 
5 AcOH, 3Å MS, rt, 24 h 4.39 observed 
 
The results in Tables 4.1 and 4.2 led us to our optimized conditions for the 
condensation/aza-Hosomi-Sakurai reaction: Namely, use of acetic acid in methanol with or 
without molecular sieves delivered 4.39 in a reproducible 67% yield and dr ≥ 20:1 after 24 hours 
(Table 4.3, entry 1). While titanium (IV) isopropoxide also gave promising results, we found the 
yields obtained from these reactions to be highly variable (Entry 2). Another titanium Lewis 
acid, TiCl4—which was used by Hosomi and Sakurai in their initial studies—resulted in a 
complex mixture with large quantities of protodesilylated 2 (Entry 3).149 We investigated other 
protic acids and again found that weak acids such as benzoic acid (Entry 4) catalyzed the 
reaction effectively, delivering the product 4.39 in 50% yield, whereas the strong acid p-
toluenesulfonic acid (p-TsOH) produced only trace amounts of 4.39 after 24 hours. Building on 
the realization that weak acids are effective promoters of the reaction, we investigated the use of 
pyridinium salts and found that pyridinium hydrochloride (Entry 6) likewise generated 4.39 in 
50% yield, while HF·pyridine resulted in the formation of a complex mixture. 
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Table 4.3. Optimized aza-Hosomi-Sakurai conditions, and additional screening; a) dr ≥ 20:1 in 
all instances where 4.39 was isolated b) comparable yields were obtained in the 
presence of 3 Å mol sieves 
 
Entry Conditions Yield of 4.39a 
1 AcOH, MeOH 67%b  
2 Ti(OiPr)4, MeOH 21–71%  
3 TiCl4, CH2Cl2, –78 ˚C
 decomposition 
4 BzOH, 3Å MS, MeOH 50% 
5 pTsOH, 3Å MS, MeOH trace 
6 Pyr·HCl, MeOH 50% 
7 HF·Pyr, MeCN decomposition 
 
With optimized conditions for the condendsation/aza-Hosomi-Sakurai reaction in hand, 
we set to applying them to β-aryl ketone substrates 4.18, 4.31–4.34, and 4.36–4.38.  We found 
that the reaction worked well with cyclohexanone and piperidone substrates, delivering [5.5] 









Table 4.4. Synthesis of aza-spirocycles 4.41–4.46; a) dr ≥ 20:1  
 
When cyclopentanone substrates 4.37 and 4.38 were subjected to our optimized 
conditions, we found that the reaction proceeded slowly, requiring 3-4 days to generate products 
4.47 and 4.48 in 59% and 45% yield, respectively (Figure 4.4a and 4.4b, entry 1). This decrease 
in reaction rate relative to cyclohexanone substrates may be explained by unfavorable torsional 
interactions generated during hemiaminal formation, and is consistent with general trends in 
which the rate of electrophilic addition to cyclopentanone substrates is slower than that of 
cyclohexanone substrates.175 The addition of molecular sieves did not appreciably increase the 
reaction rate (Figure 4.4a, entry 2); however, heating the reaction (Figure 4.4a, entries 3 and 4; 
Figure 4.4b, entry 2) resulted in reduced reaction times with comparable yields. While 
cyclizations with β-aryl cyclohexanones produced the cis isomer in diastereomeric ratios > 20:1, 
the aryl cyclopentanones tested gave diastereomeric ratios in the range of 2:1–3:1 (Figure 2b, 
entry 2). A similar erosion in diastereoselectivity has been observed in the proline-catalyzed 




Figure 4.4. Condensation/aza-Hosomi-Sakurai cyclization conditions for cyclopentanone 
substrates 4.37 (a) and 4.38 (b) 
Finally, we briefly investigated the use of the aza-Hosomi-Sakurai cyclization on the nor-
aryl ketone substrates cyclohexanone (4.12) and Boc-piperidone 4.17 (Scheme 4.3). In both 
instances we found that the reaction worked well, delivering spirocyclic piperidine 4.49 and bis-
piperidine 4.50 in 75% and 87% yield, respectively. 
 
 
Scheme 4.3. Synthesis of nor-aryl aza-spirocycles 4.49 and 4.50 
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4.3 ELABORATION AND DIVERSIFICATION OF SPIROCYCLIC SCAFFOLDS 
4.3.1. Diversification Through N-Functionalizations  
The piperidine N-H of aza-spirocycles 4.39 and 4.41–4.48 provides a convenient 
functional handle for additional scaffold elaboration. Despite being a neopentyl center, we found 
that the N-H of prototypical scaffold 4.39 readily underwent N-acetylation, reductive N-
methylation, and N-carbamoylation reactions to deliver N-functionalized derivatives 4.49, 4.50, 
and 4.51 respectively (Scheme 4.3). These reactions with 4.39 serve as examples for N-
functionalization reactions that could be potentially performed on any of our spirocyclic 
scaffolds for the synthesis of a whole library of N-functionalized aza-spirocycle derivatives. 
 
Scheme 4.4. N-Functionalization of spirocyclic scaffold 4.39 
We also performed sequential N-functionalization reactions on our bis-piperidine scaffold 
4.46 via the sequence shown in Scheme 4.5. Alkylation of the neopentyl N-H with benzyl 
bromide proceeded in 69% yield, followed by a quantitative Boc-deprotection to deliver diamine 
4.54. Reductive methylation of 4.54 with formaldehyde and sodium cyanoborohydride furnished 




Scheme 4.5. N-functionalization reactions of bis-piperidine scaffold 4.46 
Finally, we investigated N-functionalization reactions on the nor-aryl scaffolds 4.49 and 
4.50. Conversion of 4.49 to its N-acetyl derivative 4.56 proceeded in 78% yield; a one-pot 
method for preparing 4.56 from cyclohexanone (4.12), amino-allylsilane 4.2, and acetyl chloride 
was also achieved, albeit in only 29% yield (Scheme 4.6). We also attempted to elaborate bis-
piperidine scaffold 4.50 to the caged compound 4.58 by bridging the two amines through 
alkylation of 4.57 with 1,2-dibromoethane, but these reactions only resulted in returned starting 
material and uncharacterized degradation products (Scheme 4.7).  
 





Scheme 4.7. Attempted synthesis of caged tricycle 4.58  
4.3.2. Diversification Through Suzuki Couplings  
Cross-coupling reactions are robust methods to generate diversity from a common 
intermediate by utilizing different coupling partners. Accordingly, we investigated the feasibility 
of using halo-phenyl scaffold 4.42 and later 4.43 as substrates for Suzuki coupling reactions.  In 
the event, aryl chloride 4.42 underwent coupling with boronic acid 4.59 in the presence of 
Pd(tBu3P)2 to deliver the desired product 4.60 in 26% yield, along with 52% yield of a 
Suzuki/Buchwald-Hartwig coupling product with the tentative structure 4.61 (Scheme 4.8). We 
attempted to minimize the formation of this side product through screening catalysts and 
solvents, but invariably obtained either returned starting material or a mixture of 4.60 and 4.61.   
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Scheme 4.8. Troublesome Suzuki coupling of aryl chloride scaffold 4.42  
We sought to obviate this side reaction through protection of the piperidine nitrogen of 
4.42. Accordingly, Cbz-protection of 4.42 gave 4.62, which underwent Suzuki coupling with 
4.59 to deliver biaryl derivative 4.63 in 58% yield (Scheme 4.9). Unfortunately, the removal of 
the Cbz protecting group of 4.63 proved to be problematic. We anticipated that traditional 
methods of Cbz-deprotection, such as metal-catalyzed hydrogenolysis conditions, would be 
incompatible with the olefinic group of 4.63, so we attempted to apply Coleman and Shah’s 
conditions for chemoselective carbamate cleavage using triethylsilane and a palladium 
catalyst.177 After some optimization, we were able to obtain 4.60 in 59% yield (82% BRSM) 
after 72 hours. 
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Scheme 4.9. Protection, Suzuki coupling, and deprotection of 4.42 
The long reaction times, mediocre yields, and the need for discreet protection and 
deprotection steps all greatly diminished the utility of a Suzuki coupling reaction with aryl 
chloride 4.42. Accordingly, we prepared aryl bromide 4.43 to evaluate its performance as a 
Suzuki coupling partner. In retrospect, we should have investigated 4.43 sooner, but we were 
hesitant to pursue this strategy due to anticipated problems with the initial organolithium 
formation and epoxide addition (see Figure 4.2). In the event, we found that 4.43 readily 
underwent Suzuki coupling with 4.59 to deliver p-methoxy biphenyl 4.60 in 71% yield with no 
Buchwald-Hartwig side-products observed, and could also be coupled with 4.65 to prepare p-
fluoro derivative 4.65 in >95% yield.178  
  
Scheme 4.10. Suzuki coupling of aryl bromide scaffold 4.43 
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4.3.3. Hydroboration-Oxidation and Ozonolysis  
In dreaming up new ways to diversify our central scaffold, we realized that protocols for 
the addition of polar functional groups would be desirable as our core scaffold is relatively 
nonpolar. The polarity of a molecule has a large impact on its behavior in biological systems, 
especially with regard to membrane permeability, and the ability to readily modulate the polarity 
of a given set of analogs is highly desirable for the medicinal chemist.179 To this end, we 
developed protocols for the hydroboration-oxidation and ozonolysis of the olefin functionality on 
our scaffold. 
Our work on the hydroboration-oxidation of prototypical scaffold 4.39 is summarized in 
Scheme 4.10. Using conditions that were adapted from the work of Rejzek and co-workers, we 
found that treatment of 4.39 with borane-dimethyl sulfide at –78 ˚C followed by the addition of 
sodium hydroxide and hydrogen peroxide delivered 4.66 as a single diastereomer in 62% 
yield.180 Notably, Rejzek found that running the reaction at –78 ˚C resulted in a highly 
diastereoselective hydroboration, which was attributed to an initial coordination of the borane 
reagent to the piperidine nitrogen atom followed by an intramolecular hydroboration. We also 
investigated the use of the bulky borane reagent 9-BBN to see what effect, if any, it would have 
on the diastereoselectivity of the hydroboration. Interestingly, we found that using 9-BBN 
resulted in exclusive formation of the other diastereomer 4.67. Unfortunately, we were not able 




Scheme 4.11. Hydroboration-oxidation of 4.39 
Finally, we secured conditions for selective ozonolysis of the olefin moiety. To obviate 
concerns regarding amine oxidation, we used N-acetyl derivative 4.51, which readily underwent 
ozonolysis to deliver spiro-piperidone 4.69 in 69% yield. 
 
 
Scheme 4.12. Ozonolysis of 4.51 
4.3.4. Pictet-Spengler Cyclizations 
The reactions discussed in Sections 4.3.1–4.3.3 are all robust methods for introducing 
diverse substituents to the central spirocyclic scaffold; however, the only method for introducing 
scaffold diversity has been the use of different β-aryl ketone substrates in the aza-Hosomi-
Sakurai cyclization. Thus, we were interested in developing a method for late-stage scaffold 
diversification, analogous to the “pair” stage of the “build-couple-pair” strategy (see Section 
3.1.1). We noticed that the piperidine N-H and arene moieties of 4.39 and 4.41–4.48 are spatially 
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oriented such that the incorporation of a bridging methylene unit between the two groups 
appeared to be a reasonable strategy for scaffold diversification. We envisioned that we could 
achieve this transformation via the use of an intramolecular Pictet-Spengler cyclization. 
Our initial work in this area interrogated the use of phenyl scaffold 4.39 as a cyclization 
substrate. We explored several conditions adapted from literature reports on Pictet-Spengler 
cyclizations of pheylalanine derivatives, such as aqueous formaldehyde in formic acid or acetic 
acid/ethanol mixtures. We invariably obtained either returned starting material 4.39 or a complex 
mixture of degradation products with no trace of the desired tetracycle 4.70 (Equation 4.1).181 
However, we found that the use of the more electron-rich m-anisole derivative 4.41 as a substrate 
for the Pictet-Spengler reaction resulted in clean conversion to tetrahydroisoquinoline (THIQ) 
scaffold 4.71 in 73% yield (Equation 4.2). Furan substrate 4.44 likewise underwent cyclization 
under similar conditions to deliver the tetrahydrofuropyridine scaffold 4.72 in 75% yield 




Identification of reliable conditions for cyclization of the [4.5] spirocycle 4.48 to THIQ 
4.73 required some experimentation, as shown in Table 4.5. Subjecting 4.48 to the same 
conditions (10 eq CH2O, 2 eq AcOH, EtOH, reflux) identified for the synthesis of 4.71 and 4.72 
resulted in an inseparable mixture (3:1) of o- and p- cyclization products 4.73 and 4.74 in 76% 
combined yield (Table 4.5, Entry 1). On the other hand, use of Cook’s neutral aprotic Pictet-
Spengler conditions delivered only returned starting material (Entry 2).182 However, the use of 
formic acid as a solvent resulted in exclusive formation of the p- product 4.73 (Entry 3), which 
after some optimization was produced in 92% yield (Entry 4). Interestingly, a similar trend was 
observed in the Pictet-Spengler cyclization of dopamine and acetaldehyde to form salsolinol, the 
product of p- cyclization, and isosalsolinol, the product of o- cyclization. In strongly acidic 
media salsolinol was formed exclusively, while in weakly acidic and neutral media a mixture of 
salsolinol and isosalsolinol was produced.183 This phenomenon was studied computationally by 
Almodovar and co-workers, who concluded that the increase in ortho-selectivity as neutral pH is 





cyclization.183 While the formation of such a species is not possible in our system, the parallel 
trend is intriguing.  
Table 4.5. Optimization of Pictet Spengler cyclization to form 4.70 
 
Entry Conditions Yield  
1 CH2O (aq), AcOH, EtOH, reflux 76% (3:1, 4.73:4.74)  
2 (CH2O)n, PhMe, reflux  RSM  
3 CH2O (aq), HCO2H, 90 ˚C
 55% (4.73) 
4 CH2O (aq), HCO2H, 50 ˚C 92% (4.73) 
 
Finally, we identified conditions for the Pictet-Spengler cyclization of indolic spirocycle 
4.45 to prepare tetrahydro-β-carboline scaffold 4.73 (Scheme 4.13). Subjecting 4.45 to our 
“standard” conditions with aqueous formaldehyde resulted in the formation of 4.75 in 23% yield, 
along with 14% of a compound that has been tentatively assigned the structure 4.76 on the basis 
of 1H NMR (Scheme 4.13, top). The use of paraformaldehyde in ths reaction delivered 4.75 in 
45% yield, along with a different hydroxy-methylene adduct with the tentative structure of 4.77 
in 19% yield (Scheme 4.13, middle). However, by using Cook’s neutral aprotic Pictet-Spengler 




Scheme 4.13. Synthesis of tetrahydro-β-carboline scaffold 4.75  
4.4. BIOLOGICAL TESTING  
To query the potential biological relevance of our spirocyclic β-phenethylamine 
compound set, we submitted select compounds to the Psychoactive Drug Screening Program for 
a broad screen against common CNS receptors. All of the compounds were found to be potent 
inhibitors of the Sigma 1 (Sig1R) and/or Sigma 2 (Sig2R)/TMEM97 receptors, especially Pictet-
Spengler products 4.71 and 4.75, which displayed 8 nM and 45 nM Sig1R Ki values (Table 4.6). 
The amino alcohol 4.66 was found to be selective for the (Sig2R)/TMEM97 receptor, displaying 
a 452 nM Ki value and 5-fold selectivity for Sig2R/TMEM97 over Sig1R. Aza-bicyclic 
derivatives 4.45, 4.54, and 4.66 appear to be selective for the sigma receptors, as these were the 
only receptors which they inhibited with sub-micromolar potency, while THIQ 4.71 also 
inhibited the alpha-2A adrenergic receptor (Ki=531 nM), and tetrahydro-β-carboline 4.75 proved 
to be a promiscuous binder, exhibiting mid-nanomolar (100 – 500 nM) inhibition of the 
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dopamine transporter, the histamine H1 receptor, and several serotonin and adrenergic receptor 
subtypes. 
 
Table 4.6. Activity of select compounds at the Sigma 1 (Sig1R) and Sigma 2 (Sig2R)/TMEM97 
receptors 




4.45 1446 463 
4.54 542 502 
4.66 2257 452 
4.71 8 152 
4.75 45 308 
 
Unfortunately, we later identified a contaminant that may have skewed the results of the 
PDSP screen for compound 4.71. Specifically, we found that over the course of its storage at 4 
˚C, roughly 50% of 4.71 had been oxidized to benzamide 4.78 (Scheme 4.14). In 
deuterochloroform this oxidation process was more rapid, with approximately 50% conversion to 
4.78 occurring when 4.71 was left overnight in CDCl3 at room temperature. We found that we 
could inhibit this oxidation via the addition of triethylamine to the solution of 4.71 in CDCl3, 
suggesting that the oxidation is acid-catalyzed. Interestingly, no oxidation products were 
observed for the analogous cyclopentyl-THIQ 4.73 or tetrahydro-β-carboline 4.75 after 
prolonged storage, while trace amounts may have been observed in 1H NMR spectra of furan 
derivative 4.72. Unfortunately, the PDSP screen of 4.71 occurred after it had been in storage for 
several months, and we do not know the extent to which 4.78 was present at the time of the 
assay. While this certainly calls the PDSP results for 4.71 into question, a favorable 
interpretation would be that 4.71 is probably a more potent Sig1R inhibitor than indicated, as the 
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proposed pharmacophore model for the Sigma 1 receptor requires the presence of a basic amine 
group, so it seems likely that any 4.78 present in the assay probably did not contribute 
significantly to Sig1R inhibition.79  
 
 
Scheme 4.14. Spontaneous oxidation of 4.71 to benzamide 4.78 
4.5. CONCLUDING REMARKS 
In summary, we have developed a DOS methodology for the preparation and 
diversification of spirocyclic β-phenethylamines, THIQs and tetrahydro-β-carbolines. Key to this 
development was the optimization of a tandem condensation/aza-Hosomi-Sakurai spiro-
cyclization process that proceeds in good yield and excellent diastereoselectivity with cyclohexyl 
substrates under exceedingly mild conditions. We found that cyclopentyl substrates could also 
participate in this process to generate [4.5]-spirocyclic scaffolds, albeit in decreased yield and 
diastereoselectivity. We also demonstrated several strategies for subsequent elaboration of our 
spirocyclic β-phenethylamine scaffolds via N-functionalization, Suzuki coupling, olefin 
manipulation, and Pictet-Spengler cyclization. Finally, we submitted several compounds for a 
CNS receptor screen, and found them to be potent inhibitors of the Sigma 1 and Sigma 
2/TMEM97 receptors. It is our hope that this work may lead to the development of new drug 
leads or biochemical tool compounds built around or inspired by our novel, bioactive chemical 
scaffolds.   
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THE TOTAL SYNTHESIS OF EXOTINES A & B 
Chapter 5. The Isolation and Biosynthesis of Exotines A & B, the Trauner 
Synthesis of Exotine B, and [4 + 3] Cycloaddition Reactions for the Synthesis 
of Cyclohepta[b]indoles 
5.1 ISOLATION AND CHARACTERIZATION OF EXOTINES A & B 
Exotine A (5.1) and B (5.2) were isolated from the roots of Murraya exotica by the Jiang 
and coworkers in 2015 (Figure 5.1).184 The core structure of these novel alkaloids is comprised 
of isopentenyl-substituted indole (atoms no. 1–14, Liu et al. numbering system) and coumarin  
(atoms no. 1’–14’)  units, which combine to form the unique coumarin-cyclohepta[b]indole ring 
system of exotine A and B, heretofore unobserved among known natural products.184,185 The 
structures of 5.1 and 5.2 were elucidated via 2D-NMR experiments and their absolute 
stereochemistry was confirmed by single-crystal X ray diffraction using anomalous dispersion.184 
 
 
Figure 5.1. Structures of exotines A (5.1) and B (5.2) isolated from Murraya exotica (Jiang et al. 
numbering system)184 
Plants of the genus Murraya are known for being rich sources of bioactive 
coumarin,186,187 carbazole,188–190 and polyphenol191 natural products, some of which have shown 
promise as anti-inflammatory186,192, anti-microbial,193,194 anti-diabetic,188 and hepatoprotective191 
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agents. M. exotica, commonly known as the orange jasmine or Chinese box plant, is an 
ornamental shrub that grows widely throughout southern China. The extracts of the roots and 
leaves of M. exotica have a long history of use by people in this region for the treatment of 
rheumatism, cough, fever, and as anti-infective and anti-nociceptive agents.184,186,192 
Accordingly, exotine A (5.1) and B (5.2) were assayed for biological activity and were found to 
inhibit lipopolysaccharide-induced nitric oxide (NO) production in BV2 microglial cells (IC50 = 
9.2 and 39.9 µM, respectively).184 NO is a prolific signaling molecule that plays a role in many 
physiological processes,  and aberrant NO production has been linked to pathologies such as 
migraine, shock, dermatitis, necrosis, and tumor growth and metastasis.195–197 Thus, compounds 
that inhibit NO production such as 5.1 and 5.2 represent potential new leads for the treatment of 
the aforementioned disease states.195–197  
5.1.1. Jiang’s Proposed Biosynthesis of Exotines A and B 
Jiang et al. proposed a biosynthesis of exotine A (5.1) and B (5.2), which can be seen in 
Scheme 5.1.184 They proposed that 3-prenylindole (5.3) is oxidized to the conjugated indolenine 
5.4, which then undergoes a Diels-Alder cycloaddition with coumarin-dienes trans-
dehydroosthol (5.5) or gleinadiene (5.6), both of which have been isolated from M. exotica 
extracts, to generate spiro-indolenine adduct 5.7.186 Subsequent 1,2-alkyl migration  furnishes 
the natural products 5.1 and 5.2.  
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Scheme 5.1. Jiang’s proposed biosynthesis of exotine A (5.1) and B (5.2)184  
Jiang’s biosynthetic hypothesis is analogous to the proposed biosynthesis of the natural 
products murrapanine (5.9) and yuehchukene (5.10, Scheme 5.2).198,199 The cytotoxic indole-
napthoquinone alkaloid murrapanine (5.9), which was isolated from M. paniculata by Wu and 
co-workers, may arise biosynthetically from a Diels-Alder cycloaddition between oxidized 3-
prenylindole tautomer 5.11 and quinone 5.12. Indeed, Wu demonstrated the feasibility of such a 
transformation in their concise synthesis of 5.9 (Scheme 5.2, top).198  
 
Scheme 5.2. Putative biosynthesis of murrapanine (5.9) 
The dimeric prenyl-indole alkaloid yuehchukene (5.10) was isolated as a racemic mixture 
from  M. paniculata by Kong and co-workers, who found that it exhibited potent anti-
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implantation activity.199 A biosynthetic proposal and concomitant biomimetic synthesis of 
yuehchukene (5.10) was advanced by Cheng and co-workers, who reasoned that 5.10 could arise 
from a Diels-Alder cycloaddition of 5.11 with its protonated form 5.13 to generate an 
intermediate 5.14 that could then undergo electrophilic addition at indole C(2) to form the 
cyclopentyl ring and thus furnish the natural product 5.10.200 In their synthesis of yuehchukene 
(5.10) Cheng et al. found that when 5.11 was heated in benzene containing trace amounts of 
trifluoroacetic acid (TFA), it underwent the desired [4+2]/cyclization cascade to deliver 5.10 in 
10% yield.200 The subsequent work of Wenkert201,202 and Sheu203,204 further refined and 
elaborated upon the biomimetic synthesis of yuehchukene (5.10) developed by Cheng.200 
 
 
Scheme 5.3. Proposed biosynthesis of yuehchukene (5.10) 
5.2. THE TRAUNER SYNTHESIS OF EXOTINE B 
In 2018, Trauner and coworkers reported the first total synthesis of (±)-exotine B (5.2, 
Scheme 5.4).205 The researchers initially undertook exploratory studies to investigate the 
feasibility of a biomimetic synthesis of 5.2 via a Diels-Alder reaction between 5.4 and 
gleinadiene (5.6, see Scheme 5.1). However, this approach was not successful. Their subsequent 
retrosynthetic analysis hinged on a late-stage Fischer indole synthesis/ring expansion sequence to 
convert aldehyde 5.15 to the natural product 5.2 (Scheme 5.3). They envisioned arriving at 5.15 
via a Diels-Alder reaction between gleinadiene (5.6) and enal 5.16, where R is a group which can 
be elaborated to the isobutenyl moiety of the natural product.  
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Scheme 5.4. Trauner’s retrosynthetic analysis of exotine B (5.2) 
In order to investigate the feasibility of this route, Trauner and co-workers first accessed 
gleinadiene (5.6), which had previously been prepared by Reisch and co-workers from 5-
methoxy-7-hydroxycoumarin in four steps and 19% yield.206 In the event, they found that 5,7-
dimethoxycoumarin (5.17) readily underwent regioselective iodination with N-iodosuccinimide 
in the presence of catalytic TFA to furnish iodocoumarin 5.18 in 94% yield (Scheme 5.5).205 
Subsequent Suzuki coupling of 5.18 with boronic ester 5.19 using Buchwald’s conditions 
delivered gleinadiene (5.6) in 94% yield. Thus, 5.6 was accessed in two steps and 88% overall 




Scheme 5.5. Synthesis of gleinadiene (5.6) 
With gleinadiene (5.6) in hand, Trauner and co-workers investigated its participation in 
Diels-Alder reactions, initially with maleic anhydride (Scheme 5.6).205 Treatment of 5.6 with 
maleic anhydride and phenyldiethylamine in dichloromethane delivered 5.20 as a single 
diastereomer in 75% isolated yield, although the authors found that greater overall yields were 
obtained when they carried this product forward without purification. Regioselective ring-
opening (>10:1) of the anhydride 5.20 was achieved via the use of isopropylamine in DMF, 
followed by methylation of the carboxylate to deliver amido-ester 5.21 in 78% yield over three 
steps. Unfortunately, attempts to perform a chemoselective reduction of the ester or amide 




Scheme 5.6. Diels-Alder reaction of 5.6 with maleic anhydride, and attempted reduction of 
amido-ester 5.21 
Anxious to query the feasibility of a Fischer indole/ring expansion strategy for the 
synthesis of the exotine scaffold, they then pursued studies with model substrate 5.22 which they 
prepared via a Diels-Alder reaction of 5.6 with acrolein (Scheme 5.7).205 They found that 5.22 
underwent the desired Fischer indole/ring expansion reaction upon treatment with 
phenyhydrazine and trifluoroacetic acid; however, these conditions also promoted an olefin 
isomerization to furnish the conjugated cyclohepta[b]indole 5.23. In an attempt to mask the 
olefin of 5.22 the authors converted it to the epoxide 5.24. Unfortunately, 5.24 was not stable to 
Fischer indolization conditions, and a complex mixture of decomposition products was obtained.  
From these studies the authors concluded that their Fischer indolization/ring expansion strategy 
was not feasible, due to the high propensity for the olefin to isomerize under the acidic 




Scheme 5.7. Fischer indole syntheses with model substrate 5.22 
Thus thwarted, Trauner and co-workers turned their attention to a new strategy for the 
synthesis of exotine B (5.2), one which utilized Wu’s gallium(III) Lewis acid-catalyzed three-
component (3C) cyclohepta[b]indole synthesis (see Section 5.3 for further discussion) to 
construct the carbon framework of 5.2.207 This strategy was realized via the union of gleinadiene 
(5.6), indole (5.25), and thioether-aldehyde 5.26 in the presence of catalytic Ga(III) triflate to 
produce coumarin-cyclohepta[b]indole scaffold 5.27 and epi-5.27 as a mixture (2:1) of 
diastereomers in 35% combined yield, which could be separated via recrystallization (Scheme 
5.8).205 The decision to use the masked enal 5.26 followed unsuccessful attempts to use prenal as 
a substrate for the 3C reaction, which would have resulted in the direct formation of their target 
5.2 (see Chapter 6 for further discussion). Thus, all that remained in their synthesis of 5.2 was 
the conversion of the pendant thioether moiety in 5.27 to the requisite isobutenyl group. This was 
accomplished via a two-step sequence of oxidation and elimination to generate terminal olefin 
5.28 (Scheme 5.8). Isomerization of the pentant olefin in 5.28 to exotine B (5.2) proved to be 
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challenging, due to competing isomerization of the cycloheptane olefin. After some 
experimentation, they found that pre-activation of Crabtree’s catalyst with hydrogen gas 
followed by purging the system with argon and subsequent addition of 5.22 delivered a mixture 
(1:1) of exotine B (5.2) and isomer 5.23, which were separated via high-performance liquid 




Scheme 5.8. Completion of the synthesis of exotine B (5.2) using Wu’s Ga(III) 
cyclohepta[b]indole synthesis  
Having thus completed their synthesis of 5.2 in six steps LLS (8 total) and 6% overall 
yield, Trauner and co-workers also offered an alternate biosynthetic proposal for the formation of 
exotines A (5.1) and B (5.2) (Scheme 5.9, c.f. Scheme 5.1).205 Namely, they proposed that 5.1 
and 5.2 arise from a [4 + 3] cycloaddition reaction between allylindolyl cation 5.13 and 
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coumarin-diene 5.5 or 5.6. This alternate biosynthetic hypothesis is based on the proposed 
mechanism for the Ga(III) 3C cyclohepta[b]indole synthesis which, according to DFT calculations 
performed by Wu and co-workers, likely proceeds via a concerted [4 + 3] cycloaddition reaction 
(see Section 5.3).207  
 
Scheme 5.9. Alternate biosynthetic proposal advanced by Trauner 
 
5.3. [4 + 3] CYCLOADDITION REACTIONS FOR THE SYNTHESIS OF CYCLOHEPTA[B]INDOLES 
The cyclohepta[b]indole ring system (Figure 5.2, in red) can be found in numerous 
natural products (Figure 5.2a) and pharmaceutical research compounds (Figure 5.2b) that display 
potent and diverse bioactivity.185 For instance, the natural product actinophyllic acid (5.29), 
isolated from Alstonia actinophylla, is a potent carboxypeptidase U (CPU) inhibitor which has 
been the subject of total synthesis by the Martin lab (see Section 5.3.2) as well as the Overman 
lab.208,209 The bis-indole pigment arcyriacyanin A (5.30), isolated from Arcyria nutans, is a 
protein kinase C and protein tyrosine kinase inhibitor and has been prepared twice via total 
synthesis.185  Ambiguine D isonitrile (5.31) is a representative member of the large ambiguine 
(ambiguines A–Q) family of natural products, many of which (ambiguines D–G and I–Q) 
contain a cyclohepta[b]indole ring system.183,208 The ambiguines are isolated from the algae 
Fischerella ambigua and display diverse antifungal and antimicrobial activity, and in early 2019 
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the first total synthesis of an ambiguine alkaloid (ambiguine P) was reported by the Sarpong 
group.210,211 Ervatamine (5.32) is the prototypical member of another large family of alkaloids 
known as the ervitsines and ervatamines, which contain many members having a cyloheptaindole 
skeleton.185 Ervatamine (5.32) itself is a sodium channel blocker, and other members of this 
family display anti-cholinergic and anti-inflammatory activity; several ervatamines have been 
prepared via total synthesis by the Bosch lab.185,212–214 Turning from natural products to 
pharmaceutical ligands, SIRT1-inhibitor IV (5.33) is a cyclohepta[b]indole-carboxamide sirtuin 
histone deacetylase (HDAC) SIRT1 inhibitor developed by Napper and co-workers.215 HDAC 
inhibitors are a relatively new class of drugs which have shown  great promise as 
chemotherapeutic agents for the treatment of various forms of cancer.216 Finally, the 
homomorphinan-cyclohepta[b]indole 5.34 is an opioid receptor ligand developed by Fujii and 
co-workers that displays potent and selective inhibition of the 𝛿-opioid receptor.217  
 
Figure 5.2. Representative natural products (a) and pharmaceutical compounds (b) with a 
cyclohepta[b]indole motif (in red) 
Owing their interesting structures and biological activities, many methods have been 
developed for the synthesis of cyclohepta[b]indole derivatives. Classical approaches to 
cyclohepta[b]indoles have often utilized the venerable Fischer indole synthesis; however, this 
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approach has the limitation of not working well for cyclohepta[b]indoles with unsymmetrical 
functionalization of the cycloheptane ring, because regioisomeric product mixtures are often 
obtained.185 Accordingly, there have been many recent reports in the literature of methods for 
preparing the cyclohepta[b]indole ring system, several of which utilize (formal) [4 + 3] 
cycloaddition reactions (Figure 5.3, see ref. 183 for additional examples of recent 
cyclohepta[b]indole synthesis methods).185 In 2013 Tang and coworkers developed a one-pot 
platinum-catalyzed formal [4 + 3] cycloaddition for the synthesis of bridged 
cyclohepta[b]indoles 5.37 from alkynyl anilines 5.35 and siloxy-dienes 5.36 via the formation of 
a vinyl Fisher carbene (Figure 5.3a). A nearly identical method was published by the Iwasawa 
lab in the same year.218,219 Li and coworkers developed a multi-step, one-pot 
hydroamination/cycloaddition cascade sequence in which N-tosylaniline 5.38 undergoes a silver 
triflate-promoted hydroamination to form 5.39, which is subsequently treated with zinc chloride 
and a diene 5.40 to form disubstituted cyclohepta[b]indoles with the general structure 5.41 
(Figure 5.3b).220 Finally, Hsung and coworkers developed a multi-step sequence for the synthesis 
of dihydrofuran-bridged cyclohepta[b]indoles 5.44 via a putative [4 + 3] cycloaddition between 
furan and an oxyallyl cation 5.43 generated from allenamide 5.42 (Figure 5.3c).221 The resultant 
cycloadduct 5.44 then underwent an intramolecular Grignard addition/dehydration sequence to 
form the indole moiety of 5.45 (Figure 5.3c).221 The use of oxyallyl cations such as 5.43 
generated from allenamides—pioneered by Hsung in earlier studies—as 3-pi components in [4 + 
3] cycloaddition reactions is one of the few examples of nitrogen-stabilized allyl cations being 
used in such reactions, and provides important precedent for the development of Wu’s 
cyclohepta[b]indole methodology (see Section 5.3.1).222–224 Clearly, the use of (formal) [4 + 3] 
cycloaddition reactions is a powerful strategy for the synthesis of substituted 
cyclohepta[b]indoles, as demonstrated by the examples in Figure 5.3 as well as by the Ga(III) 
methodology developed by Wu, which will be  discussed in detail in the following section.  
 121 
 
Figure 5.3. Methods for synthesizing cylcohepta[b]indoles via [4 + 3] cycloaddition reactions: a) 
vinyl Fischer carbene approach developed by Tang.218 b) hydroamination approach 
developed by Li.220 c) allenamide approach developed by Hsung.221 
5.3.1. Wu’s Gallium(III)-Catalyzed Three-Component [4 + 3] Cyclohepta[b]indole 
Synthesis 
In 2012, the Wu group published a landmark study on the use of a [4 + 3] cycloaddition 
reaction for the synthesis of cyclohepta[b]indoles. This was the first reported instance of a [4 + 
3] reaction being used to prepare the cyclohepta[b]indole skeleton, a strategy which was 
subsequently utilized by numerous groups (see preceding section).207 The general features of the 
reaction can be seen in Scheme 5.10: An indole 5.46, and a ketone or aldehyde 5.47 are 
condensed in the presence of a diene 5.48 and an acid catalyst, such as a Ga(III) Lewis acid to 
 122 
form an indolyl cation 5.49, which subsequently undergoes [4 + 3] cycloaddition with diene 5.48 
to generate the substituted cycloheptaindole scaffold 5.50.   
 
 
Scheme 5.10. General features of Wu’s three-component [4 + 3] cyclohepta[b]indole synthesis 
 In addition to the precedent provided by the work of Hsung and co-workers (see Figure 
5.3c), a key inspiration for Wu’s methodology comes from the work of Winne and Pattenden, 
who discovered in their approach to the diterpene natural product rameswaralide an acid-
promoted intramolecular [4 + 3] cycloaddition of furan 5.50 to generate tetracyclic compound 
5.51 as a single diastereomer in quantitative yield (Equation 5.1).225 Winne and co-workers went 
on to develop an intermolecular variant of this reaction, in which 2-furyl alcohols 5.53 are 
reacted with dienic components 5.54 in the presence of titanium(IV)chloride (TiCl4) to generate 
cycloheptyl-furans with the general structure 5.55 (Equation 5.2).226 The reaction is thought to 
proceed via the initial ionization of the 2-furyl alcohol to generate a stabilized 2-oxyallyl cation, 
which subsequently undergoes a [4 + 3] cycloaddition with the pendant vinyl butanolide group, 
based on DFT calculations performed by Winne and co-workers.226 Their calculations indicate 
that both stepwise and concerted [4 + 3] processes are viable, but the stepwise [4 + 3] pathway 





To identify conditions for their three-component [4 + 3] cycloaddition Wu and co-
workers screened a variety of Lewis and Brønsted acids with model substrates 5.56, 5.57, and 
5.58, selected examples of which are shown in Table 5.1. They found that the gallium(III) salts 
gallium(III)bromide (GaBr3) and gallium(III)triflate (Ga(OTf)3) were excellent promoters of the 
reaction, delivering cyclohepta[b]indole 5.59 in 94% and 91% yield, respectively (Table 5.1, 
entries 1 and 2). Another group 13 Lewis acid, indium(III)bromide (InBr3) likewise catalyzed the 
reaction, delivering 5.59 in 92% yield; however, the use of indium(III)triflate resulted in only 
54% yield of 5.59, which the authors note was accompanied by substantial quantities of 
degradation products (Table 5.1, entries 3 and 4). Gallium(III)chloride and indium(III)chloride 
were not effective catalysts for this process, delivering only the addition product of 5.56 and 5.57 
with no trace of cyclohepta[b]indole 5.59. They also briefly explored the use of Brønsted acids 
p-toluenesulfonic acid (p-TsOH) and trifluoromethanesulfonic acid (TfOH) and found that p-
TsOH resulted in the slow formation of 5.59, delivering only 52% yield after two hours, while 
TfOH gave 5.59 in 83% yield after 2 hours (Table 5.1, entries 5 and 6). Under all of the 
conditions tested, 5.59 and its trans- isomer were formed as a mixture (3:1–5:1) of 




promoted by the Ga(III) salts in Entries 1 and 2 (Table 5.1), and so they embarked on an 
exploration of the substrate scope of their newly developed reaction with these catalysts.   
Table 5.1. Screening of acid catalysts for the synthesis of cyclohepta[b]indole 5.59 
 
Entry Catalyst (10 mol %) Yield  
1 GaBr3 94%  
2 Ga(OTf)3 91%  
3 InBr3 92% 
4 In(OTf)3 54% 
5 p-TsOH 52%  
6 TfOH 83% 
 
The incorporation of electron-donating and electron-withdrawing indolic substituents in 
substrate 5.60 was found to be well-tolerated in its reaction with acetone (5.61) and 
cyclopentadiene (5.62) to deliver 5'-substituted cyclohepta[b]indoles 5.63 in 73–87% yield 
(Figure 5.4a).  The scope of the carbonyl component was also also investigated, and it was found 
that (hetero)aromatic and aliphatic aldehydes 5.64 participated in the reaction with indole (5.64) 
and 5.62 to furnish 5.66 as a mixture of diastereomers in 75–91% yield (Figure 5.4b). The 
diastereoselectivity of the reaction was highly dependent on the nature of the aldehyde 
component 5.64, with electron-rich p-methoxybenzyl, 2-furyl, and 2-thiophenyl groups leading 
to ≥10:1 selectivity for the syn product 5.66, while an electron-deficient p-trifluoromethylbenzyl 
substituent resulted in only 2:1 syn selectivity; an ethyl substituent delivered a mixture (1:1) of 
5.66 and its anti- diastereomer (Figure 5.4b). Cyclic ketones such as cyclobutanone, 
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cyclopentanone, and cyclohexanone were also found to participate in the reaction with indole 
(5.65) and cyclopentadiene (5.62), delivering their respective products in 81–91% yield (not 
shown). 
 They also investigated various dienic components and found that, in general, the yield of 
the reaction suffered when dienes other than cyclopentadiene (5.62) were used, and the use of the 
more active Ga(OTf)3 catalyst at a higher catalyst loading (20 mol %) was necessary to achieve 
satisfactory conversion. For instance, hexadiene 5.67a reacted with N-methylindole (5.56) and 
benzaldehyde (5.57) to deliver 5.68a in only 54% yield, but with a high degree of 
diastereoselectivity (> 10:1 dr) for the all-syn isomer. The use of isoprene (5.67b) resulted in 
formation 5.68b in only 48% yield; however, they did not observe any regioisomeric products, 
suggesting that a high degree of regioselectivity can be expected when unsymmetrical dienes are 
used. Finally, the authors noted that the use of more electron-rich dienic components such as 
Danishefsky’s diene or heteroaromatic dienes such as pyrrole, furan, or thiophene only resulted 
in the formation of addition products with the general structure 5.69, although no experimental 
details were provided (Figure 5.4d). 
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Figure 5.4. Exploration of the substrate scope of Wu’s three-component [4 + 3] cycloaddition 
reaction. a) 5'-substituted indole substrates 5.60. b) aldehyde substrates 5.64. c) 
diene substrates 5.67a-b. d) addition product 5.69 formed when electron-rich dienes 
were used  
Finally, Wu and co-workers used DFT calculations to probe the mechanism of their 
three-component cyclohepta[b]indole synthesis.207 They found that the lowest-energy pathway 
for the reaction of indole (5.65), dimethyl ketal 5.70, and cyclopentadiene (5.62) is a stepwise [4 
+ 3] pathway, in which indolyl cation 5.71 undergoes nucleophilic addition with 5.62 to form 
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allyl cation intermediate 5.72 which subsequently undergoes ring closure at the C(2) position of 
indole, followed by rearomatization to furnish the cyclohepta[b]indole product 5.73. Their 
calculations suggest that the formation of 5.73 via a concerted [4 + 3] cycloaddition pathway is 
disfavored, in agreement with the calculations performed by Winne and co-workers (vide supra). 
226 Their calculations also suggest that the reaction pathway in which 5.73 is formed via a 
concerted or stepwise [4 + 2] cycloaddition followed by a 1,2-alkyl migration is disfavored, 
although results obtained in our studies toward the total synthesis of exotines A and B will call 
this suggestion into question (see Section 6.3).  
 
 
Scheme 5.11. Proposed mechanism for the formation of cyclohepta[b]indole 5.73 based on DFT 
calculations performed by Wu and co-workers  
5.3.2. The Martin Lab Synthesis of Actinophyllic Acid & Related Work 
In 2013, the Martin lab reported the total synthesis of the cyclohepta[b]indole natural 
product (±)-actinophyllic acid (5.29, Scheme 5.11; see also Figure 5.2 and attendant 
discussion).209,227 Their retrosynthetic analysis (Scheme 5.12) hinged on the preparation of 
functionalized cyclohepta[b]indole 5.74 via a formal [4 + 3] cycloaddition reaction between 2-




Scheme 5.12. The Martin lab retrosynthesis of (±)-actinophyllic acid (5.29) 
 The interception of β-indolyl cations with π-nucleophiles was previously investigated by 
the Martin lab for the formal synthesis of several members of the N-methylwelwitindolinone 
family of natural products (5.78, Figure 5.12a).228,229 For instance, when the unstable indole-3-
carbinol 5.79, which was generated from 5.80 via addition of methyl Grignard, was treated with 
silyl ketene acetal 5.81 in the presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf), 
the substitution product 5.82 was formed and subsequently elaborated to 5.78 (Figure 5.12a). 
This strategy was also found to be applicable generally for the synthesis of β-heteroaryl 
propionates 5.83 from heteroaromatic carbinols with the general structure 5.84 and silyl ketene 




Figure 5.5. Interception of β-aryl cations with π-nucleophiles. a) formal synthesis of N-
methylwelwitindolinones (5.78). b) synthesis of β-heteroaryl propionates 5.83 
 The details of Martin’s synthesis of (±)-actinophyllic acid (5.29) is shown in 
Scheme 5.13.209,227 Preparation of cyclization precursor 5.76 was accomplished via a one-pot 
sequence in which indole (5.65) was converted to indolyl acetate 5.76 in 85% yield via reaction 
of a C(2)-lithiated indole N-carboxylate dianion with ketone 5.86 followed by acetylation of the 
resultant alkoxide. The dienic substrate 5.77 was prepared from dihydroazepinone 5.87 via a 
straightforward sequence of N-alloc protection and silyl enol ether formation. The cascade 
ionization/formal [4 + 3] cycloaddition reaction of 5.76 and 5.77 proceeded in the presence of 
TMSOTf and 2,6-di-tert-butylpyridine to deliver cyclohepta[b]indole 5.74 in 92% yield. The 
indole nitrogen atom of 5.74 was then Boc-protected to mitigate gramine-type fragmentation, 
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and N-alloc deprotection then furnished amine 5.88 in 76% yield. Construction of the pyrrolidine 
ring was accomplished via reductive alkylation of 5.88 with chloroacetaldehyde, followed by 
treatment with sodium tert-butoxide to generate 5.89 in 83% yield. Indole Boc-deprotection and 
hydrogenolysis of the O-benzyl groups generated an intermediate diol that spontaneously 
cyclized to form tetrahydrofuranyl diol 5.90. Oxidation of the pendant hydoxymethylene group 
to the requisite carboxylic acid proved challenging, but sequential treatment with excess IBX and 
N-hydroxysuccinimide, followed by saponification of the resultant succinimidate ester delivered 
(±)-actinophyllic acid (5.29) in 31% yield as its hydrochloride salt. The remarkable efficiency 
with which (±)-actinophyllic acid (5.29) was prepared, in only 10 steps from known materials, is 
a testament to the utility of (formal) [4 + 3] cycloaddition reactions for the synthesis of  
cyclohepta[b]indole natural products, which will be further demonstrated in our synthesis of 





Scheme 5.13. The Martin lab synthesis of (±)-actinophyllic acid (5.29) 
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Chapter 6. The Total Synthesis of Exotines A and B 
 
Owing to their unique coumarin-cyclohepta[b]indole skeletons and intriguing biological 
activity (see Section 5.1), the Martin lab sought to develop a concise synthesis of exotines A 
(6.1) and B (6.2, Scheme 6.1).184  
6.1. FIRST-GENERATION SYNTHETIC STRATEGY 
In our initial strategy for the preparation of 6.1 and 6.2, we envisioned introducing the 
requisite methoxycoumarin moiety via palladium-catalyzed cross-coupling of 6.3 with the 
known halo-coumarins 6.4 (Scheme 6.1).206,231 An advantage of this approach would be that the 
nature of the functional groups participating in the cross coupling (R1 on 6.3, X on 6.4) could be 
varied to optimally achieve the desired transformation and syn-stereochemical outcome.232 For 
instance, 6.4 (X = Br, I) could be converted to an organometallic species and coupled with 6.3 
when it bears a suitable R1 group (e.g. R1 = OAc) for the generation of a π-allylpalladium 
species.232,233 Alternately, if R1 = B(OR)2,  6.3 could undergo Suzuki-type coupling with 6.4 (X = 
Br, I).234  We envisioned using Wu’s Ga(III) [4 + 3] cycloaddition methodology (see Section 
5.3.1) or an acid-catalyzed variant thereof to prepare 6.3 from indole (6.6), prenal (6.7) and diene 
6.8 in a three-component, one-pot fashion.207 While the precedent in Wu’s work suggested that 
we might expect the isobutenyl and R1 groups in 6.3 to display a syn-steroechemical relationship 
(see 5.68a, Figure 5.4c), we were unsure how relevant this precedent would be to our proposed 
reaction with prenal (6.7) and diene 6.8, which are notably different from the substrates used by 
Wu and co-workers.207 Here it is important to note that Trauner and co-workers did not publish 
their synthesis of exotine B (6.2, see Section 5.2) until after we had already prepared exotine A 
(2.1, vide infra), so our decision to utilize a variant of Wu’s methodology in our synthesis of the 





Scheme 6.1. First-generation retrosynthetic analysis of exotines A (6.1) and B (6.2, Jiang et al. 
numbering system)184 
Prior to our investigation of the synthetic sequence depicted in Scheme 6.1, we 
performed two brief model studies. First, we invesigated the viability of prenal (6.7) as a 
cyclization substrate in a three-component reaction with indole (6.6) and cyclopentadiene (6.9, 
Equation 6.1). We found that in the presence of catalytic gallium(III)triflate (Ga(OTf)3), the 
reactants were converted to cyclohepta[b]indole 6.10 in 41% yield and 10:1 dr. The 
stereochemistry 6.10 was not determined conclusively, but it appears that the dominant 
diastereomer of 6.10 displays a syn- stereochemical relationship between the isobutenyl group 
 134 
and the bridging methylene group based on comparison of its 1H NMR spectra with the products 
prepared by Wu and co-workers.207 We also investigated the reaction of indole (6.6) and prenal 
(6.7) with isoprene (6.11) and found that while it appears the desired cyclohepta[b]indole 6.12 
was formed, again based on comparison of the 1H NMR spectrum with an analogous compound 
prepared by Wu, it readily degraded under ambient conditions to produce a complex mixture.  
 
 
Having established the viability of prenal (6.7) as a cyclization substrate, we turned our 
attention to the synthesis and analysis of the dienic component 6.8 (see Scheme 6.1). We first 
investigated reactions with the acetoxy-diene 6.13, which was prepared from prenal (6.7) 
according to a literature procedure.235 In the event, treatment of 6.13 with indole (6.6), prenal 
(6.7), and gallium(III)triflate in several different aprotic solvents resulted in the formation of a 
complex mixture from which no trace of the desired product 6.14 was observed (Equation 6.3). 
We did, however, observe and partially isolate a compound to which we have tentatively 
assigned the structure of triene 6.15 (8–24% yield) , which presumably arises from 6.14 via the 
elimination of acetic acid, as well as indole-indolenine addition product 6.16 (5–20% yield). We 
also found that the presence of of the hindered base 2,6-di-tert-butyl pyridine completely shut 




formation of 6.14 in these studies, because it demonstrated that the three-component cyclization 
was viable with dienes bearing weakly electron-donating functionalities such as the acetoxy 
group in 6.13. We had been concerned about the viability of using dienes with electron-donating 
groups, owing to the observation of Wu and co-workers that electron-rich dienes failed to cyclize 
(see Section 5.3.1).207 However, these studies also made clear to us that 6.13 was not a good 
choice for a cyclization substrate, as it appears that the acetoxy group in the product 6.14 is, 




 Boronyl and sulfonyl dienes 6.17 and 6.18, each of which was prepared according to 
literature procedures, 236–238 were also investigated as cyclization substrates (Equation 6.3). 
Subjecting 6.17 to our standard reaction conditions with 6.6 and 6.7 at 0 ˚C or room temperature 
resulted in a complex mixture from which no trace of 6.19 or its elimination product was 
observed; however, we did observe isoprenyl-indole byproduct 6.20, as well as the indole-
indoline byproduct 6.16 (see Equation  6.2), returned starting material prenal (6.7) and trace 
quantities of  6.17. Reactions of sulfonyl diene 6.18 with 6.6 and 6.7 likewise failed to produce 
the desired product 6.21, delivering only returned 6.7 and 6.18 and uncharacterized side products 
(Equation 6.3). The absence of any signal corresponding to a cyclization product in reactions 
involving 6.17 or 6.18, as well as the fact that in both cases the dienes were not completely 
consumed during the course of their reactions with 6.6 and 6.7 suggests that 6.17 and 6.18 are 
too unreactive to participate in the cyclization, perhaps due to the electron-withdrawing nature of 





 Finally, we investigated the use of siloxy-dienes as cyclization substrates starting with 
tert-butyldimethylsiloxy (OTBS) diene 6.22, which was prepared according to literature 
procedure.235 Although no trace of product 6.23 was observed when the reaction of 6.22 with 6.6 
and 6.7 was performed at room temperature, trace quantities of a compound with an m/z 
corresponding to 6.23 (382.3, m + H+) were observed in the LCMS spectra when the reaction 
was carried out at 0 ˚C, as well as the m/z of cyclization-elimination product 6.15 (250.2, m + 
H+) (see Equation 6.2). However, the presence of a trace of the m/z corresponding to 6.23 could 
also be the uncyclized isomer 6.24, which is likely present in the reaction mixture. Indeed, we 
were able to partially isolate a compound that appears to be protonolysis product of  6.24, the 
uncyclized enal 6.25. Mixed oligomeric species in which two or more units of the diene have 
been incorporated into a cyclized or uncyclized product such as 6.26 were also observed, and 
6.26 was partially isolated in 12% yield. The apparent Mukaiyama aldol product 6.27 was also 
isolated in 5% yield, and higher-order oligomers of this type were also observed in the LCMS 
spectra of the mixture.  
Collectively, these results indicate that 6.22 can participate in the three-component 
cyclization to form 6.23, but, just as with acetoxy-diene 6.13 and its cyclization product 6.14, the 
-OTBS moiety of the product is not stable to the reaction conditions and either undergoes 
elimination to form triene 6.15 or substitution with an additional unit of diene 6.22 to form 
species such as the cyclic form 6.26. The use of triisopropylsiloxy (OTIPS) diene 6.28 gave 
similar results, delivering a complex mixture of products from which a trace quantities of a 
(6.3) 
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compound with the m/z (424.3, m + H+) corresponding to product 6.29 was observed, along with 
substantial quantities of 6.20 and various oligomeric species.240   
 
 
Figure 6.1. Three-component reactions with OTBS diene 6.22  
 
 
 In the above studies, the reactant stoichiometry was similar to that of Wu and co-workers, 
with a slight excess of prenal (6.7) and a larger excess of the diene (2 – 4 equivalents) relative to 
indole (6.6).  Noting that the formation of diene oligomers such as 6.26 and 6.27 appeared to be a 
major problem in the reactions with siloxy-dienes 6.22 and 6.28, we reasoned that reducing the 
stoichiometry of the dienic component and preventing it from engaging in side-reactions with 
prenal (6.7) might encourage the formation of our desired product. To this end, we prepared 
(6.3) 
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indolyl allyl alcohol 6.30 (Figure 6.2) according to the procedure of Sheu and coworkers, who 
used 6.30 as an allyl cation precursor in their biomimetic synthesis of yuehchukuene (5.10, see 
Scheme 5.3).203 In the event, treatment of 6.30 with siloxy-diene 6.28 and gallium(III)triflate 
generated no trace of the desired cyclization product 6.29; however, a product which we believe 
to be aldehyde 6.25 was isolated in 28% yield when the reaction was run at 0 ˚C. Running the 
reaction at room temperature produced significant quantities of a species with an m/z 
corresponding to the dimer 6.31 (499.3, m + H+).  
 
Figure 6.2. Reactions with indolyl allyl alcohol 6.30 
In conclusion, our studies of three-component cyclization reactions with the 
functionalized dienes 6.13, 6.17, 6.18, 6.27, and 6.28 suggested that the presence of an ionizable 
functional group at C(11') of the exotine scaffold (see Scheme 6.1) would likely lead to 
degradation of the desired cyclohepta[b]indole product. With this in mind, we set out to devise 
an alternate strategy for the preparation of exotines A (6.1) and B (6.2, see Scheme 6.1). 
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6.2 SECOND-GENERATION SYNTHETIC STRATEGY 
Our failure to prepare cyclohepta[b]indoles related to 6.3 led us to re-evaluate our 
strategy for the synthesis of exotines A (6.1) and B (6.2, see Scheme 6.1).  Since the presence of 
a suitable functional group for cross-coupling reactions seems to cause problems with the three-
component cyclization to form 6.3, we reasoned that it might be advantageous to form the 
isopentenyl-coumarin unit C(2'–15') prior to cyclization (Scheme 6.2). Specifically, we 
wondered if the coumarin-dienes trans-dehydroosthol (6.32) and gleinadiene (6.33) would 
participate in a three-component cyclization with indole (6.6) and prenal (6.7) to prepare 
exotines A (6.1) and B (6.2) in a single chemical transformation. In addition to potentially 
enabling a more efficient synthesis of our targets 6.1 and 6.2, this approach was attractive to us 
because it mirrors, in a general sense, the biosynthetic proposal advanced by Jiang (see Section 
5.1.1) and our attendant studies could shed light on the feasibility of  Jiang’s proposed  
biosynthesis (vide infra).184   
 
Scheme 6.2. Second-generation retrosynthetic analysis of exotines A (6.1) and B (6.2, Jiang et 
al. numbering system)184 
To query the potential feasibility of this approach, we first performed a model study with 
phenyl diene 6.34, which was prepared from propargyl alcohol 6.35 using Kimber’s Suzuki 
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coupling/allene isomerization methodology (Scheme 6.3).241 Gratifyingly, we found that 
incubation of 6.34 with indole (6.6) and prenal (6.7) in the presence of gallium(III)triflate 




Scheme 6.3. Model study of three-component cyclization with phenyl diene 6.34 
Encouraged by the results of this model study, we set out to investigate a three-
component cyclization with trans-dehydroosthol (6.32) as the dienic component. The synthesis 
of 6.32 proceeded from 7-hydroxycoumarin (6.37), which was iodinated and methylated to give 
6.38 in 44% yield according to the procedure of Lauret.242 Heck coupling of 6.38 with allyl 
alcohol 6.39 proceeded in 81% yield according to the procedure of Murray,243 and elimination of 
the tertiary alcohol to produce 6.32 was accomplished via a modified version of the procedure 
used by Reisch.244 In particular, we found that using pyridine as both a base and solvent instead 
of Hünig’s base in chloroform resulted in improved yields of 6.32. After Trauner and co-workers 
published their synthesis of exotine B (6.2), we investigated the use of their regioselective 5,7-
dimethoxycoumarin iodination conditions (see Scheme 5.4) on 7-methoxycoumarin (6.40, 
Equation 6.4).205 Unfortunately, we found that 6.40 preferentially undergoes iodination at C(2) 
instead of C(8) to generate the undesired iodocoumarin 6.41.  
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 With 6.32 in hand, we began our investigation of the three-component cyclization with 
indole (6.6) and prenal (6.7) (Table 6.1). To our delight, we found that the reaction of 6.32, 6.6, 
and 6.7 in the presence of catalytic gallium(III)triflate delivered a mixture (4:1) of exotine a (6.1) 
and epi-exotine A (6.42) in 17% combined yield (Table 6.1, Entry 1). The use of other group 13 
Lewis acid catalysts such as gallium(III) bromide (GaBr3) and indium(III) bromide (InBr3) 
delivered similar yields and diastereomeric ratios (Entries 2 and 3), which was in accordance 
with the results observed by Wu and co-workers in their optimization studies (see Table 5.1).207 
A major improvement in the diasteromeric ratio was obtained when the reaction was run at 0 ˚C 
in the presence of catalytic gallium(III) triflate, delivering 6.1 in 14% yield and >20:1 dr; 
however, this also extended the reaction time to 120 hours (Entry 4). Thankfully, we found when 
we used stoichiometric p-toluenesulfonic acid (p-TsOH) instead of catalytic gallium(III) triflate  
(6.4) 
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at 0 ˚C the reaction time was reduced to 24 hours while maintaining a comparable yield (13%) 
and dr (>20:1) of 6.1 (Entry 5). At room temperature the reaction was complete within one hour 
and delivered a mixture (2:1) of 6.1 and 6.42 in 26% yield (Entry 6).  
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Table 6.1. Initial screening of conditions for the preparation of exotine A (6.1) 
 
 
Entry Acid temp. (˚C) Time (h) Resulta,b 
1 Ga(OTf)3 
(20 mol %) 
rt 5  17%, 4:1 dr 
2 GaBr3  
(0.2 eq) 
rt 20  15%, 3.5:1 dr 
3 InBr3  
(0.2 eq) 
rt 5  14%, 4:1 dr 
4 Ga(OTf)3  
(0.2 eq) 
0  120  14%, >20:1 dr 
5 p-TsOH 
(1 eq) 
0 24 13%, >20:1 dr 
5 p-TsOH 
(1 eq) 
rt 1 26%, 2:1 dr 
a) Combined yield of a mixture of 6.1 and 6.42 after purification by 
column chromatography; b) Diastereomeric ratios calculated from 1H 
NMR integrations of the purified mixture of 6.1 and 6.42 
 
 
While we were pleased to have prepared exotine A (6.1) and optimized the 
diastereoselectivity of the three-component cyclization, the persistently low yields of 6.1 
indicated that the reaction required further optimization. Thus, we undertook a broad screen of 
reaction conditions, systematically varying the acid catalyst, temperature, solvent, and 
stoichiometry of the reactants (Table 6.2). By adjusting the stoichiometry to make trans-
dehydroosthol (6.32) the limiting reagent while using excess indole (6.6, 4 eq) and prenal (6.7, 3 
eq), we observed a large increase (17% → 39–45%) in the yield of 6.1 and 6.43 while 
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maintaining a high (16:1–>20:1) level of diastereoselectivity for 6.1 (Table 6.2, Entry 1). We 
then screened various solvents including diethyl ether, tetrahydrofuran, toluene, acetonitrile, 
nitromethane, dimethylformamide, trifluoroethanol, and hexafluoroisopropanol; toluene and 
acetonitrile (MeCN, Entry 2) both gave encouraging results, but neither was better than 
dichloromethane (CH2Cl2, Entry 1). We were curious as to how the gallium(III) triflate catalyst 
would perform in a reaction where 6.43 is the limiting reagent. Unfortunately, after 120 hours 
only 50% conversion of 6.43 to 6.1 was observed, and we did not pursue further studies with this 
catalyst (Entry 3).  
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Table 6.2.  Further screening of conditions for the preparation of exotine A (6.1) 
 
Entry Acid Solvent Time (h) Stoichiometry Resulta,b 
1 p-TsOH  
(1 eq) 
CH2Cl2 24 6.6 (4 eq), 6.7 (3 eq), 6.32 (1 eq) 39–45%,  
16:1–>20:1  dr 
2 p-TsOH  
(1 eq) 
MeCN 24 6.6 (4 eq), 6.7 (3 eq), 6.32 (1 eq) 30%, >20:1 dr 
3 Ga(OTf)3 
(0.2 eq) 




CH2Cl2 24 6.6 (4 eq), 6.7 (3 eq), 6.32 (1 eq) 43%, 10:1 dr 
5 Tf2NH 
(1 eq) 
CH2Cl2 24 6.6 (4 eq), 6.7 (3 eq), 6.32 (1 eq) 41%, 6:1 dr 
6 TfOH 
(1 eq) 




CH2Cl2 8 or 24  6.6 (2 eq), 6.7 (2 eq), 6.32 (1 eq) 0% 
8 TMSOTf 
(1 eq) 
CH2Cl2 24 6.6 (4 eq), 6.7 (3 eq), 6.32 (1 eq) 0–56%, 
10:1–>20:1 dr 
a) Combined yield of a mixture of 6.1 and 6.42 after purification by column chromatography; b) Diastereomeric ratios 
calculated from 1H NMR integrations of the purified mixture of 6.1 and 6.42 
 
 
We did, however, examine other protic and Lewis acid catalysts. For instance, 
trifluoroacetic acid (TFA) was found to be a competent acid catalyst, furnishing 6.1 and 6.43 in 
yields comparable to those observed with p-toluenesulfonic acid, albeit with slightly reduced 
diastereoselectivity (Table 2, Entry 3). β-Camphorsulfonic acid gave similar results, but required 
additional equivalents of indole (6.6) to be added over the course of reaction for complete 
consumption of 6.32 to be observed. Acetic acid failed to catalyze the reaction at all, even in 
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refluxing dichloromethane, suggesting that a stronger protic (or Lewis) acid is necessary for the 
reaction to occur. Thus, we turned our investigation to two of the strongest protic acids, 
trifluoromethanesulfonic acid (triflic acid, TfOH) and bistriflimide (Tf2NH).
245 The use of 
bistriflimide resulted in a 41% combined yield of 6.1 and 6.43, but the dr of 6:1 was 
disappointing, and this catalyst was not explored further (Entry 4). Triflic acid delivered 
promising but variable results (vide infra), generating 6.1 and 6.43 in 33 – 42% yield, and 10:1–
>20:1 dr, over the course of 16–24 hours using our standard reaction conditions (Entry 5). We 
undertook studies to optimize the reaction with triflic acid, screening solvents (toluene, 
acetonitrile, nitromethane), reaction time (8 – 48 h), and temperature (0 ˚C, -20 ˚C), but were not 
able to improve upon the results obtained in Entry 5. Interestingly, when the stoichiometry of the 
reaction was adjusted to two equivalents of indole (6.6) and prenal (6.7) relative to 6.32 and 
triflic acid, we did not observe or isolate any exotine A (6.1, see Section 6.3 for further 
discussion). Finally, we investigated the Lewis acid trimethylsilyl trifluoromethanesulfonate 
(TMS triflate, TMSOTf), which had been previously used in the Martin lab for the generation of 
indolyl carbocations that were subsequently trapped by π-nucleophiles (see Section 
5.3.2).209,227,230 We found that the use of TMS triflate gave highly variable results (Entry 8). In 
one trial we obtained 6.1 and 6.43 in 56% yield and 13:1 dr, while in another trial we obtained 
6.1 and 6.43 in a 29% yield and 10:1 dr. In one instance we did notisolate any 6.1! While we 
cannot offer a definitive explanation for this high degree of variability, we suspect that it is due 
to an interplay between the sparing solubility of triflic acid, which is generated during the course 
of the reaction, in dichloromethane, and experimental details such as stir rate, reaction vessel 
(conical vial vs. round-bottomed flask), and the physical distribution of insoluble precipitate that 
forms during the course of the reaction. Ultimately, we concluded that the use of p-
toluenesulfonic acid as our acid catalyst under the conditions described in Entry 1 delivered the 
best and most consistent yields of exotine A (6.1).  
Having thus secured optimized conditions for the synthesis of exotine A (6.1), we 
wondered if these same conditions could be used to prepare exotine B (6.2) in a one-pot fashion 
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from gleinadiene (6.33), indole (6.6) and prenal (6.7, see Scheme 6.2). At this point in our 
studies, Trauner and co-workers had published their synthesis of exotine B (6.2), and we were 
both concerned and intrigued by their inability to use prenal (6.7) in their gallium(III) triflate-
catalyzed three-component cyclization with indole (6.6) and gleinadiene (6.33, see Scheme 5.8 
and attendant discussion).205 In the event, we found that gleinadiene (6.33), prepared according 
to the method of Trauner, readily participated in the p-toluenesulfonic acid-catalyzed three-
component cyclization with 6.6 and 6.7, delivering a mixture (4:1) of exotine B (6.2) and its 
epimer (6.43) in 50% combined yield (Equation 6.5).205 Thus, it seems that the use of p-
toluenesulfonic acid as an acid catalyst for these types of three-component cyclization reactions 
offers some advantages over gallium(III) triflate, as its use resulted in improved yields and 
reaction times in our synthesis of exotine A (6.1) and enabled a more direct synthesis of exotine 




6.3 MECHANISTIC STUDIES  
6.3.1. Acid-Catalyzed Epimerization of Exotine A to epi-Exotine A 
During the course of our efforts to optimize the acid-catalyzed three-component 
cyclization for the synthesis of exotine A (6.1, see Tables 6.1 and 6.2), we observed several 
interesting results, side products, and general trends that warranted additional investigation. For 
(6.5) 
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instance, there was a high degree of variability in the observed diastereomeric ratios of 6.1 and 
6.42 when several different acid catalysts, especially triflic acid and TMS triflate, were used. 
This observation led us to wonder if exotine A (6.1) might be epimerizing to epi-exotine A (6.42) 
under the reaction conditions. To query this hypothesis, we incubated a mixture of 6.1 and 6.42 
(30:1) with one equivalent of p-toluenesulfonic acid in deutero-methylene chloride and 
monitored the course of the reaction by 1H NMR spectroscopy (Equation 6.6). We observed a 
swift equilibration of the mixture to an apparent equilibrium of 1.8 to 1 exotine A (6.1) to epi-
exotine A (6.42) over the course of five hours. This diastereomeric ratio is roughly equivalent to 
what was observed when we performed the three-component cyclization with p-toluenesulfonic 
acid at room temperature (see Table 6.1, Entry 6), or with gallium(III) triflate in refluxing 
dichloromethane (not shown).  
 
 
 The equilibration of 6.1 to a mixture of 6.1 and 6.42 in the presence of p-toluenesulfonic 
acid provides some insight into the variable diastereomeric ratios observed in Table 6.2, but it 
raises other questions. Namely, if this equilibration occurs within five hours at 0 ˚C, how were 
we ever able to attain high (>20:1) diastereomeric ratios of 6.1 when the reaction is performed 
over the course of 24 hours in the presence of strong acids such as p-toluenesulfonic acid? We 
believe that the answer to this question may involve the indole-indoline side product 6.16 
observed in our early studies toward the synthesis of exotine A (see Equation 6.2). We reasoned 
that the weakly basic aniline nitrogen atom of 6.16 could exert a buffering effect on the three-
(6.6) 
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component cyclization and slow the conversion of 6.1 to 6.42. We had observed trace quantities 
of 6.16 throughout our optimization studies (see Section 6.2), but we were unsure of the extent of 
its formation under our optimized reaction conditions. Thus, we first subjected indole (6.6) to 
0.25 equivalents of p-toluenesulfonic acid in CH2Cl2 at 0˚C and obtained a 38% yield of 6.16 
(with respect to 6.6) after 22 hours (Equation 6.7). We did not expect greater than a 50% yield of 
6.16, because once 50% of indole (6.6) is converted to 6.16, there would be equal quantities of 
6.16 and p-toluensulfonic acid in the reaction mixture, which we assumed would slow or shut 
down the formation of additional 6.16. With 6.16 in hand, we incubated it with mixture of 6.1 
and 6.42 (25:1) and p-toluenesulfonic acid (Equation 6.8). While we did observe some 
conversion of 6.1 to 6.42, the rate was substantially slower than what was observed in the 
absence of 6.16 (see Equation 6.6), and after 20 hours at 0˚C the original mixture (25:1) of 6.1 
and 6.42 had been transformed into a 15:1 mixture (Equation 6.7). While these studies do not 
offer definitive proof that 6.16 is exerting a buffering effect in our three-component cyclization 
reactions, they do offer a plausible explanation for the discrepancy between the results obtained 
in Equation 6.6 and the generally high levels of diastereoselectivity observed in our three-





 Another question that emerged from the preceding studies was the nature of the 
mechanism by which 6.1 is converted to 6.42. To probe this question, we treated a mixture of 6.1 
and 6.42 (10:1) with d1-trifluoroacetic acid (F3CCO2D) and observed the formation of a mixture 
(2:1) of 6.44 and 6.45 with deuterium incorporated exclusively at C11' (Scheme 6.5). Based on 
this result, we believe that epimerization of 6.1 occurs via an initial deuteration at C3, followed 
by deprotonation at C11' to generate the enamine 6.46, which is then deuterated at C11' and 
dedeuterated at C3 to regenerate the indole ring system of 6.44 and 6.45. A similar experiment 
was performed with exotine B (6.2) and its epimer 6.43 (see Equation 6.5), and exclusive 
incorporation of deuterium at C11' was again observed. Epimerization of the indole C(2) α-
position (C11' in 6.1 and 6.2) is well-precedented in the literature. For example, such a process 
was utilized for one of the final steps of Woodward’s synthesis of reserpine.246   
 
Scheme 6.5. Deuterium incorporation experiment to probe the mechanism of acid-catalyzed 
epimerization of 6.1 
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6.3.2. Side-Products and Proposed Intermediates of the Three-Component Cyclization 
During our optimization studies we also observed the persistent presence of large 
quantities of various compounds that appeared to be isomeric with exotine A (6.1) based on low-
resolution mass spectrometry analysis. The yield of one group of these byproducts increased 
when the reactions were run at lower temperatures. For example, when the reaction was run at –
20 ˚C we isolated a mixture (10:1) of 6.1 and 6.42 in 19% yield. An inseparable mixture of 
isomeric compounds was also produced in 58% yield, and we hypothesized that these 
compounds might be uncyclized intermediates such as 6.47 or spirocyclic indolenine 
intermediates/byproducts 6.48 (Equation 6.9).  
 
 Intrigued by the possibility that we had isolated intermediates of the three-component 
cyclization, we subjected the mixture, which we believed comprised 6.47 and/or 6.48, to 
additional treatment with p-toluenesulfonic acid in dichlormethane, and we observed the 
formation of additional quantities of exotine A (6.1) and epi-exotine A (6.42). We also isolated 
(6.9) 
 152 
another inseparable mixture of isomeric compounds that we referred to as nonpolar isomers, as 
they were less polar than 6.1. These same nonpolar isomers were also observed and isolated as a 
mixture from various three-component reaction experiments. 
 
 We made extensive efforts to purify this mixture of [6.47 + 6.48] via HPLC, but 
invariably obtained a mixture of compounds even when the HPLC trace suggested a clean 
separation. This observation suggested to us that at least some of the compounds that comprise 
the mixture are unstable. Analysis of the major components of the [6.47 + 6.48] mixture by 1H, 
13C, and 2D (HSQC) NMR revealed characteristic signals that suggest the major components 
diastereomeric are 3,3'-spiroindolenines 6.48. We observed singlets at δ 8.65 and 8.34 ppm in the 
1H NMR spectrum that correlate (HSQC) to peaks at δ 175.1 and 174.5 ppm in the 13C NMR 
spectrum. We also observed peaks at δ 65.6 and 65.5 ppm in the 13C NMR spectrum which do 
not correlate (HSQC) with any 1H NMR signals. These signals are consistent with the known 
chemical shifts of N=C-H groups and spiro- carbon atoms of other 3,3'-spiroindolenine 
compounds.247,248  
Thankfully, we were eventually able to isolate the major component of the “nonpolar 
isomers” mixture via HPLC, which was unambiguously assigned as the rearranged isomer 6.49 
via 2D-NMR and X-ray crystallography (Figure 6.3). While we were not able to isolate and fully 
characterize the minor isomer of the “nonpolar isomer” mixture, we strongly suspect that it is the 
cis-epimer of 6.49, 6.50 based on analysis of the 1H NMR spectra (Figure 6.4). The structure of 
the rearranged isomer 6.49 lends further support to our hypothesis that the [6.47 + 6.48] mixture 
(6.10) 
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is (primarily) 3,3'-spiroindolenine diastereomers 6.48 (see Equation 6.9), as 6.49 is formed from 
the [6.47 + 6.48] mixture, and there is no plausible mechanism by which 6.49 could arise during 
the course of our three-component cyclization reactions except via the intermediacy of 6.48. 
 
Figure 6.3. Rearranged isomer 6.49 and its epimer 6.50 
Having partially elucidated the nature of these intermediates and byproducts, we desired 
a more rigorous accounting of the relative proportions of (epi-)exotine A (6.1, 6.43), 6.48, and 
6.49 formed under our optimized three-component cyclization conditions. To address this, we 
performed another reaction of 6.6, 6.7, and 6.32 with p-toluenesulfonic acid and obtained a 
mixture (10:1) of exotine A (6.1) and its epimer (6.42) in 45% combined yield, and a mixture 
(1.7:1) of 6.49 and its putative epimer 6.51 in 31% combined yield, and 6.48 in 28% yield. This 
accounts for nearly 100% of the mass balance of our limiting reagent 6.32 (Scheme 6.6).  
When 6.48 was treated with p-toluenesulfonic acid in dichloromethane, we isolated an 
additional 5% of a mixture (2:1) of exotine A (6.1) and epi-exotine A (6.43) (Scheme 6.6). This 
result suggests that our “optimized” conditions are in fact close to optimal, at least with respect 
to conversion of the productive diastereomer of the 6.48 mixture to exotine A (6.1).  
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Scheme 6.6. Quantitation and analysis of the byproducts of the three-component cyclization of 
6.6, 6.7, and 6.32  
6.4 CONCLUDING REMARKS 
In conclusion, we have developed extraordinarily concise syntheses of the 
cyclohepta[b]indole-coumarin natural products exotines A (6.1) and B (6.2), by a process that 
features a single chemical transformation from the known compounds trans-dehydroosthol 
(6.32) and gleinadiene (6.33) (see Table 6.2 and Equation 6.5). The synthesis of exotine A (6.1) 
proceeds in 43% yield and 17:1 dr, whereas the synthesis of exotine B (6.2) proceeds in 50% 
yield and 4:1 dr. To achieve these syntheses, we undertook extensive studies toward optimizing 
an acid-catalyzed three-component cyclization reaction between indole (6.6), prenal (6.7), and 
trans-dehydroosthol (6.32), using p-toluenesulfonic acid in dichloromethane at 0 ˚C.207 We 
found that exotine A (6.1) is partially epimerized in the presence of strong acids such as p-
toluensulfonic acid and d1-trifluoroacetic acid, and provided a plausible mechanism for this 
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epimerization based on our deuterium incorporation experiments (see Scheme 6.5). Finally, we 
isolated and characterized a byproduct of the three-component cyclization, the rearranged 
cyclohepta[b]indole-coumarin isomer 6.49 that, along with our partial characterization and 
attendant studies of the 3,3'-spiroindolenine mixture 6.48,  lends support to Jiang’s biosynthetic 
proposal of a [4+2] cycloaddition followed by ring expansion (see Scheme 6.6, see also Section 
5.1.1).184 It is our hope this work may inform and enable future studies on the biological 
activities of the exotines or synthetic analogs thereof, as well as the use of acid-catalyzed three-
component cyclization reactions for the synthesis of indole alkaloids. 
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Chapter 7. Experimental Procedures 
General. Tetrahydrofuran and diethyl ether were dried by filtration through two columns 
of activated, neutral alumina prior to use. Methanol, acetonitrile and dimethylformamide were 
dried by filtration through two columns of activated molecular sieves, and toluene was dried by 
filtration through one column of activated, neutral alumina followed by one column of Q5 
reactant.  Benzene was distilled from sodium and benzophenone. Methylene chloride, 
diisopropylamine, triethylamine, and diisopropylethylamine were distilled from calcium hydride 
immediately prior to use.  Pyridine was distilled from potassium hydroxide (KOH) and calcium 
hydride and stored over KOH. Dioxane was distilled from sodium metal and benzophenone prior 
to use. All solvents were determined to have less than 50 ppm H2O by Karl Fischer coulometric 
moisture analysis. All reagents were reagent grade and used without purification unless 
otherwise noted. All reactions involving air or moisture sensitive reagents or intermediates were 
performed under an inert atmosphere of nitrogen or argon in glassware that was flame dried.  
Solutions were degassed using three freeze-thaw cycles under vacuum. Reaction temperatures 
refer to the temperature of the cooling/heating bath. Volatile solvents were removed under 
reduced pressure using a Büchi rotary evaporator at 25–30 °C.  Thin layer chromatography 
performed using run on pre-coated plates of silica gel with a 0.25 mm thickness containing 60F-
254 indicator (Merck).  Chromatography was performed using forced flow (flash 
chromatography) and the indicated solvent system on 230-400 mesh silica gel (E. Merck reagent 
silica gel 60) according to the method of Still,249 unless otherwise noted. 
Infrared (IR) spectra were obtained either neat on sodium chloride or as solutions in the 
solvent indicated and reported as wavenumbers (cm-1).  Proton nuclear magnetic resonance (1H 
NMR) and carbon nuclear magnetic resonance (13C NMR) spectra were obtained at the indicated 
field as solutions in CDCl3 unless otherwise indicated.  Chemical shifts are referenced to the 
deuterated solvent and are reported in parts per million (ppm, δ) downfield from 
tetramethylsilane (TMS, δ = 0.00 ppm).  Coupling constants (J) are reported in Hz and the 
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splitting abbreviations used are: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; comp, 
overlapping multiplets of magnetically nonequivalent protons; br, broad; app, apparent.  
 




(2.16) (LTL-IV-084). To a stirred solution of amine 2.22 (16 mg, 0.11 mmol) and 3,5-
dichlorobenzaldehyde (25 mg, 0.314 mmol) in 1,2-dichloroethane (1.4 mL) was added sodium 
triacetoxyborohydride (45 mg, 0.21 mmol). The reaction was stirred for 4 h, whereupon it was 
diluted with CH2Cl2 (50 mL) and washed with sat. NaHCO3 (50 mL) and brine (50 mL). The 
organic layer was dried (Na2SO4) and concentrated under reduced pressure to afford crude 2.16. 
The crude material was purified via flash column chromatography, eluting with 
hexanes:EtOAc:TEA (40:60:1) to furnish 17 mg (68%) of 2.16 as a yellow solid. 1H NMR (400 
MHz, CDCl3) δ 8.10 (s, 1 H), 7.66 (d, J = 7.9 Hz, 1 H), 7.37 (d, J = 8.1 Hz, 1 H), 7.24 (s, 1 H), 
7.31 – 7.25 (comp, 3 H), 7.18 (td, J = 8.1, 7.0 Hz, 1 H), 7.10 (td, J = 7.9, 7.0 Hz, 1 H), 7.05 (d, J 
= 2.3 Hz, 1 H), 3.74 – 3.50 (comp, 4 H), 3.17 – 3.00  (comp, 4 H), 2.94 – 2.81 (m, 1 H), 2.65 
(dd, J = 17.2, 5.2 Hz, 1 H), 2.51 – 2.41 (m, 1 H), 2.16 (s, 3 H), 2.05 – 1.91 (m, 1 H), 1.60 (qd, J 
= 11.5, 6.0 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 144.0, 137.0, 135.6, 128.2, 127.9, 127.4, 
122.7, 122.5, 120.0, 119.4, 113.9, 111.8, 57.31, 57.29, 48.4, 46.9, 37.6, 35.0, 26.6, 23.7; IR 
(NaCl, film) 3624, 2509, 2929, 2855, 2793, 2242, 1623, 1569, 1499, 1456, 1433, 1345, 1303, 
1231, 1209, 1158, 1125, 1098, 1074, 1036 cm-1; HRMS (ESI) m/z calc’d for C23H25Cl2N3O 
(M+H)+ 430.1447; found 430.1448. 
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NMR assignment. 1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1 H, H1), 7.66 (d, J = 7.9 Hz, 
1 H, H5), 7.37 (d, J = 8.1 Hz, 1 H, H8), 7.24 (s, 1 H, H22), 7.31 – 7.25 (comp, 3 H, H20, H22), 
7.13 (t, J = 7 Hz, 1 H, H7), 7.05 (d, J = 2.3 Hz, 1 H, H2), 3.74 – 3.50 (comp, 4 H, H10, H18), 
3.17 – 3.00 (comp, 4 H, H12, H11), 2.94 – 2.81 (m, 1 H, H14), 2.65 (dd, J = 3 Hz, 17 Hz, 1 H, 
H15), 2.51 – 2.41 (m, 1 H, H15), 2.16 (s, 3 H, H17), 2.05 – 1.91 (m, 1 H, H13), 1.60 (qd, J = 
11.5, 6.0 Hz, 1 H, H13); 13C NMR (100 MHz, CDCl3) δ 170.0 (C16), 144.0 (C19), 137.0 (C9), 
135.6 (C22), 128.2 (C4), 127.9 (C21), 127.4 (C20), 122.7 (C6), 122.5 (C2), 120.0 (C7), 119.4 
(C5), 113.9 (C3), 111.8 (C8), 57.31 (C18), 57.29 (C14), 48.4 (C10), 46.9 (C12), 37.6 (C15), 35.0 




(2.19) (LTL-II-150). Amine 2.18 (3.00 g, 11.5 mmol) and malonic acid 2.9 (1.68 g, 12.6 mmol) 
were dissolved in CH2Cl2 (250 mL) and the solution was cooled to 0 °C, whereupon EDCI•HCl 
(2.43 g, 12.6 mmol) and i-Pr2NEt (3.30 g, 25.2 mmol, 4.38 mL) were added. The reaction was 
warmed to room temperature and stirred for 40 h, whereupon the reaction was diluted with 
CH2Cl2 (250 mL) and washed with 1 M HCl (500 mL). The aqueous layer was then extracted 
with an additional portion of CH2Cl2 (250 mL). The combined organic layers were washed with 
brine (500 mL), dried (Na2SO4) and concentrated under reduced pressure to yield 4.3g (99%) of 
crude 2.19 as an amber oil (4.3g 99%) which was judged to be >90% pure by 1H NMR and 
carried forward without further purification. For characterization, a portion of the crude product 
was purified via column chromatography, eluting with hexanes/EtOAc (3:1 → 1:1) to provide 
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2.18 as an off-white solid. 1H NMR (3:2 rotamer mixture) (400 MHz, CDCl3) δ 8.24 (s, 0.5 H), 
8.15 (s, 0.3 H), 7.71 (d, J = 7.8 Hz, 0.3 H), 7.59 (d, J = 7.8 Hz, 0.6 H), 7.40 (t, J = 8.7 Hz, 0.9 
H), 7.25 – 7.18 (m, 1 H), 7.18 – 7.11 (m, 0.9 H), 7.06 (d, J = 2.3 Hz, 0.3 H), 7.00 (d, J = 2.4 Hz, 
0.6 H), 4.26 (q, J = 7.1 Hz, 0.7 H), 4.18 – 4.11 (comp, 3 H), 3.70 (t, J = 7.0 Hz, 1.2 H), 3.65 – 
3.59 (comp, 1.9 H), 3.58 (s, 0.7 H), 3.55 (t, J = 7.1 Hz, 0.7 H), 3.16 (s, 1.2 H), 3.08 – 3.01 
(comp, 1.9 H), 2.69 (t, J = 7.0 Hz, 1.2 H), 2.57 (t, J = 7.1 Hz, 0.7 H), 1.32 (t, J = 7.1 Hz, 1.2 H), 
1.28 – 1.22 (comp, 4.7 H); 13C NMR (100 MHz, CDCl3) (3:2 rotamer mixture) δ 172.1, 170.1, 
167.8, 167.6, 166.4, 166.1, 136.3, 127.3, 126.9, 122.4, 122.3, 122.1, 122.0, 119.7, 119.4, 118.8, 
118.1, 112.9, 111.7, 111.4, 111.1, 61.4, 61.3, 61.0, 60.6, 49.9, 46,9, 44.5, 42.4, 41.2, 40.9, 36.6, 
32.6, 29.7, 24.8, 23.2, 14.2, 14.1, 14.0; IR (NaCl, film) 3417, 2983, 2920, 2361, 2255, 2128, 
1731, 1642, 1458, 1370, 1319, 1260, 1190, 1159, 1097, 1027, 1007, 824, 746, 618 cm-1; HRMS 
(ESI) m/z calcd for C20H26N2O5 (M+Na)+ 397.1734; found 397.1733. 
NMR Assignment. 1H NMR (3:2 rotamer mixture) (400 MHz, CDCl3 δ 8.24 (s, 0.5 H, 
H1), 8.15 (s, 0.3 H, H1), 7.71 (d, J = 7.8 Hz, 0.3 H, H5), 7.59 (d, J = 7.8 Hz, 0.6 H, H5), 7.40 (t, 
J = 8.7 Hz, 0.9 H, H8), 7.25 – 7.18 (m, 1 H, H6), 7.18 – 7.11 (m, 0.9 H, H7), 7.06 (d, J = 2.3 Hz, 
0.3 H, H2), 7.00 (d, J = 2.4 Hz, 0.6 H, H2), 4.26 (q, J = 7.1 Hz, 0.7 H, H15, H20), 4.18 – 4.11 
(comp, 3 H, H15, H20), 3.70 (t, J = 7.0 Hz, 1.2 H, H12), 3.65 – 3.59 (comp, 1.9 H, H11), 3.58 
(s, 0.7 H, H18), 3.55 (t, J = 7.1 Hz, 0.7 H, H12), 3.16 (s, 1.2 H, H18), 3.08 – 3.01 (comp, 1.9 H, 
H10), 2.69 (t, J = 7.0 Hz, 1.2 H, H13), 2.57 (t, J = 7.1 Hz, 0.7 H, H13), 1.32 (t, J = 7.1 Hz, 1.2 
H, H16, H21), 1.28 – 1.22 (comp, 4.7 H, H16, H21); 13C NMR (100 MHz, CDCl3) (3:2 rotamer 
mixture) δ 172.1 (C19), 170.1 (C19), 167.8 (C14), 167.6 (C14), 166.4 (C17), 166.1 (C17), 
136.28 (C9), 136.26 (C9), 127.3 (C4), 126.9 (C4), 122.4 (C6), 122.3 (C2), 122.1 (C6), 122.0 
(C2), 119.7 (C7), 119.4 (C7), 118.8 (C5), 118.1 (C5), 112.9 (C3), 111.7 (C3), 111.4 (C8), 111.1 
(C8), 61.4 (C15/C20), 61.3 (C15/C20), 61.0 (C15/C20), 60.6 (C15/C20), 49.9 (C11), 46.9 (C11), 
44.5 (C12), 42.4 (C12), 41.2 (C18), 40.9 (C18), 36.6 (C13), 32.6 (C13), 24.8 (C10), 23.2 (C10), 




1-(2-(1H-Indol-3-yl)ethyl)piperidine-2,4-dione (2.20) (LTL-II-139). A suspension of 
NaH (60% w/w in mineral oil, 135 mg, 3.80 mmol) in cyclohexane (20 mL) was heated under 
reflux, and a solution of 13 (700 mg, 1.90 mmol) in toluene (3 mL) was added dropwise. The 
reaction was stirred under reflux for 6 h during which time a tan precipitate formed. The reaction 
was then cooled to room temperature, and the solvent was removed under reduced pressure. The 
flask was then cooled to 0 °C, EtOH (20 mL) was added, and the reaction was stirred for an 
additional 2 h. The solution was then diluted with H2O (200 mL) and 1 M HCl was added until 
pH = 1, and the aqueous solution was extracted with CH2Cl2 (3x 100 mL). The combined organic 
layers were washed with brine (100 mL), dried (MgSO4) and concentrated under reduced 
pressure to afford a tan solid which was then resuspended in AcOH (2 mL) and H2O (18 ml). 
The solution was heated under reflux until all starting material was consumed, as judged by LC-
MS. The solution was cooled to room temperature, neutralized with sat. NaHCO3 (100 mL), and 
extracted with CH2Cl2 (3x 100 mL). The combined organic extracts were then washed with brine 
(200 mL), dried (MgSO4) and concentrated under reduced pressure to afford crude 2.20. The 
crude material was purified via flash column chromatography, eluting with hexanes:EtOAc 
(75:25 → 40:60)  to furnish 313 mg (64%) of 2.20 as an off-white solid. 1H NMR (400 MHz, 
CDCl3) δ 8.04 (bs, 0.5 H), 7.65 (d, J = 7.8 Hz, 0.99 H), 7.39 (d, J = 8.0 Hz, 1.05 H), 7.23 (t, J = 
7.2 Hz, 1.18 H), 7.16 (t, J = 7.2, 1.08 H), 7.07 (s, 0.96 H), 3.85 (t, J = 6.9 Hz, 2.00 H), 3.34 (t,s 
overlapping, 3.90 H), 3.11 (t, J = 7 Hz, 2.05 H), 2.34 (t, J = 6.1 Hz, 1.91 H); 13C NMR (100 
MHz, CDCl3) δ 203.8, 168.1, 136.3, 127.3, 122.3, 122.1, 119.6, 118.5, 112.9, 111.4, 49.0, 44.4, 
38.5, 23.7; IR (NaCl, film) 3283, 2924, 2854, 2362, 1726, 1644, 1489, 1644, 1489, 1457, 1350, 




NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.04 (bs, 0.5 H, H1), 7.65 (d, J = 7.8 
Hz, 0.99 H, H5), 7.39 (d, J = 8 Hz, 1.05 H, H8), 7.23 (t, J = 7.2 Hz, 1.18 H, H6), 7.16 (t, J = 7.2, 
1.08 H, H7), 7.07 (s, 0.96 H, H2), 3.85 (t, J = 6.9 Hz, 2.00 H, H10), 3.34 (t,s overlapping, 3.90 
H, H12, H15), 3.11 (t, J = 7 Hz, 2.05 H, H11), 2.34 (t, J = 6.1 Hz, 1.91 H, H13); 13C NMR (100 
MHz, CDCl3) δ 203.8 (C14), 168.1 (C16), 136.3 (C9), 127.3 (C4), 122.3 (C6), 122.1 (C2), 119.6 




1-(2-(1H-Indol-3-yl)ethyl)-4-(methylamino)piperidin-2-one (2.22) (LTL-IV-080). To 
a solution of ketone 2.20 (65 mg, 0.25 mmol) in methanol (2.5 mL) was added methylamine (78 
mg, 2.5 mmol, 33% wt. soln. in EtOH), AcOH (150 mg, 2.5 mmol), and NaBH3CN (31 mg, 0.5 
mmol) and the resulting mixture was stirred for 16 hours at room temperature, whereupon an 
additional portion of NaBH3CN (31 mg, 0.5 mmol) was added. After stirring for an additional 3 
h, the reaction was diluted in 1 M HCl (50 mL) and washed with Et2O (50 mL). The aqueous 
layer was treated with 1 M NaOH until the solution turned cloudy and pH > 10, and the resulting 
mixture was diluted with brine (20 mL) and extracted with CH2Cl2 (3 x 50 mL). The combined 
organic layers were dried (Na2SO4) and concentrated under reduced pressure. The crude material 
was purified via column chromatography, eluting with CH2Cl2:MeOH:Et3N (95 : 5 : 1) to yield 
45 mg (66%) of 2.22 as a white foam. 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1 H), 7.66 (d, J = 
7.9 Hz, 1 H), 7.37 (dt, J = 8.1, 1.0 Hz, 1 H), 7.20 (ddd, J = 8.1, 7.0, 1.3 Hz, 1 H), 7.13 (ddd, J = 
7.9, 7.0, 1.1 Hz, 1 H), 7.06 (d, J = 2.3 Hz, 1 H), 3.66 (td, J = 7.1, 2.9 Hz, 2 H), 3.25 – 3.18 (m, 1 
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H), 3.16 – 3.08 (m, 1 H), 3.07 – 3.02 (comp, 2 H), 2.86 – 2.78 (m, 1 H), 2.68 (ddd, J = 17.1, 5.3, 
1.8 Hz, 1 H), 2.41 (s, 3 H), 2.22 (dd, J = 17.1, 8.6 Hz, 1 H), 1.90 (dt, J = 8.1, 5.0 Hz, 1 H), 1.58 – 
1.46 (m, 1 H); 13C NMR (500 MHz, CDCl3) δ 168.3, 136.3, 127.5, 122.001, 121.968, 119.3, 
118.7, 113.1, 111.2, 53.2, 48.12, 45.7, 43.42, 38.8, 33.3, 28.4, 22.9; IR (NaCl, film) 3252, 3053, 
2926, 2856, 2799, 2361, 1624, 1498, 1456, 1344, 1302, 1264, 1233, 1158, 1102, 1011 cm-1; 
HRMS (ESI) m/z calcd for C16H21N3O (M+Na)+ 294.1577; found 294.1574. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1 H, H1), 7.66 (d, J = 7.9 Hz, 
1 H, H5), 7.37 (dt, J = 8.1, 1.0 Hz, 1 H, H8), 7.20 (ddd, J = 8.1, 7.0, 1.3 Hz, 1 H, H6), 7.13 (ddd, 
J = 7.9, 7.0, 1.1 Hz, 1 H, H7), 7.06 (d, J = 2.3 Hz, 1 H, H2), 3.66 (td, J = 7.1, 2.9 Hz, 2 H, H10), 
3.25 – 3.18 (m, 1 H, H12), 3.16 – 3.08 (m, 1 H, H12), 3.07 – 3.02 (comp, 2 H, H11), 2.86 – 2.78 
(m, 1 H, H14), 2.68 (ddd, J = 17.1, 5.3, 1.8 Hz, 1 H, H15), 2.41 (s, 3 H, H18), 2.22 (dd, J = 17.1, 
8.6 Hz, 1 H, H15), 1.90 (dt, J = 8.1, 5.0 Hz, 1 H, H13), 1.58 – 1.46 (m, 1 H, H13); 13C NMR 
(500 MHz, CDCl3) δ 168.3 (C16), 136.3 (C9), 127.5 (C4), 122.001(C6), 121.968 (C2), 119.3 
(C7), 118.7 (C5), 113.1 (C3), 111.2 (C8), 53.2 (C14), 48.12 (C10), 45.7 (C12), 38.8 (C15), 33.3 




ylmethyl)(methyl)amino)piperidin-2-one (2.23) (LTL-IV-087). The title compound was 
prepared following the general procedure of 2.16. The crude material was purified by flash 
column chromatography, eluting with hexanes:EtOAc:Et3N (33:66:1) to furnish 14 mg (58%) of  
2.23 as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1 H), 7.65 (d, J = 7.8 Hz, 1 H), 7.36 
(d, J = 8.2 Hz, 1 H), 7.19 (ddd, J = 8.2, 7.0, 1.3 Hz, 1 H), 7.11 (ddd, J = 7.8, 7.0, 1.1 Hz, 1 H), 
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7.03 (d, J = 2.3 Hz, 1 H), 6.82 (d, J = 1.5 Hz, 1 H), 6.77 – 6.69 (comp, 2 H), 5.94 (s, 2 H), 3.74 – 
3.58 (comp, 2 H), 3.45 (s, 2 H), 3.21 – 3.09 (comp, 2 H), 3.09 – 2.99 (comp, 2 H), 2.80 (dtd, J = 
11.0, 5.8, 5.2, 3.5 Hz, 1 H), 2.62 (ddd, J = 16.9, 5.2, 2.2 Hz, 1 H), 2.44 (dd, J = 17.0, 10.8 Hz, 1 
H), 2.16 (s, 3 H), 1.91 (d, J = 12.7 Hz, 1 H), 1.61 (dtd, J = 12.8, 11.1, 5.7 Hz, 1 H); 13C NMR 
(100 MHz, CDCl3) δ 169.4, 148.0, 146.9, 136.5, 127.8, 122.3, 122.2, 122.0, 119.6, 119.0, 113.5, 
111.5, 109.3, 108.2, 101.2, 58.0, 56.7, 48.4, 47.0, 37.4, 35.1, 26.6, 23.3; IR (film, NaCl) 3260, 
2927, 1625, 1489, 1442, 1343, 1302, 1240, 1096, 1038, 929, 807, 741 cm-1; HRMS (ESI) m/z 
calc’d for C24H27N3O3 (M+Na)+ 428.1945; found 428.1939. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1 H, H1), 7.65 (d, J = 7.8 Hz, 
1 H, H5), 7.36 (d, J = 8.2 Hz, 1 H, H8), 7.19 (ddd, J = 8.2, 7.0, 1.3 Hz, 1 H, H6), 7.11 (ddd, J = 
7.8, 7.0, 1.1 Hz, 1 H, H7), 7.03 (d, J = 2.3 Hz, 1 H, H2), 6.82 (d, J = 1.5 Hz, 1 H, H24), 6.77 – 
6.69 (comp, 2 H, H20, H21), 5.94 (s, 2 H, H25), 3.74 – 3.58 (comp, 2 H, H10), 3.45 (s, 2 H, 
H18), 3.21 – 3.09 (comp, 2 H, H12, H11), 3.09 – 2.99 (comp, 2 H, H12, H11), 2.80 (dtd, J = 
11.0, 5.8, 5.2, 3.5 Hz, 1 H, H14), 2.62 (ddd, J = 16.9, 5.2, 2.2 Hz, 1 H, H15), 2.44 (dd, J = 17.0, 
10.8 Hz, 1 H, H15), 2.16 (s, 3 H, H17), 1.91 (d, J = 12.7 Hz, 1 H, H13), 1.61 (dtd, J = 12.8, 11.1, 
5.7 Hz, 1 H, H13); 13C NMR (100 MHz, CDCl3) δ 169.4 (C2), 148.0 (C23), 146.9 (C22), 136.5 
(C9), 127.8 (C4), 122.3 (C6), 122.2 (C2), 122.0 (C20), 119.6 (C7), 119.0 (C5), 113.5 (C3), 111.5 
(C8), 109.3 (C21), 108.2 (C24), 101.2 (C25), 58.0 (C18), 56.7 (C14), 48.4 (C10), 47.0 (C12), 




one (2.24) (LTL-II-185). The title compound was prepared following the general procedure of 
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2.16. The crude material was purified via flash column chromatography, eluting with 
EtOAc:Et3N (99:1) to furnish 19 mg (64%) of 2.24 as a pale yellow solid.
 1H NMR (400 MHz, 
CDCl3) δ 8.16 (s, 1 H), 7.65 (d, J = 7.8 Hz, 1 H), 7.36 (dt, J = 8.1, 0.9 Hz, 1 H), 7.19 (ddd, J = 
8.1, 7.0, 1.2 Hz, 1 H), 7.11 (ddd, J = 7.8, 7.0, 1.1 Hz, 1 H), 7.03 (d, J = 2.4 Hz, 1 H), 6.90 (app s, 
1 H), 6.79 (t, J = 2.1 Hz, 1 H), 6.75 (app s, 1 H), 3.79 (s, 3 H), 3.73 – 3.59 (comp, 2 H), 3.47 (s, 2 
H), 3.22 – 2.99 (comp, 4 H), 2.79 (tdd, J = 11.0, 5.2, 3.1 Hz, 1 H), 2.62 (ddd, J = 17.0, 5.2, 2.2 
Hz, 1 H), 2.43 (dd, J = 17.0, 10.8 Hz, 1 H), 2.17 (s, 3 H), 1.90 (dt, J = 9.8, 3.6 Hz, 1 H), 1.60 
(dtd, J = 12.8, 11.1, 5.7 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 169.1, 160.3, 142.6, 136.2, 
134.7, 127.5, 122.03, 121.94 120.8, 119.3, 118.8, 113.2, 112.73, 112.69, 111.2, 57.6, 56.7, 55.5, 
48.1, 46.7, 37.4, 34.9, 26.3, 23.0; IR (NaCl, film) 3262, 3056, 2933, 2853, 2361, 1623, 1576, 
1498, 1459, 1431, 1344, 1312, 1271, 1233, 1150, 1097, 1053, 980, 845, 743, 679, 621 cm-1; 
HRMS (ESI) m/z calc’d for C24H28ClN3O2 (M+Na)+ 448.1762; found, 448.1758.  
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1 H, H1), 7.65 (d, J = 7.8 Hz, 
1 H, H5), 7.36 (dt, J = 8.1, 0.9 Hz, 1 H, H8), 7.19 (ddd, J = 8.1, 7.0, 1.2 Hz, 1 H, H7), 7.11 (ddd, 
J = 7.8, 7.0, 1.1 Hz, 1 H, H6), 7.03 (d, J = 2.4 Hz, 1 H, H2), 6.90 (app s, 1 H, H22), 6.79 (t, J = 
2.1 Hz, 1 H, H20), 6.75 (app s, 1 H, H24), 3.79 (s, 3 H, H25), 3.73 – 3.59 (comp, 2 H, H10), 3.47 
(s, 2 H, H18), 3.22 – 2.99 (comp, 4 H, H12, H11), 2.79 (tdd, J = 11.0, 5.2, 3.1 Hz, 1 H, H14), 
2.62 (ddd, J = 17.0, 5.2, 2.2 Hz, 1 H, H15), 2.43 (dd, J = 17.0, 10.8 Hz, 1 H, H15), 2.17 (s, 3 H, 
H17), 1.90 (dt, J = 9.8, 3.6 Hz, 1 H, H13), 1.60 (dtd, J = 12.8, 11.1, 5.7 Hz, 1 H, H13); 13C NMR 
(100 MHz, CDCl3) δ 169.1 (C16), 160.3 (C23), 142.6 (C19), 136.2 (C9), 134.7 (C21), 127.5 
(C4), 122.03 (C6), 121.94 (C2), 120.8 (C20), 119.3 (C5), 118.8 (C7), 113.2 (C3), 112.73 (C22), 
112.69 (C24), 111.2 (C8), 57.6 (C18), 56.7 (C14), 55.5 (C25), 48.1 (C10), 46.7 (C12), 37.4 





(2.25) (LTL-II-154). The title compound was prepared following the general procedure of 2.16. 
The crude material was purified via flash column chromatography, eluting with 
hexanes:EtOAc:Et3N (50:50:1 → 0:99:1) to furnish 31 mg (67%) of 2.25 as a white solid. 
1H 
NMR (400 MHz, CDCl3) δ 8.31 (s, 1 H), 7.64 (d, J = 7.9 Hz, 1 H), 7.35 (dt, J = 8.1, 1.0 Hz, 1 
H), 7.18 (ddd, J = 8.2, 7.0, 1.2 Hz, 1 H), 7.11 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H), 6.99 (d, J = 2.4 Hz, 
1 H), 6.49 (d, J = 2.3 Hz, 2 H), 6.37 (t, J = 2.3 Hz, 1 H), 3.79 (s, 6 H), 3.73 – 3.57 (comp, 2 H), 
3.49 (s, 2 H), 3.16 (ddd, J = 12.1, 5.5, 3.1 Hz, 1 H), 3.11 – 2.95 (comp, 3 H), 2.81 (tdd, J = 10.9, 
5.0, 3.0 Hz, 1 H), 2.62 (ddd, J = 17.0, 5.2, 2.2 Hz, 1 H), 2.45 (dd, J = 17.0, 10.8 Hz, 1 H), 2.20 
(s, 3 H), 1.94 – 1.86 (m, 1 H), 1.61 (dtd, J = 12.8, 11.2, 5.6 Hz, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 170.1, 161.6, 137.0, 128.1, 122.64, 122.58, 119.9, 119.3, 113.7, 111.8, 107.0, 99.5, 
58.5, 56.7, 55.6, 48.3, 46.9, 37.6, 35.1, 26.2, 23.1; IR (NaCl, film) 3261, 3057, 2936, 2840, 2792, 
2243, 1613, 1498, 1457, 1430, 1344, 1299, 1234, 1204, 1154, 1101, 1065, 983, 910, 836, 739 
cm-1; HRMS (ESI) m/z calcd for C25H31N3O3 (M+Na)+ 444.2258; found 444.2252. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.31 (s, 1 H, H1), 7.64 (d, J = 7.9 Hz, 
1 H, H5), 7.35 (dt, J = 8.1, 1.0 Hz, 1 H, H8), 7.18 (ddd, J = 8.2, 7.0, 1.2 Hz, 1 H, H6), 7.11 (ddd, 
J = 8.0, 7.0, 1.1 Hz, 1 H, H7), 6.99 (d, J = 2.4 Hz, 1 H, H2), 6.49 (d, J = 2.3 Hz, 2 H, H20), 6.37 
(t, J = 2.3 Hz, 1 H, H22), 3.79 (s, 6 H, H23), 3.73 – 3.57 (comp, 2 H, H10), 3.49 (s, 2 H, H18), 
3.16 (ddd, J = 12.1, 5.5, 3.1 Hz, 1 H, H12), 3.11 – 2.95 (comp, 3 H, H12, H11), 2.81 (tdd, J = 
10.9, 5.0, 3.0 Hz, 1 H, H14), 2.62 (ddd, J = 17.0, 5.2, 2.2 Hz, 1 H, H15), 2.45 (dd, J = 17.0, 10.8 
Hz, 1 H, H15), 2.20 (s, 3 H, H17), 1.94 – 1.86 (m, 1 H, H13), 1.61 (dtd, J = 12.8, 11.2, 5.6 Hz, 1 
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H, H13); 13C NMR (100 MHz, CDCl3) δ 170.1 (C16), 161.6 (C21), 140.9 (C19), 137.0 (C9), 
128.1 (C4), 122.64 (C6), 122.58 (C2), 119.9 (C5), 119.3 (C7), 113.7 (C3), 111.8 (C8), 107.0 
(C20), 99.5 (C22), 58.5 (C18), 56.7 (C14), 55.6 (C23), 48.3 (C10), 46.9 (C12), 37.6 (C17), 35.1 




(2.26) (LTL-IV-013). The title compound was prepared following the general procedure of 2.16. 
The crude material was purified via flash column chromatography, eluting with 
hexanes:EtOAc:Et3N (50:50:1) to furnish 29 mg (81%) 2.26 as a pale yellow solid. 
1H NMR 
(400 MHz, CDCl3) δ 8.15 (s, 0.89 H), 7.65 (d, J = 8 Hz, 1.24 H), 7.27 (m, 4.76 H), 7.21 (t, J = 7 
Hz, 1.59 H), 7.13 (t, J = 7 Hz, 1.37 H), 7.05 (d, J = 2 Hz, 1.31 H), 3.74 (comp, 3.96 H), 3.12 
(comp, 5.07 H), 2.69 (d, J = 18 Hz, 0.99 H), 2.53 (m, 0.83 H), 2.25 (s, 2.93 H), 2.10 (m, 1.21 H), 
1.69 (m, 1.49 H); 13C NMR (100 MHz, CDCl3) δ 135.2, 133.3, 128.6, 127.6, 126.4, 123.8, 121.0, 
120.9, 118.3, 117.7, 112.2, 110.2, 56.4, 55.8, 47.1, 45.6, 36.2, 33.7, 25.3, 22.0; IR (NaCl, film) 
3251, 3055, 2925, 2853, 1742, 1626, 1575, 1497, 1456, 1433, 1344, 1303, 1260, 1231, 1161, 
1097, 1075, 1030, 784, 742, 684 cm-1; HRMS (ESI) m/z calcd for C23H26ClN3O (M+Na)+ 
418.1657; found 418.1649.  
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.15 (s, 0.89 H, H1), 7.65 (d, J = 8 
Hz, 1.24 H, H5), 7.38 (d, J = 8 Hz, 2.80 H, H8) 7.27 (m, 4.76 H, H20, H22, H23, H24), 7.21 (t, J 
= 7 Hz, 1.59 H, H6), 7.13 (t, J = 7 Hz, 1.37 H, H7), 7.05 (d, J = 2 Hz, 1.31 H, H2), 3.74 (comp, 
3.96 H, H10, H18), 3.12 (comp, 5.07 H, H12, H11, H14), 2.69 (d, J = 18 Hz, 0.99 H, H15), 2.53 
(m, 0.83 H, H15), 2.25 (s, 2.93 H, H17), 2.10 (m, 1.21 H, H13), 1.69 (m, 1.49 H, H13); 13C 
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NMR (100 MHz, CDCl3) δ 135.2 (C9), 133.3 (C21), 128.6 (C23), 127.6 (C4), 126.6 (C22), 
126.4 (C20), 123.8 (C24), 121.0 (C6), 120.9 (C2), 118.3 (C7), 117.7 (C5), 112.2 (C3), 110.2 





(2.27) (LTL-II-153). The title compound was prepared following the general procedure of 2.16. 
The crude material was purified via flash column chromatography, eluting with EtOAc:Et3N 
(99:1) to furnish 26 mg (60%) of 2.27 as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1 
H), 7.64 (d, J = 7.6 Hz, 1 H), 7.35 (dt, J = 8.1, 0.9 Hz, 1 H), 7.23 (t, J = 8.0 Hz, 1 H), 7.18 (ddd, 
J = 8.1, 7.0, 1.3 Hz, 1 H), 7.11 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H), 7.00 (d, J = 2.4 Hz, 1 H), 6.92 – 
6.84 (comp, 2 H), 6.81 (ddd, J = 8.2, 2.6, 1.1 Hz, 1 H), 3.81 (s, 3 H), 3.72 – 3.58 (comp, 2 H), 
3.53 (s, 2 H), 3.16 (ddd, J = 12.1, 5.6, 3.1 Hz, 1 H), 3.13 – 2.95 (comp, 3 H), 2.81 (tdd, J = 11.0, 
5.1, 3.1 Hz, 1 H), 2.64 (ddd, J = 16.9, 5.2, 2.2 Hz, 1 H), 2.46 (dd, J = 16.9, 10.8 Hz, 1 H), 2.19 
(s, 3 H), 1.92 (d, J = 12.7 Hz, 1 H), 1.62 (dtd, J = 12.8, 11.2, 5.6 Hz, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 169.2, 159.7, 136.3, 129.3, 127.5, 122.02, 121.97, 121.0, 119.3, 118.7, 114.2, 113.1, 
112.5, 111.2, 58.0, 56.5, 55.2, 48.1, 46.7, 37.3, 34.9, 26.2, 23.0; IR (NaCl, film) 3261, 3055, 
2935, 2852, 2791, 2360, 2242, 1624, 1491, 1456, 1344, 1304, 1268, 1152, 1011, 1043, 978, 910, 
784, 743, 695 cm-1; HRMS (ESI) m/z calcd for C24H29N3O2 (M+H)+ 392.2333; found 392.2329.  
NMR assignment. 1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1 H, H1), 7.64 (d, J = 7.6 Hz, 
1 H, H5), 7.35 (dt, J = 8.1, 0.9 Hz, 1 H, H8), 7.23 (t, J = 8.0 Hz, 1 H, H23), 7.18 (ddd, J = 8.1, 
7.0, 1.3 Hz, 1 H, H6), 7.11 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H, H7), 7.00 (d, J = 2.4 Hz, 1 H, H2), 
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6.92 – 6.84 (comp, 2 H, H20, H24), 6.81 (ddd, J = 8.2, 2.6, 1.1 Hz, 1 H, H22), 3.81 (s, 3 H, 
H25), 3.72 – 3.58 (comp, 2 H, H10), 3.53 (s, 2 H, H18), 3.16 (ddd, J = 12.1, 5.6, 3.1 Hz, 1 H, 
H12), 3.13 – 2.95 (comp, 3 H, H12, H11), 2.81 (tdd, J = 11.0, 5.1, 3.1 Hz, 1 H, H14), 2.64 (ddd, 
J = 16.9, 5.2, 2.2 Hz, 1 H, H15), 2.46 (dd, J = 16.9, 10.8 Hz, 1 H, H15), 2.19 (s, 3 H, H17), 1.92 
(d, J = 12.7 Hz, 1 H, H13), 1.62 (dtd, J = 12.8, 11.2, 5.6 Hz, 1 H, H13); 13C NMR (100 MHz, 
CDCl3) δ 169.2 (C16), 159.7 (C21), 136.3 (C9), 129.3 (C24), 127.5 (C4), 122.02 (C6), 121.97 
(C2), 121.0 (C23), 119.3 (C5), 118.7 (C7), 114.2 (C20), 113.1 (C3), 112.5 (C22), 111.2 (C8), 





(2.28) (LTL-II-157). The title compound was prepared following the general procedure of 2.16. 
The crude material was purified via flash column chromatography, eluting with EtOAc:Et3N 
(99:1) to furnish 32 mg (71%) of 2.28 as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 8.28 
(s, 1 H), 7.64 (d, J = 7.8 Hz, 1 H), 7.35 (dt, J = 8.1, 1.0 Hz, 1 H), 7.26 – 7.08 (comp, 5 H), 7.06 
(dt, J = 7.5, 1.4 Hz, 1 H), 6.99 (d, J = 2.4 Hz, 1 H), 3.66 (t, J = 7.5 Hz, 2 H), 3.51 (s, 2 H), 3.16 
(ddd, J = 12.1, 5.5, 3.1 Hz, 1 H), 3.12 – 2.96 (comp, 3 H), 2.80 (tdd, J = 11.0, 5.1, 3.1 Hz, 1 H), 
2.63 (ddd, J = 16.9, 5.2, 2.2 Hz, 1 H), 2.48 (comp, 4 H), 2.18 (s, 3 H), 1.90 (dt, J = 12.8, 3.4 Hz, 
1 H), 1.61 (dtd, J = 12.8, 11.2, 5.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 169.2, 140.0, 138.4, 
136.3, 128.8, 127.4, 126.6, 125.4, 125.1, 121.96, 119.26, 118.7, 113.1, 111.2, 57.8, 56.5, 48.1, 
46.7, 37.3, 34.9, 26.3, 23.0, 15.8; IR (NaCl, film) 3261, 3054, 2922, 2854, 1622, 1498, 1456, 
 169 
1344, 1303, 1232, 1158, 1100, 1030, 780, 743, 686 cm-1; HRMS (ESI) m/z calcd for 
C24H29N3OS (M+Na)+ 430.1924; found 430.1920. 
NMR assignment. 1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1 H, H1), 7.64 (d, J = 7.8 Hz, 
1 H, H5), 7.35 (dt, J = 8.1, 1.0 Hz, 1 H, H8), 7.26 – 7.08 (comp, 5 H, H24, H23, H20, H7, H6), 
7.06 (dt, J = 7.5, 1.4 Hz, 1 H, H22), 6.99 (d, J = 2.4 Hz, 1 H, H2), 3.66 (t, J = 7.5 Hz, 2 H, H10), 
3.51 (s, 2 H, H18), 3.16 (ddd, J = 12.1, 5.5, 3.1 Hz, 1 H, H12), 3.12 – 2.96 (comp, 3 H, H12, 
H11), 2.80 (tdd, J = 11.0, 5.1, 3.1 Hz, 1 H, H14), 2.63 (ddd, J = 16.9, 5.2, 2.2 Hz, 1 H, H15), 
2.48 (comp, 4 H, H25, H15), 2.18 (s, 3 H, H17), 1.90 (dt, J = 12.8, 3.4 Hz, 1 H, H13), 1.61 (dtd, 
J = 12.8, 11.2, 5.6 Hz, 1 H, H13); 13C NMR (100 MHz, CDCl3) δ 169.2 (C16), 140.0 (C19), 
138.4 (C21), 136.3 (C9), 128.8 (24), 127.4 (C4), 126.6 (C23), 125.4 (C20), 125.1 (C21), 122.0 
(C6, C2), 119.3 (C7), 118.7 (C5), 113.1 (C3), 111.2 (C8), 57.8 (C18), 56.5 (C14), 48.1 (C10), 




012). The title compound was prepared following the general procedure of 2.16. The crude 
material was purified via flash column chromatography, eluting with EtOAc:Et3N (99:1) to 
furnish 23 mg (70%) of 2.29 as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1 H), 7.65 
(d, J = 7.8 Hz, 1 H), 7.36 (d, J = 8.2 Hz, 1 H), 7.34 – 7.26 (comp, 5 H), 7.19 (ddd, J = 8.2, 7.0, 
1.2 Hz, 1 H), 7.12 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H), 7.03 (d, J = 2.3 Hz, 1 H), 3.66 (hept, J = 6.8, 
6.1 Hz, 2 H), 3.56 (s, 2 H), 3.21 – 2.99 (comp, 4 H), 2.87 – 2.77 (m, 1 H), 2.69 – 2.61 (m, 1 H), 
2.47 (dd, J = 17.0, 10.8 Hz, 1 H), 2.19 (s, 3 H), 1.98 – 1.89 (m, 1 H), 1.63 (qd, J = 11.5, 5.6 Hz, 
1 H); 13C NMR (100 MHz, CDCl3) δ 136.2, 128.9, 128.4, 127.5, 122.05, 121.91, 119.4, 118.8, 
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113.2, 111.2, 57.9, 56.6, 48.1, 46.7, 26.3, 23.0; IR (NaCl, film) 2923, 2851, 2793, 2242, 1625, 
1496, 1456, 1343, 1302, 1260, 1233, 1159, 1101, 1074, 1025, 909, 813, 741, 700 cm-1; HRMS 
(ESI) m/z calcd for C23H27N3O (M+Na)+ 384.2046; found 384.2039. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1 H, H1), 7.65 (d, J = 7.8 Hz, 
1 H, H5), 7.36 (d, J = 8.2 Hz, 1 H, H8), 7.34 – 7.26 (comp, 5 H, H22, H21, H20), 7.19 (ddd, J = 
8.2, 7.0, 1.2 Hz, 1 H, H6), 7.12 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H, H7), 7.03 (d, J = 2.3 Hz, 1 H, 
H2), 3.66 (hept, J = 6.8, 6.1 Hz, 2 H, H10), 3.56 (s, 2 H, H18), 3.21 – 2.99 (comp, 4 H, H12, 
H11), 2.87 – 2.77 (m, 1 H, H14), 2.69 – 2.61 (m, 1 H, H15), 2.47 (dd, J = 17.0, 10.8 Hz, 1 H, 
H15), 2.19 (s, 3 H, H17), 1.98 – 1.89 (m, 1 H, H13), 1.63 (qd, J = 11.5, 5.6 Hz, 1 H, H13); 13C 
NMR (100 MHz, CDCl3) δ 136.2 (C9), 128.9 (C21), 128.4 (C20), 127.5 (C4), 122.05 (C6), 
121.91 (C2), 119.4 (C7), 118.8 (C5), 113.2 (C3), 111.2 (C8), 57.9 (C18), 56.6 (C14), 48.1 (C10), 
46.7 (C12), 26.3 (C13), 23.0 (C11). 
 
 
1-(2-(1H-Indol-3-yl)ethyl)-4-aminopiperidin-2-one (LTL-IV-011). A solution of 2.20 
(26 mg, 0.1 mmol), NH4OAc (144 mg, 2 mmol), and NaBH3CN (32 mg, 0.5 mmol) in MeOH (2 
mL) was stirred while heating under reflux for 3 h, whereupon the solution was cooled to rt and 
diluted with 1 M aq NaOH. The aqueous layer was extracted with CH2Cl2 (3 x 20 mL), dried 
(Na2SO4) and concentrated via rotary evaporation. The crude material was purified by flash 
chromatography eluting with CH2Cl2:MeOH:Et3N (97:3:1 → 95:5:1) to give 14 mg (54%) of 
2.30 as a white solid. 1H NMR (400 MHz, CD3CN) δ 9.20 (s, 1 H), 7.64 (ddt, J = 7.8, 1.4, 0.8 
Hz, 1 H), 7.40 (dt, J = 8.1, 1.0 Hz, 1 H), 7.15 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.11 (d, J = 2.2 Hz, 
1H), 7.07 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 3.64 – 3.49 (comp, 2 H), 3.29 (dt, J = 12.1, 5.3 Hz, 1 
H), 3.22 – 3.06 (comp, 2 H), 2.96 (dddd, J = 8.0, 7.2, 1.8, 0.9 Hz, 2 H), 2.47 (ddd, J = 17.0, 5.1, 
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1.8 Hz, 1 H), 2.05 – 1.98 (m, 1 H), 1.82 (dtdd, J = 13.2, 5.1, 3.2, 1.8 Hz, 1 H), 1.47 (dtdd, J = 
13.0, 9.2, 5.4, 0.6 Hz, 1 H), 1.30 – 1.20 (m, 2 H); 13C NMR (101 MHz, CD3OD) δ 168.1, 136.7, 
127.4, 122.1, 121.0, 118.3, 117.8, 111.6, 110.9, 48.6, 48.2, 45.6, 44.8, 38.0, 28.7, 22.4; IR (film, 
NaCl) 3728, 2926, 1617, 1500, 1456, 1343, 1304, 1261, 1232, 1158, 1103, 1016 cm -1; HRMS 
(ESI) m/z calcd for C15H19N3O (M+Na)+ 280.1420; found 280.1427. 
NMR Assignment. 1H NMR (400 MHz, CD3CN) δ 9.20 (s, 1 H, N-H), 7.64 (ddt, J = 7.8, 
1.4, 0.8 Hz, 1 H, H14), 7.40 (dt, J = 8.1, 1.0 Hz, 1 H, H11), 7.15 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H, 
H12), 7.11 (d, J = 2.2 Hz, 1H, H9), 7.07 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, H13), 3.64 – 3.49 (comp, 
2 H, H6), 3.29 (dt, J = 12.1, 5.3 Hz, 1 H, H5), 3.22 – 3.06 (comp, 2 H, H5, H3), 2.96 (dddd, J = 
8.0, 7.2, 1.8, 0.9 Hz, 2 H, H7), 2.47 (ddd, J = 17.0, 5.1, 1.8 Hz, 1 H, H2), 2.05 – 1.98 (m, 1 H, 
H2), 1.82 (dtdd, J = 13.2, 5.1, 3.2, 1.8 Hz, 1 H, H4), 1.47 (dtdd, J = 13.0, 9.2, 5.4, 0.6 Hz, 1 H, 





(LTL-IV-006). A solution of 2.30 (20 mg, 0.08 mmol), 3,5-dichlorobenzaldehyde (15 mg, 0.09 
mmol), and AcOH (0.08 mL, 0.08 mmol) in MeOH (1.5 mL) was stirred at room temperature for 
3 h. Then, NaBH3CN (10 mg, 0.16 mmol) was added and the reaction was stirred for an 
additional 14 h, whereupon the reaction was diluted with saturated NaHCO3 (20 mL) and 
extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried (Na2SO4) and 
concentrated via rotary evaporation. The crude material was purified by flash column 
 172 
chromatography, eluting with hexanes:EtOAc:Et3N (50:50:1 → 0:100:1) to give 25 mg (78%) of 
2.31 (25 mg, 78%) as a white foam. 1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1 H), 7.68 – 7.62 (d, 
J = 8.1 Hz  1 H), 7.35 (d, J = 8.1 Hz, 1 H), 7.25 (t, J = 1.9 Hz, 1 H), 7.22 – 7.16 (comp, 3 H), 
7.11 (m, 1 H), 7.04 (d, J = 2.3 Hz, 1 H), 3.78 – 3.59 (comp, 4 H), 3.21 (dt, J = 11.3, 5.4 Hz, 1 H), 
3.15 – 3.01 (comp, 3 H), 2.92 (tdd, J = 8.4, 5.1, 3.1 Hz, 1 H), 2.67 (dd, J = 17.1, 5.2 Hz, 1 H), 
2.24 (dd, J = 17.1, 8.2 Hz, 1 H), 1.93 – 1.81 (m, 1 H), 1.54 (m, 1 H). 13C NMR (101 MHz, 
CDCl3) δ 168.2, 143.7, 136.2, 134.9, 127.5, 127.2, 126.3, 122.0, 121.9, 119.3, 118.7, 113.3, 
111.2, 50.9, 49.9, 48.2, 45.6, 39.4, 29.0, 23.0; IR (NaCl, film) 3263, 3058, 2926, 2855, 1624, 
1568, 1456, 1431, 1343, 1301, 1229, 1100 cm-1. HRMS (ESI) m/z calcd for C22 H23Cl2N3O 
(M+H)+ 438.1112; found 438.1110. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1 H, H21), 7.68 – 7.62 (d, J = 
8.1 Hz, 1 H, H16), 7.35 (d, J = 8.1 Hz, 1 H, H19), 7.25 (t, J = 1.9 Hz, 1 H, H1), 7.22 – 7.16 
(comp, 3 H, H3, H18), 7.11 (m, 1 H, H17), 7.04 (d, J = 2.3 Hz, 1 H, H22), 3.78 – 3.59 (comp, 4 
H, H5, H13), 3.21 (dt, J = 11.3, 5.4 Hz, 1 H, H10), 3.15 – 3.01 (comp, 3 H, H12, H10), 2.92 (tdd, 
J = 8.4, 5.1, 3.1 Hz, 1 H, H7), 2.67 (dd, J = 17.1, 5.2 Hz, 1 H, H8), 2.24 (dd, J = 17.1, 8.2 Hz, 1 
H, H8), 1.93 – 1.81 (m, 1 H, H11), 1.54 (m, 1 H, H11). 13C NMR (101 MHz, CDCl3) δ 168.20 
(C9), 143.74 (C4), 136.23 (C20), 134.93 (C1), 127.47 (C15), 127.23 (C2), 126.32 (C3), 122.03 
(C17), 121.93 (C22), 119.34 (C18), 118.73 (C16), 113.25 (C14), 111.18 (C19), 50.86 (C5), 




(2.32) (LTL-IV-007). The title compound was prepared following the general procedure of 2.31. 
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The crude material was purified by flash column chromatography, eluting with 
hexanes:EtOAc:Et3N (50:50:1 → 0:100:1) to give 23 mg (74%) of 2.32 (25 mg, 78%) as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 8.24 (s, 0.78 H), 7.65 (d, J = 8 Hz, 0.88 H), 7.37 (d, J = 8 
Hz, 0.96 H), 7.21 (t, J = 7 Hz, 1.00 H), 7.13 (t, J = 7 Hz, 0.97 H), 7.04 (d, J = 2 Hz, 0.92 H), 
6.87 (s, 0.88 H), 6.80 (t, J = 8 Hz, 1.99 H), 5.95 (s, 2.15 H), 3.26 (comp, 4.10 H), 3.19 (comp, 
4.18 H), 3.00 (m, 1.05 H), 2.74 (dd, J = 3 Hz, 17 Hz, 0.95 H), 2.39 (m, 0.96 H), 1.94 (m, 0.86 
H), 1.68 (m, 1.03 H), 0.89 (m, 1.11 H); 13C NMR (100 MHz, CDCl3) δ 186.1, 147.8, 146.9, 
136.2, 127.4, 122.0, 122.0, 121.5, 119.3, 118.7, 113.1, 111.2, 108.8, 108.2, 101.0, 50.4, 50.3, 
48.1, 45.7, 38.8, 28.5, 23.0; IR (NaCl, film) 3264, 2925, 1622, 1502, 1490, 1444, 1244, 1302, 
1249, 1100, 1038, 928, 810, 743 cm-1; HRMS (ESI) m/z calcd for C23H25N3O3 (M+H)+ 
392.1969; found 392.1969. 
NMR assignment. 1H NMR (400 MHz, CDCl3) δ 8.24 (s, 0.78 H, H1), 7.65 (d, J = 8 Hz, 
0.88 H, H5), 7.37 (d, J = 8 Hz, 0.96 H, H8), 7.21 (t, J = 7 Hz, 1.00 H, H6), 7.13 (t, J = 7 Hz, 
0.97 H, H7), 7.04 (d, J = 2 Hz, 0.92 H, H2), 6.87 (s, 0.88 H, H20), 6.80 (t, J = 8 Hz, 1.99 H, 
H21, H24), 5.95 (s, 2.15 H, H25), 3.26 (comp, 4.10 H, H10, H18), 3.19 (comp, 4.18 H, H12, 
H11), 3.00 (m, 1.05 H, H14), 2.74 (dd, J = 3 Hz, 17 Hz, 0.95 H, H15), 2.39 (m, 0.96 H, H15), 
1.94 (m, 0.86 H, H13), 1.68 (m, 1.03 H, H13), 0.89 (m, 1.11 H, H17); 13C NMR (100 MHz, 
CDCl3) δ 168.1 (C16), 147.8 (C23), 146.9 (C22), 136.2 (C9), 127.4 (C4), 122.0 (C6), 122.0 
(C2), 121.5 (C20), 119.3 (C4), 118.7 (C5), 113.1 (C3), 111.2 (C8), 108.8 (C21), 108.2 (C24), 





202). Powdered KOH (22.4 mg, 0.4 mmol) and 2.14 (30 mg, 0.1 mmol) were dissolved in 
DMSO (1 mL). Then β-bromophenetole (40.2 mg, 0.2 mmol) was added, and the reaction was 
stirred at room temperature for 2 h, whereupon it was poured into 1 M HCl (50 mL) and the 
aqueous layer was washed with hexanes (50 mL). 1 M NaOH was then added to the aqueous 
layer until the solution became opaque. The aqueous layer was then extracted with CH2Cl2 (3 x 
50 mL). The combined organic layers were then dried (Na2SO4) and concentrated via rotary 
evaporation. The crude material was then purified by flash column chromatography, eluting with 
hexanes:EtOAc (2:1) to give 18 mg (44%) of 2.36 as a white solid. 1H NMR (400 MHz, CDCl3) 
δ 7.33 – 7.17 (comp, 5 H), 6.95 (tt, J = 7.3, 1.1 Hz, 1 H), 6.92 – 6.84 (comp, 2 H), 4.17 (t, J = 5.1 
Hz, 2 H), 3.83 – 3.66 (comp, 2 H), 3.58 (ddd, J = 12.3, 5.5, 3.1 Hz, 1 H), 3.49 (d, J = 12.1 Hz, 3 
H), 2.89 (tdd, J = 11.0, 5.2, 3.2 Hz, 1 H), 2.61 (ddd, J = 17.0, 5.3, 2.2 Hz, 1 H), 2.41 (dd, J = 
17.0, 10.8 Hz, 1 H), 2.18 (s, 3 H), 2.05 (dq, J = 6.6, 3.4 Hz, 1 H), 1.75 (dtd, J = 12.9, 11.3, 5.5 
Hz, 1 H) ppm; 13C NMR (101 MHz, CDCl3) δ 169.4, 158.5, 143.2, 134.9, 129.5, 127.2, 126.7, 
121.0, 114.4, 66.4, 57.0, 48.1, 47.1, 37.4, 34.8, 26.6 ppm. IR (NaCl, film) 3064, 2938, 2872, 
2791, 1644, 1599, 1568, 1496, 1456, 1433, 1341, 1301, 1242, 1172, 1153, 1125, 1098, 1079, 
1046 cm-1; HRMS (ESI) m/z calcd for C21H24Cl2N2O2 (M+H)+ 407.1288; found 407.1291. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.17 (m, 5 H, H1, H3, H14), 
6.95 (tt, J = 7.3, 1.1 Hz, 1 H, H16), 6.92 – 6.84 (m, 2 H, H15), 4.17 (t, J = 5.1 Hz, 2 H, H13), 
3.83 – 3.66 (m, 2 H, H12), 3.58 (ddd, J = 12.3, 5.5, 3.1 Hz, 1 H, H9), 3.49 (d, J = 12.1 Hz, 3 H, 
H9, H5), 2.89 (tdd, J = 11.0, 5.2, 3.2 Hz, 1 H, H7), 2.61 (ddd, J = 17.0, 5.3, 2.2 Hz, 1 H, H10), 
2.41 (dd, J = 17.0, 10.8 Hz, 1 H, H10), 2.18 (s, 3 H, H6), 2.05 (dq, J = 6.6, 3.4 Hz, 1 H, H8), 
1.75 (dtd, J = 12.9, 11.3, 5.5 Hz, 1 H, H8); 13C NMR (101 MHz, CDCl3) δ 169.38 (C11), 158.48 
(C14), 143.21 (C4), 134.88 (C1), 129.51 (C16), 127.22 (C2), 126.71 (C3), 120.96 (C17), 114.36 




Tert-butyl 4-((3,5-dichlorobenzyl)(methyl)amino)piperidine-1-carboxylate (7.1) 
(LTL-IV-026). A solution of tert-butyl 4-(methylamino)piperidine-1-carboxylate (44 mg, 0.2 
mmol), 3,5-dichlorobenzaldehyde (53 mg, 0.3 mmol), acetic acid (12 mg, 0.2 mmol), and 
sodium triacetoxyborohydride (85 mg, 0.4 mmol) in 1,2-dichloroethane (2 mL) was stirred at 
room temperature for 18 h, whereupon the solution was diluted with 1 M NaOH (15 mL) and 
extracted with Et2O (3 x 15 mL). The combined organic extracts were dried (Na2SO4) and 
concentrated via rotary evaporation. The crude material was purified by flash chromatography 
eluting with hexane:EtOAc:Et3N (95:5:1) to give 48 mg (64%) of 7.1 as an opaque white oil. 
1H 
NMR (400 MHz, CDCl3 δ 7.23 – 7.19 (comp, 3 H), 4.16 (s, 2 H), 3.50 (s, 2 H), 2.75 – 2.61 
(comp, 2 H), 2.55 (tt, J = 11.5, 3.6 Hz, 1 H), 2.17 (s, 3 H), 1.83 – 1.70 (comp, 2 H), 1.45 (comp, 
11 H). 13C NMR (101 MHz, CDCl3) δ 154.7, 143.9, 134.7, 126.9, 126.7, 79.4, 61.1, 57.0, 43.1, 
37.7, 28.4, 27.9; IR (NaCl, film) 2975, 2940, 2854, 2788, 1694, 1590, 1569, 1451, 1425, 1365, 
1330, 1275, 1244, 1159, 1111, 1046, 1004 cm-1. HRMS (ESI) m/z calcd for C18 H26Cl2N2O2 
(M+H)+ 373.1444; found 373.1454. 
NMR Assignment. 1H NMR (400 MHz, CDCl3 δ 7.23 – 7.19 (comp, 3 H, H12, H10), 
4.16 (s, 2 H, H4), 3.50 (s, 2 H, H8), 2.75 – 2.61 (comp, 2 H, H4), 2.55 (tt, J = 11.5, 3.6 Hz, 1 H, 
H6), 2.17 (s, 3 H, H7), 1.83 – 1.70 (comp, 2 H, H5), 1.45 (comp, 11 H, H5, H1). 13C NMR (101 
MHz, CDCl3) δ 154.7 (C3), 143.9 (C9), 134.7 (C12), 126.9 (C11), 126.7 (C10), 79.4 (C2), 61.1 





(7.2) (LTL-IV-027). The title compound was prepared following the general procedure of 7.1. 
The crude material was purified via flash column chromatography, eluting with 
hexane:EtOAc:Et3N (95:5:1) to give 57 mg (77%) of 7.2 as a clear oil. 
1H NMR (400 MHz, 
CDCl3) δ 6.91 (t, J = 1.6 Hz, 1 H), 6.76 (d, J = 1.7 Hz, 2 H), 4.15 (s, 2 H), 3.78 (s, 3 H), 3.49 (s, 
2 H), 2.68 (s, 2 H), 2.54 (tt, J = 11.4, 3.6 Hz, 1 H), 2.18 (s, 3 H), 1.77 (d, J = 12.8 Hz, 2 H), 1.45 
(comp, 11 H). 13C NMR (101 MHz, CDCl3) δ 160.2, 154.7, 143.2, 134.6, 120.8, 112.6, 112.5, 
79.4, 60.8, 57.5, 55.4, 43.1, 37.7, 28.4, 27.9; IR (NaCl, film) 2939, 2853, 2789, 1694, 1599, 
1578, 1460, 1425, 1365, 1315, 1272, 1244, 1159, 1111, 1053 cm-1. HRMS (ESI) m/z calcd for 
C19H29ClN2O3 (M+H)+ 369.1939; found 369.1944. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 6.91 (t, J = 1.6 Hz, 1 H, H12), 6.76 (d, 
J = 1.7 Hz, 2 H, H10, H14), 4.15 (s, 2 H, H4), 3.78 (s, 3 H, H15), 3.49 (s, 2 H, H8), 2.68 (s, 2 H, 
H4), 2.54 (tt, J = 11.4, 3.6 Hz, 1 H, H6), 2.18 (s, 3 H, H7), 1.77 (d, J = 12.8 Hz, 2 H, H5), 1.45 
(comp, 11 H, H5, H1). 13C NMR (101 MHz, CDCl3) δ 160.2 (C13), 154.7 (C3), 143.2 (C9), 
134.6 (C11), 120.8 (C10), 112.6 (C12), 112.5 (C14), 79.4 (C2), 60.8 (C6), 57.5 (C8), 55.4 (C15), 




Tert-butyl 4-((3-chlorobenzyl)(methyl)amino)piperidine-1-carboxylate (7.3) (LTL-
IV-028). The title compound was prepared following the general procedure of 7.1. The crude 
material was dissolved in hexanes and a solution of HCl in 1,4-dioxane was added until the HCl 
salt of 7.3 precipitated out of solution. The suspension was decanted and washed with additional 
hexanes (2 x 10 mL), and the resultant residue was resuspended in 1M aq. NaOH (20 mL). The 
aqueous layer was extracted with Et2O (3 x 15 mL), dried (Na2SO4) and concentrated via rotary 
evaporation to give 48 mg (71%) of 7.3 as a clear oil. 1H NMR (300 MHz, CDCl3) δ 7.33 (s, 1 
H), 7.25 – 7.16 (comp, 3 H), 4.17 (s, 2 H), 3.54 (s, 2 H), 2.82 – 2.45 (comp, 3 H), 2.19 (s, 3 H), 
1.79 (d, J = 12.6 Hz, 2 H), 1.46 (comp, 11 H); 13C NMR (101 MHz, CDCl3) δ 154.7, 142.2, 
134.1, 129.4, 128.5, 127.0, 126.6, 79.4, 60.9, 57.4, 43.4 37.6, 28.4, 28.0; IR (NaCl, film) 2937, 
2853, 2788, 1694, 1598, 1574, 1475, 1452, 1424, 1365, 1330, 1275, 1243, 1158, 1111, 1075, 
1043, 1001 cm-1. HRMS (ESI) m/z calcd for C18H27ClN2O2 (M+H)+ 339.1834; found 339.1842. 
NMR Assignment. 1H NMR (300 MHz, CDCl3) δ 7.33 (s, 1 H, H10), 7.25 – 7.16 (comp, 
3 H, H12, H13, H14), 4.17 (s, 2 H, H4), 3.54 (s, 2 H, H8), 2.82 – 2.45 (comp, 3 H, H4, H6), 2.19 
(s, 3 H, H7), 1.79 (d, J = 12.6 Hz, 2 H, H5), 1.46 (comp, 11 H, H5, H1). 13C NMR (101 MHz, 
CDCl3) δ 154.7 (C3), 142.2 (C9), 134.1 (C11), 129.4 (C13), 128.5 (C10), 127.0 (C14), 126.6 




Tert-butyl 4-((3-methoxybenzyl)(methyl)amino)piperidine-1-carboxylate (7.4) 
(LTL-IV-016). The title compound was prepared following the general procedure of 7.1. The 
crude material was purified by flash chromatography eluting with hexane/EtOAc/Et3N (90:10:1) 
to give 44 mg (69%) of 7.4 as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.22 (t, J = 8.0 Hz, 1 H), 
6.89 (dt, J = 3.6, 1.5 Hz, 2 H), 6.78 (ddd, J = 8.1, 2.6, 1.0 Hz, 1 H), 4.15 (s, 2 H), 3.80 (s, 3 H), 
3.55 (s, 2 H), 2.67 (d, J = 13.4 Hz, 2 H), 2.62 – 2.51 (m, 1 H), 2.20 (s, 3 H), 1.79 (d, J = 12.6 Hz, 
2H), 1.46 (s, 11 H); 13C NMR (101 MHz, CDCl3) δ 159.6, 154.7, 141.6, 129.1, 120.9, 114.0, 
112.2, 79.3, 60.6, 57.9, 55.1, 43.4, 37.6, 28.4, 27.9; IR (NaCl, film) 2940, 2853, 2787, 1695, 
1601, 1587, 1488, 1454, 1425, 1365, 1330, 1274, 1243, 1158, 1110, 1046, 1003 cm-1. HRMS 
(ESI) m/z calcd for C19H30N2O3 (M+H)+ 335.2329; found 335.2324. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.22 (t, J = 8.0 Hz, 1 H, H13), 6.89 
(comp, 2 H, H12, H10), 6.78 (ddd, J = 8.1, 2.6, 1.0 Hz, 1 H, H14), 4.15 (s, 2 H, H4), 3.80 (s, 3 H, 
H15), 3.55 (s, 2 H, H8), 2.67 (d, J = 13.4 Hz, 2 H, H4), 2.62 – 2.51 (m, 1 H, H6), 2.20 (s, 3 H, 
H7), 1.79 (d, J = 12.6 Hz, 2H, H5), 1.46 (s, 11 H H5, H1); 13C NMR (101 MHz, CDCl3) δ 159.6 
(C11), 154.7 (C3), 141.6 (C9), 129.1 (C13), 120.9 (C14), 114.0 (C10), 112.2 (C12), 79.3 (C2), 





Tert-butyl 4-(methyl(3-(methylthio)benzyl)amino)piperidine-1-carboxylate (7.5) 
(LTL-IV-020). The title compound was prepared following the general procedure of 7.1. The 
crude material was purified by flash chromatography eluting with hexane/EtOAc/Et3N (90:10:1) 
to give 45 mg 967%) of 7.5 as an off-white oil. 1H NMR (400 MHz, CDCl3) δ 7.22 (s, 2 H), 7.12 
(dt, J = 7.9, 1.3 Hz, 1 H), 7.10 – 7.05 (m, 1 H), 4.16 (s, 2 H), 3.53 (s, 2 H), 2.68 (t, J = 12.5 Hz, 2 
H), 2.56 (tt, J = 11.3, 3.6 Hz, 1 H), 2.48 (s, 3 H), 2.19 (s, 3 H), 1.79 (d, J = 12.8 Hz, 2 H) 1.46 
(comp, 11 H). 13C NMR (101 MHz, CDCl3) δ 154.7, 140.7, 138.2, 128.6, 126.7, 125.4, 124.9, 
79.3, 60.8, 57.8, 43.4, 37.6, 28.4, 27.9, 15.8. IR (NaCl, film) 2975, 2929, 2854, 2787, 1695, 
1592, 1574, 1474, 1425, 1365, 1330, 1275, 1243, 1159, 1110, 1082, 1043, 1001 cm-1. HRMS 
(ESI) m/z calcd for C19H30N2O2S (M+Na)+ 373.1920; found 373.1934. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.22 (s, 2 H, H10, H12), 7.12 (dt, J = 
7.9, 1.3 Hz, 1 H, H13), 7.10 – 7.05 (m, 1 H, H14), 4.16 (s, 2 H, H4), 3.53 (s, 2 H, H8), 2.68 (t, J 
= 12.5 Hz, 2 H, H4), 2.56 (tt, J = 11.3, 3.6 Hz, 1 H, H6), 2.48 (s, 3 H, H15), 2.19 (s, 3 H, H7), 
1.79 (d, J = 12.8 Hz, 2 H, H5) 1.46 (comp, 11 H, H5, H1). 13C NMR (101 MHz, CDCl3) δ 154.7 
(C3), 140.7 (C9), 138.2 (C11), 128.6 (C10), 126.7 (C13), 125.4 (C12), 124.9 (C14), 79.3 (C2), 




N-(3-Chloro-5-methoxybenzyl)-N-methylpiperidin-4-amine (2.47) (LTL-IV-033). A 
solution of tert-butyl 4-((3-chloro-5-methoxybenzyl)(methyl)amino)piperidine-1-carboxylate (52 
mg, 0.14 mmol) and trifluoroacetic acid (160 mg, 1.4 mmol) in CH2Cl2 (2.8 mL) was stirred at 
room temperature for 24 h, whereupon the solvent was removed by rotary evaporation. The 
resulting solid was resuspended in 1 M HCl (20 mL) and washed with Et2O (20 mL). 3 M NaOH 
was added to the aqueous layer until the solution became cloudy, whereupon it was extracted 
with CH2Cl2 (3 x 20 mL), dried (Na2SO4) and concentrated via rotary evaporation to give 33 mg, 
(87%) of 2.47 as a clear oil. 1H NMR (400 MHz, CDCl3) δ 6.92 (ddd, J = 1.9, 1.3, 0.6 Hz, 1 H), 
6.79 – 6.74 (comp, 2 H), 3.78 (d, J = 0.5 Hz, 3 H), 3.51 (s, 2 H), 3.24 – 3.11 (comp, 2 H), 2.64 – 
2.47 (comp, 3 H), 2.20 (s, 3 H), 1.80 (s, 2 H), 1.58 – 1.44 (comp, 2 H). 13C NMR (101 MHz, 
CDCl3) δ 160.2, 143.4, 134.5, 120.9, 112.7, 112.5, 60.9, 57.3, 55.4, 46.1, 37.6, 29.0. IR (NaCl, 
film) 3303, 2940, 2849, 2791, 1599, 1578, 1461, 1430, 1356, 1316, 1271, 1148, 1094, 1053, 
1006 cm-1. HRMS (ESI) m/z calcd for C14H21ClN2O (M+H)+ 269.1415; found 269.1418. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 6.92 (ddd, J = 1.9, 1.3, 0.6 Hz, 1 H, 
H9), 6.79 – 6.74 (comp, 2 H, H7, H11), 3.78 (d, J = 0.5 Hz, 3 H, H12), 3.51 (s, 2 H, H5), 3.24 – 
3.11 (comp, 2 H, H1), 2.64 – 2.47 (comp, 3 H, H1, H3), 2.20 (s, 3 H, H4), 1.80 (s, 2 H, H2), 1.58 
– 1.44 (comp, 2 H, H2). 13C NMR (101 MHz, CDCl3) δ 160.2 (C10), 143.4 (C6), 134.5 (C8), 




N-(3,5-Dichlorobenzyl)-N-methylpiperidin-4-amine (2.46) (LTL-IV-032). The title 
compound was prepared following the general procedure of 2.47 to give 25 mg (76%) of 2.46 as 
a yellow paste. 1H NMR (400 MHz, CDCl3) δ 7.22 (t, J = 0.6 Hz, 3 H), 3.52 (s, 2 H), 3.18 (d, J = 
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12.2 Hz, 2 H), 2.66 – 2.46 (m, 4 H), 2.19 (s, 3 H), 1.51 (qd, J = 12.1, 4.1 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 144.1, 134.7, 126.9, 126.8, 61.1, 56.9, 46.1, 37.7, 29.0; IR (NaCl, film) 
2941, 2851, 2791, 1589, 1568, 1449, 1432, 1384, 1353, 1273, 1208, 1045 cm-1; HRMS (ESI) m/z 
calcd for C13H18Cl2N2 (M+H)+ 273.0920; found 273.0923. 
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 7.22 (t, J = 0.6 Hz, 3 H, H1, H3), 
3.52 (s, 2 H, H5), 3.18 (d, J = 12.2 Hz, 2 H, H9), 2.66 – 2.46 (m, 3 H, H9, H7), 2.19 (s, 3 H, H6), 
1.81 (d, J = 12.2 Hz, 2 H, H8) 1.51 (qd, J = 12.1, 4.1 Hz, 2 H, H8); 13C NMR (100 MHz, CDCl3) 
δ 144.13 (C4), 134.71 (C1), 126.93 (C2), 126.78 (C3), 61.14 (C7), 56.86 (C5), 46.11 (C9), 37.72 




N-(3-Chlorobenzyl)-N-methylpiperidin-4-amine (2.56) (LTL-IV-031). The title 
compound was prepared following the general procedure of 2.47 to give 15 mg (79%) of 2.56 as 
a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.31 (m, 1 H), 7.25 – 7.16 (comp, 3 H), 3.54 
(s, 2 H), 3.15 (dt, J = 12.7, 3.4 Hz, 2 H), 2.64 – 2.46 (comp, 3 H), 2.19 (s, 3 H), 1.82 (dt, J = 
12.7, 2.7 Hz, 2 H), 1.49 (qd, J = 12.3, 4.3 Hz, 2 H). 13C NMR (101 MHz, CDCl3) δ 142.5, 134.1, 
129.4, 128.6, 126.9, 126.6, 61.2, 57.2, 46.3, 37.6, 29.3. IR (NaCl, film) 3291, 3061, 2939, 2850, 
2789, 1597, 1574, 1472, 1451, 1429, 1356, 1324, 1260, 1209, 1147, 1075, 1043, 1003 cm-1. 
HRMS (ESI) m/z calcd for C13H19ClN2 (M+H)+ 239.1310; found 239.1313. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.31 (m, 1 H, H7), 7.25 – 7.16 
(comp, 3 H, H9, H10, H11), 3.54 (s, 2 H, H5), 3.15 (dt, J = 12.7, 3.4 Hz, 2 H, H1), 2.64 – 2.46 
(comp, 3 H, H1, H3), 2.19 (s, 3 H, H4), 1.82 (dt, J = 12.7, 2.7 Hz, 2 H, H2), 1.49 (qd, J = 12.3, 
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4.3 Hz, 2 H, H2). 13C NMR (101 MHz, CDCl3) δ 142.5 (C6), 134.1 (C8), 129.4 (C10), 128.6 
(C7), 126.9 (C11), 126.6 (C9), 61.2 (C3), 57.2 (C5), 46.3 (C1), 37.6 (C4), 29.3 (C2). 
 
 
N-(3-Methoxybenzyl)-N-methylpiperidin-4-amine (2.57) (LTL-IV-029). The title 
compound was prepared following the general procedure of 2.47 to give 15 mg (79%) of 2.57 as 
a yellow oil. 1H NMR (400 MHz,CDCl3) δ 7.21 (t, J = 8.0 Hz, 1 H), 6.92 – 6.87 (comp, 2 H), 
6.78 (ddd, J = 8.3, 2.6, 1.0 Hz, 1 H), 3.80 (s, 3 H), 3.55 (s, 2 H), 3.19 – 3.09 (d, J = 12.3 Hz, 2 
H), 2.62 – 2.47 (comp, 3 H), 2.21 (s, 3 H), 1.87 – 1.79 (br, 2 H), 1.51 (td, J = 12.1, 4.0 Hz, 2 H). 
13C NMR (101 MHz, CDCl3) δ 159.6, 141.8, 129.1, 121.0, 114.1, 112.2, 61.0, 57.7, 55.1, 46.4, 
37.6, 29.3. IR (NaCl, film) 3306, 2939, 2839, 2788, 1691, 1600, 1488, 1454, 1361, 1318, 1269, 
1150, 1046 cm-1. HRMS (ESI) m/z calcd for C14H22N2O (M+H)+ 235.1805; found 235.1805. 
NMR Assignment. 1H NMR (400 MHz,CDCl3) δ 7.21 (t, J = 8.0 Hz, 1 H, H10), 6.92 – 
6.87 (comp, 2 H, H7, H9), 6.78 (ddd, J = 8.3, 2.6, 1.0 Hz, 1 H, H11), 3.80 (s, 3 H, H12), 3.55 (s, 
2 H, H5), 3.19 – 3.09 (d, J = 12.3 Hz, 2 H, H1), 2.62 – 2.47 (comp, 3 H, H1, H3), 2.21 (s, 3 H, 
H4), 1.87 – 1.79 (comp, 2 H, H2), 1.51 (td, J = 12.1, 4.0 Hz, 2 H, H2). 13C NMR (101 MHz, 
CDCl3) δ 159.6 (C8), 141.8 (C6), 129.1 (C10), 121.0 (C11), 114.1 (C7), 112.2 (C9), 61.0 (C3), 




N-Methyl-N-(3-(methylthio)benzyl)piperidin-4-amine (2.58) (LTL-IV-034). The title 
compound was prepared following the general procedure of 2.47 to give 23 mg (84%) of 2.58 as 
a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.19 (comp, 2 H), 7.12 (ddd, J = 7.8, 2.0, 
1.2 Hz, 1 H), 7.10 – 7.06 (m, 1 H), 3.54 (s, 2 H), 3.19 – 3.08 (comp, 2 H), 2.62 – 2.45 (comp, 6 
H), 2.19 (s, 3 H), 1.85 (d, J = 8.8 Hz, 2 H), 1.56 – 1.42 (comp, 2 H); 13C NMR (101 MHz, 
CDCl3) δ 140.9, 138.1, 128.6, 126.8, 125.5, 124.9, 61.0, 57.6, 46.4, 37.6, 29.3, 15.8; IR (NaCl, 
film) 3292, 2938, 2850, 2790, 1591, 1572, 1471, 1422, 1356, 1325, 1273, 1213, 1147, 1084, 
1042 cm-1. HRMS (ESI) m/z calcd for C14H22N2S (M+H)+ 251.1576; found 251.1584. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.19 (comp, 2 H, H7, H9), 7.12 
(ddd, J = 7.8, 2.0, 1.2 Hz, 1 H, H10), 7.10 – 7.06 (m, 1 H, H11), 3.54 (s, 2 H, H5), 3.19 – 3.08 
(comp, 2 H, H1), 2.62 – 2.45 (comp, 6 H, H1, H3, H12), 2.19 (s, 3 H, H4), 1.85 (d, J = 8.8 Hz, 2 
H, H2), 1.56 – 1.42 (comp, 2 H, H2); 13C NMR (101 MHz, CDCl3) δ 140.9 (C6), 138.1 (C8), 
128.6 (C7), 126.8 (C10), 125.5 (C9), 124.9 (C11), 61.0 (C3), 57.6 (C5), 46.4 (C1), 37.6 (C4), 




one (2.51) (LTL-II-269). Indole-3-acetic acid (72 mg, 0.41 mmol) was suspended in CH2Cl2 (4 
mL), then EDCI-HCl (79 mg, 0.41 mmol) and iPr2NEt (0.14 mL, 0.82 mmol) were added. 2.46 
dissolved in CH2Cl2 (1 mL) was then added, followed by DMAP (5 mg, 0.04 mmol). The 
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reaction was stirred at room temperature for 24 hours whereupon it was diluted with CH2Cl2 (25 
mL) and washed with 1 M aq. NaOH (50 mL). The aqueous layer was then extracted with an 
additional volume of CH2Cl2 (25 mL). The organic layers were combined and dried (Na2SO4) 
and concentrated in vacuo to give a yellow oil. Purification via flash column chromatography, 
eluting with 50 : 50 : 1 hexanes : ethyl acetate : TEA gave 67 mg (42%) of 2.51 as a white solid. 
1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1 H), 7.65 (dq, J = 7.9, 0.9 Hz, 1 H), 7.35 (dt, J = 8.1, 1.0 
Hz, 1 H), 7.22 (t, J = 2.0 Hz, 1 H), 7.19 (ddd, J = 8.2, 7.0, 1.2 Hz, 1 H), 7.16 - 7.14 (m, 2 H), 
7.13 (ddd, J = 8.0, 7.1, 1.1 Hz, 1 H), 7.09 (dd, J = 2.3, 1.1 Hz, 1 H), 4.74 (d, J = 13.7 Hz, 1 H), 
4.05 – 3.93 (m, 1 H), 3.86 (dd, J = 4.4, 1.0 Hz, 2 H), 3.37 (s, 2 H), 2.93 (td, J = 12.9, 2.7 Hz, 1 
H), 2.55 (td, J = 11.2, 10.6, 3.0 Hz, 2 H), 2.07 (s, 3 H), 1.80 (d, J = 13.0 Hz, 1 H), 1.58 (d, J = 
13.0 Hz, 1 H), 1.40 (qd, J = 12.3, 4.4 Hz, 1 H), 1.12 (qd, J = 12.3, 4.3 Hz, 1 H) ppm; 13C NMR 
(126 MHz, CDCl3) δ 170.1, 144.0, 136.4, 135.0, 127.3, 127.3, 126.9, 122.6, 122.5, 119.9, 119.1, 
111.4, 109.8, 61.1, 57.1, 46.1, 41.8, 37.9, 31.9, 28.7, 27.7 ppm; IR (NaCl, film) 3058, 2926, 
2857, 2790, 1624, 1568, 1454, 1434, 1353, 1268, 1227, 1149, 1125, 1098, 1047 cm-1; HRMS 
(ESI) m/z calcd for C23H25Cl2N3O (M+Na)+ 452.1267; found, 452.1268.  
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1 H, H13), 7.65 (dq, J = 7.9, 
0.9 Hz, 1 H, H18), 7.35 (dt, J = 8.1, 1.0 Hz, 1 H, H15), 7.22 (t, J = 2.0 Hz, 1 H, H1), 7.19 (ddd, J 
= 8.2, 7.0, 1.2 Hz, 1 H, H16), 7.16 - 7.14 (m, 2 H, H3), 7.13 (ddd, J = 8.0, 7.1, 1.1 Hz, 1 H, 
H17), 7.09 (dd, J = 2.3, 1.1 Hz, 1 H, H12), 4.74 (d, J = 13.7 Hz, 1 H, H9), 3.99 (d, J = 13.7 Hz, 1 
H, H9), 3.86 (dd, J = 4.4, 1.0 Hz, 2 H, H11), 3.37 (s, 2 H, H5), 2.93 (td, J = 12.9, 2.7 Hz, 1 H, 
H9), 2.55 (td, J = 11.2, 10.6, 3.0 Hz, 2 H, H9), 2.07 (s, 3 H, H6), 1.80 (d, J = 13.0 Hz, 1 H, H8), 
1.58 (d, J = 13.0 Hz, 1 H, H8) 1.40 (qd, J = 12.3, 4.4 Hz, 1 H, H8), 1.12 (qd, J = 12.3, 4.3 Hz, 1 
H, H8) ppm; 13C NMR (126 MHz, CDCl3) δ 170.1 (C10), 144.0 (C4), 136.4 (C14), 135.0 (C1), 
127.3 (C2), 127.3 (C3), 126.9 (C19), 122.6 (C17), 122.5 (C12), 120.0 (C16), 119.1 (C18), 111.4 





yl)ethan-1-one (2.52) (LTL-II-259). Following the general procedure described for 2.51, 30 mg 
(31%) of 2.52 was obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1 H), 7.65 
(ddt, J = 7.8, 1.5, 0.8 Hz, 1 H), 7.36 (dt, J = 8.1, 1.0 Hz, 1 H), 7.20 (ddd, J = 8.2, 7.0, 1.3 Hz, 1 
H), 7.13 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H), 7.09 (dt, J = 2.3, 1.0 Hz, 1 H), 6.86 (dd, J = 2.0, 1.3 Hz, 
1 H), 6.76 (t, J = 2.2 Hz, 1 H), 6.72 (dd, J = 2.5, 1.3 Hz, 1 H), 4.79 – 4.68 (m, 1 H), 4.05 – 3.92 
(m, 1 H), 3.90 – 3.84 (comp, 2 H), 3.78 (s, 3 H), 3.39 (s, 2 H), 2.98 – 2.87 (m, 1 H), 2.63 – 2.49 
(comp, 2 H), 2.09 (s, 3 H), 1.81 (d, J = 12.9 Hz, 1 H), 1.63 (d, J = 12.9 Hz, 1 H), 1.49 – 1.32 
(comp, 3 H), 1.22 – 1.10 (comp, 2 H); 13C NMR (101 MHz, CDCl3) δ 169.8, 160.7, 143.1, 136.1, 
134.6, 127.1, 122.3, 122.2, 120.8, 119.7, 118.8, 112.7, 112.5, 111.2, 109.6, 60.4, 57.4, 55.5, 45.9, 
41.6, 37.7, 31.6, 28.4, 27.5; IR (NaCl, film) 3057, 2933, 2862, 2791, 1624, 1576, 1458, 1355, 
1315, 1228, 1150, 1097, 1052 cm-1; HRMS (ESI) m/z calcd for C24H28ClN3O2 (M+Na)+ 
448.1762; found 448.1764. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1 H, H13), 7.65 (ddt, J = 7.8, 
1.5, 0.8 Hz, 1 H, H18), 7.36 (dt, J = 8.1, 1.0 Hz, 1 H, H15), 7.20 (ddd, J = 8.2, 7.0, 1.3 Hz, 1 H, 
H16), 7.13 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H, H17), 7.09 (dt, J = 2.3, 1.0 Hz, 1 H, H12), 6.86 (dd, J 
= 2.0, 1.3 Hz, 1 H, H1), 6.76 (t, J = 2.2 Hz, 1 H, H3), 6.72 (dd, J = 2.5, 1.3 Hz, 1 H, H22), 4.79 – 
4.68 (m, 1 H, H9), 4.05 – 3.92 (m, 1 H, H9), 3.90 – 3.84 (m, 2 H, H11), 3.78 (s, 3 H, H21), 3.39 
(s, 2 H, H5), 2.98 – 2.87 (m, 1 H, H9), 2.63 – 2.49 (m, 2 H, H9, H7), 2.09 (s, 3 H, H6), 1.81 (d, J 
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= 12.9 Hz, 1 H, H8), 1.63 (d, J = 12.9 Hz, 1 H, H8), 1.49 – 1.32 (m, 3 H, H8), 1.22 – 1.10 (m, 2 
H, H8); 13C NMR (101 MHz, CDCl3) δ 169.8 (C10), 160.7 (C23), 143.1 (C4), 136.1 (C14), 
134.6 (C2), 127.1 (C19), 122.3 (C13), 122.2 (C12), 120.8 (C3), 119.7 (C18), 118.8 (C16), 112.7 
(C1), 112.5 (C22), 111.2 (C20), 109.6 (C15), 60.4 (C7), 57.4 (C5), 55.5 (C21), 45.9 (C9), 41.6 




yl)ethan-1-one (2.53) (LTL-II-278). Following the genearl procedure described for 2.51, 45 mg 
(54%) of 2.53 was obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.31 (s, 1 H), 7.23 – 
7.20 (comp, 2 H), 7.16 – 7.14 (comp, 2 H), 7.10 – 7.08 (m, 1 H), 7.03 – 7.01 (m, 1 H), 6.84 (ddd, 
J = 8.8, 2.5, 0.4 Hz, 1 H), 4.74 (dt, J = 13.3, 2.2 Hz, 1 H), 4.04 – 3.93 (m, 1 H), 3.88 – 3.77 
(comp, 5 H), 3.36 (s, 2 H), 2.92 (ddd, J = 13.5, 12.3, 2.7 Hz, 1 H), 2.55 (tt, J = 12.5, 3.1 Hz, 2 
H), 2.06 (s, 3 H), 1.85 – 1.75 (m, 1 H), 1.67 – 1.55 (m, 1 H), 1.46 – 1.33 (m, 1 H), 1.21 – 1.03 
(m, 1 H); 13C NMR (101 MHz, CDCl3) δ 169.8, 154.1, 143.7, 134.7, 131.3, 127.4, 127.0, 126.6, 
123.0, 112.4, 111.9, 109.0, 100.5, 77.3, 77.2, 77.0, 76.7, 60.7, 57.0, 56.8, 55.9, 45.8, 41.5, 37.6, 
31.9, 31.8, 29.7, 29.6, 29.3, 29.2, 28.4, 27.8, 27.4, 26.1, 22.5, 14.0; IR (NaCl, film) 2926, 2855, 
1623, 1588, 1568, 1487, 1452, 1354, 1270, 1216, 1170, 1098, 1056 cm-1; HRMS (ESI) m/z calcd 
for C24H27Cl2N3O2 (M+H)+ 460.1553; found 460.1560. 
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NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.31 (s, 1 H, H13), 7.23 – 7.20 (m, 2 
H, H1, H15), 7.16 – 7.14 (m, 2 H, H3), 7.10 – 7.08 (m, 1 H, H18), 7.03 – 7.01 (m, 1 H, H12), 
6.84 (ddd, J = 8.8, 2.5, 0.4 Hz, 1 H, H16), 4.74 (dt, J = 13.3, 2.2 Hz, 1 H, H9), 4.04 – 3.93 (m, 1 
H, H9), 3.88 – 3.77 (m, 5 H, H21, H11), 3.36 (s, 2 H, H5), 2.92 (ddd, J = 13.5, 12.3, 2.7 Hz, 1 H, 
H9), 2.55 (m, 2 H, H9, H7), 2.06 (s, 3 H, H6), 1.85 – 1.75 (m, 1 H, H8), 1.67 – 1.55 (m, 1 H, 
H8), 1.46 – 1.33 (m, 1 H, H8), 1.21 – 1.03 (m, 1 H, H8); 13C NMR (101 MHz, CDCl3) δ 169.9 
(C10), 154.1 (C17), 143.8 (C4), 134.7 (C1), 131.3 (C14), 127.4 (C2), 127.0 (C3), 126.7 (C19), 
123.1 (C12), 112.5 (C16), 112.0 (C15), 109.1 (C20), 100.5 (C18), 60.8 (C7), 56.8 (C5), 55.9 




one (2.54) (LTL-III-012). A solution of indole-3-propionic acid (62 mg, 0.33 mmol), 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI-HCl) (59 mg, 0.31 mmol), 4-
dimethylaminopyridine (2 mg, 0.02 mmol), N,N-diisopropylethylamine (0.15 mL, 0.88 mmol), 
and amine 2.46 (60 mg, 0.22 mmol) in CH2Cl2 (5 mL) was stirred at room temperature for 24 h. 
The reaction was diluted with additional CH2Cl2 (20 mL), and the solution was washed with sat. 
NaHCO3 (50 mL). The aqueous layer was extracted with an additional portion of CH2Cl2 (25 
mL). The combined organic layers were dried (Na2SO4) and concentrated via rotary evaporation. 
The crude material was purified by flash chromatography eluting with EtOAc/hexane/Et3N 
(50:50:1) to give 48 mg (50 %) of the 2.54 as a white foam. 1H NMR (400 MHz, CDCl3) δ 8.26 
(s, 1 H), 7.61 (dd, J = 8.0, 1.1 Hz, 1 H), 7.33 (dt, J = 8.1, 0.9 Hz, 1 H), 7.23 (t, J = 2.0 Hz, 1 H), 
7.20 – 7.15 (comp, 3 H), 7.12 (m, 1 H), 7.03 (d, J = 2.3 Hz, 1 H, H), 4.71 (d, J = 13.2 Hz, 1 H), 
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3.88 – 3.74 (m, 1 H), 3.40 (s, 2 H), 3.21 – 3.05 (comp, 2 H), 2.92 – 2.64 (comp, 3 H), 2.60 – 2.43 
(comp, 2 H), 2.10 (s, 3 H), 1.77 (d, J  = 12.8 Hz  1 H), 1.63 (d, J = 12.8 Hz, 1 H), 1.32 (qd, J = 
12.2, 4.2 Hz, 1 H), 1.08 (qd, J = 12.2, 4.2 Hz, 1 H). 13C NMR (101 MHz, CDCl3) δ 171.1, 143.8, 
136.3, 134.7, 127.2, 127.0, 126.7, 121.9, 121.7, 119.2, 118.7, 115.3, 111.2, 60.9, 56.9, 45.2, 41.2, 
37.6, 33.9, 28.5. IR (film, NaCl) 3266, 3058, 2926, 2856, 2791, 2243, 1622, 1568, 1454, 1434, 
1354, 1267, 1228, 1148, 1124, 1098, 1047 cm-1. HRMS (ESI) m/z calcd for C24H27Cl2N3O 
(M+H)+ 444.1604; found 444.1610  
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.26 (s, 1 H, H20), 7.61 (dd, J = 8.0, 
1.1 Hz, 1 H, H15), 7.33 (dt, J = 8.1, 0.9 Hz, 1 H, H18), 7.23 (t, J = 2.0 Hz, 1 H, H1), 7.20 – 7.15 
(comp, 3 H, H3, H17), 7.12 (m, 1 H, H16) 7.03 (d, J = 2.3 Hz, 1 H, H21), 4.71 (d, J = 13.2 Hz, 1 
H, H9), 3.88 – 3.74 (m, 1 H, H9), 3.40 (s, 2 H H5), 3.21 – 3.05 (comp, 2 H, H12), 2.92 – 2.64 
(comp, 3 H, H11, H9), 2.60 – 2.43 (comp, 2 H, H9, H7), 2.10 (s, 3 H, H6), 1.77 (d, J  = 12.8 Hz  
1 H, H8), 1.63 (d, J = 12.8 Hz, 1 H, H8), 1.32 (qd, J = 12.2, 4.2 Hz, 1 H, H8), 1.08 (qd, J = 12.2, 
4.2 Hz, 1 H, H8); 13C NMR (101 MHz, CDCl3) δ 171.1 (C10), 143.8 (C4), 136.3 (C19), 134.7 
(C1), 127.2 (C2), 127.0 (C3), 126.7 (C14), 121.9 (C21), 121.7 (C15), 119.2 (C17), 118.7 (C16), 





III-048). A solution of 2.51 (50 mg, 0.12 mmol) in THF (0.6 mL) was added to a suspension of 
LiAlH4 (20 mg, 0.50 mmol) in THF (0.6 mL) at 0 °C. The mixture was then warmed to room 
temperature and stirred for 4 h. The reaction was then cooled to 0 °C and sat. aq. NH4Cl (5 mL) 
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was added. A precipitate formed, which was removed by vacuum filtration. The filtrate was then 
made basic by the addition of sat. aq. NaHCO3 and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic layers were dried (Na2SO4) and concentrated via rotary evaporation. The 
crude material was purified via flash chromatography eluting with EtOAc/hexane/Et3N (50:50:1) 
to give 36 mg (72%) of 2.55 as a white paste. 1H NMR (400 MHz, CDCl3) δ 8.13 – 8.05 (s, 1 H), 
7.61 (d, J = 7.8 Hz, 1 H), 7.34 (dt, J = 8.0, 0.9 Hz, 1 H), 7.23 (s, 3 H), 7.21 – 7.16 (m, 1 H), 7.15 
– 7.09 (m, 1 H), 7.01 (d, J = 2.2 Hz, 1 H), 3.80 – 3.71 (m, 1 H), 3.53 (s, 2 H), 3.21 – 3.11 (comp, 
2 H), 3.02 – 2.93 (comp, 2 H), 2.75 – 2.65 (comp, 2 H), 2.46 (tt, J = 11.5, 3.8 Hz, 1 H), 2.21 (s, 3 
H), 2.05 (td, J = 11.8, 2.4 Hz, 2 H), 1.85 (comp, 3 H), 1.70 (qd, J = 12.0, 3.8 Hz, 2 H). 13C NMR 
(101 MHz, CDCl3) δ 144.2, 136.2, 134.7, 127.4, 126.9, 126.8, 122.0, 121.4, 119.2, 118.8, 114.5, 
111.1, 61.3, 59.3, 57.0, 53.4, 37.9, 27.9, 23.2. IR (NaCl, film) 3412, 3179, 3057, 2943, 2853, 
2808, 2360, 1620, 1589, 1568, 1455, 1433, 1376, 1353, 1303, 1228, 1145, 1097, 1049, 1014 cm-
1. HRMS (ESI) m/z calcd for C23H27Cl2N3 (M+H)+ 416.1655; found 416.1656. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 8.13 – 8.05 (s, 1 H, H19), 7.61 (d, J = 
7.8 Hz, 1 H, H14), 7.34 (d, J = 8.0 Hz, 1 H, H17), 7.23 (comp, 3 H, H1, H3), 7.21 – 7.16 (m, 1 
H, H16), 7.15 – 7.09 (m, 1 H, H15), 7.01 (d, J = 2.2 Hz, 1 H, H20), 3.53 (s, 2 H, H5), 3.21 – 3.11 
(m, 2 H, H9), 3.02 – 2.93 (comp, 2 H, H10), 2.75 – 2.65 (comp, 2 H, H11), 2.46 (tt, J = 11.5, 3.8 
Hz, 1 H, H7), 2.21 (s, 3 H, H6), 2.05 (td, J = 11.8, 2.4 Hz, 2 H, H9), 1.85 (comp, 2 H, H8), 1.70 
(qd, J = 12.0, 3.8 Hz, 2 H, H8). 13C NMR (101 MHz, CDCl3) δ 144.2 (C4), 136.2 (C18), 134.7 
(C1), 127.4 (C13), 126.9 (C2), 126.8 (C3), 122.0 (C15), 121.4 (C20), 119.2 (C16), 118.8 (C14), 






dichlorobenzyl)(methyl)amino)piperidin-1-yl)propan-1-one (2.61) (LTL-III-163). The title 
compound was prepared following a procedure analogous to that of 2.54. The crude material was 
purified by flash chromatography eluting with EtOAc/Et3N (100:1) to give 82 mg (61%) of 2.61 
as a ____.  1H NMR (400 MHz, CDCl3) δ 10.31 (s, 1 H), 7.74 – 7.38 (m, 2 H), 7.24 – 7.17 
(comp, 5 H), 4.71 (d, J = 13.1 Hz, 1 H), 3.90 (d, J = 13.6 Hz, 1 H), 3.48 (s, 2 H), 3.32 – 3.23 
(comp, 2 H), 3.06 – 2.94 (m, 1 H), 2.84 (dd, J = 7.3, 4.2 Hz, 2 H), 2.70 – 2.57 (comp, 2 H), 2.15 
(s, 3 H), 1.91 – 1.81 (comp, 2 H), 1.45 (qd, J = 14.2, 12.9, 6.2 Hz, 2 H). 13C NMR (101 MHz, 
CDCl3) δ 170.6, 154.6, 143.6, 134.8, 127.1, 126.7, 122.0, 60.7, 57.0, 45.0, 41.6, 37.6, 31.6, 28.4, 
27.7, 24.5; IR (NaCl, film) 3200, 3057, 2945, 2857, 2789, 2360, 2344, 1631, 1568, 1538, 1450, 
1353, 1271, 1226, 1152, 1098, 1046 cm-1. HRMS (ESI) m/z calcd for C23H26Cl2N4O (M+Na)+ 
467.1376; found 467.1385. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 10.31 (s, 1 H, N-H), 7.74 – 7.38 (m, 2 
H, H15), 7.24 – 7.17 (comp, 5 H, H16, H13, H1), 4.71 (d, J = 13.1 Hz, 1 H, H9), 3.90 (d, J = 
13.6 Hz, 1 H, H9), 3.48 (s, 2 H, H5), 3.32 – 3.23 (comp, 2 H, H12), 3.06 – 2.94 (m, 1 H, H7), 
2.84 (dd, J = 7.3, 4.2 Hz, 2 H, H11), 2.70 – 2.57 (comp, 2 H, H9), 2.15 (s, 3 H, H6), 1.91 – 1.81 
(comp, 2 H, H8), 1.45 (qd, J = 14.2, 12.9, 6.2 Hz, 2 H, H8). 13C NMR (101 MHz, CDCl3) δ 
170.6 (C10), 154.6 (C13), 143.6 (C4), 134.8 (C1), 127.1 (C2), 126.7 (C3), 122.0 (C16), 60.7 






yl)ethan-1-one (2.62) (LTL-IV-070). A solution 2.56 (28 mg, 0.12 mmol), 2-(5-methoxy-1H-
indol-3-yl)acetic acid (37 mg, 0.18 mmol), EDCI·HCl (35 mg, 0.18 mmol), and iPr2NEt (0.8 mL, 
0.48 mmol) in THF (1.2 mL) was stirred at rt for 2 h. The reaction was then diluted with 1 M aq. 
NaOH (20 mL) and extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were 
dried (Na2SO4) and concentrated via rotary evaporation. The crude material was purified by flash 
chromatography, eluting with hexanes:EtOAc:Et3N (40:60:1) to give the title compound (40 mg, 
78%) as an amber solid. 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1 H), 7.29 – 7.27 (m, 1 H), 7.24 
(dd, J = 8.8, 0.6 Hz, 1 H), 7.22 – 7.19 (m, 2 H), 7.15 – 7.11 (m, 1 H), 7.10 (d, J = 2.5 Hz, 1 H), 
7.07 (d, J = 2.2 Hz, 1 H), 6.89 – 6.82 (m, 1 H), 4.73 (d, J = 13.5 Hz, 1 H), 4.02 (d, J = 16.7 Hz, 1 
H), 3.86 (s, 3 H), 3.83 (dd, J = 2.9, 1.0 Hz, 2 H), 3.42 (s, 2 H), 2.93 (s, 1 H), 2.63 – 2.50 (m, 2 
H), 2.08 (s, 3 H), 1.82 (d, J = 13.1 Hz, 1 H), 1.64 (d, J = 12.8 Hz, 1 H), 1.43 (qd, J = 12.1, 4.3 
Hz, 1 H), 1.22 – 1.10 (m, 1 H). 13C NMR (101 MHz, CDCl3) δ 169.8, 154.1, 142.1, 134.2, 131.3, 
129.5, 128.5, 127.4, 127.0, 126.6, 123.0, 112.5, 111.9, 109.2, 100.5, 60.6, 57.3, 55.9, 45.9, 41.6, 
37.6, 31.8, 28.5, 27.4. IR (NaCl, flim) 3267, 3056, 2941, 2858, 2244, 2127, 1625, 1486, 1451, 
1357, 1332, 1302, 1267, 1216, 1171, 1097, 1055 cm-1. HRMS (ESI) m/z calcd for C24H28ClN3O2 






amine (2.63) (LTL-IV-068). The title compound was prepared following a procedure analogous 
to that of 2.65. The crude material was purified by flash chromatography eluting with 
hexanes/EtOAc/Et3N (50:50:1) to give 18 mg (82%) of 2.63 as a white solid. 
1H NMR (400 
MHz, CDCl3) δ 7.92 (s, 1 H), 7.23 (s, 4 H), 7.05 (d, J = 2.4 Hz, 1 H), 7.00 (d, J = 2.4 Hz, 1 H), 
6.85 (dd, J = 8.8, 2.4 Hz, 1 H), 3.86 (s, 3 H), 3.54 (s, 2 H), 3.17 (d, J = 11.3 Hz, 2 H), 3.00 – 2.89 
(comp, 2 H), 2.74 – 2.65 (comp, 2 H), 2.47 (tt, J = 11.4, 3.8 Hz, 1 H), 2.21 (s, 3 H), 2.06 (t, J = 
11.4 Hz, 2 H), 1.84 (d, J = 12.2 Hz, 2 H), 1.72 (td, J = 12.1, 3.7 Hz, 2 H); 13C NMR (101 MHz, 
CDCl3) δ 154.1, 144.5, 135.0, 131.6, 128.1, 127.2, 127.0, 122.5, 114.4, 112.4, 112.0, 101.0, 61.5, 
59.5, 57.5, 56.2, 53.7, 38.2, 28.2, 23.5; IR (NaCl, film) 3412, 3143, 2927, 2854, 2808, 1625, 
1588, 1568, 1486, 1454, 1435, 1377, 1354, 1281, 1263, 1217, 1173, 1144, 1119, 1098, 1064 cm-
1; HRMS (ESI) m/z calcd for C24H29Cl2N3O (M+H)+ 446.1760; found 446.1770. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.92 (s, 1 H, H1), 7.23 (comp, 4 H, 
H8, H19, H21), 7.05 (d, J = 2.4 Hz, 1 H, H5), 7.00 (d, J = 2.4 Hz, 1 H, H2), 6.85 (dd, J = 8.8, 2.4 
Hz, 1 H, H7), 3.86 (s, 3 H, H10), 3.54 (s, 2 H, H17), 3.17 (d, J = 11.3 Hz, 2 H, H13 eq), 3.00 – 
2.89 (comp, 2 H, H12), 2.74 – 2.65 (comp, 2 H, H11), 2.47 (tt, J = 11.4, 3.8 Hz, 1 H, H15), 2.21 
(s, 3 H, H16), 2.06 (t, J = 11.4 Hz, 2 H, H13 ax), 1.84 (d, J = 12.2 Hz, 2 H, H14 eq), 1.72 (td, J = 
12.1, 3.7 Hz, 2 H, H14 ax); 13C NMR (101 MHz, CDCl3) δ 154.1 (C10), 144.5 (C18), 135.0 
(C21), 131.6 (C9), 128.1 (C20), 127.2 (C19), 127.0 (C4), 122.5 (C2), 114.4 (C3), 112.4 (C8), 
112.0 (C7), 101.0 (C5), 61.5 (C15), 59.5 (C13), 57.5 (C17), 56.2 (C10), 53.7 (C12), 38.2 (C16), 






methylpiperidin-4-amine (2.64) (LTL-III-165). To a stirred suspension of NaBH4 (32 mg, 0.85 
mmol) in THF (0.7 mL) was added a solution of I2 (99 mg, 0.39 mmol) in THF (0.7 mL) while 
cooling at 0 ˚C. Once the solution turned clear, 2.61 (40 mg, 0.09 mmol) was added, and the 
solution was warmed to room temperature and stirred overnight, whereupon the reaction was 
quenched via the slow addition of MeOH (1 mL). The mixture was concentrated via rotary 
evaporation, resuspended in 3 M HCl (3 mL), and heated under reflux for an additional 6 h. The 
reaction was then cooled to room temperature, 1 M NaOH (20 mL) was added, and the aqueous 
solution was extracted with CH2Cl2 (3 x 15 mL. The combined organic layers were dried 
(Na2SO4) and concentrated via rotary evaporation, and the crude material was purified via 
column chromatography, eluting with EtOAc:MeOH:Et3N (100:0:1 → 95:5:1) to give the title 
compound (32 mg, 82%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 6.0, 3.2 
Hz, 2 H), 7.26 – 7.24 (comp, 3 H), 7.19 (dd, J = 6.0, 3.2 Hz, 2 H), 3.57 (s, 2 H), 3.17 – 3.04 
(comp, 4 H), 2.61 – 2.54 (comp, 2 H), 2.50 (ddt, J = 11.4, 7.6, 3.8 Hz, 1 H), 2.27 (s, 3 H), 2.07 
(td, J = 12.0, 2.4 Hz, 2 H), 2.02 – 1.95 (comp, 2 H), 1.91 (d, J = 13.0, 2.8 Hz, 2 H), 1.81 – 1.68 
(comp, 2 H); 13C NMR (101 MHz, CDCl3) δ 155.7, 143.9, 134.8, 127.1, 126.8, 121.7, 114.6, 
60.7, 59.0, 57.4, 53.3, 37.8, 29.5, 28.2, 23.7; IR (NaCl, film) 3056, 2944, 2785, 2248, 2192, 
1622, 1590, 1568, 1541, 1451, 1431, 1379, 1352, 1304, 1272, 1211, 1123, 1098, 1051, 1026 cm-
1; HRMS (ESI) m/z calcd for C23H28Cl2N4 (M+H)+ 431.1764; found 431.1785. 
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NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 6.0, 3.2 Hz, 2 H, H15), 
7.26 – 7.24 (comp, 3 H, H3, H1), 7.19 (dd, J = 6.0, 3.2 Hz, 2 H, H16), 3.57 (s, 2 H, H5), 3.17 – 
3.04 (comp, 4 H, H12, H9), 2.61 – 2.54 (comp, 2 H, H10), 2.50 (ddt, J = 11.4, 7.6, 3.8 Hz, 1 H, 
H7), 2.27 (s, 3 H, H6), 2.07 (td, J = 12.0, 2.4 Hz, 2 H, H9), 2.02 – 1.95 (comp, 2 H, H11), 1.91 
(d, J = 13.0, 2.8 Hz, 2 H, H8), 1.81 – 1.68 (comp, 2 H, H8); 13C NMR (101 MHz, CDCl3) δ 
155.7 (C13), 143.9 (C4), 134.8 (C1), 127.1 (C2), 126.8 (C3), 121.7 (C16), 114.6 (C15), 60.7 






amine (2.65) (LTL-IV-071). To a solution of 2.62 (22 mg, 0.05 mmol) in THF (1 mL) was 
added a 0.5 M solution of alane in toluene (0.15 mmol, 0.3 mL) and stirred for 3 h at rt. The 
reaction was then diluted with 1 M NaOH (20 mL) and extracted with CH2Cl2 (3 x 15 mL). The 
combined organic extracts were dried (Na2SO4) and concentrated via rotary evaporation. The 
crude material purified by flash chromatography eluting with hexanes/EtOAc/Et3N (40:60:1) to 
give 13 mg (62%) of 2.65 as a yellow paste. 1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1 H), 7.34 (t, 
J = 1.8 Hz, 1 H), 7.25 – 7.17 (comp, 4 H), 7.05 (d, J = 2.4 Hz, 1 H), 6.99 (d, J = 2.2 Hz, 1 H), 
6.84 (dt, J = 8.9, 2.3 Hz, 1 H), 3.85 (s, 3 H), 3.56 (s, 2 H), 3.18 (d, J = 11.3 Hz, 2 H), 2.99 – 2.90 
(comp, 2 H), 2.74 – 2.65 (comp, 2 H), 2.56 – 2.40 (m, 1 H), 2.21 (s, 3 H), 2.12 – 2.02 (comp, 2 
H), 1.85 (d, J = 12.5 Hz, 2 H), 1.80 – 1.66 (comp, 2 H). 13C NMR (101 MHz, CDCl3) δ 153.9, 
142.5, 134.1, 131.3, 129.4, 128.6, 127.8, 126.9, 126.7, 122.3, 114.1, 112.1, 111.8, 100.7, 61.0, 
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59.2, 57.4, 56.0, 53.4, 37.8, 27.8, 23.2. IR (NaCl, film) 3156, 3049, 2939, 2853, 2808, 2249, 
1625, 1581, 1484, 1453, 1356, 1301, 1261, 1216, 1172, 1144, 1119, 1068, 1040 cm-1. HRMS 
(ESI) m/z calcd for C24H30ClN3O (M+Na)+ 434.1970; found 434.1977. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1 H, H1), 7.34 (t, J = 1.8 Hz, 
1 H, H21), 7.25 – 7.17 (comp, 4 H, H19, H20, H23, H8), 7.05 (d, J = 2.4 Hz, 1 H, H5), 6.99 (d, J 
= 2.2 Hz, 1 H, H2), 6.84 (dt, J = 8.9, 2.3 Hz, 1 H, H7), 3.85 (s, 3 H, H10), 3.56 (s, 2 H, H17), 
3.18 (d, J = 11.3 Hz, 2 H, H13), 2.99 – 2.90 (comp, 2 H, H12), 2.74 – 2.65 (comp, 2 H, H11), 
2.56 – 2.40 (m, 1 H, H15), 2.21 (s, 3 H, H16), 2.12 – 2.02 (comp, 2 H, H13), 1.85 (d, J = 12.5 





yl)ethane-1,2-dione (7.6) (LTL-III-147). To a solution of 2.58 (23 mg, 0.09 mmol) and iPr2NEt 
(0.03 mL, 0.18 mmol) in CH2Cl2 (1 mL) was added 2-(5-methoxy-1H-indol-3-yl)-2-oxoacetyl 
chloride (32 mg, 0.13 mmol) , and the reaction was stirred at rt for 48 h. The reaction was then 
diluted with 1 M aq. NaOH (20 mL) and extracted with CH2Cl2 (3 x 15 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated via rotary evaporation. The crude 
material was purified by flash chromatography, eluting with hexanes:EtOAc:Et3N (20:80:1) to 
give 32 mg (79%) of 7.6 as a light tan foam. 1H NMR (400 MHz, CDCl3) δ 8.99 (s, 1 H), 7.85 
(d, J = 3.0 Hz, 2 H), 7.14 (d, J = 7.5 Hz, 1 H), 7.08 (d, J = 7.6 Hz, 1 H), 6.95 (dd, J = 8.9, 2.5 Hz, 
1 H), 4.71 (d, J = 13.4 Hz, 1 H), 3.91 (d, J = 1.8 Hz, 4 H), 3.56 (s, 2 H), 3.06 (t, J = 11.7 Hz, 1 
H), 2.84 – 2.67 (comp, 2 H), 2.49 (d, J = 0.6 Hz, 3 H), 2.21 (s, 3 H), 2.01 – 1.94 (m, 1 H), 1.84 
 196 
(d, J = 13.0 Hz, 1 H), 1.68-1.52 (comp, 2 H). 13C NMR (101 MHz, CDCl3) δ 186.1, 166.3, 156.8, 
140.3, 138.4, 131.4, 128.8, 126.6, 126.1, 125.4, 125.0, 114.7, 114.3, 112.8, 103.2, 60.4, 57.8, 
55.8, 45.9, 41.1, 37.7, 28.6, 27.8, 15.8. IR (NaCl, film) 3225, 2947, 2248, 1627, 1518, 1474, 
1439, 1367, 1298, 1268, 1243, 1211, 1179, 1128, 1088, 1033 cm-1. HRMS (ESI) m/z calcd for 




yl)ethane-1,2-dione (7.7) (LTL-III-152). The title compound was prepared following a 
procedure analogous to that of 7.6. The crude material was purified by flash chromatography 
eluting with EtOAc/Et3N (100:1) to give 82 mg (75%) of 7.7 as a white foam. 
1H NMR (400 
MHz, CDCl3) δ 10.12 (s, 1 H), 7.78 (d, J = 2.5 Hz, 1 H), 7.65 (s, 1 H), 7.22 (t, J = 8.3 Hz, 2 H), 
6.91 – 6.85 (comp, 3 H), 6.78 (ddd, J = 8.2, 2.5, 1.1 Hz, 1 H), 4.66 (d, J = 13.4 Hz, 1 H), 3.87 
(comp, 4 H), 3.79 (s, 3 H), 3.55 (s, 2 H), 3.02 (td, J = 13.8, 13.0, 2.7 Hz, 1 H), 2.83 – 2.64 
(comp, 2 H), 2.20 (s, 3 H), 1.97 (dd, J = 10.1, 5.7 Hz, 1 H), 1.81 (d, J = 12.7 Hz, 1 H), 1.61 (dtd, 
J = 16.1, 12.3, 4.2 Hz, 2 H). 13C NMR (101 MHz, CDCl3) δ 186.1, 166.4, 159.7, 156.7, 141.2, 
135.5, 131.4, 129.3, 126.1, 121.0, 114.7, 114.3, 114.1, 112.9, 112.3, 103.1, 60.2, 58.0, 55.8, 55.2, 
45.88, 41.1, 37.7, 28.6, 27.8. IR (NaCl, film) 3231, 2949, 2362, 2249, 1628, 1519, 1487, 1439, 
1364, 1299, 1211, 1179, 1149, 1089, 1042 cm-1. HRMS (ESI) m/z calcd C25H29N3O4 (M+H)+ 





dione (7.8) (LTL-III-150). The title compound was prepared following a procedure analogous 
to that of 7.6. The crude material was purified by flash chromatography eluting with EtOAc/Et3N 
(100:1) to give 80 mg (80%) of 7.8 as a white foam. 1H NMR (400 MHz, CDCl3) δ 9.85 (s, 1 H), 
7.80 (d, J = 2.5 Hz, 1 H), 7.70 (d, J = 1.9 Hz, 1 H), 7.33 – 7.27 (comp, 4 H), 7.26 – 7.21 (comp, 2 
H), 6.89 (ddd, J = 8.9, 2.5, 0.3 Hz, 1 H), 3.88 (comp, 4 H), 3.57 (s, 2 H), 3.03 (ddd, J = 13.8, 
12.1, 2.8 Hz, 1 H), 2.83 – 2.65 (comp, 2 H), 2.20 (s, 3 H), 2.03 – 1.93 (m, 1 H), 1.83 (d, J = 12.7 
Hz, 1 H), 1.71 – 1.53 (comp, 2 H). 13C NMR (101 MHz, CDCl3) δ 186.08, 166.27, 156.77, 
139.46, 135.33, 131.34, 128.64, 128.30, 126.96, 126.11, 114.72, 114.44, 112.73, 103.24, 60.33, 
58.04, 55.76, 45.84, 41.06, 37.58, 28.67, 27.83. IR (NaCl, film) 3216, 2948, 1627, 1518, 1487, 
1442, 1365, 1299, 1268, 1243, 1211, 1179, 1129, 1089, 1030, 958 cm-1. HRMS (ESI) m/z calcd 




indol-3-yl)ethane-1,2-dione (7.9) (LTL-III-170). The title compound was prepared following a 
procedure analogous to that of 7.6. The crude material was purified by flash chromatography 
eluting with hexanes:EtOAc:Et3N (50:50:1) to give 160 mg (86%) of 7.9 as a white paste. 
1H 
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NMR (500 MHz, CDCl3) δ 10.14 (s, 1 H), 8.24 (dd, J = 8.5, 5.3 Hz, 1 H), 7.76 (s, 1 H), 7.25 – 
7.18 (comp, 3 H), 7.09 – 6.96 (comp, 2 H), 4.69 (ddt, J = 13.3, 4.7, 2.5 Hz, 1 H), 3.91 (ddt, J = 
13.6, 5.0, 2.6 Hz, 1 H), 3.52 (s, 2 H), 3.10 – 2.99 (m, 1 H), 2.84 – 2.75 (m, 1 H), 2.70 (tt, J = 
11.4, 3.6 Hz, 1 H), 2.18 (s, 3 H), 1.97 – 1.93 (m, 1 H), 1.85 – 1.78 (m, 1 H), 1.59 (pd, J = 12.5, 
4.3 Hz, 2 H); 13C NMR (126 MHz, CDCl3) δ 185.9, 166.1, 161.6, 159.7, 143.6, 136.9, 136.8, 
135.8, 135.8, 134.8, 127.2, 126.7, 125.5, 123.0, 123.0, 121.6, 114.5, 111.9, 111.7, 98.7, 98.5, 
60.8, 57.1, 56.0, 45.8, 45.6, 41.1, 37.7, 34.6, 34.2, 30.3, 29.7, 28.6, 27.9, 23.4, 22.7, 21.2, 14.8, 
14.2, 14.1; IR (NaCl, film) 2926, 2855, 1623, 1595, 1568, 1525, 1504, 1446, 1432, 1372, 1268, 







amine (2.67) (LTL-III-186). To a stirred suspension of NaBH4 (20 mg, 0.53 mmol) in THF (2 
mL) was added I2 (63 mg, 0.25 mmol) while cooling at 0 ˚C. Once the solution turned clear, 1-
(4-((3,5-dichlorobenzyl)(methyl)amino)piperidin-1-yl)-2-(6-fluoro-1H-indol-3-yl)ethane-1,2-
dione (46 mg, 0.10 mmol) was added at 0 ˚C, and the solution was then heated under reflux 
overnight, whereupon saturated aq. NaHCO3 (10 mL) was added and the solution was extracted 
with CH2Cl2 (3 x 15 mL). The combined organic layers were dried (Na2SO4) to give a white 
paste which was then dissolved in EtOH (5 mL) and treated with CsF (60 mg, 0.39 mmol) and 
Na2CO3 (60 mg, 0.57 mmol), and the resulting solution was heated under reflux for 24 h, 
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whereupon it was cooled to room temperature and filtered over celite, rinsing with EtOAc. The 
solution was concentrated via rotary evaporation and the resultant crude material was purified 
via column chromatography, eluting with hexanes:EtOAc:Et3N (20:80:1) to give 19 mg (44%) of 
the title compound as a clear paste. 1H NMR (500 MHz, CDCl3) δ 8.02 (s, 1 H), 7.50 (dd, J = 
8.7, 5.3 Hz, 1 H), 7.23 (s, 3 H), 7.06 – 6.98 (comp, 2 H), 6.88 (td, J = 9.2, 2.2 Hz, 1 H), 3.53 (s, 2 
H), 3.15 (d, J = 10.8 Hz, 2 H), 2.98 – 2.92 (comp, 2 H), 2.69 (dd, J = 9.8, 6.6 Hz, 2 H), 2.47 (tt, J 
= 11.4, 3.7 Hz, 1 H), 2.21 (s, 3 H), 2.07 (t, J = 11.6 Hz, 2 H), 1.87 – 1.80 (comp, 2 H), 1.71 (qd, 
J = 12.2, 3.6 Hz, 2 H); 13C NMR (126 MHz, CDCl3) δ 161.0, 159.1, 144.2, 136.2, 136.1, 134.7, 
127.0, 126.8, 124.1, 121.7, 121.6, 119.6, 119.5, 114.6, 108.1, 107.9, 97.5, 97.3, 61.2, 59.2, 57.0, 
53.4, 37.9, 27.9, 23.1; IR (NaCl, film) 2918, 2849, 1567, 1457, 1432, 1245, 1140 cm -1 HRMS 
(ESI) m/z calcd C23H26Cl2FN3 (M+H)+ 434.1561; found 434.1571. 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 8.02 (s, 1 H, N-H), 7.50 (dd, J = 8.7, 
5.3 Hz, 1 H, H15), 7.23 (s, 3 H, H1, H3), 7.06 – 6.98 (comp, 2 H, H18, H13), 6.88 (td, J = 9.2, 
2.2 Hz, 1 H, H17), 3.53 (s, 2 H, H5), 3.15 (d, J = 10.8 Hz, 2 H, H9), 2.98 – 2.92 (comp, 2 H, 
H10), 2.69 (dd, J = 9.8, 6.6 Hz, 2 H, H11), 2.47 (tt, J = 11.4, 3.7 Hz, 1 H, H7), 2.21 (s, 3 H, H6), 
2.07 (t, J = 11.6 Hz, 2 H, H9), 1.87 – 1.80 (comp, 2 H, H8), 1.71 (qd, J = 12.2, 3.6 Hz, 2 H, H8); 
13C NMR (126 MHz, CDCl3) δ 161.0 (C16), 159.1 (C16), 144.2 (C4), 136.2 (C19), 136.1 (C19), 
134.7 (C1), 127.0 (C2), 126.8 (C3), 124.1 (C14), 121.7 (C13), 121.6 (C13), 119.6 (C15), 119.5 
(C15), 114.6 (C12), 108.1 (C17), 107.9 (C17), 97.5 (C18), 97.3 (C18), 61.2 (C7), 59.2 (C11), 








4-amine (2.70) (LTL-III-151). A solution of 7.6 (68 mg, 0.15 mmol) in THF (0.5 mL) was 
added to a stirred suspension of LiAlH4 (57 mg, 1.5 mmol) in THF (1.0 mL) while cooling at 0 
˚C. The reaction vessel was removed from the ice bath and stirred while heating under reflux for 
19 hours. The reaction vessel was then cooled to 0 ˚C, whereupon H2O (0.06 mL) was carefully 
added, followed by 3M NaOH (0.06 mL) and H2O (0.18 mL). The mixture was stirred at room 
temperature for 30 min, during which time the visible precipitate turned from grey to white. 
MgSO4 was added, and the mixture was stirred for an additional 30 minutes, and then filtered 
over a pad of celite, washing with EtOAc. The solution was concentrated via rotary evaporation, 
and the crude material was purified by flash chromatography eluting with hexanes/EtOAc/Et3N 
(25:75:1 → 0:100:1) to give 42 mg (66%) of 2.70 as an off-white solid. 1H NMR (400 MHz, 
CDCl3) δ 7.87 (s, 1 H), 7.25 – 7.20 (comp, 2 H), 7.11 (comp, 2 H), 7.05 (d, J = 2.4 Hz, 1 H), 
7.00 (d, J = 2.4 Hz, 1 H), 6.85 (dd, J = 8.8, 2.4 Hz, 1 H), 3.86 (d, J = 0.6 Hz, 3 H), 3.56 (s, 2 H), 
3.15 (d, J = 11.3 Hz, 2 H), 2.98 – 2.90 (comp, 2 H), 2.71 – 2.63 (comp, 2 H), 2.49 (comp, 4 H), 
2.25 – 2.19 (s, 3 H), 2.04 (t, J = 11.2 Hz, 2 H), 1.85 (d, J = 12.1 Hz, 2 H), 1.74 (td, J = 12.0, 3.9 
Hz, 2 H). 13C NMR (101 MHz, CDCl3) δ 153.9, 140.9, 138.2, 131.3, 128.7, 127.8, 126.8, 125.5, 
124.9, 122.3, 114.2, 112.1, 111.8, 110.0, 100.7, 59.2, 57.8, 56.0, 53.5, 37.8, 27.8, 23.2, 15.8. IR 
(NaCl, film) 3415, 3163, 3047, 2926, 2854, 2807, 1624, 1587, 1484, 1452, 1356, 1301, 1261, 
1216, 1172, 1144, 1099, 1037 cm-1. LRMS (ESI) m/z calcd for C25H33N3OS (M+Na)+ 446.2237; 
found 446.2249. 
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NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.87 (s, 1 H, H1), 7.25 – 7.20 (comp, 
2 H, H19, H20), 7.11 (comp, 2 H, H21, H23), 7.05 (d, J = 2.4 Hz, 1 H, H5), 7.00 (d, J = 2.4 Hz, 
1 H, H2), 6.85 (dd, J = 8.8, 2.4 Hz, 1 H, H7), 3.86 (d, J = 0.6 Hz, 3 H, H10), 3.56 (s, 2 H, H17), 
3.15 (d, J = 11.3 Hz, 2 H, H13), 2.98 – 2.90 (comp, 2 H, H12), 2.71 – 2.63 (comp, 2 H, H11), 
2.49 (comp, 4 H, H24, H15), 2.25 – 2.19 (s, 3 H, H16), 2.04 (t, J = 11.2 Hz, 2 H, H13), 1.85 (d, J 




amine (2.69) (LTL-III-155). The title compound was prepared following the procedure 
described for 2.70. The crude material purified by flash chromatography eluting with 
hexanes/EtOAc/Et3N (25:75:1 → 0:100:1) to give 23 mg (62%) of 2.69 as a yellow paste. 
1H 
NMR (400 MHz, CDCl3) δ 7.85 (s, 1 H), 7.25 – 7.20 (comp, 2 H), 7.05 (d, J = 2.4 Hz, 1 H), 7.01 
(d, J = 2.3 Hz, 1 H), 6.94 – 6.89 (comp, 2 H), 6.85 (dd, J = 8.8, 2.5 Hz, 1 H), 6.79 (dd, J = 8.1, 
2.6 Hz, 1 H), 3.86 (s, 3 H), 3.81 (s, 3 H), 3.58 (s, 2 H), 3.16 (d, J = 11.2 Hz, 2 H), 2.98 – 2.91 
(comp, 2 H), 2.72 – 2.63 (comp, 2 H), 2.56-2.44 (m, 1 H), 2.24 (s, 3 H), 2.10 – 2.00 (comp, 2 H), 
1.86 (d, J = 12.6 Hz, 2 H), 1.80 – 1.68 (comp, 2 H). 13C NMR (101 MHz, CDCl3) δ 159.7, 153.9, 
141.9, 131.4, 129.1, 127.9, 122.3, 121.1, 114.1, 112.3, 112.1, 111.8, 100.7, 60.8, 59.2, 57.9, 56.0, 
55.2, 53.5, 37.8, 27.8, 23.2. IR (NaCl, film) 3415, 3154, 3046, 2941, 2831, 1587, 1487, 1455, 
1357, 1308, 1267, 1216, 1170, 1147, 1120, 1045 cm-1. LRMS (ESI) m/z calcd for C25H33N3O2 
(M+H)+ 408.2646; found 408.2643. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.85 (s, 1 H, H1), 7.25 – 7.20 (comp, 
2 H, H8, H23), 7.05 (d, J = 2.4 Hz, 1 H, H5), 7.01 (d, J = 2.3 Hz, 1 H, H2), 6.94 – 6.89 (comp, 2 
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H, H, H23, H24), 6.85 (dd, J = 8.8, 2.5 Hz, 1 H, H22), 6.79 (dd, J = 8.1, 2.6 Hz, 1 H, H7), 3.86 
(s, 3 H, H24), 3.81 (s, 3 H, H10), 3.58 (s, 2 H, H17), 3.16 (d, J = 11.2 Hz, 2 H, H13 eq), 2.98 – 
2.91 (comp, 2 H, H12), 2.72 – 2.63 (comp, 2 H, H11), 2.56-2.44 (m, 1 H, H15), 2.24 (s, 3 H, 





(LTL-III-154). The title compound was prepared following the procedure described for 2.70. 
The crude material purified by flash chromatography eluting with hexanes/EtOAc/Et3N (25:75:1 
→ 0:100:1) to give 43 mg (96%) of 2.70 as a yellow paste. 1H NMR (400 MHz, CDCl3) δ 7.85 
(s, 1 H), 7.35 – 7.29 (comp, 5 H), 7.24 – 7.21 (m, 1 H), 7.05 (d, J = 2.5 Hz, 1 H), 7.00 (d, J = 2.4 
Hz, 1 H), 6.85 (dd, J = 8.8, 2.4 Hz, 1 H), 3.86 (s, 3 H), 3.60 (s, 2 H), 3.16 (d, J = 11.2 Hz, 2 H), 
2.98 – 2.90 (comp, 2 H), 2.71 – 2.63 (comp, 2 H), 2.55-2.45 (m, 1 H), 2.22 (s, 3 H), 2.09 – 2.00 
(comp, 2 H), 1.86 (d, J = 12.6 Hz, 2 H), 1.79 – 1.73 (comp, 2 H). 13C NMR (101 MHz, CDCl3) δ 
153.9, 140.0, 131.4, 128.8, 128.2, 127.9, 126.8, 122.3, 114.1, 112.1, 111.8, 100.7, 60.8, 59.2, 
57.9, 56.0, 53.5, 37.8, 27.8, 23.2. IR (NaCl, film 3416, 3155, 3030, 2942, 2801, 1625, 1584, 
1487, 1452, 1360, 1305, 1261, 1216, 1173, 1143, 1118, 1035 cm-1. HRMS (ESI) m/z calcd for 
C24H31N3O (M+H)+ 378.2540; found 378.2550. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.85 (s, 1 H, H1), 7.35 – 7.29 (comp, 
5 H, H19-21), 7.24 – 7.21 (m, 1 H, H8), 7.05 (d, J = 2.5 Hz, 1 H, H5), 7.00 (d, J = 2.4 Hz, 1 H, 
H2), 6.85 (dd, J = 8.8, 2.4 Hz, 1 H, H7), 3.86 (s 3 H, H10), 3.60 (s, 2 H, H17), 3.16 (d, J = 11.2 
Hz, 2 H, H13), 2.98 – 2.90 (comp, 2 H, H12), 2.71 – 2.63 (comp, 2 H, H11), 2.55-2.45 (m, 1 H, 
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H15), 2.22 (s, 3 H, H16), 2.09 – 2.00 (comp, 2 H, H13), 1.86 (d, J = 12.6 Hz, 2 H, H14), 1.79 – 




methylpiperidin-4-amine (2.72) (LTL-III-128). A solution of amine 2.46 (50 mg, 0.18 mmol) 
and alkyl bromide 2.35 (25 mg, 0.11 mmol) in MeCN (1 mL) was stirred under reflux and stirred 
for 8 h, whereupon the reaction was cooled to room temperature and stirred for an additional 72 
h. The reaction mixture was concentrated via rotary evaporation, and the crude material was 
purified by flash chromatography eluting with Et2O/CH2Cl2/Et3N (100:0:1 → 66:33:1) to give 15 
mg (33%) of 2.72 as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.20 (d, J = 4.3 Hz, 1 H), 
8.09 (dd, J = 7.9, 1.5 Hz, 1 H), 7.35 (comp, 4 H), 7.14 (dd, J = 7.9, 4.8 Hz, 1 H), 4.60 (s, 3 H), 
3.65 (s, 3 H), 3.38 (s, 1 H), 3.27 – 3.18 (comp, 4 H), 3.06 (s, 2 H), 2.80 (s, 1 H), 2.25 (s, 3 H), 
2.12 (d, J = 13.2 Hz, 2 H), 1.88 (s, 2 H). 13C NMR (101 MHz, (CD3)2SO) δ 198.2, 170.8, 148.9, 
143.0, 134.3, 127.3, 127.0, 126.8, 123.9, 119.5, 115.3, 60.2, 56.4, 52.4, 37.8, 21.2, 14.5, 7.6. IR 
(NaCl, film) 3144, 3096, 3036, 2928, 2856, 2477, 2632, 1570, 1459, 1422,1344, 1288, 1203, 
1126, 1103, 1044 cm-1. HRMS (ESI) m/z calcd for C22H26Cl2N4 (M+H)+ 417.1607; found 
417.1623. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) δ 8.20 (d, J = 4.3 Hz, 1 H, H7), 8.09 
(dd, J = 7.9, 1.5 Hz, 1 H, H5), 7.35 (comp, 4 H, H17, H19, H2), 7.14 (dd, J = 7.9, 4.8 Hz, 1 H, 
H6), 4.60 (s, 3 H), 3.65 (s, 3 H), 3.38 (s, 1 H), 3.27 – 3.18 (comp, 4 H), 3.06 (s, 2 H), 2.80 (s, 1 





(LTL-III-172). A solution of 2.46 (28 mg, 0.1 mmol), phenyl isocyanate (24 mg, 0.2 mmol) and 
(i-Pr)2NEt (13 mg, 0.1 mmol) in CH2Cl2 was stirred overnight at room temperature, and the 
solvent was removed via rotary evaporation. The crude material was resuspended in 1 M aq. HCl 
(10 mL) and washed with Et2O (2 x 20 mL). The aqueous layer was then made basic via the 
addition of 3 M aq. NaOH (10 mL) and extracted with CH2Cl2 (5 x 15 mL). The combined 
organic layers were dried (Na2SO4) and concentrated via rotary evaporation to give 22 mg (56%) 
of the title compound as a white solid. 1H NMR (400 MHz, CD3OD) δ 7.37 – 7.29 (comp, 5 H), 
7.29 – 7.20 (comp, 2 H), 7.04 – 6.97 (m, 1 H), 4.24 (d, J = 13.2 Hz, 2 H), 3.61 (s, 2 H), 2.87 (td, 
J = 13.7, 2.5 Hz, 2 H), 2.69 (tt, J = 11.5, 3.7 Hz, 1 H), 2.21 (s, 3 H), 1.90 (d, J = 12.9 Hz, 2 H), 
1.57 (qd, J = 12.4, 4.2 Hz, 2 H); 13C NMR (101 MHz, CD3OD) δ 156.4, 144.0, 139.6, 134.6, 
128.1, 126.9, 126.5, 122.6, 120.8, 60.9, 56.5, 43.5, 36.6, 27.7; IR (NaCl, film) 3625, 3127, 3054, 
2944, 2855, 2796, 2360, 1636, 1595, 1569, 1536, 1501, 1447, 1353, 1329, 1306, 1243, 1160, 
1100, 1041 cm-1. HRMS (ESI) m/z calcd for C20H23Cl2N3O (M+Na)+ 414.1110; found 414.1121. 
 NMR Assignment. 1H NMR (400 MHz, CD3OD) δ 7.37 – 7.29 (comp, 5 H, H12, H3, 
H1), 7.29 – 7.20 (comp, 2 H, H13), 7.04 – 6.97 (m, 1 H, H14), 4.24 (d, J = 13.2 Hz, 2 H, H9), 
3.61 (s, 2 H, H5), 2.87 (td, J = 13.7, 2.5 Hz, 2 H, H9), 2.69 (tt, J = 11.5, 3.7 Hz, 1 H, H7), 2.21 





yl)acetaldehyde (LTL-III-312). Dihydro-β-carboline 2.95 (20 mg, 0.1 mmol) was dissolved in 1 
mL THF and cooled to −78 °C. Silyl enol ether 1.33 (63 mg, 0.4 mmol) and acryloyl chloride 
1.22 in THF (0.13 mL, 0.13 mmol, 1M) were added sequentially, and the solution was stirred at 
−78 °C for 15 min, during which time a tan precipitate formed. The flask was then removed from 
the ice bath and stirred for an additional 90 min at room temperature. A solution of saturated 
NaHCO3 (10 mL) was added, and the solution was extracted with CH2Cl2 (3 x 15 mL). The 
combined organic layers were dried (Na2SO4) and concentrated via rotary evaporation. The 
crude material was purified by flash chromatography, eluting with EtOAc:hexane (1:1) to give 
22 mg (73%) of the title compound as a yellow foam. 1H NMR (400 MHz, CDCl3) δ 9.92 (d, J = 
7.4 Hz, 1 H), 8.54 (s, 1 H), 7.23 (d, J = 8.7 Hz, 1 H), 6.90 (d, J = 2.5 Hz, 1 H), 6.84 (dd, J = 8.8, 
2.4 Hz, 1 H), 6.66 (dd, J = 16.8, 10.6 Hz, 1 H), 6.33 (dd, J = 16.8, 1.7 Hz, 1 H), 6.10 (dd, J = 9.1, 
3.9 Hz, 1 H), 5.77 (dd, J = 10.6, 1.7 Hz, 1 H), 4.25 (dd, J = 13.8, 4.9 Hz, 1 H), 3.84 (d, J = 0.6 
Hz, 3 H), 3.48 – 3.36 (m, 1 H), 3.22 – 3.05 (m, 2 H), 2.92 – 2.69 (m, 2 H); 13C NMR (101 MHz, 
CDCl3) δ 201.6, 165.8, 154.1, 133.4, 131.0, 128.5, 127.8, 126.6, 112.0, 111.9, 107.5, 100.4, 56.0, 
48.9, 44.8, 41.4, 22.2; IR (film, NaCl) 3284, 2935, 2847, 1717, 1643, 1592, 1485, 1436, 1293, 
1258, 1218, 1139, 1114, 1037 cm-1; HRMS (ESI) m/z calcd for C17H18N2O3 (M+Na)+, 321.1210; 
found, 321.1220; 
NMR Assignments. 1H NMR (400 MHz, CDCl3) δ 9.92 (d, J = 7.4 Hz, 1 H, H10), 8.54 
(s, 1 H, H1), 7.23 (d, J = 8.7 Hz, 1 H, H4), 6.90 (d, J = 2.5 Hz, 1 H, H2), 6.84 (dd, J = 8.8, 2.4 
Hz, 1 H, H3), 6.66 (dd, J = 16.8, 10.6 Hz, 1 H, H11), 6.33 (dd, J = 16.8, 1.7 Hz, 1 H, H12a), 6.10 
(dd, J = 9.1, 3.9 Hz, 1 H, H8), 5.77 (dd, J = 10.6, 1.7 Hz, 1 H, H12b), 4.25 (dd, J = 13.8, 4.9 Hz, 
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1 H, H7ax), 3.84 (d, J = 0.6 Hz, 3 H, H5), 3.48 – 3.36 (m, 1 H, H7eq), 3.22 – 3.05 (comp, 2 H, 
H9), 2.92 – 2.69 (comp, 2 H, H6); 13C NMR (101 MHz, CDCl3) δ 201.6 (C10), 165.8 (C18), 
154.1 (C16), 133.4 (C17), 131.0 (C15), 128.5 (C12), 127.8 (C11), 126.6 (C13), 112.0 (C3), 




indolo[2,3-a]isoxazolo[4,3-g]quinolizin-4-one (2.97) (LTL-IV-001). A solution of aldehyde 
2.96 (74 mg, 0.25 mmol), N-methylhydroxylamine hydrochloride (25 mg, 0.3 mmol), and 
triethylamine (0.08 mL, 0.6 mmol) in toluene (5 mL) was heated under reflux for 2.5 h. The 
reaction was then cooled to room temperature and concentrated via rotary evaporation. The crude 
material was purified by flash chromatography eluting with EtOAc:MeOH:Et3N (99:0:1 → 
97:2:1) to give 42 mg (51%) of the title compound as a yellow solid. 1H NMR (400 MHz, 
DMSO-d6) δ 10.76 (s, 1 H), 7.19 (dd, J = 8.7, 0.5 Hz, 1 H), 6.91 (d, J = 2.4 Hz, 1 H), 6.69 (dd, J 
= 8.7, 2.5 Hz, 1 H), 4.89 – 4.72 (comp, 2 H), 4.24 (t, J = 9.3 Hz, 1 H), 3.80 (dd, J = 8.2, 6.4 Hz, 1 
H), 3.73 (s, 3 H), 3.58 (q, J = 8.3 Hz, 1 H), 3.32 (s, 1 H), 2.82 (td, J = 12.3, 3.8 Hz, 1 H), 2.72 
(ddd, J = 13.6, 4.1, 2.2 Hz, 1 H), 2.67 – 2.51 (comp, 5 H), 1.30 (q, J = 11.9 Hz, 1 H);  13C NMR 
(101 MHz, DMSO-d6) δ 169.4, 153.5, 134.5, 131.5, 126.8, 112.0, 111.2, 107.4, 100.3, 67.9, 62.7, 
55.6, 55.2, 50.6, 47.2, 43.2, 39.3, 33.8, 21.0, 20.9 ppm; IR (film, NaCl) 3263, 2890, 1600, 1484, 
1436, 1324, 1272, 1234, 1173, 1137, 1098, 1044 cm-1; HRMS (ESI) m/z calcd for C18H21N3O3 
(M+H)+, 328.16560; found, 328.16640; 
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NMR Assignment. 1H NMR (400 MHz, DMSO-d6) δ 10.76 (s, 1 H, H1), 7.19 (dd, J = 
8.7, 0.5 Hz, 1 H, H4), 6.91 (d, J = 2.4 Hz, 1 H, H2), 6.69 (dd, J = 8.7, 2.5 Hz, 1 H, H3), 4.89 – 
4.72 (comp, 2 H, H7, H8), 4.24 (t, J = 9.3 Hz, 1 H, H12), 3.80 (dd, J = 8.2, 6.4 Hz, 1 H, H12), 
3.73 (s, 3 H, H5), 3.58 (q, J = 8.3 Hz, 1 H, H13), 3.32 (s, 1 H, H10), 2.82 (td, J = 12.3, 3.8 Hz, 1 
H, H7), 2.72 (ddd, J = 13.6, 4.1, 2.2 Hz, 1 H, H6), 2.67 – 2.51 (comp, 5 H, H9, H6, H11), 1.30 
(q, J = 11.9 Hz, 1 H, H9);  13C NMR (101 MHz, DMSO-d6) δ 169.4 (C19), 153.5 (C17), 134.5 
(C18), 131.5 (C16), 126.8 (C14), 112.0 (C4), 111.2 (C3), 107.4 (C15), 100.3 (C2), 67.9 (C12), 





hexahydroindolo[2,3-a]quinolizin-4(1H)-one (7.9) (LTL-III-284). Oxazolidinone 2.97 (70 
mg, 0.23 mmol) and nickel (II) chloride hexahydrate (109 mg, 0.46 mmol) were dissolved in 
MeOH (4.5 mL). The solution was cooled to 0 °C, and sodium borohydride (52 mg, 1.38 mmol) 
was added slowly. The flask was then removed from the ice bath and stirred for 2h at room 
temperature whereupon the solvent was removed via rotary evaporation. The residue was 
dissolved in CH2Cl2 (2 mL), and 30% aqueous NH4OH (2 mL) was added. The mixture was 
stirred for 1.5 h, and the layers were separated. The aqueous layer was extracted with CH2Cl2 (3 
× 15 mL), and the combined organic layers were dried (Na2SO4) and concentrated via rotary 
evaporation. The crude material was purified by flash chromatography, eluting with 
CH2Cl2MeOH:Et3N (94:5:1) to give 53 mg (70%) of the title compound as a tan solid. 
1H NMR 
(400 MHz, DMSO-d6) δ 10.74 (s, 1 H), 7.18 (d, J = 8.7 Hz, 1 H), 6.87 (d, J = 2.6 Hz, 1 H), 6.67 
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(dd, J = 8.7, 2.5 Hz, 1 H), 4.91 – 4.81 (m, 1 H), 4.79 – 4.71 (m, 1 H), 3.81 – 3.67 (comp, 5 H), 
3.12 – 2.99 (m, 1 H), 2.78 (td, J = 12.2, 4.1 Hz, 1 H), 2.69 – 2.52 (comp, 4 H), 2.33 (s, 3 H), 1.85 
(q, J = 11.7 Hz, 1 H). 13C NMR (126 MHz, DMSO-d6) δ 169.6, 153.6, 135.7, 131.6, 127.1, 
112.2, 111.1, 107.2, 100.4, 60.2, 55.8, 54.9, 52.8, 47.5, 34.1, 31.1, 21.3 ppm; IR (film, NaCl) 
3247, 2963, 1627,1561, 1435, 1262, 1216, 1091, 1022 cm-1; HRMS (ESI) m/z calcd for 
C18H23N3O3 (M+Na)+, 352.1632; found, 352.1641. 
NMR Assignment. 1H NMR (400 MHz, DMSO-d6) δ 10.74 (s, 1 H, H1), 7.18 (d, J = 8.7 
Hz, 1 H, H4), 6.87 (d, J = 2.6 Hz, 1 H, H2), 6.67 (dd, J = 8.7, 2.5 Hz, 1 H, H3), 4.91 – 4.81 (m, 1 
H, H7), 4.79 – 4.71 (m, 1 H, H8), 3.81 – 3.67 (comp, 5 H, H5, H12), 3.12 – 2.99 (m, 1 H, H13), 
2.78 (td, J = 12.2, 4.1 Hz, 1 H, H7), 2.69 – 2.52 (comp, 4 H, H6, H9, H10), 2.33 (s, 3 H, H11), 
1.85 (q, J = 11.7 Hz, 1 H, H9). 13C NMR (126 MHz, DMSO-d6) δ 169.6 (C19), 153.6 (C17), 
135.7 (C18), 131.6 (C16), 127.1 (C14), 112.2 (C4), 111.1 (C3), 107.2 (C15), 100.4 (C2), 60.2 




2,3,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-4(1H)-one (2.98) (LTL-IV-003). A solution 
of amine 7.9 (20 mg, 0.06 mmol) and 3,5-dichlorobenzaldehyde (21 mg, 0.12 mmol) in MeOH 
(1.2 mL) was stirred under reflux for 2h. The reaction was cooled to room temperature, acetic 
acid (0.02 mL, 0.3 mmol) and sodium cyanoborohydride (7.5 mg, 0.12 mmol) were added. The 
reaction was stirred for 14 h, whereupon additional benzaldehyde 32 (21mg, 0.12 mmol) and 
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sodium cyanoborohydride (7.5 mg, 0.12 mmol) were added. The reaction was stirred for an 
additional 24 h, whereupon saturated aqueous NaHCO3 (10 mL) was added, and the resulting 
mixture was extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were dried 
(Na2SO4) and concentrated via rotary evaporation, and the crude material was purified by flash 
chromatography, eluting with hexanes:EtOAc:Et3N (75:25:1 → 50:50:1) to give 20 mg (68%) of 
the title compound as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1 H), 7.23 (s, 1 H), 
7.18 (d, J = 2.0 Hz, 2 H), 6.96 (d, J = 2.5 Hz, 1 H), 6.86 (dd, J = 8.8, 2.5 Hz, 1 H), 5.01 (dd, J = 
14.0, 2.2 Hz, 1 H), 4.76 (d, J = 12.3 Hz, 1 H), 4.02 (d, J = 6.8 Hz, 2 H), 3.86 (s, 4 H), 3.60 (d, J = 
13.8 Hz, 1 H), 3.49 (d, J = 13.7 Hz, 1 H), 3.25 (dt, J = 11.2, 5.9 Hz, 1 H), 3.06 – 2.93 (m, 2 H), 
2.82 (s, 2 H), 2.58 – 2.46 (m, 1 H), 2.20 (s, 3 H), 1.98 – 1.87 (m, 1 H); 13C NMR (101 MHz, 
DMSO) δ 170.5, 153.6, 145.0, 135.5, 134.4, 131.6, 127.4, 127.0, 126.9, 112.2, 111.2, 107.3, 
100.4, 60.2, 59.9, 57.8, 57.0, 55.8, 52.2, 47.6, 38.8, 29.2, 21.2; IR (film, NaCl) 3271, 2921, 2849, 
2357, 1616, 1567, 1455, 1433, 1361, 1319, 1285, 1263, 1215, 1175, 1137, 1033 cm-1; HRMS 
(ESI) m/z calcd for C25H27Cl2N3O3 (M+H)+, 488.1502; found, 488.1514; 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1 H, H1), 7.18 (d, J = 2.0 Hz, 
2 H, H15), 6.96 (d, J = 2.5 Hz, 1 H, H2), 6.86 (dd, J = 8.8, 2.5 Hz, 1 H, H3), 5.01 (dd, J = 14.0, 
2.2 Hz, 1 H, H7), 4.76 (d, J = 12.3 Hz, 1 H, H8), 4.02 (d, J = 6.8 Hz, 2 H, H12), 3.86 (comp, 4 
H, H5, H17), 3.60 (d, J = 13.8 Hz, 1 H, H14), 3.49 (d, J = 13.7 Hz, 1 H, H14), 3.25 (dt, J = 11.2, 
5.9 Hz, 1 H, H10), 3.06 – 2.93 (comp, 2 H, H7, H13), 2.82 (comp, 2 H, H9, H6), 2.58 – 2.46 (m, 
1 H, H6), 2.20 (s, 3 H, H11), 1.98 – 1.87 (m, 1 H, H9); 13C NMR (101 MHz, DMSO) δ 170.5 
(C23), 153.6 (C21), 145.0 (C25), 135.5 (C22), 134.4 (C20), 131.6 (C18), 127.4 (C15), 127.0 
(C24), 126.9 (C16), 112.2 (C4), 111.2 (C3), 107.3 (C19), 100.4 (C2), 60.2, 59.9 (C12), 57.8 





2,3,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-4(1H)-one (LTL-IV-004). A 1 M solution of 
BBr3 in CH2Cl2 (0.06 mmol, 0.06 mL) was added to a stirred solution of 2.98 (10 mg, 0.02 
mmol) in CH2Cl2 (0.4 mL) at −78 °C, and stirring was continued for 2 h. The flask was then 
removed from the dry ice/acetone bath and stirred for an additional 3 h at room temperature, 
whereupon the solvent was removed via rotary evaporation. The residue was resuspended in 
saturated aqueous NaHCO3 (0.5 mL) and MeOH (0.5 mL), and the mixture was stirred for 1 h. 
The reaction was then diluted with additional saturated aqueous NaHCO3 (10 mL) and extracted 
with CH2Cl2 (3 x 10 mL). The combined organic layers were dried (Na2SO4) and concentrated 
via rotary evaporation. The crude material was purified by flash chromatography, eluting with 
hexanes:EtOAc:Et3N (50:50:1 → 100:0:1) to give 7 mg (78%) of the title compound as a white 
solid. 1H NMR (400 MHz, CD3OD) δ 7.35 (d, J = 1.9 Hz, 2 H), 7.32 (t, J = 1.9 Hz, 1 H), 7.13 
(dd, J = 8.6, 0.6 Hz, 1 H), 6.80 (dd, J = 2.4, 0.6 Hz, 1 H), 6.64 (dd, J = 8.6, 2.4 Hz, 1 H), 4.97 – 
4.90 (m, 1 H), 4.84 – 4.77 (m, 1 H), 4.10 – 3.98 (comp, 2 H), 3.65 (q, J = 14.1 Hz, 2 H), 3.24 – 
3.15 (m, 1 H), 3.03 – 2.94 (m, 1 H), 2.94 – 2.86 (m, 1 H), 2.83 – 2.66 (comp, 3 H), 2.23 (s, 3 H), 
2.12 – 2.01 (m, 1 H); 13C NMR (101 MHz, CD3OD) δ 171.5, 150.1, 143.7, 134.7, 133.8, 131.6, 
127.2, 126.7, 126.6, 111.1, 110.8, 106.9, 101.9, 60.0, 58.1, 57.2, 52.6, 40.1, 37.6, 28.8, 20.5; IR 
(film, NaCl) 2923, 2851, 2361, 1614, 1569, 1433, 1358, 1261, 1195, 1036 cm -1; HRMS (ESI) 
m/z calcd for C24H25Cl2N3O3 (M+H)+, 474.1350; found, 474.1346. 
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NMR Assignment. 1H NMR (400 MHz, CD3OD) δ 7.35 (d, J = 1.9 Hz, 2 H, H15), 7.32 
(t, J = 1.9 Hz, 1 H, H16), 7.13 (dd, J = 8.6, 0.6 Hz, 1 H, H4), 6.80 (dd, J = 2.4, 0.6 Hz, 1 H, H2), 
6.64 (dd, J = 8.6, 2.4 Hz, 1 H, H3), 4.97 – 4.90 (m, 1 H, H7), 4.84 – 4.77 (m, 1 H, H8), 4.10 – 
3.98 (comp, 2 H, H12), 3.65 (q, J = 14.1 Hz, 2 H, H14), 3.24 – 3.15 (m, 1 H, H10), 3.03 – 2.94 
(m, 1 H, H7), 2.94 – 2.86 (m, 1 H, H13), 2.83 – 2.66 (comp, 3 H, H9, H6), 2.23 (s, 3 H, H11), 
2.12 – 2.01 (m, 1 H, H9). 13C NMR (101 MHz, CD3OD) δ 171.5 (C23), 150.1 (C21), 143.7 
(C25), 134.7 (C20), 133.8 (C22), 131.6 (C18), 127.2 (C24), 126.7 (C15), 126.6 (C16), 111.1 
(C4), 110.8 (C3), 106.9 (C19), 101.9 (C2), 60.0 (C12), 58.1 (C10), 57.2 (C14), 52.6 (C8), 40.1 
(C7), 37.6 (C11), 28.8 (C9), 20.5 (C6). 
 
 
Expression of full-length TbMetRS and truncated TbMetRS 
A 30 ml solution of LB-ampicillin (100 mg / L) was inoculated with one colony of BL21 
(de3) transformed with MetRS or truncated MetRS plasmid (plasmids were a generous gift from 
Wim J. G. Hol). The inoculated solution was cultured overnight at 30 °C, 150 RPM in a shaking 
incubator. The saturated culture was then diluted 100 x (10 ml : 1000 ml) in 3 x 1 L sterile LB 
and cultured at 37 °C, 200 RPM until an OD600 of 0.6 was reached. At this time, IPTG was added 
to a final concentration of 0.5 mM, and the temperature of the incubator was reduced to 15 °C. 
Expression continued for 24 hours, at which time the cells were harvested via centrifugation (15 
min, 4000 x g) and the resulting cell pellet was stored at -80 °C until further use.   
 
Purification of full-length TbMetRS 
-Thawed frozen cell pellets from 3L of culture and re-suspended in 30 mL of lysis buffer 
(25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 10 mM imidazole, 10 mM MgCl2, 10 mM 
L-Met, 0.025% NaN3). 
-Added 240 uL of DNAse I (40 uL/pellet) and 4 mg PMSF 
-Lysed 2x via cell press at 1 drop/sec, 1200 psi 
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-Spun down lysate 45 min, 12000 RPM, 4 deg C 
-Ran FPLC NiNTA column with step gradient. (10 – 30 - 250 mM imidazole) 
-Pooled peak fractions and dialyzed into anion exchange buffer A (25 mM HEPES pH 
7.0, 5% glycerol, 10 mM L-Met, 0.025% NaN3). 
-Ran FPLC SP/HP column  (gradient: 0 – 1 M NaCl) 
-Analyzed peak fractions via SDS PAGE, pooled fractions and concentrated with Pall 
centrifugal concentrator. 
-Added glycerol to a final concentration of 50% and stored at -80 ˚C. 
 
Purification of truncated TbMetRS 
-Thawed frozen cell pellets from 3L of culture and re-suspended in 30 mL of lysis buffer 
(25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 10 mM imidazole, 10 mM MgCl2, 10 mM 
L-Met, 0.025% NaN3). 
-Added 240 uL of DNAse I (40 uL/pellet) and 4 mg PMSF 
-Lysed 2x via cell press at 1 drop/sec, 1200 psi 
-Spun down lysate 45 min, 12000 RPM, 4 deg C 
-Ran FPLC NiNTA column with step gradient. (10 – 30 - 250 mM imidazole) 
-Pooled peak fractions and dialyzed into anion exchange buffer A (25 mM HEPES pH 
7.0, 5% glycerol, 10 mM L-Met, 0.025% NaN3). 
-Ran FPLC Q column  (gradient: 0 – 1 M NaCl) 
-Analyzed peak fractions via SDS PAGE, pooled fractions and concentrated with Pall 
centrifugal concentrator. 
-Added glycerol to a final concentration of 50% and stored at -80 ˚C. 
 
TbMetRS aminoacylation assay 
Protocol was adapted from the procedure of Cestari and Stuart.48 Reactions were 
performed in 25 mM HEPES pH 9, 100 mM NaCl, 10 mM MgCl, 50 mM KCl, 1 mM DTT and 
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3% glycerol with 0.8 mg/mL yeast tRNA (Sigma), 0.2 mM L-methionine, 0.2 mM ATP, 0.1 µM  
recombinant TbMetRS, and 2 U/mL pyrophosphatase (Sigma) in 50 µL total volume. The 
reactions were performed in clear, flat-bottom 96-well plates and incubated for 2 hours at room 
temperature, whereupon 75 µL of a 2:1 mixture of H2O and freshly prepared malachite green 
reagent49 was added, and the mixture was incubated for an additional 20 minutes. Absorbances 
were then measured at 620 nM using a plate reader. Reactions were performed in triplicate with 
median values used, and the reported results are the average of two runs. For IC50 determination 
inhibitors were added to the reaction as a solution in DMSO, and the values were calculated in 





7.2 DIVERSITY-ORIENTED SYNTHESIS OF SPIROCYCLIC B-PHENETHYLAMINES 
 
 
(6S,7R)-4-Methylene-7-phenyl-1-azaspiro[5.5]undecane (4.39) (LTL-IV-271). A 
solution of 4.30 (17 mg, 0.1 mmol), 4.2 (19 mg, 0.12 mmol) and AcOH (6 mg, 0.1 mmol) in 
MeOH (1 mL) was stirred at room temperature for 24 h, whereupon the mixture was diluted with 
aqueous Na2CO3 (1.4 M) and extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts 
were dried (Na2SO4) and concentrated via rotary evaporation. The crude material was purified by 
flash column chromatography, eluting with hexanes:Et3N (99 : 1) to give 16 mg (67%) of the 
title compound as a white solid, mp 63–66 ˚C. 1H NMR (500 MHz, CDCl3) δ 7.23 (t, J = 7.5 Hz, 
2 H), 7.18 – 7.13 (comp, 3 H), 4.60 (s, 1 H), 4.50 (s, 1 H), 2.82 (dd, J = 13.5, 6.2 Hz, 1 H), 2.62 
(td, J = 12.9, 3.6 Hz, 1 H), 2.48 (dd, J = 12.8, 3.4 Hz, 1 H), 2.22 – 2.08 (comp, 2 H), 1.99 (dd, J 
= 13.2, 3.4 Hz, 1 H), 1.84 – 1.72 (comp, 3 H), 1.62 – 1.52 (m, 1 H), 1.52 – 1.37 (comp, 3 H), 
1.30 (qt, J = 13.0, 4.1 Hz, 1 H), 1.12 (s, 1 H), 0.88 (td, J = 13.7, 3.8 Hz, 1 H); 13C NMR (126 
MHz, CDCl3) δ 145.5, 142.3, 129.6, 128.0, 126.5, 108.6, 55.2, 53.9, 47.2, 41.3, 36.2, 31.8, 27.7, 
26.9, 21.0; IR (film, NaCl) 3731, 3632, 3065, 2928, 2853, 2361, 2338, 1651, 1456 cm-1; HRMS 
(ESI) m/z calcd for C17H23N (M+H)+, 242.1903; found 242.1906  
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.23 (t, J = 7.5 Hz, 2 H, H15), 7.18 – 
7.13 (comp, 3 H, H14, H16), 4.60 (s, 1 H, H7), 4.50 (s, 1 H, H7), 2.82 (dd, J = 13.5, 6.2 Hz, 1 H, 
H6), 2.62 (td, J = 12.9, 3.6 Hz, 1 H, H6), 2.48 (dd, J = 12.8, 3.4 Hz, 1 H, H8), 2.22 – 2.08 
(comp, 2 H, H9, H12), 1.99 (dd, J = 13.2, 3.4 Hz, 1 H, H5), 1.84 – 1.72 (comp, 3 H, H3, H9), 
1.62 – 1.52 (m, 1 H, H5), 1.52 – 1.37 (comp, 3 H, H9, H8), 1.30 (qt, J = 13.0, 4.1 Hz, 1 H, H10), 
1.12 (s, 1 H, H1), 0.88 (td, J = 13.7, 3.8 Hz, 1 H, H7). 13C NMR (126 MHz, CDCl3) δ 145.5 
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(C4), 142.3 (C13), 129.6 (C16), 128.0 (C15), 126.5 (C14), 108.6 (C7), 55.2 (C2), 53.9 (C8), 47.2 




291). The title compound was prepared following the general procedure of 4.39. The crude 
material was purified by flash column chromatography, eluting with hexanes:Et3N (99 : 1) to 
give 55 mg (65%) of the title compound as a white paste. 1H NMR (500 MHz, CDCl3) δ 7.22 (t, 
J = 7.8 Hz, 1 H), 6.86 – 6.75 (comp, 3 H), 4.68 (s, 1 H), 4.57 (s, 1 H), 3.81 (s, 3 H), 2.90 (dd, J = 
13.6, 6.2 Hz, 1 H), 2.69 (td, J = 13.0, 3.6 Hz, 1 H), 2.53 (dd, J = 12.8, 3.4 Hz, 1 H), 2.29 – 2.15 
(comp, 2 H), 2.12 – 2.02 (d, J = 13.6 Hz, 1 H), 1.89 (comp, 3 H), 1.68 (td, J = 12.8, 5.6 Hz, 1 
H), 1.56 (comp, 2 H), 1.48 (m, 1 H), 1.36 (comp, 2 H), 0.94 (td, J = 13.8, 3.8 Hz, 1 H); 13C 
NMR (126 MHz, CDCl3) δ 159.3, 145.5, 143.9, 128.9, 122.1, 115.5, 111.6, 108.6, 55.2, 55.2, 
54.0, 47.3, 41.3, 36.2, 31.8, 27.7, 26.9, 20.9; HRMS (ESI) m/z calcd for C18H25NO (M+H)+, 
272.2009; found 272.2008. 
NMR Assignment. 1H NMR (499 MHz, CDCl3) δ 7.22 (t, J = 7.8 Hz, 1 H, H17), 6.86 – 
6.75 (comp, 3 H, H14, H16, H18), 4.68 (s, 1 H, H7), 4.57 (s, 1 H, H7), 3.81 (s, 3 H, H19), 2.90 
(dd, J = 13.6, 6.2 Hz, 1 H, H6), 2.69 (td, J = 13.0, 3.6 Hz, 1 H, H6), 2.53 (dd, J = 12.8, 3.4 Hz, 1 
H, H8), 2.29 – 2.15 (comp, 2 H, H9, H12), 2.07 (d, J = 13.6 Hz, 1 H, H5), 1.89 (comp, 3 H, H3, 
H10), 1.68 (td, J = 12.8, 5.6 Hz, 1 H, H5), 1.56 (comp, 2 H, H9, H11), 1.48 (m, 1 H, H11), 1.36 
(comp, 2 H, H10, H1), 0.94 (td, J = 13.8, 3.8 Hz, 1 H, H12); 13C NMR (126 MHz, CDCl3) δ 
159.3 (C15), 145.5 (C4), 143.9 (C13), 128.9 (C17), 122.1 (C18), 115.5 (C14), 111.6 (C16), 
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108.6 (C7), 55.2 (C2), 55.2 (C19), 54.0 (C8), 47.3 (C3), 41.3 (C6), 36.2 (C5), 31.8 (C12), 27.7 




288). The title compound was prepared following the general procedure of 4.39. The crude 
material was purified by flash column chromatography, eluting with hexanes:Et3N (100 : 1) to 
give 65 mg (69 %) of the title compound as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.28 (d, 
J = 8.5 Hz, 2 H), 7.19 (d, J = 8.5 Hz, 2 H), 4.70 (s, 1 H), 4.59 (s, 1 H), 2.95 – 2.83 (m, 1 H), 2.70 
(td, J = 12.8, 3.5 Hz, 1 H), 2.54 (dd, J = 12.8, 3.4 Hz, 1 H), 2.26 – 2.04 (comp, 3 H), 1.90 – 1.80 
(comp, 3 H), 1.70 (td, J = 12.8, 5.7 Hz, 1 H), 1.54 (comp, 3 H), 1.37 (qt, J = 12.6, 4.2 Hz, 1 H), 
1.29 – 1.17 (m, 1 H), 0.95 (ddd, J = 14.5, 12.4, 4.3 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ 
145.1, 140.8, 132.2, 130.9, 128.1, 108.9, 55.1, 53.3, 47.0, 41.2, 36.0, 31.6, 27.8, 26.8, 20.8. 
HRMS (ESI) m/z calcd for C17H22ClN (M+H)+, 276.1514; found 276.1517. 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.5 Hz, 2 H, H15), 7.19 
(d, J = 8.5 Hz, 2 H, H14), 4.70 (s, 1 H, H7), 4.59 (s, 1 H, H7), 2.95 – 2.83 (m, 1 H, H6), 2.70 (td, 
J = 12.8, 3.5 Hz, 1 H, H6), 2.54 (dd, J = 12.8, 3.4 Hz, 1 H, H8), 2.26 – 2.04 (comp, 3 H, H9, 
H12, H5), 1.90 – 1.80 (comp, 3 H, H3, H10), 1.70 (td, J = 12.8, 5.7 Hz, 1 H, H5), 1.54 (comp, 3 
H, H9, H11), 1.37 (qt, J = 12.6, 4.2 Hz, 1 H, H10), 1.29 – 1.17 (m, 1 H, H1), 0.95 (ddd, J = 
14.5, 12.4, 4.3 Hz, 1 H, H12); 13C NMR (126 MHz, CDCl3) δ 145.1 (C4), 140.8 (C13), 132.2 
(C16), 130.9 (C14), 128.1 (C15), 108.9 (C7), 55.1 (C2), 53.3 (C8), 47.0 (C3), 41.2 (C6), 36.0 





038). The title compound was prepared following the general procedure of 4.39. The crude 
material was purified by flash column chromatography, eluting with hexanes:Et3N (100 : 1) to 
give 105 mg (82%) of the title compound as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.45 – 
7.40 (d, J = 8.4 Hz, 2 H), 7.15 – 7.09 (d, J = 8.4 Hz, 2 H), 4.68 (s, 1 H), 4.57 (s, 1 H), 2.88 (ddd, 
J = 13.2, 6.1, 1.6 Hz, 1 H), 2.68 (td, J = 12.8, 3.6 Hz, 1 H), 2.51 (dd, J = 12.8, 3.4 Hz, 1 H), 2.25 
– 2.03 (comp, 3 H), 1.84 (s, 3 H), 1.69 (td, J = 12.7, 6.1 Hz, 1 H), 1.52 (ddt, J = 12.7, 8.2, 3.1 
Hz, 3 H), 1.36 (qq, J = 12.7, 4.7, 4.2 Hz, 1 H), 0.99 – 0.87 (m, 1 H); 13C NMR (126 MHz, 
CDCl3) δ 145.2, 141.3, 131.3, 131.0, 120.3, 108.9, 55.0, 53.4, 47.0, 41.2, 36.0, 31.6, 27.8, 26.8, 
20.8; HRMS (ESI) m/z calcd for C17H22BrN (M+H)+ 320.1008; found 320.1000. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.40 (d, J = 8.4 Hz, 2 H, H15), 
7.15 – 7.09 (d, J = 8.4 Hz, 2 H, H14), 4.68 (s, 1 H, H7), 4.57 (s, 1 H, H7), 2.88 (ddd, J = 13.2, 
6.1, 1.6 Hz, 1 H, H6), 2.68 (td, J = 12.8, 3.6 Hz, 1 H, H6), 2.51 (dd, J = 12.8, 3.4 Hz, 1 H, H8), 
2.25 – 2.03 (comp, 3 H, H9, H12, H5), 1.84 (s, 3 H, H3, H6), 1.69 (td, J = 12.7, 6.1 Hz, 1 H, 
H5), 1.52 (comp, 3 H, H9, H11), 1.36 (qq, J = 12.7, 4.7, 4.2 Hz, 1 H, H10), 0.99 – 0.87 (m, 1 H, 
H12); 13C NMR (126 MHz, CDCl3) δ 145.2 (C4), 141.3 (C13), 131.3 (C15), 131.0 (C14), 120.3 
(C16), 108.9 (C7), 55.0 (C2), 53.4 (C8), 47.0 (C3), 41.2 (C6), 36.0 (C5), 31.6 (C12), 27.8 (C9), 




(6S,7S)-7-(Furan-2-yl)-4-methylene-1-azaspiro[5.5]undecane (4.44) (LTL-IV-281). 
The title compound was prepared following the general procedure of 4.39. The crude material 
was purified by flash column chromatography, eluting with hexanes:Et3N (100 : 1) to give 34 mg 
(74 %) of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.34 (dd, J = 1.9, 
0.8 Hz, 1 H), 6.33 (dd, J = 3.2, 1.9 Hz, 1 H), 6.11 (dd, J = 3.2, 0.8 Hz, 1 H), 4.71 (m, 1 H), 4.61 
(m, 1 H), 2.91 (ddd, J = 13.3, 5.8, 2.6 Hz, 1 H), 2.74 (dd, J = 11.5, 3.8 Hz, 1 H), 2.67 (ddd, J = 
13.3, 11.5, 3.8 Hz, 1 H), 2.16 – 1.93 (comp, 5 H), 1.87 – 1.75 (comp, 2 H), 1.66 – 1.50 (comp, 2 
H), 1.49 – 1.40 (m, 1 H), 1.40 – 1.25 (comp, 2 H), 0.99 (ddd, J = 14.1, 11.8, 3.7 Hz, 1 H).13C 
NMR (126 MHz, CDCl3) δ 157.2, 145.3, 141.0, 110.1, 108.8, 106.8, 55.2, 46.6, 46.2, 41.4, 36.2, 
31.7, 26.8, 25.8, 20.7. HRMS (ESI) m/z calcd for C15H21NO (M+H)+, 232.1696; found 
232.1695. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.34 (dd, J = 1.9, 0.8 Hz, 1 H, H16), 
6.33 (dd, J = 3.2, 1.9 Hz, 1 H, H15), 6.11 (dd, J = 3.2, 0.8 Hz, 1 H, H14), 4.71 (m, 1 H, H7), 
4.61 (m, 1 H, H7), 2.91 (ddd, J = 13.3, 5.8, 2.6 Hz, 1 H, H6), 2.74 (dd, J = 11.5, 3.8 Hz, 1 H, 
H8), 2.67 (ddd, J = 13.3, 11.5, 3.8 Hz, 1 H, H6), 2.16 – 1.93 (comp, 5 H, H3, H5, H9, H12), 1.87 
– 1.75 (comp, 2 H, H5, H10), 1.66 – 1.50 (comp, 2 H, H9, H11), 1.49 – 1.40 (m, 1 H, H11), 1.40 
– 1.25 (comp, 2 H, H1, H10), 0.99 (ddd, J = 14.1, 11.8, 3.7 Hz, 1 H, H12).13C NMR (126 MHz, 
CDCl3) δ 157.2 (C13), 145.3 (C4), 141.0 (C16), 110.1 (C15), 108.8 (C7), 106.8 (C14), 55.2 






282). The title compound was prepared following the general procedure of 4.39. The crude 
material was purified by flash column chromatography, eluting with hexanes:EtOAc:Et3N (75 : 
25 : 1) to give 21 mg (75 %) of the title compound as a white solid, mp 178–180 ˚C. 1H NMR 
(500 MHz, CDCl3) δ 8.17 (s, 1 H), 7.66 (d, J = 7.9 Hz, 1 H), 7.40 (d, J = 8.1 Hz, 1 H), 7.22 (t, J 
= 7.6 Hz, 1 H), 7.16 (comp, 2 H), 4.68 (s, 1 H), 4.60 (s, 1 H), 2.99 (dd, J = 12.6, 3.5 Hz, 1 H), 
2.93 (dd, J = 13.7, 5.9 Hz, 1 H), 2.72 (td, J = 12.9, 3.5 Hz, 1 H), 2.28 – 2.11 (comp, 2 H), 2.11 – 
1.94 (comp, 3 H), 1.86 (dt, J = 13.0, 3.8 Hz, 1 H), 1.71 – 1.48 (comp, 6 H), 1.42 (qt, J = 12.4, 
3.8 Hz, 1 H), 1.10 (td, J = 13.6, 3.7 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ 145.6, 135.8, 
128.6, 122.1, 122.0, 119.7, 119.4, 117.8, 111.0, 108.5, 55.5, 47.7, 41.5, 36.3, 31.7, 29.0, 27.0, 
20.9; HRMS (ESI) m/z calcd for C19H24N2 (M+H)+, 281.2012; found 281.2011. 
NMR Assignment. 1H NMR (499 MHz, CDCl3) δ 8.17 (s, 1 H, H15), 7.66 (d, J = 7.9 
Hz, 1 H, H17), 7.40 (d, J = 8.1 Hz, 1 H, H20), 7.22 (t, J = 7.6 Hz, 1 H, H19), 7.16 (comp, 2 H, 
H14, H18), 4.68 (s, 1 H, H7), 4.60 (s, 1 H, H7), 2.99 (dd, J = 12.6, 3.5 Hz, 1 H, H8), 2.93 (dd, J 
= 13.7, 5.9 Hz, 1 H, H6), 2.72 (td, J = 12.9, 3.5 Hz, 1 H, H6), 2.28 – 2.11 (comp, 2 H, H9, H12), 
2.11 – 1.94 (comp, 3 H, H5, H3), 1.86 (dt, J = 13.0, 3.8 Hz, 1 H, H10), 1.71 – 1.48 (comp, 6 H, 
H9, H5, H11, H1), 1.42 (qt, J = 12.4, 3.8 Hz, 1 H, H10), 1.10 (td, J = 13.6, 3.7 Hz, 1 H, H12); 
13C NMR (126 MHz, CDCl3) δ 145.6 (C4), 135.8 (C16), 128.6 (C21), 122.1 (C14), 122.0 (C19), 
119.7 (C17), 119.4 (C18), 117.8 (C13), 111.0 (C20), 108.5 (C7), 55.5, 47.7 (C3), 43.9 (C8), 41.5 






(LTL-V-077). A stirred solution of 4.18 (28 mg, 0.1 mmol), 4.2 (19 mg, 0.12 mmol), and AcOH 
(6 mg, 0.1 mmol) in MeOH (1 mL) was heated to 50 ˚C (bath temp.) for 24 h, whereupon the 
mixture was diluted with aqueous Na2CO3 (1.4 M, 20 mL) and extracted with CH2Cl2 (3 x 15 
mL). The combined organic extracts were dried (Na2SO4) and concentrated via rotary 
evaporation. The crude material was purified by flash column chromatography, eluting with 
hexanes:EtOAc:Et3N (90 : 10 : 1) to give 27 mg (79%) of the title compound as an off-white 
solid. 1H NMR (400 MHz, CDCl3) δ 7.33 (comp, 3 H), 7.20 (comp, 2 H), 4.72 (s, 1 H), 4.62 (s, 1 
H), 3.85 (comp, 2 H), 3.63 (br, 1 H), 3.16 (t, J = 13.0 Hz, 1 H), 2.91 (dd, J = 13.9, 5.9 Hz, 1 H), 
2.73 – 2.59 (comp, 2 H), 2.09 (comp, 2 H), 1.93 (s, 2 H), 1.68 (td, J = 12.9, 6.0 Hz, 1 H), 1.43 (s, 
10 H), 1.18 (s, 1 H); 13C NMR (126 MHz, CDCl3) δ 155.0, 144.5, 138.6, 129.5, 128.4, 127.2, 
109.5, 83.7, 79.4, 54.1, 51.9, 50.3, 46.2, 44.0, 43.1, 41.5, 39.9, 38.9, 36.2, 30.7, 28.5, 28.1; 
HRMS (ESI) m/z calcd for C21H30N2O2 (M+H)+ 343.2380; found 343.2375;  
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.33 (comp, 3 H, H13, H15), 7.20 
(comp, 2 H, H14), 4.72 (s, 1 H, H7), 4.62 (s, 1 H, H7), 3.85 (comp, 2 H, H9, H10), 3.63 (br, 1 H, 
H9), 3.16 (t, J = 13.0 Hz, 1 H, H10), 2.91 (dd, J = 13.9, 5.9 Hz, 1 H, H6), 2.73 – 2.59 (comp, 2 
H, H6, H8), 2.09 (comp, 2 H, H5, H11), 1.93 (s, 2 H, H3), 1.68 (td, J = 12.9, 6.0 Hz, 1 H, H5), 
1.43 (s, 10 H, H1, H18), 1.18 (s, 1 H), H11; 13C NMR (126 MHz, CDCl3) δ 155.0 (C16), 144.5 
(C4), 138.6 (C12), 129.5 (C14), 128.4 (C13), 127.2 (C15), 109.5 (C7), 83.7 (C17*), 79.4 (C17), 
54.1 (C2), 51.9 (C8), 46.2 (C3), 44.0 (C9), 43.1 (C9), 41.5 (C6), 39.9 (C10), 38.9 (C10), 36.2 




(1R,5S)-9-Methylene-1-phenyl-6-azaspiro[4.5]decane (4.47) (LTL-V-027). A stirred 
solution of 4.37 (16 mg, 0.1 mmol), 4.2 (19 mg, 0.12 mmol), and AcOH (6 mg, 0.1 mmol) in 
MeOH (1 mL) was heated under reflux for 11 h, whereupon the mixture was diluted with 
aqueous Na2CO3 (1.4 M, 15 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were dried (Na2SO4) and concentrated via rotary evaporation. The crude material was 
purified by flash column chromatography, eluting with hexanes:Et3N (100 : 1) to give 12 mg 
(52%) of the title compound as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.31 (comp, 2 
H), 7.29 – 7.25 (comp, 3 H), 4.68 (s, 1 H), 4.66 (s, 1 H), 2.88 (ddd, J = 13.3, 5.6, 2.3 Hz, 1 H), 
2.80 (dd, J = 10.8, 7.5 Hz, 1 H), 2.68 (ddd, J = 13.3, 11.8, 3.6 Hz, 1 H), 2.26 – 2.15 (m, 1 H), 
2.13 – 2.05 (comp, 3 H), 2.05 – 1.97 (m, 1 H), 1.92 – 1.82 (comp, 2 H), 1.79 – 1.70 (m, 1 H), 
1.70 – 1.62 (m, 1 H), 1.62 – 1.56 (m, 1 H), 1.14 – 0.94 (s, 1 H); 13C NMR (126 MHz, CDCl3) δ 
146.2, 139.9, 129.5, 128.2, 126.7, 108.1, 64.6, 56.4, 46.7, 43.0, 36.2, 34.5, 30.3, 22.0; HRMS 
(ESI) m/z calcd for C16H21N (M+H)+, 228.1747; found 228.1745. 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.31 (comp, 2 H, H14), 7.29 – 
7.25 (comp, 3 H, H13, H15), 4.68 (s, 1 H, H7), 4.66 (s, 1 H, H7), 2.88 (ddd, J = 13.3, 5.6, 2.3 
Hz, 1 H, H6), 2.80 (dd, J = 10.8, 7.5 Hz, 1 H, H8), 2.68 (ddd, J = 13.3, 11.8, 3.6 Hz, 1 H, H6), 
2.26 – 2.15 (m, 1 H, H9), 2.13 – 2.05 (comp, 3 H, H5, H3), 2.05 – 1.97 (m, 1 H, H9), 1.92 – 1.82 
(comp, 2 H, H10, H11), 1.79 – 1.70 (m, 1 H, H5), 1.70 – 1.62 (m, 1 H, H11), 1.62 – 1.56 (m, 1 
H, H10), 1.14 – 0.94 (s, 1 H, H1); 13C NMR (126 MHz, CDCl3) δ 146.2 (C4), 139.9 (C8), 129.5 
(C15), 128.2 (C14), 126.7 (C13), 108.1 (C7), 64.6 (C2), 56.4 (C8), 46.7 (C3), 43.0 (C6), 36.2 





036). The title compound was prepared following the procedure of 4.47. The crude material was 
purified by flash column chromatography, eluting with hexanes:Et3N (100 : 1) to give 76 mg 
(59%) of the title compound as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.21 (m, 1 H), 6.83 
(dt, J = 7.6, 1.4 Hz, 1 H), 6.80 – 6.75 (comp, 2 H), 4.64 (s, 1 H), 4.62 (s, 1 H), 3.78 (s, 3 H), 2.86 
(ddd, J = 13.3, 5.6, 2.4 Hz, 1 H), 2.74 (dd, J = 10.8, 7.5 Hz, 1 H), 2.65 (ddd, J = 13.3, 11.8, 3.6 
Hz, 1 H), 2.16 (dddd, J = 17.5, 10.9, 8.7, 3.6 Hz, 1 H), 2.10 – 2.02 (comp, 3 H), 2.01 – 1.92 (m, 
1 H), 1.89 – 1.79 (comp, 2 H), 1.77 – 1.68 (m, 1 H), 1.68 – 1.58 (m, 1 H), 1.58 – 1.49 (m, 1 H); 
13C NMR (126 MHz, CDCl3) δ 159.4, 146.3, 141.6, 129.1, 122.0, 115.2, 111.9, 108.0, 64.7, 56.5, 
55.2, 46.7, 43.0, 36.2, 34.4, 30.3, 21.9; HRMS (ESI) m/z calcd for C17H23NO (M+H)+ 258.1852; 
found 258.1849. 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.21 (m, 1 H, H16), 6.83 (dt, J = 7.6, 
1.4 Hz, 1 H, H17), 6.80 – 6.75 (comp, 2 H, H13, H15), 4.64 (s, 1 H, H7), 4.62 (s, 1 H, H7), 3.78 
(s, 3 H, H18), 2.86 (ddd, J = 13.3, 5.6, 2.4 Hz, 1 H, H6), 2.74 (dd, J = 10.8, 7.5 Hz, 1 H, H8), 
2.65 (ddd, J = 13.3, 11.8, 3.6 Hz, 1 H, H6), 2.16 (dddd, J = 17.5, 10.9, 8.7, 3.6 Hz, 1 H, H9), 
2.10 – 2.02 (comp, 3 H, H5, H3), 2.01 – 1.92 (m, 1 H, H9), 1.89 – 1.79 (comp, 2 H, H10, H11), 
1.77 – 1.68 (m, 1 H, H5), 1.68 – 1.58 (m, 1 H, H11), 1.58 – 1.49 (m, 1 H, H10); 13C NMR (126 
MHz, CDCl3) δ 159.4 (C14), 146.3 (C4), 141.6 (C12), 129.1 (C16), 122.0 (C17), 115.2 (C13), 
111.9 (C15), 108.0 (C7), 64.7 (C2), 56.5 (C8), 55.2 (C18), 46.7 (C3), 43.0 (C6), 36.2 (C5), 34.4 





(LTL-V-060). A solution of 4.39 (241 mg, 1.0 mmol), AcCl (157 mg, 0.14 mmol), and iPr2NEt 
(387 mg, 3.0 mmol) in THF (10 mL) was stirred at room temperature overnight, whereupon an 
additional equivalent of AcCl (78 mg, 1.0 mmol) and iPr2NEt (129 mg, 1.0 mmol) was added 
every 3 h until 4.39 was consumed. The solvent was removed via rotary evaporation, and the 
resulting solid was resuspended in Et2O and decanted into a separatory funnel. The solid was 
rinsed with Et2O and decanted an additional two times. The combined organic layer was washed 
sequentially with aqueous HCl (3M, 20 mL), aqueous NaOH (3M, 20 mL), and brine (20 mL). 
The organic layer was dried (Na2SO4) and concentrated via rotary evaporation. The crude 
material was purified by flash column chromatography, eluting with hexanes:EtOAc (85 : 15) to 
give 247 mg (87 %) of the title compound as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.38 – 
7.34 (comp, 2 H), 7.26 – 7.20 (comp, 2 H), 7.18 – 7.13 (m, 1 H), 4.85 (s, 2 H), 3.23 – 3.12 (m, 1 
H), 3.11 – 3.01 (m, 1 H), 3.00 – 2.86 (comp, 2 H), 2.53 (s, 1 H), 2.27 – 2.09 (comp, 4 H), 2.03 
(dt, J = 14.7, 3.9 Hz, 1 H), 1.85 (s, 3 H), 1.80 – 1.71 (m, 1 H), 1.70 – 1.62 (m, 1 H), 1.61 – 1.36 
(comp, 3 H); 13C NMR (126 MHz, CDCl3) δ 171.2, 142.6, 142.0, 129.4, 127.9, 126.1, 112.1, 
64.1, 47.5, 44.0, 43.4, 32.6, 32.1, 29.1, 25.9, 21.2, 20.7; HRMS (ESI) m/z calcd for C19H25NO 
284.2009; found 284.2000; 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.34 (comp, 2 H, H15), 7.26 – 
7.20 (comp, 2 H, H16), 7.18 – 7.13 (m, 1 H, H17), 4.85 (s, 2 H, H8), 3.23 – 3.12 (m, 1 H, H13), 
3.11 – 3.01 (m, 1 H, H7), 3.00 – 2.86 (comp, 2 H, H9, H6), 2.53 (s, 1 H, H7), 2.27 – 2.09 (comp, 
4 H, H6, H10, H4), 2.03 (dt, J = 14.7, 3.9 Hz, 1 H, H13), 1.85 (s, 3 H, H1), 1.80 – 1.71 (m, 1 H, 
H12), 1.70 – 1.62 (m, 1 H, H10), 1.61 – 1.36 (comp, 3 H, H11, H12); 13C NMR (126 MHz, 
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CDCl3) δ 171.2 (C2), 142.6 (C5), 142.0 (C14), 129.4 (C15), 127.9 (C16), 126.1 (C17), 112.1 
(C8), 64.1 (C3), 47.5 (C9), 44.0 (C6), 43.4 (C7), 32.6 (C4), 32.1 (C13), 29.1 (C10), 25.9 (C1), 




113). A solution of 4.39 (22 mg, 0.09 mmol), 37% aq. CH2O (73 mg, 0.9 mmol), and NaBH3CN 
(11 mg, 0.18 mmol) was stirred for 24 h, whereupon the reaction was diluted with 1M NaOH (20 
mL) and extracted with Et2O (3 x 10 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated via rotary evaporation.  The crude material was purified via flash column 
chromatography, eluting with hexanes:Et3N (100 : 1) to give 18 mg (78%) of the title compound 
as a tan solid, mp 55–56 ˚C. 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.43 (comp, 2 H), 7.30 – 7.22 
(comp, 2 H), 7.19 – 7.13 (m, 1 H), 4.78 (s, 1 H), 4.69 (s, 1 H), 3.12 (t, J = 4.4 Hz, 1 H), 2.84 – 
2.65 (comp, 2 H), 2.54 (d, J = 13.4 Hz, 1 H), 2.26 (s, 3 H), 2.24 – 2.04 (comp, 4 H), 1.87 (dddd, 
J = 13.7, 10.8, 7.4, 4.7 Hz, 1 H), 1.82 – 1.71 (comp, 2 H), 1.68 – 1.57 (m, 1 H), 1.54 – 1.42 
(comp, 2 H), 1.42 – 1.33 (m, 1 H); 13C NMR (101 MHz, CDCl3) δ 145.9, 144.6, 130.3, 127.5, 
125.3, 108.3, 59.2, 49.6, 46.0, 37.5, 36.1, 32.3, 30.4, 29.2, 22.1, 20.3; IR (film, NaCl) 3066, 
3024, 2937, 2862, 2791, 1648, 1601, 1494, 1454, 1375, 1348, 1289, 1239, 1196, 1155, 1120, 
1073, 1056, 1033, 1004 cm-1; HRMS (ESI) m/z calcd for C18H25N (M+H)+, 256.2060; found 
256.2066. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.43 (comp, 2 H, H14), 7.30 – 
7.22 (comp, 2 H, H15), 7.19 – 7.13 (m, 1 H, H16), 4.78 (s, 1 H, H7), 4.69 (s, 1 H, H7), 3.12 (t, J 
= 4.4 Hz, 1 H, H8), 2.84 – 2.65 (comp, 2 H, H6), 2.54 (d, J = 13.4 Hz, 1 H, H3), 2.26 (s, 3 H, 
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H1), 2.24 – 2.04 (comp, 4 H, H3, H5, H12), 1.87 (dddd, J = 13.7, 10.8, 7.4, 4.7 Hz, 1 H, H9), 
1.82 – 1.71 (comp, 2 H, H11, H12), 1.68 – 1.57 (m, 1 H, H9), 1.54 – 1.42 (comp, 2 H, H10, 
H11), 1.42 – 1.33 (m, 1 H, H10); 13C NMR (101 MHz, CDCl3) δ 145.9 (C4), 144.6 (C13), 130.3 
(C14), 127.5 (C15), 125.3 (C16), 108.3 (C7), 59.2 (C2), 49.6 (C6), 46.0 (C8), 37.5 (C3), 36.1 
(C1), 32.3 (C12), 30.4 (C9), 29.2 (C5), 22.1 (C11), 20.3 (C10). 
 
 
Benzyl (6S,7R)-4-methylene-7-phenyl-1-azaspiro[5.5]undecane-1-carboxylate (4.53) 
(LTL-V-095). A solution of 4.39 (12 mg, 0.05 mmol), benzyl chloroformate (26 mg, 0.15 
mmol), and K2CO3 (28 mg, 0.2 mmol) in THF (0.5 mL) in a 1 dram vial was capped, sealed with 
Teflon tape, and submerged in an oil bath heated at 60 ˚C for 3 h, whereupon the reaction was 
cooled to room temperature, diluted with aqueous Na2CO3 (1.4 M, 15 mL) and extracted with 
CH2Cl2 (3 x 10 mL). The combined organic extracts dried (Na2SO4) and concentrated via rotary 
evaporation. The crude material was purified by flash column chromatography, eluting with 
hexanes:EtOAc (100 : 1) to give 13 mg (68%) of the title compound as a white solid. 1H NMR 
(500 MHz, CDCl3) δ 7.41 – 7.37 (comp, 2 H), 7.35 – 7.27 (comp, 3 H), 7.25 – 7.14 (comp, 5 H), 
5.03 (d, J = 12.6 Hz, 1 H), 4.92 (d, J = 12.6 Hz, 1 H), 4.88 (s, 1 H), 4.85 (s, 1 H), 3.86 (d, J = 
14.4 Hz, 1 H), 3.29 (s, 2 H), 2.98 (d, J = 13.7 Hz, 1 H), 2.58 (s, 1 H), 2.30 – 2.03 (comp, 4 H), 
1.99 – 1.89 (m, 1 H), 1.87 – 1.71 (comp, 2 H), 1.56 – 1.40 (comp, 3 H). 13C NMR (126 MHz, 
CDCl3) δ 155.4, 143.0, 142.6, 137.2, 129.5, 128.4, 127.9, 127.7, 127.6, 125.9, 111.4, 66.3, 62.8, 
45.4, 44.2, 41.6, 33.4, 33.2, 29.8, 22.0, 20.2; HRMS (ESI) m/z calcd for C25H29NO2 375.2198; 
found 375.2198. 
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NMR Assignment. 1H NMR (500 MHz, CDCl3) δ [7.41 – 7.37 (comp, 2 H), 7.35 – 7.27 
(comp, 3 H), 7.25 – 7.14 (comp, 5 H)] [H15, H16, H17, H19, H20, H21], 5.03 (d, J = 12.6 Hz, 1 
H, H1), 4.92 (d, J = 12.6 Hz, 1 H, H1), 4.88 (s, 1 H, H8), 4.85 (s, 1 H, H8), 3.86 (d, J = 14.4 Hz, 
1 H, H7), 3.29 (comp, 2 H, H9, H13), 2.98 (d, J = 13.7 Hz, 1 H, H6), 2.58 (s, 1 H, H7), 2.30 – 
2.03 (comp, 4 H, H4, H6, H13), 1.99 – 1.89 (m, 1 H, H10), 1.87 – 1.71 (comp, 2 H, H10, H12), 
1.56 – 1.40 (comp, 3 H, H11, H12). 13C NMR (126 MHz, CDCl3) δ 155.4 (C2), 143.0 (C14), 
142.6 (C5), 137.2 (C18), [129.5, 128.4, 127.9, 127.7, 127.6, 125.9] [C15, C16, C17, C19, C20, 
C21], 111.4 (C8), 66.3 (C1), 62.8 (C4), 45.4 (C9), 44.2 (C6), 41.6 (C7), 33.4 (C13), 33.2 (C4), 




carboxylate (7.10) (LTL-V-065). A solution of 4.46 (100 mg, 0.29 mmol), BnBr (248 mg, 1.45 
mmol), and K2CO3 (200 mg, 1.45 mmol) in MeCN (3 mL) was heated under reflux for 24 h, 
whereupon the reaction was cooled to room temperature, diluted with aqueous Na2CO3 (1.4 M, 
30 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were washed 
with brine (20 mL), dried (MgSO4) and concentrated via rotary evaporation. The crude material 
was purified by flash column chromatography, eluting with hexanes:Et3N (100 : 1) to give 105 
mg (84%) of the title compound as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.43 – 7.35 
(comp, 2 H), 7.22 (comp, 3 H), 7.14 – 7.06 (comp, 3 H), 6.84 (d, J = 6.7 Hz, 2 H), 4.85 (s, 1 H), 
4.74 (s, 1 H), 4.42 – 3.87 (comp, 2 H), 3.67 (d, J = 14.6 Hz, 1 H), 3.37 – 2.88 (comp, 4 H), 2.86 
– 2.62 (comp, 2 H), 2.48 (dt, J = 13.7, 5.0 Hz, 1 H), 2.43 – 2.31 (m, 1 H), 2.26 (d, J = 13.6 Hz, 1 
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H), 2.13 (comp, 2 H), 1.75 – 1.59 (m, 1 H), 1.42 (s, 3 H), 1.18 (s, 6 H); 13C NMR (126 MHz, 
CDCl3) δ 154.8, 144.9, 142.3, 141.4, 129.8, 128.6, 128.4, 127.9, 127.8, 126.3, 126.1, 109.6, 79.3, 
69.8, 58.8, 50.0, 47.3, 45.1, 44.8, 39.6, 39.3, 31.7, 30.2, 28.2; HRMS (ESI) m/z calcd for 
C28H36N2O2 (M+H)+ 433.2850; found 433.2847. 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.43 – 7.35 (comp, 2 H, H14), 7.22 
(comp, 3 H, H13, H15), 7.14 – 7.06 (comp, 3 H, H21, H22), 6.84 (d, J = 6.7 Hz, 2 H, H20), 4.85 
(s, 1 H, H7), 4.74 (s, 1 H, H7), 4.42 – 3.87 (comp, 2 H, H6, H9), 3.67 (d, J = 14.6 Hz, 1 H, H1), 
3.37 – 2.88 (comp, 4 H, H1, H6, H8, H9), 2.86 – 2.62 (comp, 2 H, H10, H11), 2.48 (dt, J = 13.7, 
5.0 Hz, 1 H, H11), 2.43 – 2.31 (m, 1 H, H5), 2.26 (d, J = 13.6 Hz, 1 H, H10), 2.13 (comp, 2 H, 
H3), 1.75 – 1.59 (m, 1 H, H5), 1.42 (s, 3 H, H18), 1.18 (s, 6 H, H18); 13C NMR (126 MHz, 
CDCl3) δ 154.8 (C16), 144.9 (C4), 142.3 (C19), 141.4 (C12), (129.8, 128.6, 128.4, 127.9, 127.8, 
126.3, 126.1) (C13, C14, C15, C20, C21, C22), 109.6 (C7), 79.3 (C17), 69.8, 58.8 (C2), 50.0 




091). A solution of 7.10 (20 mg, 0.046 mmol) in HCl/dioxane (4 M, 0.46 mL) was stirred for 30 
min. Saturated aqueous Na2CO3 was then added dropwise until the solution reached pH 10 as 
determined by pH paper. The solution was extracted with EtOAc (3 x 10 mL), and the combined 
organic extracts were dried (MgSO4) and concentrated via rotary evaporation. The crude material 
was purified by flash column chromatography, eluting with hexanes:EtOAc:Et3N (60 : 40 : 1) to 
give 12 mg (80%) of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.59 – 
7.53 (comp, 2 H), 7.33 – 7.26 (comp, 2 H), 7.24 – 7.20 (m, 1 H), 7.16 – 7.08 (comp, 3 H), 6.87 
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(d, J = 7.0 Hz, 2 H), 4.82 (s, 1 H), 4.73 (s, 1 H), 3.74 (d, J = 14.1 Hz, 1 H), 3.52 (d, J = 14.1 Hz, 
1 H), 3.22 – 3.08 (comp, 3 H), 2.94 – 2.82 (comp, 2 H), 2.71 (d, J = 13.4 Hz, 1 H), 2.63 (dt, J = 
13.5, 6.5 Hz, 1 H), 2.53 – 2.43 (m, 1 H), 2.31 (d, J = 13.4 Hz, 1 H), 2.27 – 2.15 (m, 1 H), 2.11 (s, 
2 H), 1.75 (d, J = 13.5 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ 145.3, 143.3, 141.4, 130.4, 
128.1, 127.9, 127.8, 126.3, 125.9, 109.4, 58.5, 50.3, 48.9, 46.2, 43.7, 43.0, 39.1, 33.3, 29.0; 
HRMS (ESI) m/z calcd for C23H28N2 C23H28N2 (M+H)+ 333.2325; found 333.2319. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.53 (comp, 2 H, H13), 7.33 – 
7.26 (comp, 2 H, H14), 7.24 – 7.20 (m, 1 H, H15), 7.16 – 7.08 (comp, 3 H, H19, H20), 6.87 (d, J 
= 7.0 Hz, 2 H, H18), 4.82 (s, 1 H, H7), 4.73 (s, 1 H, H7), 3.74 (d, J = 14.1 Hz, 1 H, H1), 3.52 (d, 
J = 14.1 Hz, 1 H, H1), 3.22 – 3.08 (comp, 3 H, H6, H8, H9), 2.94 – 2.82 (comp, 2 H, H6, H9), 
2.71 (d, J = 13.4 Hz, 1 H, H10), 2.63 (dt, J = 13.5, 6.5 Hz, 1 H, H11), 2.53 – 2.43 (m, 1 H, H11), 
2.31 (d, J = 13.4 Hz, 1 H, H10), 2.27 – 2.15 (m, 1 H, H5), 2.11 (s, 2 H, H3), 1.75 (d, J = 13.5 Hz, 
1 H, H5); 13C NMR (126 MHz, CDCl3) δ 145.3 (C17), 143.3 (C4), 141.4 (C12), 130.4 (C13), 
128.1 (C19), 127.9 (C18), 127.8 (C14), 126.3 (C20), 125.9 (C15), 109.4 (C7), 58.5 (C2), 50.3 




(LTL-V-072). A solution of 4.54 (18 mg, 0.054 mmol), aqueous formaldehyde (37%, 40 mg, 0.5 
mmol), and NaBH3CN (6 mg, 0.1 mmol) in MeCN (0.5 mL) was stirred for 20 h, whereupon the 
reaction was diluted with aqueous Na2CO3 (1.4 M, 30 mL) and extracted with CH2Cl2 (3 x 20 
mL). The combined organic extracts were dried (Na2SO4) and concentrated via rotary 
evaporation. The crude material was purified by flash column chromatography, eluting with 
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hexanes:EtOAc:Et3N (95 : 5 : 1) to give 17 mg (89%) of the title compound as a white paste. 
1H 
NMR (500 MHz, CDCl3) δ 7.74 – 7.69 (comp, 2 H), 7.31 – 7.23 (comp, 3 H), 7.16 – 7.08 (comp, 
3 H), 6.90 – 6.85 (comp, 2 H), 4.85 (s, 1 H), 4.75 (s, 1 H), 3.73 (d, J = 14.8 Hz, 1 H), 3.24 – 3.11 
(comp, 2 H), 2.90 (ddt, J = 11.3, 4.8, 2.3 Hz, 1 H), 2.86 – 2.73 (comp, 2 H), 2.70 (dt, J = 11.9, 
2.1 Hz, 1 H), 2.50 (comp, 3 H), 2.33 – 2.26 (m, 1 H), 2.21 (s, 3 H), 2.14 (comp, 3 H), 1.64 (d, J = 
13.4 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ 145.4, 144.0, 141.9, 130.7, 127.9, 127.8, 127.5, 
126.2, 125.9, 109.2, 59.1, 58.1, 52.3, 50.3, 46.5, 45.8, 45.3, 40.4, 33.1, 30.8; HRMS (ESI) m/z 
calcd for C24H30N2 347.2482; found 347.2481.  
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.74 – 7.69 (comp, 2 H, H13), 7.31 – 
7.23 (comp, 3 H, H14, H15), 7.16 – 7.08 (comp, 3 H, H19, H20), 6.90 – 6.85 (comp, 2 H, H18), 
4.85 (s, 1 H, H7), 4.75 (s, 1 H, H7), 3.73 (d, J = 14.8 Hz, 1 H, H1), 3.24 – 3.11 (comp, 2 H, H1, 
H8), 2.90 (ddt, J = 11.3, 4.8, 2.3 Hz, 1 H, H6), 2.86 – 2.73 (comp, 2 H, H10, H11), 2.70 (dt, J = 
11.9, 2.1 Hz, 1 H, H9), 2.50 (comp, 3 H, H5, H9, H10), 2.33 – 2.26 (m, 1 H, H6), 2.21 (s, 3 H, 
H16), 2.14 (comp, 3 H, H3, H11), 1.64 (d, J = 13.4 Hz, 1 H, H5); 13C NMR (126 MHz, CDCl3) δ 
145.4 (C17), 144.0 (C4), 141.9 (C12), 130.7 (C13), 127.9 (C19), 127.8 (C18), 127.5 (C14), 
126.2 (C20), 125.9 (C15), 109.2 (C7), 59.1 (C9), 58.1 (C2), 52.3 (C6), 50.3 (C1), 46.5 (C16), 




(4.60) (LTL-V-086). A solution of 4.43 (30 mg, 0.09 mmol), 4.59 (25 mg, 0.18 mmol), SPhos (6 
mg, 0.014 mmol), K3PO4-7H2O (61 mg, 0.18 mmol), and Pd(OAc)2 (1 mg, 0.0045 mmol) in 
THF (0.5 mL) was stirred at rt for 24 h, whereupon the reaction was diluted with Et2O (10 mL) 
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and filtered over a 1:1 slurry of celite:SiO2 (6 mL), eluting with Et2O. The filtrate was 
concentrated by rotary evaporation, and the crude material was purified by flash column 
chromatography, eluting with hexanes:Et3N (100 : 1) to give 21 mg (70 %) of the title compound 
as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 8.7 Hz, 2 H), 7.50 (d, J = 8.1 Hz, 2 
H), 7.28 (d, J = 8.1 Hz, 2 H), 6.97 (d, J = 8.7 Hz, 2 H), 4.69 (s, 1 H), 4.59 (s, 1 H), 3.85 (s, 3 H), 
2.91 (dd, J = 13.4, 6.1 Hz, 1 H), 2.71 (td, J = 12.9, 3.6 Hz, 1 H), 2.59 (dd, J = 12.8, 3.4 Hz, 1 H), 
2.31 – 2.19 (comp, 2 H), 2.08 (d, J = 13.5 Hz, 1 H), 1.99 – 1.82 (comp, 3 H), 1.71 (tt, J = 12.7, 
3.2 Hz, 1 H), 1.63 – 1.48 (comp, 3 H), 1.45 – 1.34 (comp, 1 H), 0.97 (ddd, J = 14.3, 13.0, 3.9 Hz, 
1 H); HRMS (ESI) m/z calcd for C24H29NO (M+H)+ 348.2322; found 348.2321. 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 8.7 Hz, 2 H, H18), 7.50 
(d, J = 8.1 Hz, 2 H, H15), 7.28 (d, J = 8.1 Hz, 2 H, H14), 6.97 (d, J = 8.7 Hz, 2 H, H19), 4.69 (s, 
1 H, H7), 4.59 (s, 1 H, H7), 3.85 (s, 3 H, H21), 2.91 (dd, J = 13.4, 6.1 Hz, 1 H, H6), 2.71 (td, J = 
12.9, 3.6 Hz, 1 H, H6), 2.59 (dd, J = 12.8, 3.4 Hz, 1 H, H8), 2.31 – 2.19 (comp, 2 H, H9, H12), 
2.08 (d, J = 13.5 Hz, 1 H, H5), 1.99 – 1.82 (comp, 3 H, H3, H10), 1.71 (tt, J = 12.7, 3.2 Hz, 1 H, 
H5), 1.63 – 1.48 (comp, 3 H, H9, H11), 1.45 – 1.34 (comp, 1 H, H1), 0.97 (ddd, J = 14.3, 13.0, 




(4.65) (LTL-V-085). The title compound was prepared following the procedure of 4.60. The 
crude material was purified by flash column chromatography, eluting with hexanes:Et3N (100 : 
1) to give 30 mg (100%) of the title compound as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 
7.55 (q, J = 5.6, 5.2 Hz, 2 H), 7.49 (d, J = 8.1 Hz, 2 H), 7.31 (d, J = 8.1 Hz, 2 H), 7.12 (t, J = 8.7 
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Hz, 2 H), 4.69 (s, 1 H), 4.60 (s, 1 H), 2.91 (ddd, J = 13.5, 6.1, 1.6 Hz, 1 H), 2.71 (td, J = 12.9, 3.6 
Hz, 1 H), 2.60 (dd, J = 12.9, 3.4 Hz, 1 H), 2.31 – 2.18 (comp, 2 H), 2.09 (d, J = 13.3 Hz, 1 H), 
1.98 – 1.83 (comp, 3 H), 1.71 (tt, J = 13.0, 3.9 Hz, 1 H), 1.65 – 1.48 (comp, 3 H), 1.46 – 1.34 (m, 
1 H), 1.23 – 1.14 (br, 1 H), 0.97 (ddd, J = 14.4, 13.0, 4.0 Hz, 1 H); 13C NMR (126 MHz, CDCl3) 
δ 163.3, 161.4, 145.4, 141.4, 138.3, 137.0, 137.0, 130.0, 128.5, 128.4, 126.5, 115.7, 115.5, 108.8, 
77.3, 55.3, 53.5, 47.2, 41.3, 36.1, 31.7, 27.8, 26.9, 20.9; HRMS (ESI) m/z calcd for C23H26FN 
336.2122; found 336.2117. 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.55 (q, J = 5.6, 5.2 Hz, 2 H, H18), 
7.49 (d, J = 8.1 Hz, 2 H, H15), 7.31 (d, J = 8.1 Hz, 2 H, H14), 7.12 (t, J = 8.7 Hz, 2 H, H19), 4.69 
(s, 1 H, H7), 4.60 (s, 1 H, H7), 2.91 (ddd, J = 13.5, 6.1, 1.6 Hz, 1 H, H6), 2.71 (td, J = 12.9, 3.6 
Hz, 1 H, H6), 2.60 (dd, J = 12.9, 3.4 Hz, 1 H, H8), 2.31 – 2.18 (comp, 2 H, H9, H12), 2.09 (d, J 
= 13.3 Hz, 1 H, H5), 1.98 – 1.83 (comp, 3 H, H3, H10), 1.71 (tt, J = 13.0, 3.9 Hz, 1 H, H5), 1.65 
– 1.48 (comp, 3 H, H9, H11), 1.46 – 1.34 (m, 1 H, H10), 1.23 – 1.14 (br, 1 H, H1), 0.97 (ddd, J = 
14.4, 13.0, 4.0 Hz, 1 H, H12); 13C NMR (126 MHz, CDCl3) δ 163.3 (C20), 161.4 (C20), 145.4 
(C4), 141.4 (C13), 138.3 (C16), 137.0 (C17), 130.0 (C14), 128.5 (C18), 128.4 (C18), 126.5 
(C15), 115.7 (C19), 115.5 (C19), 108.8 (C7), 55.3 (C2), 53.5 (C8), 47.2 (C3), 41.3 (C6), 36.1 
(C5), 31.7 (C12), 27.8 (C9), 26.9 (C10), 20.9 (C11). 
 
 
((4R,6S,7R)-7-Phenyl-1-azaspiro[5.5]undecan-4-yl)methanol (4.66) (LTL-V-071). 
BH3·DMS (15 mg, 0.2 mmol), was added dropwise to a solution of 4.39 (24 mg, 0.1 mmol) in 
THF (2 mL) at  ̵78 ˚C and stirred for 1 h, whereupon the reaction was warmed to room 
temperature and stirred for an additional 3.5 h. The reaction was cooled to 0 ˚C, and MeOH (0.5 
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mL), NaOH (3 M aq., 0.5 mmol), and H2O2 (11.6 M, 1 mmol) were added, the reaction was 
warmed to room temperature and stirred for 2.5 h. The mixture was diluted with sat. Na2CO3 (15 
mL) and extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated via rotary evaporation. The crude material was purified by flash 
column chromatography, eluting with hexanes:EtOAc:Et3N (80 : 20 : 1) to give 16 mg (62 %) of 
the title compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.26 (comp, 2 H), 7.24 – 
7.18 (comp, 3 H), 3.27 (d, J = 6.4 Hz, 2 H), 2.85 (ddd, J = 13.6, 5.0, 1.8 Hz, 1 H), 2.72 (ddd, J = 
13.7, 12.7, 3.1 Hz, 1 H), 2.53 (dd, J = 13.0, 3.3 Hz, 1 H), 2.43 – 2.35 (m, 1 H), 2.18 (qd, J = 
13.1, 3.9 Hz, 1 H), 1.97 – 1.78 (comp, 2 H), 1.70 – 1.58 (m, 1 H), 1.58 – 1.49 (comp, 3 H), 1.41 
– 1.30 (comp, 3 H), 1.03 (td, J = 13.5, 3.8 Hz, 1 H), 0.78 (t, J = 12.6 Hz, 1 H), 0.55 (qd, J = 12.6, 
5.0 Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ 142.4, 129.6, 127.9, 126.3, 69.0, 54.5, 53.4, 39.9, 
39.8, 34.0, 31.8, 30.5, 27.8, 26.9, 21.1; HRMS (ESI) m/z calcd for C17H25NO 260.2009; found 
260.2008. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.26 (comp, 2 H), 7.24 – 7.18 
(comp, 3 H), 3.27 (d, J = 6.4 Hz, 2 H), 2.85 (ddd, J = 13.6, 5.0, 1.8 Hz, 1 H), 2.72 (ddd, J = 13.7, 
12.7, 3.1 Hz, 1 H), 2.53 (dd, J = 13.0, 3.3 Hz, 1 H), 2.43 – 2.35 (m, 1 H), 2.18 (qd, J = 13.1, 3.9 
Hz, 1 H), 1.97 – 1.78 (comp, 2 H), 1.70 – 1.58 (m, 1 H), 1.58 – 1.49 (comp, 3 H), 1.41 – 1.30 
(comp, 3 H), 1.03 (td, J = 13.5, 3.8 Hz, 1 H), 0.78 (t, J = 12.6 Hz, 1 H), 0.55 (qd, J = 12.6, 5.0 
Hz, 1 H); 13C NMR (126 MHz, CDCl3) δ 142.4, 129.6, 127.9, 126.3, 69.0, 54.5, 53.4, 39.9, 39.8, 
34.0, 31.8, 30.5, 27.8, 26.9, 21.1. 
 
 
(6S,7R)-1-Acetyl-7-phenyl-1-azaspiro[5.5]undecan-4-one (4.69) (LTL05076). 4.51 
(28 mg, 0.1 mmol) was dissolved in CH2Cl2:MeOH (0.9 mL : 0.1 mL) and cooled to  –78 ˚C. 
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O3/O2 was bubbled through the solution until a blue color persisted (ca. 3 min). N2 was then 
bubbled through the solution for 5 min, and DMS (31 mg, 0.04 mL) was added. The reaction was 
stirred at  ̵78 ˚C for 1 h, then overnight at room temperature. The solvent was removed via rotary 
evaporation, and the crude material was purified by flash column chromatography, eluting with 
hexanes:EtOAc (80 : 20) to give 20 mg (69%) of the title compound as a white solid. 1H NMR 
(500 MHz, CDCl3) δ 7.26 – 7.21 (comp, 4 H), 7.21 – 7.16 (m, 1 H), 3.30 – 3.18 (m, 1 H), 3.07 
(d, J = 14.2 Hz, 1 H), 2.95 (t, J = 12.6 Hz, 1 H), 2.73 – 2.62 (m, 1 H), 2.61 – 2.43 (comp, 3 H), 
2.21 (ddd, J = 18.2, 12.3, 5.8 Hz, 1 H), 2.10 (ddd, J = 18.2, 3.9, 2.1 Hz, 1 H), 1.92 (s, 3 H), 1.81 
– 1.67 (comp, 2 H), 1.59 – 1.39 (comp, 4 H); 13C NMR (126 MHz, CDCl3) δ 208.9, 171.0, 141.4, 
129.2, 128.1, 126.8, 64.0, 51.6, 51.6, 43.1, 39.9, 32.1, 27.1, 25.7, 21.4, 19.4; HRMS (ESI) m/z 
calcd for C18H23NO2 (M+H)+ 286.1802; found 286.1794. 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 7.26 – 7.21 (comp, 4 H, H15, H16), 
7.21 – 7.16 (m, 1 H, H17), 3.30 – 3.18 (m, 1 H, H7), 3.07 (d, J = 14.2 Hz, 1 H, H4), 2.95 (t, J = 
12.6 Hz, 1 H, H12), 2.73 – 2.62 (m, 1 H, H9), 2.61 – 2.43 (comp, 3 H, H4, H7, H8), 2.21 (ddd, J 
= 18.2, 12.3, 5.8 Hz, 1 H, H6), 2.10 (ddd, J = 18.2, 3.9, 2.1 Hz, 1 H, H6), 1.92 (s, 3 H, H1), 1.81 
– 1.67 (comp, 2 H, H10, H11), 1.59 – 1.39 (comp, 4 H, H9, H10, H11, H12); 13C NMR (126 
MHz, CDCl3) δ 208.9 (C5), 171.0 (C2), 141.4 (C13), 129.2 (C15), 128.1 (C16), 126.8 (C17), 
64.0 (C3), 51.6 (C8), 51.6 (C4), 43.1 (C7), 39.9 (C6), 32.1 (C12), 27.1 (C9), 25.7 (C1), 21.4 




e]phenanthridine (4.71) (LTL-IV-180). A solution of 4.41 (10 mg, 0.04 mmol) and aq. 
formaldehyde (37%, 0.03 mL, 0.4 mmol) in EtOH (0.8 mL) was stirred for 2h at rt. AcOH (0.02 
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mL, 0.4 mmol) was added, and the reaction was heated under reflux for 24 h, whereupon the 
reaction was cooled to rt and diluted with 1M aq. NaOH (10 mL). The mixture was extracted 
with CH2Cl2 (3 x 10 mL), and the combined organic extracts were dried (Na2SO4) and 
concentrated via rotary evaporation. The crude material was purified via flash column 
chromatography, eluting with hexanes:Et3N (100 : 1) to give 8 mg (80%) of the title compound 
as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 6.95 (d, J = 8.4 Hz, 1 H), 6.90 – 6.85 (m, 1 
H), 6.71 (ddd, J = 8.3, 2.6, 0.8 Hz, 1 H), 4.79 (d, J = 2.0 Hz, 1 H), 4.71 (s, 1 H), 3.87 (d, J = 
16.0 Hz, 1 H), 3.78 (s, 3 H), 3.71 (d, J = 16.0 Hz, 1 H), 2.85 – 2.75 (comp, 2 H), 2.75 – 2.63 
(comp, 2 H), 2.40 (td, J = 11.6, 10.3, 5.3 Hz, 1 H), 2.33 – 2.12 (comp, 4 H), 1.88 (ddt, J = 20.3, 
15.7, 5.9 Hz, 2 H), 1.55 – 1.37 (m, 6 H), 1.11 (d, J = 13.0 Hz, 1 H). HRMS (ESI) m/z calcd for 




j]quinoline (4.72) (LTL-V-096). A solution of 4.44 (46 mg, 0.2 mmol), paraformaldehyde (60 
mg, 2 mmol) and AcOH (24 mg, 0.4 mmol) in EtOH (2 mL) was heated under reflux for 7 h, 
whereupon the mixture was diluted with aqueous Na2CO3 (1.4 M, 25 mL) and extracted with 
CH2Cl2 (3 x 15 mL). The combined organic extracts were dried (Na2SO4) and concentrated via 
rotary evaporation. The crude material was purified by flash column chromatography, eluting 
with hexanes:Et3N (200 : 1) to give 31 mg (65%) of the title compound as a clear oil. 
1H NMR 
(400 MHz, CDCl3) δ 7.31 – 7.27 (m, 1 H), 6.18 (d, J = 1.8 Hz, 1 H), 4.79 (s, 1 H), 4.71 (s, 1 H), 
3.66 (dd, J = 15.5, 3.0 Hz, 1 H), 3.51 (dd, J = 15.5, 1.9 Hz, 1 H), 2.89 (m, 1 H), 2.81 (dt, J = 
10.9, 5.3 Hz, 1 H), 2.70 (ddd, J = 11.5, 8.7, 4.8 Hz, 1 H), 2.60 (d, J = 13.2 Hz, 1 H), 2.39 – 2.24 
(comp, 4 H), 1.70 (tt, J = 13.9, 4.1 Hz, 1 H), 1.56 – 1.45 (comp, 3 H), 1.42 – 1.34 (comp, 2 H), 
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1.01 – 0.86 (m, 1 H); 13C NMR (126 MHz, CDCl3) δ 150.5, 144.0, 140.8, 113.9, 109.5, 108.3, 
57.2, 50.5, 47.8, 42.0, 38.3, 34.6, 23.8, 23.0, 21.9, 21.8; HRMS (ESI) m/z calcd for C16H21NO 
244.1696; found 244.1690. 
NMR Assignment. 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.27 (m, 1 H, H15), 6.18 (d, J 
= 1.8 Hz, 1 H, H16), 4.79 (s, 1 H, H1), 4.71 (s, 1 H, H1), 3.66 (dd, J = 15.5, 3.0 Hz, 1 H, H12), 
3.51 (dd, J = 15.5, 1.9 Hz, 1 H, H12), 2.89 (m, 1 H, H7), 2.81 (dt, J = 10.9, 5.3 Hz, 1 H, H4), 
2.70 (ddd, J = 11.5, 8.7, 4.8 Hz, 1 H, H4), 2.60 (d, J = 13.2 Hz, 1 H, H3), 2.39 – 2.24 (comp, 4 
H, H3, H6, H8), 1.70 (tt, J = 13.9, 4.1 Hz, 1 H, H8), 1.56 – 1.45 (comp, 3 H, H9, H10, H11), 
1.42 – 1.34 (comp, 2 H, H10, H11), 1.01 – 0.86 (m, 1 H, H9); 13C NMR (126 MHz, CDCl3) δ 
150.5 (C14), 144.0 (C2), 140.8 (C15), 113.9 (C13), 109.5 (C1), 108.3 (C16), 57.2 (C5), 50.5 




cyclopenta[c]pyrido[1,2-b]isoquinoline (4.73) (LTL-V-083). A solution of 4.48 (24 mg, 0.09 
mmol) in aqueous formaldehyde (37%, 0.45 mL) and formic acid (0.45 mL) was submerged in 
an oil bath heated at 55 ˚C and stirred for 1 h, whereupon the mixture was diluted with aqueous 
Na2CO3 (1.4 M, 15 mL) and extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts 
were dried (Na2SO4) and concentrated via rotary evaporation. The crude material was purified by 
flash column chromatography, eluting with hexanes:EtOAc:Et3N (95 : 5 : 1) to give 22 mg 
(92%) of the title compound as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.97 (d, J = 7.9 Hz, 1 
H), 6.71 – 6.67 (comp, 2 H), 4.80 (s, 1 H), 4.71 (s, 1 H), 3.79 (s, 3 H), 3.67 (d, J = 14.8 Hz, 1 H), 
3.58 (d, J = 14.9 Hz, 1 H), 2.94 (dd, J = 7.9, 4.5 Hz, 1 H), 2.85 (ddd, J = 11.3, 5.5, 3.1 Hz, 1 H), 
2.59 (td, J = 11.4, 3.5 Hz, 1 H), 2.50 – 2.39 (m, 1 H), 2.37 – 2.14 (comp, 4 H), 1.78 – 1.64 
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(comp, 2 H), 1.63 – 1.45 (comp, 3 H); 13C NMR (126 MHz, CDCl3) δ 158.4, 144.8, 140.3, 126.9, 
126.8, 113.0, 111.3, 109.5, 65.7, 55.3, 52.0, 51.2, 48.2, 46.9, 34.2, 33.7, 25.4, 23.0; HRMS (ESI) 
m/z calcd for 270.1852; found 270.1848. 
NMR Assignment. 1H NMR (500 MHz, CDCl3) δ 6.97 (d, J = 7.9 Hz, 1 H, H13), 6.71 – 
6.67 (comp, 2 H, H14, H16), 4.80 (s, 1 H, H1), 4.71 (s, 1 H, H1), 3.79 (s, 3 H, H18), 3.67 (d, J = 
14.8 Hz, 1 H, H11), 3.58 (d, J = 14.9 Hz, 1 H, H11), 2.94 (dd, J = 7.9, 4.5 Hz, 1 H, H10), 2.85 
(ddd, J = 11.3, 5.5, 3.1 Hz, 1 H, H4), 2.59 (td, J = 11.4, 3.5 Hz, 1 H, H4), 2.50 – 2.39 (m, 1 H, 
H5), 2.37 – 2.14 (comp, 4 H, H5, H6, H9), 1.78 – 1.64 (comp, 2 H, H7, H9), 1.63 – 1.45 (comp, 
3 H, H7, H8); 13C NMR (126 MHz, CDCl3) δ 158.4 (C15), 144.8 (C2), 140.3 (C17), 126.9 
(C13), 126.8 (C12), 113.0 (C16), 111.3 (C14), 109.5 (C1), 65.7 (C5), 55.3 (C18), 52.0 (C4), 51.2 




c]pyrido[2,1-j]quinoline (4.75) (LTL-IV-254). A solution of 4.45 (26 mg, 0.09 mmol) and 
paraformaldehyde (5 mg, 0.18 mmol) in toluene (1.8 mL) was heated under reflux for 24 h, 
whereupon the reaction was cooled to rt and diluted with 1.4 M aqueous Na2CO3. The mixture 
was extracted with CH2Cl2 (3 x 10 mL), and the combined organic extracts were dried (Na2SO4) 
and concentrated via rotary evaporation. The crude material was purified via flash column 
chromatography, eluting with EtOAc:hexanes:Et3N (75 : 25 : 1) to give 31 mg (69%) of the title 
compound as a pale pink solid, mp 198–202 ˚C. 1H NMR (499 MHz, CDCl3) δ 7.69 (s, 1 H), 
7.59 (d, J = 7.9 Hz, 1 H), 7.22 (d, J = 8.0 Hz, 1 H), 7.04 (t, J = 8.0 Hz, 1 H), 6.98 (t, J = 7.9 Hz, 
1 H), 4.74 (s, 1 H), 4.68 (s, 1 H), 3.95 (d, J = 16.1 Hz, 1 H), 3.58 (d, J = 16.1 Hz, 1 H), 3.12 (s, 1 
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H), 2.78 (dt, J = 11.6, 5.7 Hz, 1 H), 2.65 (ddd, J = 11.6, 7.2, 5.6 Hz, 1 H), 2.62 – 2.54 (m, 1 H), 
2.51 (d, J = 13.3 Hz, 1 H), 2.40 (d, J = 13.3 Hz, 1 H), 2.29 (comp, 2 H), 1.80 (tt, J = 13.9, 3.9 
Hz, 1 H), 1.56 (m, 1 H), 1.46 – 1.33 (comp, 4 H), 1.01 (m, 1 H). 13C NMR (126 MHz, CDCl3) δ 
144.3, 136.5, 131.1, 127.1, 120.9, 119.7, 119.1, 110.7, 109.8, 109.4, 77.3, 77.2, 77.0, 76.8, 57.3, 
50.7, 47.8, 42.0, 36.8, 34.6, 25.3, 24.3, 22.0, 21.5. HRMS (ESI) m/z calcd for C20H24N2 (M+H)+, 
293.2012; found 293.2015. 
NMR Assignment. 1H NMR (499 MHz, CDCl3) δ 7.69 (s, 1 H, H15), 7.59 (d, J = 7.9 
Hz, 1 H, H20), 7.22 (d, J = 8.0 Hz, 1 H, H17), 7.04 (t, J = 8.0 Hz, 1 H, H18), 6.98 (t, J = 7.9 Hz, 
1 H, H19), 4.74 (s, 1 H, H7), 4.68 (s, 1 H, H7), 3.95 (d, J = 16.1 Hz, 1 H, H1), 3.58 (d, J = 16.1 
Hz, 1 H, H1), 3.12 (s, 1 H, H8), 2.78 (dt, J = 11.6, 5.7 Hz, 1 H, H6), 2.65 (ddd, J = 11.6, 7.2, 5.6 
Hz, 1 H, H6), 2.62 – 2.54 (m, 1 H, H9), 2.51 (d, J = 13.3 Hz, 1 H, H3), 2.40 (d, J = 13.3 Hz, 1 
H, H3), 2.29 (comp, 2 H, H5), 1.80 (tt, J = 13.9, 3.9 Hz, 1 H, H9), 1.56 (m, 1 H, H12), 1.46 – 
1.33 (comp, 4 H, H10, H11, H12), 1.01 (m, 1 H, H10). 13C NMR (126 MHz, CDCl3) δ 144.3 
(C4), 136.5 (C16), 131.1 (C21), 127.1 (C14), 120.9 (C18), 119.7 (C20), 119.1 (C19), 110.7 
(C17), 109.8 (C13), 109.4 (C7), 57.3 (C2), 50.7 (C6), 47.8 (C1), 42.0 (C3), 36.8 (C8), 34.6 (C5), 
25.3 (C9), 24.3 (C12), 22.0 (C11), 21.5 (C10). 
 
 
X-ray Experimental for C17H24N
1+ Cl1- (4.39 · HCl):   Crystals grew as clear, 
colorless prisms by slow evaporation from CHCl3.  The data crystal was cut from a larger crystal 
and had approximate dimensions; 0.16 x 0.14 x 0.12 mm.  The data were collected at -150 C on 
a Nonius Kappa CCD diffractometer using a Bruker AXS Apex II detector and a graphite 
monochromator with MoK radiation ( = 0.71073Å).  Reduced temperatures were maintained 
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by use of an Oxford Cryosystems 700 low-temperature device.  A total of 1322 frames of data 
were collected using  and -scans with a scan range of 0.7 and a counting time of 39 seconds 
per frame.  Details of crystal data, data collection and structure refinement are listed in Table 7.1.  
Data reduction were performed using SAINT V8.27B.  The structure was solved by direct 
methods using SHELXT and refined by full-matrix least-squares on F2 with anisotropic 
displacement parameters for the non-H atoms using SHELXL-2014/7.250,251 Structure analysis 
was aided by use of the programs PLATON98 and WinGX.252  The hydrogen atoms bound to 
carbon atoms were calculated in idealized positions.  The hydrogen atoms on the nitrogen atoms 
were observed in a ∆F map and constrained in a riding model with Uiso set to 1.5xUeq of the 
water molecule, O3.  While the contents of the unit cell are racemic, the crystal symmetry is 
chiral.  The absolute structure was determined by the method of Flack.253 The Flack x parameter 
refined to 0.09(3).  The assignment was corroborated by use of the Hooft y-parameter method (y 
= 0.08(3)).254    
The function, w(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[((Fo))2 + (0.0469*P)2 + 
(0.5368*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.106, with R(F) equal to 0.0455 and a 
goodness of fit, S, = 1.03.  Definitions used for calculating R(F),Rw(F2) and the goodness of fit, 
S, are as follows: Rw(F2) =  {w(|Fo|2 - |Fc|2)2/w(|Fo|)4}1/2 where w is the weight given each 
reflection; R(F) =  (|Fo| - |Fc|)/|Fo|} for reflections with Fo > 4((Fo)); S =  [w(|Fo|2 - 
|Fc|2)2/(n - p)]1/2, where n is the number of reflections and p is the number of refined 
parameters.  The data were checked for secondary extinction but no correction was necessary.  
Neutral atom scattering factors and values used to calculate the linear absorption coefficient are 
from the International Tables for X-ray Crystallography (1992). All figures were generated using 
SHELXTL/PC. Tables of positional and thermal parameters, bond lengths and angles, torsion 
angles and figures are found in Tables 7.1 – 7.7.   
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Table 7.1. Crystal data and structure refinement for 4.39·HCl. 
Empirical formula  C17 H24 Cl N 
Formula weight  277.82 
Temperature  123(2) K 
Wavelength  0.71073 Å 
Crystal system  orthorhombic 
Space group  P 21 21 2 
  Unit cell dimensions a = 13.5380(10) Å = 90°. 
 b = 13.8012(10) Å = 90°. 
 c = 16.2638(11) Å  = 90°. 
Volume 3038.7(4) Å3 
Z 8 
Density (calculated) 1.215 Mg/m3 
Absorption coefficient 0.239 mm-1 
F(000) 1200 
Crystal size 0.160 x 0.140 x 0.120 mm3 
Theta range for data collection 1.252 to 27.558°. 
Index ranges -17<=h<=17, -17<=k<=17, -21<=l<=13 
Reflections collected 50611 
Independent reflections 7020 [R(int) = 0.0959] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.869 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7020 / 0 / 359 
Goodness-of-fit on F2 1.034 
Final R indices [I>2sigma(I)] R1 = 0.0455, wR2 = 0.0979 
R indices (all data) R1 = 0.0677, wR2 = 0.1064 
Absolute structure parameter 0.09(3) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.354 and -0.268 e.Å-3 
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Table 7.2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103) for 4.39·HCl. U(eq) is defined as one third of the trace of the orthogonalized 
Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C1 7062(2) 3252(2) -373(2) 17(1) 
C2 8056(2) 3740(3) -552(2) 20(1) 
C3 8148(2) 4040(3) -1445(2) 22(1) 
C4 7313(2) 4659(3) -1734(2) 20(1) 
C5 6315(2) 4234(2) -1533(2) 18(1) 
C6 8903(3) 3785(3) -1909(2) 34(1) 
C7 6961(2) 3024(2) 555(2) 20(1) 
C8 6031(3) 2422(2) 751(2) 21(1) 
C9 5981(3) 1502(2) 239(2) 26(1) 
C10 6028(3) 1746(2) -676(2) 25(1) 
C11 6959(3) 2308(2) -859(2) 22(1) 
C12 7051(2) 3887(2) 1126(2) 18(1) 
C13 6277(3) 4528(2) 1253(2) 21(1) 
C14 6368(3) 5298(3) 1799(2) 26(1) 
C15 7231(3) 5429(3) 2237(2) 28(1) 
C16 8013(3) 4787(3) 2122(2) 31(1) 
C17 7923(2) 4034(3) 1570(2) 25(1) 
C18 6802(2) 3007(2) 4643(2) 16(1) 
C19 6320(2) 2021(2) 4463(2) 18(1) 
C20 6033(3) 1926(2) 3568(2) 19(1) 
C21 5381(2) 2726(2) 3269(2) 19(1) 
C22 5800(2) 3718(2) 3473(2) 17(1) 
C23 6331(3) 1204(3) 3103(2) 32(1) 
C24 7023(2) 3109(2) 5572(2) 18(1) 
C25 7613(2) 4035(3) 5769(2) 21(1) 
C26 8559(2) 4103(3) 5266(2) 25(1) 
C27 8326(2) 4045(3) 4352(2) 24(1) 
C28 7771(2) 3117(3) 4165(2) 21(1) 
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Table 7.2 continued: 
C29 6142(2) 3003(2) 6138(2) 18(1) 
C30 5995(3) 2145(2) 6569(2) 23(1) 
C31 5220(3) 2046(3) 7119(2) 30(1) 
C32 4562(3) 2799(3) 7237(2) 27(1) 
C33 4687(2) 3651(3) 6803(2) 23(1) 
C34 5477(2) 3753(3) 6265(2) 20(1) 
N1 6272(2) 3970(2) -642(2) 15(1) 
N2 6067(2) 3768(2) 4365(2) 14(1) 
Cl1 4039(1) 3752(1) -394(1) 22(1) 




Table 7.3. Bond lengths [Å] and angles [°] for 4.39·HCl. 
 
 
C1-N1  1.523(4) 
C1-C11  1.531(4) 
C1-C2  1.532(4) 
C1-C7  1.548(4) 
C2-C3  1.516(4) 
C2-H2A  0.99 
C2-H2B  0.99 
C3-C6  1.318(5) 
C3-C4  1.492(5) 
C4-C5  1.510(4) 
C4-H4A  0.99 
C4-H4B  0.99 
C5-N1  1.495(4) 
C5-H5A  0.99 
C5-H5B  0.99 
C6-H6A  0.95 
C6-H6B  0.95 
C7-C12  1.516(4) 
C7-C8  1.541(5) 
C7-H7  1.00 
C8-C9  1.520(5) 
C8-H8A  0.99 
C8-H8B  0.99 
C9-C10  1.527(5) 
C9-H9A  0.99 
C9-H9B  0.99 
C10-C11  1.509(5) 
C10-H10A  0.99 
C10-H10B  0.99 
C11-H11A  0.99 
C11-H11B  0.99 
C12-C13  1.387(5) 
C12-C17  1.399(4) 
C13-C14  1.390(5) 
C13-H13  0.95 
C14-C15  1.380(5) 
C14-H14  0.95 
C15-C16  1.393(5) 
C15-H15  0.95 
C16-C17  1.380(5) 
C16-H16  0.95 
C17-H17  0.95 
C18-N2  1.515(4) 
C18-C28  1.533(4) 
C18-C19  1.537(4) 
C18-C24  1.547(4) 
C19-C20  1.512(4) 
C19-H19A  0.99 
C19-H19B  0.99 
C20-C23  1.315(5) 
C20-C21  1.495(4) 
C21-C22  1.520(4) 
C21-H21A  0.99 
C21-H21B  0.99 
C22-N2  1.495(4) 
C22-H22A  0.99 
C22-H22B  0.99 
C23-H23A  0.95 
C23-H23B  0.95 
C24-C29  1.514(4) 
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Table 7.3 continued: 
C24-C25  1.540(5) 
C24-H24  1.00 
C25-C26  1.523(4) 
C25-H25A  0.99 
C25-H25B  0.99 
C26-C27  1.521(5) 
C26-H26A  0.99 
C26-H26B  0.99 
C27-C28  1.515(5) 
C27-H27A  0.99 
C27-H27B  0.99 
C28-H28A  0.99 
C28-H28B  0.99 
C29-C34  1.387(5) 
 
C29-C30  1.391(4) 
C30-C31  1.384(5) 
C30-H30  0.95 
C31-C32  1.383(5) 
C31-H31  0.95 
C32-C33  1.383(5) 
C32-H32  0.95 
C33-C34  1.390(5) 
C33-H33  0.95 
C34-H34  0.95 
N1-H1NA  0.94(4) 
N1-H1NB  1.00(4) 
N2-H2NB  0.89(3) 



















































































































































































Table 7.4. Anisotropic displacement parameters (Å2x 103) for 4.39·HCl. The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* 
U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C1 17(2)  20(2) 14(2)  -1(1) -1(1)  5(1) 
C2 15(1)  28(2) 17(2)  3(1) 1(1)  3(1) 
C3 20(2)  26(2) 18(2)  0(2) 1(1)  1(2) 
C4 23(2)  23(2) 13(2)  1(1) 1(1)  4(1) 
C5 22(2)  20(2) 11(2)  3(1) -2(1)  3(1) 
C6 26(2)  56(3) 19(2)  4(2) 2(2)  13(2) 
C7 19(2)  21(2) 18(2)  3(1) 0(1)  4(1) 
C8 23(2)  20(2) 18(2)  5(1) 1(1)  2(2) 
C9 28(2)  17(2) 32(2)  2(2) 1(2)  2(1) 
C10 31(2)  18(2) 25(2)  -4(1) 0(2)  3(2) 
C11 26(2)  21(2) 18(2)  0(1) -1(1)  8(2) 
C12 23(2)  22(2) 10(2)  5(1) 0(1)  -4(1) 
C13 21(2)  26(2) 15(2)  2(1) 0(1)  -1(1) 
C14 35(2)  25(2) 17(2)  0(2) 2(2)  -4(2) 
C15 42(2)  27(2) 16(2)  1(2) -3(2)  -10(2) 
C16 34(2)  42(2) 18(2)  7(2) -10(2)  -18(2) 
C17 22(2)  31(2) 20(2)  9(2) -1(1)  -1(2) 
C18 18(2)  16(2) 14(2)  0(1) -1(1)  5(1) 
C19 27(2)  14(2) 13(2)  0(1) -3(1)  2(1) 
C20 26(2)  18(2) 14(2)  -2(1) -1(1)  2(2) 
C21 23(2)  18(2) 15(2)  -4(1) -3(1)  2(1) 
C22 23(2)  18(2) 10(2)  2(1) -2(1)  5(1) 
C23 49(2)  27(2) 20(2)  -3(2) -6(2)  16(2) 
C24 19(2)  16(2) 18(2)  -1(1) -2(1)  4(1) 
C25 20(2)  24(2) 17(2)  -1(2) -4(1)  0(2) 
C26 18(2)  31(2) 28(2)  -4(2) -2(1)  1(2) 
C27 18(2)  31(2) 24(2)  0(2) 4(1)  3(2) 
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Table 7.4 continued: 
C28 19(2)  25(2) 18(2)  -1(1) 1(1)  7(1) 
C29 23(2)  21(2) 9(2)  -1(1) -5(1)  -1(1) 
C30 30(2)  20(2) 19(2)  -1(1) -7(2)  1(2) 
C31 46(2)  27(2) 16(2)  7(2) -6(2)  -16(2) 
C32 28(2)  39(2) 15(2)  1(2) -1(2)  -9(2) 
C33 24(2)  30(2) 15(2)  -5(2) 1(1)  -2(2) 
C34 26(2)  21(2) 12(2)  0(1) -1(1)  0(1) 
N1 14(1)  17(1) 13(1)  0(1) 0(1)  2(1) 
N2 17(1)  13(1) 12(1)  -2(1) 0(1)  1(1) 
Cl1 17(1)  20(1) 28(1)  4(1) 1(1)  -1(1) 




Table 7.5. Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) for 
4.39·HCl. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H2A 8126 4319 -197 24 
H2B 8597 3286 -414 24 
H4A 7366 4745 -2337 24 
H4B 7368 5306 -1476 24 
H5A 5791 4711 -1660 21 
H5B 6199 3650 -1873 21 
H6A 8938 3997 -2464 41 
H6B 9412 3389 -1688 41 
H7 7533 2594 691 23 
H8A 6033 2249 1342 25 
H8B 5436 2820 643 25 
H9A 5358 1154 360 31 
H9B 6538 1071 386 31 
H10A 6020 1141 -1003 30 
H10B 5444 2136 -832 30 
H11A 6974 2461 -1454 26 
H11B 7535 1890 -738 26 
H13 5675 4440 963 25 
H14 5834 5737 1870 31 
H15 7290 5951 2614 34 
H16 8608 4868 2424 38 
H17 8464 3606 1489 29 
H19A 6787 1497 4608 22 
H19B 5724 1946 4810 22 
H21A 4720 2659 3524 22 
H21B 5300 2669 2666 22 
H22A 6395 3841 3134 21 
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Table 7.5 continued: 
H22B 5305 4224 3345 21 
H23A 6131 1171 2543 39 
H23B 6746 715 3325 39 
H24 7473 2558 5710 21 
H25A 7196 4609 5655 25 
H25B 7781 4041 6362 25 
H26A 8897 4723 5386 31 
H26B 9008 3567 5420 31 
H27A 7920 4610 4188 29 
H27B 8947 4062 4032 29 
H28A 8203 2559 4293 25 
H28B 7624 3096 3569 25 
H30 6434 1617 6485 28 
H31 5141 1458 7415 36 
H32 4029 2731 7613 33 
H33 4232 4168 6873 27 
H34 5564 4347 5978 24 
H1NA 5630(30) 3760(30) -510(20) 27(10) 
H1NB 6330(20) 4580(30) -310(20) 25(9) 
H2NB 5500(20) 3700(20) 4630(20) 13(8) 






















































































Table 7.7. Hydrogen bonds for 4.39·HCl [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N1-H1NA...Cl1 0.94(4) 2.16(4) 3.065(3) 160(3) 
 N1-H1NB...Cl1#1 1.00(4) 2.37(4) 3.196(3) 140(3) 
 N2-H2NB...Cl2#1 0.89(3) 2.43(3) 3.198(3) 146(3) 
 N2-H2NA...Cl2 0.89(3) 2.22(3) 3.074(3) 159(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+1,z       
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Figure 7.1. View of 4.39·HCl showing the atom labeling scheme.  Displacement ellipsoids are 







X-ray Experimental for complex C17H26NO1+ - Cl1- - ¼ H2O (4.66):  Crystals grew as clusters 
of multiply intergrown colorless plates by evaporation from ethyl acetate.  The data crystal was 
cut from a cluster of crystals and had approximate dimensions; 0.13 x 0.08 x 0.07 mm.  The data 
were collected on an Agilent Technologies SuperNova Dual Source diffractometer using a -
focus Cu K radiation source ( = 1.5418Å) with collimating mirror monochromators.  A total 
of 750 frames of data were collected using -scans with a scan range of 1 and a counting time 
of 15 seconds per frame with a detector offset of 0.0 and 41 seconds per frame with a detector 
offset of +/- 78.3.  The data were collected at 100 K using an Oxford Cryostream low 
temperature device.  Details of crystal data, data collection and structure refinement are listed in 
Table 7.8.  Data collection, unit cell refinement and data reduction were performed using Agilent 
Technologies CrysAlisPro V 1.171.38.46.  The structure was solved by direct methods using 
SHELXT2 and refined by full-matrix least-squares on F2 with anisotropic displacement 
parameters for the non-H atoms using SHELXL-2016/6.255,256  Structure analysis was aided by 
use of the programs PLATON and WinGX.252,257  The hydrogen atoms were calculated in ideal 
positions with isotropic displacement parameters set to 1.2xUeq of the attached atom (1.5xUeq 
for methyl hydrogen atoms). 
The crystal was refined as a 2-component twin.  The twin law was determined using 
CrysAlisPro.  The twin was due to a 180º rotation about the [1,0,0] direct axis direction.  The 
twin fraction refined to 0.308(2).  There are four ion pairs in the asymmetric unit.  The four are 
clustered around a single water molecule.  The hydroxyl groups for all four are directed toward 
the water molecule and are presumably H-bound to it.  The four hydroxyl groups are disordered 
about two orientations each.   
   The function, w(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[((Fo))2 + (0.0961*P)2] 
and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.268, with R(F) equal to 0.0972 and a goodness of 
fit, S, = 1.01.  Definitions used for calculating R(F), Rw(F2) and the goodness of fit, S, are as 
follows: Rw(F2) =  {w(|Fo|2 - |Fc|2)2/w(|Fo|)4}1/2 where w is the weight given each 
reflection; R(F) =  (|Fo| - |Fc|)/|Fo|} for reflections with Fo > 4((Fo)); S =  [w(|Fo|2 - 
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|Fc|2)2/(n - p)]1/2, where n is the number of reflections and p is the number of refined 
parameters.  The data were checked for secondary extinction effects but no correction was 
necessary.  Neutral atom scattering factors and values used to calculate the linear absorption 
coefficient are from the International Tables for X-ray Crystallography (1992). All figures were 
generated using SHELXTL/PC. Tables of positional and thermal parameters, bond lengths and 
















Table 7.8. Crystal data and structure refinement for 4.66. 
 
Empirical formula  C17 H26 Cl N O1.25 
Formula weight  299.84 
Temperature  100(2) K 
Wavelength  1.54184 Å 
 256 
Crystal system  triclinic 
Space group  P -1 
  Unit cell dimensions a = 12.6755(8) Å = 108.860(9)°. 
 b = 15.7168(12) Å = 98.379(8)°. 
 c = 17.551(3) Å  = 90.045(6)°. 
Volume 3269.1(6) Å3 
Z 8 
Density (calculated) 1.218 Mg/m3 
Absorption coefficient 2.041 mm-1 
F(000) 1296 
Crystal size 0.130 x 0.080 x 0.070 mm3 
Theta range for data collection 4.500 to 59.670°. 
Index ranges -13<=h<=14, -17<=k<=17, -19<=l<=19 
Reflections collected 14543 
Independent reflections 14543 [R(int) = ?] 
Completeness to theta = 59.670° 97.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.607 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 14543 / 566 / 761 
Goodness-of-fit on F2 1.002 
Final R indices [I>2sigma(I)] R1 = 0.0972, wR2 = 0.2498 
R indices (all data) R1 = 0.1982, wR2 = 0.2681 
Extinction coefficient n/a 
Largest diff. peak and hole 0.713 and -0.492 e.Å-3 
 257 
Table 7.9. Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for 4.66.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C1 9154(8) 5432(7) 2754(7) 23(3) 
C2 8825(8) 4642(7) 3035(7) 25(3) 
C3 8941(8) 4934(6) 3996(6) 27(3) 
C4 8330(9) 5749(7) 4313(7) 33(3) 
C5 8569(9) 6526(8) 4005(7) 39(3) 
C6 8987(8) 5113(7) 1796(7) 29(3) 
C7 9427(8) 5865(8) 1497(7) 37(3) 
C8 10561(9) 6177(8) 1831(8) 48(3) 
C9 10755(9) 6462(8) 2773(8) 43(3) 
C10 10359(8) 5718(7) 3068(7) 32(3) 
C11 7900(8) 4757(7) 1382(6) 24(3) 
C12 7065(8) 5330(8) 1277(7) 32(3) 
C13 6051(9) 4976(9) 870(7) 40(3) 
C14 5845(10) 4062(9) 559(7) 38(3) 
C15 6649(10) 3498(8) 682(7) 43(3) 
C16 7633(10) 3837(8) 1078(7) 38(3) 
C17 8588(9) 4108(8) 4199(8) 54(4) 
C18 5766(8) 6202(7) 7182(7) 31(3) 
C19 6074(8) 5246(7) 6918(6) 24(3) 
C20 6046(8) 4817(6) 6001(6) 29(3) 
C21 6735(9) 5372(7) 5697(7) 30(3) 
C22 6481(9) 6365(7) 5939(7) 29(3) 
C23 5877(8) 6655(7) 8116(6) 24(3) 
C24 5515(9) 7624(7) 8365(7) 36(3) 
C25 4401(9) 7695(8) 7989(8) 42(3) 
C26 4245(10) 7288(7) 7049(7) 37(3) 
C27 4588(8) 6321(7) 6797(7) 31(3) 
C28 6943(9) 6548(7) 8599(7) 30(3) 
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Table 7.9 continued: 
C29 7057(9) 5884(8) 8942(7) 35(3) 
C30 8025(9) 5804(7) 9418(7) 31(3) 
C31 8885(10) 6356(8) 9511(8) 43(3) 
C32 8801(9) 7048(8) 9160(7) 39(3) 
C33 7816(8) 7157(7) 8726(6) 31(3) 
C34 6365(9) 3848(7) 5803(6) 44(4) 
C35 4954(8) -1208(7) 2871(7) 22(3) 
C36 5363(9) -222(7) 3132(7) 37(3) 
C37 5735(9) 209(6) 4044(7) 39(3) 
C38 6609(10) -376(8) 4298(8) 47(4) 
C39 6266(10) -1347(8) 4048(8) 45(4) 
C40 4603(8) -1606(7) 1934(7) 29(3) 
C41 4166(8) -2588(7) 1663(7) 33(3) 
C42 3210(9) -2651(8) 2092(7) 45(3) 
C43 3550(9) -2235(8) 3045(7) 35(3) 
C44 3960(9) -1303(8) 3245(7) 38(3) 
C45 5439(8) -1499(7) 1418(6) 24(3) 
C46 5422(9) -754(8) 1137(7) 40(3) 
C47 6155(10) -600(9) 693(8) 45(4) 
C48 6943(11) -1204(9) 521(8) 44(3) 
C49 6977(10) -1966(9) 756(8) 47(4) 
C50 6227(9) -2090(8) 1227(7) 41(3) 
C51 6083(9) 1169(8) 4232(7) 54(4) 
C52 10083(9) -424(7) 7396(7) 34(3) 
C53 9664(9) 354(7) 7100(7) 31(3) 
C54 9472(9) 114(7) 6160(7) 37(3) 
C55 8671(10) -692(8) 5801(8) 45(3) 
C56 9016(9) -1477(8) 6079(7) 40(3) 
C57 10228(8) -151(7) 8352(7) 30(3) 
C58 10628(8) -951(7) 8624(7) 33(3) 
C59 11663(9) -1268(8) 8343(8) 45(3) 
C60 11546(9) -1498(8) 7409(8) 46(4) 
C61 11153(10) -755(8) 7128(8) 44(3) 
C62 9298(9) 284(8) 8737(7) 30(3) 
C63 9257(10) 1226(8) 9048(7) 37(3) 
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Table 7.9 continued: 
C64 8423(11) 1602(9) 9412(8) 52(4) 
C65 7542(11) 1088(9) 9476(8) 47(4) 
C66 7600(10) 178(9) 9155(8) 43(3) 
C67 8411(9) -229(8) 8796(7) 36(3) 
C68 9070(10) 922(9) 5955(8) 65(4) 
N1 8451(6) 6205(5) 3093(5) 26(2) 
N2 6553(6) 6725(5) 6857(5) 23(2) 
N3 5852(7) -1677(6) 3165(5) 30(2) 
N4 9234(6) -1202(5) 7005(5) 22(2) 
O1 9429(8) 3577(6) 4274(7) 44(3) 
O1A 8740(20) 4172(14) 4982(10) 46(8) 
O2 6352(9) 3393(6) 5004(6) 43(3) 
O2A 5496(15) 3243(9) 5521(16) 43(3) 
O1W 8520(7) 2448(6) 4984(6) 67(3) 
O3 5295(11) 1758(7) 4499(10) 41(4) 
O3A 6518(12) 1652(8) 4992(7) 45(4) 
O4 9860(12) 1410(10) 5795(11) 67(6) 
O4A 8862(12) 871(9) 5174(8) 48(5) 
Cl4 9073(2) -3133(2) 7035(2) 38(1) 
Cl3 5971(2) -3695(2) 3063(2) 40(1) 
Cl1 8248(2) 8031(2) 2810(2) 56(1) 
Cl2 6723(2) 8719(2) 6972(2) 45(1) 
________________________________________________________________________________  
 260 
Table 7.10. Bond lengths [Å] and angles [°] for 4.66  
 
C1-N1  1.521(12) 
C1-C2  1.554(14) 
C1-C10  1.559(14) 
C1-C6  1.572(15) 
C2-C3  1.582(14) 
C2-H2A  0.99 
C2-H2B  0.99 
C3-C4  1.488(13) 
C3-C17  1.536(14) 
C3-H3  1.00 
C4-C5  1.532(15) 
C4-H4A  0.99 
C4-H4B  0.99 
C5-N1  1.500(14) 
C5-H5A  0.99 
C5-H5B  0.99 
C6-C11  1.478(14) 
C6-C7  1.571(14) 
C6-H6  1.00 
C7-C8  1.490(15) 
C7-H7A  0.99 
C7-H7B  0.99 
C8-C9  1.547(16) 
C8-H8A  0.99 
C8-H8B  0.99 
C9-C10  1.533(15) 
C9-H9A  0.99 
C9-H9B  0.99 
C10-H10A  0.99 
C10-H10B  0.99 
C11-C16  1.391(14) 
C11-C12  1.420(14) 
C12-C13  1.395(14) 
C12-H12  0.95 
C13-C14  1.372(15) 
C13-H13  0.95 
C14-C15  1.390(16) 
C14-H14  0.95 
C15-C16  1.352(15) 
C15-H15  0.95 
C16-H16  0.95 
C17-O1A  1.330(10) 
C17-O1  1.371(9) 
C17-H17A  0.96 
C17-H17B  0.96 
C17-H17C  0.96 
C17-H17D  0.96 
C18-C19  1.493(14) 
C18-C23  1.546(14) 
C18-N2  1.570(12) 
C18-C27  1.584(14) 
C19-C20  1.525(14) 
C19-H19A  0.99 
C19-H19B  0.99 
C20-C21  1.498(13) 
C20-C34  1.517(13) 
C20-H20  1.00 
C21-C22  1.527(14) 
C21-H21A  0.99 
C21-H21B  0.99 
C22-N2  1.513(13) 
C22-H22A  0.99 
C22-H22B  0.99 
C23-C28  1.527(15) 
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C23-C24  1.534(14) 
C23-H23  1.00 
Table 7.10 continued: 
C24-C25  1.489(15) 
C24-H24A  0.99 
C24-H24B  0.99 
C25-C26  1.547(16) 
C25-H25A  0.99 
C25-H25B  0.99 
C26-C27  1.523(14) 
C26-H26A  0.99 
C26-H26B  0.99 
C27-H27A  0.99 
C27-H27B  0.99 
C28-C29  1.360(15) 
C28-C33  1.408(14) 
C29-C30  1.411(15) 
C29-H29  0.95 
C30-C31  1.349(15) 
C30-H30  0.95 
C31-C32  1.409(16) 
C31-H31  0.95 
C32-C33  1.406(15) 
C32-H32  0.95 
C33-H33  0.95 
C34-O2  1.350(9) 
C34-O2A  1.378(10) 
C34-H34A  0.96 
C34-H34B  0.96 
C34-H34C  0.96 
C34-H34D  0.96 
C35-N3  1.476(12) 
C35-C44  1.532(14) 
C35-C36  1.534(14) 
C35-C40  1.554(14) 
C36-C37  1.523(14) 
C36-H36A  0.99 
C36-H36B  0.99 
 
C37-C51  1.488(14) 
C37-C38  1.548(14) 
C37-H37  1.00 
C38-C39  1.491(15) 
C38-H38A  0.99 
C38-H38B  0.99 
C39-N3  1.481(14) 
C39-H39A  0.99 
C39-H39B  0.99 
C40-C45  1.532(14) 
C40-C41  1.536(13) 
C40-H40  1.00 
C41-C42  1.535(15) 
C41-H41A  0.99 
C41-H41B  0.99 
C42-C43  1.579(16) 
C42-H42A  0.99 
C42-H42B  0.99 
C43-C44  1.467(14) 
C43-H43A  0.99 
C43-H43B  0.99 
C44-H44A  0.99 
C44-H44B  0.99 
C45-C50  1.368(15) 
C45-C46  1.410(15) 
C46-C47  1.365(15) 
C46-H46  0.95 
C47-C48  1.375(17) 
C47-H47  0.95 
C48-C49  1.387(17) 
C48-H48  0.95 
C49-C50  1.400(16) 
C49-H49  0.95 
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C50-H50  0.95 
C51-O3A  1.337(9) 
Table 7.10 continued: 
C51-O3  1.390(9) 
C51-H51A  0.96 
C51-H51B  0.96 
C51-H51C  0.96 
C51-H51D  0.96 
C52-C61  1.536(15) 
C52-N4  1.538(12) 
C52-C53  1.542(15) 
C52-C57  1.574(15) 
C53-C54  1.551(15) 
C53-H53A  0.99 
C53-H53B  0.99 
C54-C68  1.498(15) 
C54-C55  1.526(15) 
C54-H54  1.00 
C55-C56  1.510(16) 
C55-H55A  0.99 
C55-H55B  0.99 
C56-N4  1.522(14) 
C56-H56A  0.99 
C56-H56B  0.99 
C57-C62  1.500(15) 
C57-C58  1.544(15) 
C57-H57  1.00 
C58-C59  1.498(14) 
C58-H58A  0.99 
C58-H58B  0.99 
C59-C60  1.545(16) 
C59-H59A  0.99 
C59-H59B  0.99 
C60-C61  1.467(16) 
C60-H60A  0.99 
C60-H60B  0.99 
C61-H61A  0.99 
 
 
C61-H61B  0.99 
C62-C63  1.407(15) 
C62-C67  1.418(15) 
C63-C64  1.352(16) 
C63-H63  0.95 
C64-C65  1.416(17) 
C64-H64  0.95 
C65-C66  1.364(15) 
C65-H65  0.95 
C66-C67  1.339(15) 
C66-H66  0.95 
C67-H67  0.95 
C68-O4A  1.332(10) 
C68-O4  1.374(10) 
C68-H68A  0.96 
C68-H68B  0.96 
C68-H68C  0.96 
C68-H68D  0.96 
N1-H1A  0.91 
N1-H1B  0.91 
N2-H2C  0.91 
N2-H2D  0.91 
N3-H3A  0.91 
N3-H3B  0.91 
N4-H4C  0.91 
N4-H4D  0.91 
O1-H1  0.84 
O1A-H17B  0.7835 
O1A-H1A1  0.84 
O2-H2  0.84 
O2A-H2A1  0.84 
O3-H3C  0.84 
O3A-H3A1  0.84 
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O4-H4  0.84 O4A-H4A1  0.84 





































































































































































































































































































































































































































Table 7.11. Anisotropic displacement parameters  (Å2x 103) for 4.66.  The anisotropic 
displacement factor exponent takes the form:  -22[h2a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C1 21(5)  24(6) 27(6)  8(5) 9(5)  -3(5) 
C2 17(5)  28(6) 32(6)  12(5) 2(5)  1(5) 
C3 24(5)  30(6) 30(7)  15(5) 5(5)  6(5) 
C4 39(6)  40(7) 23(7)  10(5) 11(5)  -4(5) 
C5 29(6)  45(7) 38(7)  9(6) 6(5)  -1(5) 
C6 28(6)  32(6) 34(7)  17(5) 9(5)  6(5) 
C7 33(6)  50(7) 34(7)  21(6) 6(5)  -5(5) 
C8 44(7)  51(7) 56(8)  28(6) 11(6)  0(6) 
C9 22(6)  51(7) 49(8)  7(6) 7(6)  -9(5) 
C10 32(6)  32(6) 32(7)  13(5) -1(5)  12(5) 
C11 27(6)  31(6) 17(6)  9(5) 8(5)  8(5) 
C12 36(6)  33(6) 24(6)  4(5) 6(5)  4(5) 
C13 26(6)  58(8) 37(7)  21(6) -8(5)  13(6) 
C14 40(7)  49(7) 18(6)  5(6) -3(5)  -10(6) 
C15 54(7)  34(7) 28(7)  -9(5) 10(6)  -5(6) 
C16 52(7)  38(7) 21(6)  8(5) 0(6)  16(6) 
C17 42(7)  73(8) 64(9)  42(7) 14(6)  20(6) 
C18 28(6)  32(6) 35(7)  14(5) 9(5)  -5(5) 
C19 20(5)  29(6) 26(6)  14(5) 3(5)  8(5) 
C20 24(6)  25(6) 36(7)  9(5) 1(5)  1(5) 
C21 35(6)  21(6) 29(7)  7(5) -6(5)  -14(5) 
C22 35(6)  33(6) 22(6)  14(5) 3(5)  -7(5) 
C23 27(6)  28(6) 17(6)  7(5) 5(5)  -3(5) 
C24 40(6)  45(7) 26(7)  12(5) 11(5)  2(6) 
C25 38(6)  37(7) 51(8)  11(6) 12(6)  6(5) 
C26 44(6)  32(6) 35(7)  12(5) 6(6)  -1(5) 
C27 37(6)  28(6) 26(6)  9(5) -5(5)  -9(5) 
C28 37(6)  33(6) 17(6)  2(5) 10(5)  1(5) 
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Table 7.11 continued: 
C29 32(6)  44(7) 33(7)  12(6) 13(5)  5(5) 
C30 42(6)  34(6) 19(6)  13(5) 0(5)  -2(5) 
C31 46(7)  49(7) 33(7)  10(6) 6(6)  6(6) 
C32 38(6)  47(7) 30(7)  14(6) -2(5)  -8(5) 
C33 34(6)  34(6) 20(6)  6(5) -1(5)  -3(5) 
C34 44(7)  34(7) 45(8)  -1(6) 9(6)  -6(6) 
C35 15(5)  22(6) 28(6)  5(5) 10(5)  9(4) 
C36 37(6)  41(7) 34(7)  15(5) 0(5)  21(6) 
C37 48(7)  34(7) 24(7)  0(5) -4(5)  11(6) 
C38 56(7)  45(7) 36(7)  15(6) -5(6)  17(6) 
C39 49(7)  48(7) 35(7)  15(6) -10(6)  4(6) 
C40 24(5)  29(6) 35(7)  16(5) -2(5)  -2(5) 
C41 35(6)  28(6) 35(7)  12(5) 2(5)  -2(5) 
C42 42(6)  43(7) 50(8)  22(6) -6(6)  -7(6) 
C43 26(6)  47(7) 36(7)  18(6) 8(5)  2(5) 
C44 30(6)  51(7) 34(7)  18(6) 3(5)  4(6) 
C45 27(6)  26(6) 17(6)  3(5) 5(5)  7(5) 
C46 39(6)  45(7) 37(7)  17(6) 6(6)  6(6) 
C47 52(7)  48(7) 36(7)  15(6) 10(6)  -11(6) 
C48 50(7)  46(7) 32(7)  9(6) 9(6)  -13(6) 
C49 50(7)  51(7) 33(7)  1(6) 12(6)  13(6) 
C50 41(6)  45(7) 36(7)  14(6) 2(6)  -5(6) 
C51 56(7)  33(7) 55(8)  -4(6) -6(7)  13(6) 
C52 31(6)  28(6) 36(7)  4(5) 1(5)  -6(5) 
C53 34(6)  28(6) 34(7)  16(5) -2(5)  -7(5) 
C54 33(6)  40(7) 38(7)  11(6) 11(5)  6(5) 
C55 44(7)  54(7) 37(7)  18(6) 1(6)  5(6) 
C56 25(6)  54(7) 37(7)  10(6) 2(5)  -11(6) 
C57 29(6)  27(6) 26(7)  1(5) -8(5)  -7(5) 
C58 28(6)  29(6) 33(7)  1(5) -3(5)  14(5) 
C59 38(6)  37(7) 52(8)  12(6) -7(6)  0(5) 
C60 30(6)  50(7) 54(8)  6(6) 18(6)  5(6) 
C61 48(7)  49(7) 35(7)  13(6) 13(6)  18(6) 
C62 32(6)  31(6) 26(6)  8(5) -3(5)  4(5) 
C63 41(7)  42(7) 20(6)  1(5) -2(5)  3(6) 
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Table 7.11 continued: 
C64 68(8)  47(7) 35(7)  12(6) -5(6)  17(7) 
C65 45(7)  56(8) 39(7)  17(6) 2(6)  23(6) 
C66 47(7)  46(7) 39(7)  18(6) 8(6)  18(6) 
C67 41(6)  39(7) 37(7)  24(6) 10(6)  14(6) 
C68 66(8)  78(9) 66(9)  50(7) 0(7)  -17(7) 
N1 21(5)  25(5) 31(6)  7(4) -1(4)  -14(4) 
N2 24(5)  16(5) 31(6)  7(4) 10(4)  -9(4) 
N3 35(5)  25(5) 28(6)  3(4) 9(4)  3(4) 
N4 11(4)  26(5) 25(5)  4(4) 0(4)  8(4) 
O1 54(7)  37(7) 59(8)  38(6) 9(6)  22(6) 
O1A 51(15)  45(15) 40(16)  10(13) 12(13)  17(13) 
O2 67(7)  29(6) 30(7)  7(5) 6(5)  -1(5) 
O2A 67(7)  29(6) 30(7)  7(5) 6(5)  -1(5) 
O1W 76(6)  77(6) 50(6)  21(5) 17(6)  -15(6) 
O3 54(10)  23(8) 53(11)  17(8) 23(9)  4(8) 
O3A 61(10)  47(10) 25(10)  14(8) -5(8)  13(8) 
O4 61(11)  77(12) 70(13)  47(10) -15(10)  -42(10) 
O4A 48(10)  48(10) 41(11)  2(8) 9(9)  2(8) 
Cl4 28(2)  35(2) 54(2)  17(2) 12(2)  6(1) 
Cl3 25(2)  26(2) 71(2)  18(2) 8(2)  1(1) 
Cl1 30(2)  44(2) 106(3)  43(2) 2(2)  -4(2) 




Table 7.12. Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 103) for 
4.66. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H2A 9281 4131 2836 30 
H2B 8075 4438 2794 30 
H3 9713 5087 4227 32 
H4A 8490 5965 4916 40 
H4B 7558 5576 4158 40 
H5A 8071 7009 4188 46 
H5B 9306 6778 4239 46 
H6 9460 4598 1628 35 
H7A 9352 5634 895 45 
H7B 8976 6390 1647 45 
H8A 10744 6694 1661 57 
H8B 11033 5686 1607 57 
H9A 11527 6596 2975 52 
H9B 10377 7016 3000 52 
H10A 10476 5932 3671 38 
H10B 10788 5185 2883 38 
H12 7199 5964 1488 38 
H13 5501 5370 808 48 
H14 5163 3818 263 46 
H15 6506 2865 485 51 
H16 8162 3432 1153 45 
H17A 8051 3760 3765 65 
H17B 8282 4296 4692 65 
H17C 8974 3604 3923 65 
H17D 7846 3973 3978 65 
H19A 5587 4886 7101 29 
H19B 6805 5217 7195 29 
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Table 7.12 continued: 
H20 5294 4813 5730 35 
H21A 6648 5120 5095 36 
H21B 7491 5325 5912 36 
H22A 6997 6705 5760 35 
H22B 5754 6431 5677 35 
H23 5343 6313 8287 29 
H24A 5566 7862 8966 43 
H24B 6003 8003 8202 43 
H25A 4226 8336 8146 50 
H25B 3902 7376 8202 50 
H26A 3485 7302 6823 44 
H26B 4675 7651 6826 44 
H27A 4529 6087 6196 38 
H27B 4087 5950 6958 38 
H29 6475 5467 8858 43 
H30 8073 5357 9677 37 
H31 9543 6278 9811 52 
H32 9403 7435 9216 47 
H33 7740 7645 8517 37 
H34A 5900 3528 6014 53 
H34B 7077 3851 6080 53 
H34C 6750 3774 6289 53 
H34D 6832 3721 5400 53 
H36A 5965 -185 2841 45 
H36B 4785 131 2961 45 
H37 5118 188 4334 46 
H38A 7248 -318 4050 56 
H38B 6816 -143 4897 56 
H39A 6879 -1698 4168 54 
H39B 5703 -1426 4359 54 
H40 3988 -1253 1804 34 
H41A 3940 -2809 1065 39 
H41B 4733 -2971 1800 39 
H42A 2962 -3289 1946 54 
H42B 2615 -2319 1910 54 
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Table 7.12 continued: 
H43A 2926 -2248 3322 42 
H43B 4108 -2593 3234 42 
H44A 4132 -1034 3845 45 
H44B 3390 -956 3054 45 
H46 4876 -340 1262 47 
H47 6123 -94 508 53 
H48 7479 -1095 232 52 
H49 7499 -2396 600 57 
H50 6265 -2593 1417 49 
H51A 6269 1246 3746 65 
H51B 6707 1320 4641 65 
H51C 5479 1480 4079 65 
H51D 6598 1179 3885 65 
H53A 10185 876 7337 37 
H53B 8985 538 7307 37 
H54 10160 -49 5947 44 
H55A 7968 -509 5965 54 
H55B 8586 -884 5199 54 
H56A 9670 -1712 5856 48 
H56B 8449 -1965 5865 48 
H57 10829 318 8560 36 
H58A 10723 -767 9226 40 
H58B 10082 -1455 8403 40 
H59A 11863 -1808 8493 54 
H59B 12235 -791 8612 54 
H60A 12249 -1658 7235 55 
H60B 11047 -2031 7144 55 
H61A 11069 -956 6526 52 
H61B 11693 -246 7342 52 
H63 9817 1600 9003 45 
H64 8428 2240 9635 62 
H65 6953 1358 9723 56 
H66 7027 -192 9189 52 
H67 8393 -867 8580 43 
H68A 8771 1302 6411 77 
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Table 7.12 continued: 
H68B 8512 737 5493 77 
H68C 8414 1057 6172 77 
H68D 9569 1424 6237 77 
H1A 8618 6673 2926 32 
H1B 7757 6025 2883 32 
H2C 6404 7317 7010 28 
H2D 7233 6684 7089 28 
H3A 6401 -1646 2892 36 
H3B 5642 -2269 3025 36 
H4C 9454 -1686 7150 27 
H4D 8615 -1034 7204 27 
H1 9216 3126 4378 67 
H1A1 8523 3690 5030 68 
H2 6538 2866 4947 65 
H2A1 5705 2717 5420 65 
H3C 5522 2289 4591 61 
H3A1 7066 1408 5135 67 
H4 10341 1584 6204 100 






















































































































































































Table 7.14. Hydrogen bonds for 4.66 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N1-H1A...Cl1 0.91 2.25 3.072(9) 149.6 
 N1-H1B...Cl3#1 0.91 2.35 3.141(8) 144.9 
 N2-H2C...Cl2 0.91 2.26 3.080(8) 149.1 
 N2-H2D...Cl4#1 0.91 2.37 3.164(8) 146.0 
 N3-H3A...Cl1#2 0.91 2.41 3.192(9) 144.1 
 N3-H3B...Cl3 0.91 2.30 3.123(9) 150.2 
 N4-H4C...Cl4 0.91 2.26 3.060(8) 146.1 
 N4-H4D...Cl2#2 0.91 2.38 3.176(8) 145.7 
 O1-H1...O1W 0.84 2.01 2.805(14) 157.1 
 O1A-H1A1...O1W 0.84 1.93 2.72(2) 158.1 
 O2-H2...O1W 0.84 2.59 3.125(14) 122.3 
 O2-H2...O3 0.84 2.21 2.713(15) 118.5 
 O2A-H2A1...O3A 0.84 1.96 2.77(2) 160.4 
 O3-H3C...O2 0.84 1.90 2.713(15) 163.3 
 O3A-H3A1...O4A 0.84 2.43 3.23(2) 159.7 
 O4-H4...Cl1#3 0.84 2.23 3.068(17) 173.3 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





Figure 7.2. View of cation 1 of 4.66 showing the atom labeling scheme.  Displacement 
ellipsoids are scaled to the 50% probability level.   The lower occupancy atoms of 
the disordered hydroxyl group are not shown. 
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7.3. THE TOTAL SYNTHESIS OF EXOTINES A AND B 
 
 
trans-Dehydroosthol (6.32) (LTL-V-211). To a stirred solution of alcohol 7.11243 (1.31 
g, 5 mmol) in pyridine (25 mL) was added POCl3 (2.3 mL, 25 mmol). The flask was submerged 
in an oil bath pre-heated to 60 ˚C and stirred for 1 h, whereupon the reaction was cooled to room 
temperature and diluted with H2O (25 mL). The aqueous mixture was extracted with Et2O (3 x 
25 mL), and the combined organic extracts were washed sequentially with sat. CuSO4 (20 mL), 1 
M HCl (20 mL), sat. NaHCO3 (20 mL), and brine (20 mL). The organic phase was dried 
(MgSO4) and concentrated via rotary evaporation to afford 3 (1.08 g, 89%) as a tan solid which 
was used without further purification. The 1H NMR spectra of 6.32 thus obtained is consistent 




(±)-Exotine A (6.1) (LTL-V-257). Indole (6.6, 70 mg, 0.6 mmol), prenal (10, 38 mg, 
0.45 mmol), and trans-dehydroosthol (6.32, 36 mg, 0.15 mmol) were dissolved in CH2Cl2 (1.5 
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mL) and cooled to 0 ˚C, whereupon p-TsOH (29 mg, 0.15 mmol) was added. The solution was 
stirred for 24 h, whereupon CH2Cl2 (15 mL) was added, and the solution was washed with 
saturated aq. NaHCO3 (30 mL). The organic layer was separated, and the aqueous layer was 
extracted with CH2Cl2 (2 x 15 mL). The combined organic extracts were dried (MgSO4) and 
concentrated under reduced pressure. The residue was purified via flash column 
chromatography, eluting with EtOAc/hexanes (20 : 80) to afford 26 mg (43%) of a mixture of 
(±)-exotine A (6.1) and trans-diastereomer 6.42 in a 17 : 1 ratio as an amorphous yellow-orange 
solid. A sample of pure (±)-exotine A (6.1) was obtained via reverse-phase HPLC, eluting with 
MeCN : H2O (35 : 65 → 50 : 50, 90 min) and recrystallized (MeOH-CHCl3) to afford pure (±)-
exotine A as pale yellow needles, mp 246–247 ˚C (lit.
184 mp 249–250 °C). 
1H NMR (500 MHz, CDCl3) δ 7.70 (d, J = 9.5 Hz, 1 H), 7.50 (d, J = 8.6 Hz, 1 H), 7.37 – 
7.34 (m, 1 H), 7.07 – 7.03 (comp, 2 H), 7.02 – 6.99 (comp, 2 H), 6.96 (d, J = 8.6 Hz, 1 H), 6.29 
(d, J = 9.5 Hz, 1 H), 6.00 (s, 1 H), 5.54 – 5.49 (m, 1 H), 5.46 (d, J = 10.0 Hz, 1 H), 4.16 – 4.09 
(m, 1 H), 3.76 (s, 3 H), 3.16 (d, J = 13.1 Hz, 1 H), 2.25 (dd, J = 13.2, 5.1 Hz, 1 H), 1.96 (s, 3 H), 
1.83 (s, 3 H), 1.74 (s, 3 H); 13C NMR (126 MHz, CDCl3) δ 161.2, 160.6, 153.1, 143.6, 137.5, 
133.7, 132.6, 129.6, 129.0, 128.9, 128.3, 126.6, 120.6, 118.8, 118.4, 118.1, 114.8, 113.6, 113.2, 
109.9, 108.4, 56.4, 37.7, 33.0, 32.8, 27.4, 25.9, 18.1; IR (neat) max 3462, 2932, 1721, 1606, 












Table 7.15. Tabulated 1H and 13C NMR data for natural and synthetic 6.1.184 
Position



















































5.51 (dd, 1.6, 3.2)
3.16 (d, 13.1)
































7.37 - 7.34 (m)
7.02 - 6.99 (comp)
7.02 - 6.99 (comp)
7.07 - 7.03 (comp)









5.54 - 5.49 (m)
3.16 (d, 13.1)
2.25 (dd, 5.1, 13.2)
1.83 (s)
3.76 (s)
































Basis for assignment of the structure of 6.42 as being 11'-epi-6.1: 
Although we isolated pure 6.1 via preparative HPLC, attempts to isolate a pure sample of 
6.42 have not been successful, and mixtures of 6.1 and 6.42 were invariably obtained. Despite 
our inability to fully characterize a pure sample of 6.42, analysis of the 1H NMR and COSY 
spectra of a mixture (3:1) of 6.1:6.42 supports our assignment of 6.42 being the 11'-epimer of 
6.1, not a double bond isomer. 
 























The presence of three methyl singlets belonging to 6.42 in the 1.7 – 2.0 ppm region rules 
out the possibility of 6.42 being a terminal olefin isomer such as 7.12 or 7.13, or an isomer that 











Table 7.16. Comparison of diagnostic peaks of 6.1 and 6.42 
Position

















5.54 - 5.49 (m)
3.16 (d, 13.1)
2.25 (dd, 5.1, 13.2)
1.83 (s)
3.76 (s)





5.59 - 5.56 (m)
2.62 (d, 12.6)
2.77 (dd, 9.6, 13.8)
1.87 (s)




Figure 7.3. Key COSY correlations of 6.1 and 6.42 that support the assignments in Table 7.2. 
 
The presence of COSY correlations in both 6.1 and 6.42 between H10 and H14'α/H14'β, 
and between H11' and H12'/H15' exclude the possibility that 6.42 is isomer 7.16. Based on these 
observations, we conclude that the identity of 6.42 is 11'-epi-6.1. 
 
 Deuterium incorporation experiment (LTL-V-275):  
A mixture (10:1) of 6.1 and 6.42 (10 mg, 0.02 mmol) was dissolved in CD2Cl2 (0.8 mL) 
at 0 °C, CF3CO2D (12 mg, 0.1 mmol) was added, the mixture was stirred briefly and then stored 
at 0 ˚C for 5 h. CH2Cl2 (10 mL) was added, and the resultant solution was washed with saturated 
NaHCO3 (20 mL). The organic layer was separated, and the aqueous layer was extracted with 
CH2Cl2 (2 x 10 mL). The combined organic extracts were dried (MgSO4) and concentrated under 
reduced pressure. The residue was purified via flash column chromatography, eluting with 
EtOAc/hexanes (20 : 80) to afford 5 mg of an epimeric mixture (1.6:1) containing a mixture (1:4, 
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1H NMR spectrum of mixture of 6.1, 6.42, 6.1(11'-d1) and 6.42(11'-d1) in CDCl3 showing 
residual proton at C11' centered at 𝛿 6.0: 
 
 
(±)-Exotine B (6.2) (LTL-V-298). Indole (6.6, 47 mg, 0.4 mmol), prenal (6.7, 25 mg, 0.3 
mmol), and gleinadiene (6.43, 27 mg, 0.1 mmol) were dissolved in CH2Cl2 (1 mL) and cooled to 
0 ˚C, whereupon p-TsOH·H2O (19 mg, 0.1 mmol) was added. The solution was stirred for 24 h, 
whereupon CH2Cl2 (15 mL) was added, and the solution was washed with saturated aq. NaHCO3 
(30 mL). The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (2 x 
15 mL). The combined organic extracts were dried (MgSO4) and concentrated under reduced 
pressure. The residue was purified via flash column chromatography, eluting with 
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EtOAc/hexanes (15 : 85) to afford 23 mg (50%) of a mixture (4:1) of (±)-exotine B and epi-
exotine B as an amorphous pale yellow solid. A sample of pure (±)-exotine B (6.2) was obtained 
via reverse-phase HPLC, eluting with MeCN : H2O (50 : 50 → 60 : 40, 60 min). 
1H NMR (500 
MHz, CDCl3) δ 8.06 (d, J = 9.6 Hz, 1 H), 7.37 – 7.32 (m, 1 H), 7.09 (s, 1 H), 7.07 – 7.03 (m, 1 
H), 7.03 – 6.97 (comp, 2 H), 6.42 (s, 1 H), 6.19 (d, J = 9.7 Hz, 1 H), 5.89 (d, J = 2.9 Hz, 1 H), 
5.51 (dq, J = 3.3, 1.6 Hz, 1 H), 5.44 (ddd, J = 10.0, 2.8, 1.4 Hz, 1 H), 4.11 (ddt, J = 9.9, 5.0, 2.7 
Hz, 1 H), 4.00 (s, 3 H), 3.76 (s, 3 H), 3.15 (d, J = 13.1 Hz, 1 H), 2.23 (ddd, J = 13.2, 4.9, 1.4 Hz, 
1 H), 1.95 (d, J = 1.4 Hz, 3 H), 1.82 (t, J = 1.9 Hz, 3 H), 1.74 (d, J = 1.4 Hz, 3 H); 13C NMR (126 
MHz, CDCl3) δ 162.1, 160.9, 156.5, 153.9, 138.7, 137.1, 133.6, 133.1, 129.7, 129.0, 128.9, 
127.4, 120.5, 118.7, 118.0, 114.5, 111.3, 110.6, 109.8, 103.8, 91.1, 56.3, 56.0, 37.7, 33.1, 32.4, 
27.3, 25.8, 18.1; IR (neat) max 2923, 1724, 1619, 1599, 1499, 1459, 1434, 1336, 1145, 1118 cm 
-




X-ray Experimental for C28H27NO3 (6.49): Crystals grew as clusters of colorless 
needles by slow evaporation from methanol.  The data crystal had approximate dimensions; 0.14 
x 0.065 x 0.042 mm.  The data were collected on an Agilent Technologies SuperNova Dual 
Source diffractometer using a -focus Cu K radiation source ( = 1.5418Å) with collimating 
mirror monochromators.  A total of 1020 frames of data were collected using -scans with a 
scan range of 1 and a counting time of 15 seconds per frame using a detector offset of +/- 42.7 
and a counting time of 38.5 seconds per frame using a detector offset of +/- 111.0.  The data 
 291 
were collected at 100 K using an Oxford Cryostream low temperature device.  Details of crystal 
data, data collection and structure refinement are listed in Table 7.17.  Data collection, unit cell 
refinement and data reduction were performed using Agilent Technologies CrysAlisPro V 
1.171.39.46f.1  The structure was solved by direct methods using SIR2004 and refined by full-
matrix least-squares on F2 with anisotropic displacement parameters for the non-H atoms using 
SHELXL-2016/6.250,256  Structure analysis was aided by use of the programs PLATON and 
WinGX.252,257 The hydrogen atoms were calculated in ideal positions with isotropic displacement 
parameters set to 1.2xUeq of the attached atom (1.5xUeq for methyl hydrogen atoms.  The 
hydrogen atoms bound to the nitrogen atoms were observed in a F map and refined with 
isotropic displacement parameters. A molecule of unknown composition was found to be badly 
disordered.  The contributions to the scattering factors due to this solvent molecule were 
removed by use of the utility SQUEEZE in PLATON.  PLATON was used as incorporated in 
WinGX. 
The function, w(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[( (Fo))2 + (0.0668*P)2] 
and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.213, with R(F) equal to 0.0797 and a goodness of 
fit, S, = 1.00.  Definitions used for calculating R(F), Rw(F2) and the goodness of fit, S, are as 
follows: Rw(F2) =  {w(|Fo|2 - |Fc|2)2/w(|Fo|)4}1/2 where w is the weight given each 
reflection; R(F) =  (|Fo| - |Fc|)/|Fo|} for reflections with Fo > 4((Fo)); S =  [w(|Fo|2 - 
|Fc|2)2/(n - p)]1/2, where n is the number of reflections and p is the number of refined 
parameters. The data were checked for secondary extinction effects but no correction was 
necessary.  Neutral atom scattering factors and values used to calculate the linear absorption 
coefficient are from the International Tables for X-ray Crystallography (1992). All figures were 
generated using SHELXTL/PC.  Tables of positional and thermal parameters, bond lengths and 




Table 7.17.  Crystal data and structure refinement for 6.49. 
 
Empirical formula  C28 H27 N O3 
Formula weight  425.50 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  triclinic 
Space group  P -1 
  Unit cell dimensions a = 11.4662(15) Å = 82.877(9)°. 
 b = 13.068(2) Å = 88.111(9)°. 
 c = 16.186(2) Å  = 79.015(11)°. 
Volume 2362.4(6) Å3 
Z 4 
Density (calculated) 1.196 Mg/m3 
Absorption coefficient 0.077 mm-1 
F(000) 904 
Crystal size 0.140 x 0.065 x 0.042 mm3 
Theta range for data collection 1.268 to 26.484°. 
Index ranges -14<=h<=14, -16<=k<=11, -20<=l<=18 
Reflections collected 15116 
Independent reflections 9259 [R(int) = 0.0821] 
Completeness to theta = 25.242° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.739 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9259 / 0 / 593 
Goodness-of-fit on F2 1.004 
Final R indices [I>2sigma(I)] R1 = 0.0797, wR2 = 0.1745 
R indices (all data) R1 = 0.1310, wR2 = 0.2133 
Extinction coefficient n/a 
Largest diff. peak and hole 0.293 and -0.379 e.Å-3 
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Table 7.18. Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for 6.49.  U(eq) is defined as one third of  the trace of the orthogonalized 
Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C1 3921(3) 7080(3) 4718(2) 25(1) 
C2 3095(3) 7139(3) 4001(2) 28(1) 
C3 1868(3) 6925(3) 4325(2) 30(1) 
C4 1105(3) 7766(3) 4776(2) 29(1) 
C5 1462(3) 8310(3) 5328(2) 28(1) 
C6 2642(3) 8232(3) 5735(2) 25(1) 
C7 3710(3) 7511(3) 5439(2) 25(1) 
C8 4796(3) 7218(3) 5903(2) 26(1) 
C9 5148(4) 7407(3) 6684(2) 30(1) 
C10 6306(4) 7032(3) 6941(2) 36(1) 
C11 7131(4) 6471(3) 6423(3) 38(1) 
C12 6811(4) 6254(3) 5657(2) 34(1) 
C13 5647(3) 6618(3) 5413(2) 26(1) 
C14 3559(3) 6384(3) 3379(2) 30(1) 
C15 4161(4) 6566(3) 2679(2) 31(1) 
C16 4587(4) 7577(3) 2415(2) 37(1) 
C17 4437(4) 5745(3) 2082(2) 36(1) 
C18 -186(3) 7948(3) 4549(3) 38(1) 
C19 2883(3) 9333(3) 5788(2) 24(1) 
C20 2705(3) 9779(3) 6529(2) 24(1) 
C21 2062(3) 9515(3) 7965(2) 29(1) 
C22 2241(4) 10555(3) 8058(2) 32(1) 
C23 2616(3) 11158(3) 7412(2) 31(1) 
C24 2876(3) 10785(3) 6621(2) 26(1) 
C25 3251(3) 11385(3) 5919(2) 29(1) 
C26 3435(3) 10970(3) 5169(2) 28(1) 
C27 3250(3) 9967(3) 5102(2) 25(1) 
C28 3793(3) 10139(3) 3670(2) 30(1) 
C29 8560(3) 8336(3) 9567(2) 24(1) 
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Table 7.18 continued: 
C30 7762(3) 8643(3) 8828(2) 28(1) 
C31 6477(4) 9060(3) 9080(3) 38(1) 
C32 5808(3) 8274(3) 9555(2) 35(1) 
C33 6215(3) 7517(3) 10160(2) 32(1) 
C34 7395(3) 7209(3) 10605(2) 28(1) 
C35 8407(3) 7737(3) 10310(2) 23(1) 
C36 9464(3) 7653(3) 10783(2) 25(1) 
C37 9836(4) 7151(3) 11568(2) 29(1) 
C38 10953(4) 7209(3) 11835(2) 34(1) 
C39 11696(4) 7773(3) 11333(2) 36(1) 
C40 11343(4) 8293(3) 10556(2) 32(1) 
C41 10226(3) 8220(3) 10292(2) 27(1) 
C42 8188(4) 9459(3) 8208(2) 32(1) 
C43 8839(3) 9298(3) 7529(2) 31(1) 
C44 9305(4) 8246(3) 7256(3) 45(1) 
C45 9157(4) 10218(3) 6956(2) 38(1) 
C46 4536(4) 8421(4) 9278(3) 50(1) 
C47 7769(3) 6005(3) 10702(2) 25(1) 
C48 7715(3) 5397(3) 11463(2) 28(1) 
C49 7278(4) 5424(3) 12935(2) 32(1) 
C50 7460(4) 4306(3) 13024(2) 42(1) 
C51 7789(4) 3772(3) 12368(2) 38(1) 
C52 7947(4) 4304(3) 11563(2) 32(1) 
C53 8303(4) 3791(3) 10860(2) 36(1) 
C54 8406(4) 4365(3) 10102(2) 34(1) 
C55 8137(3) 5448(3) 10019(2) 27(1) 
C56 8635(4) 5534(3) 8584(2) 34(1) 
N1 5079(3) 6538(2) 4692(2) 27(1) 
N2 9647(3) 8633(2) 9569(2) 24(1) 
O1 2335(2) 9155(2) 7208(1) 27(1) 
O2 1684(2) 8910(2) 8496(2) 32(1) 
O3 3375(2) 9534(2) 4379(1) 28(1) 
O4 7406(2) 5930(2) 12150(2) 28(1) 
O5 7027(3) 5984(2) 13486(2) 35(1) 
O6 8176(2) 6062(2) 9277(1) 28(1) 
 295 
Table 7.19. Bond lengths [Å] and angles [°] for 6.49. 
_____________________________________________________  
C1-C7  1.354(5) 
C1-N1  1.383(5) 
C1-C2  1.507(5) 
C2-C14  1.510(5) 
C2-C3  1.548(5) 
C2-H2  1.0000 
C3-C4  1.515(5) 
C3-H3A  0.99 
C3-H3B  0.99 
C4-C5  1.328(5) 
C4-C18  1.505(5) 
C5-C6  1.504(5) 
C5-H5  0.95 
C6-C7  1.500(5) 
C6-C19  1.530(5) 
C6-H6  1.0000 
C7-C8  1.439(5) 
C8-C9  1.405(5) 
C8-C13  1.416(5) 
C9-C10  1.384(6) 
C9-H9  0.95 
C10-C11  1.405(6) 
C10-H10  0.95 
C11-C12  1.380(6) 
C11-H11  0.95 
C12-C13  1.382(6) 
C12-H12  0.95 
C13-N1  1.380(5) 
C14-C15  1.328(5) 
C14-H14  0.95 
C15-C16  1.504(5) 
C15-C17  1.514(5) 
C16-H16A  0.98 
C16-H16B  0.98 
C16-H16C  0.98 
C17-H17A  0.98 
C17-H17B  0.98 
C17-H17C  0.98 
C18-H18A  0.98 
C18-H18B  0.98 
C18-H18C  0.98 
C19-C20  1.390(5) 
C19-C27  1.404(5) 
C20-O1  1.390(4) 
C20-C24  1.391(5) 
C21-O2  1.220(5) 
C21-O1  1.372(4) 
C21-C22  1.439(5) 
C22-C23  1.340(6) 
C22-H22  0.95 
C23-C24  1.429(5) 
C23-H23  0.95 
C24-C25  1.402(5) 
C25-C26  1.384(5) 
C25-H25  0.95 
C26-C27  1.384(5) 
C26-H26  0.95 
C27-O3  1.354(4) 
C28-O3  1.433(4) 
C28-H28A  0.98 
C28-H28B  0.98 
C28-H28C  0.98 
C29-N2  1.374(4) 
C29-C35  1.377(5) 
C29-C30  1.497(5) 
C30-C42  1.512(5) 
 296 
Table 7.19 continued: 
C30-C31  1.531(5) 
C30-H30  1.00 
C31-C32  1.517(6) 
C31-H31A  0.99 
C31-H31B  0.99 
C32-C33  1.330(6) 
C32-C46  1.510(6) 
C33-C34  1.516(5) 
C33-H33  0.95 
C34-C35  1.495(5) 
C34-C47  1.539(5) 
C34-H34  1.00 
C35-C36  1.434(5) 
C36-C37  1.396(5) 
C36-C41  1.414(5) 
C37-C38  1.383(6) 
C37-H37  0.95 
C38-C39  1.404(6) 
C38-H38  0.95 
C39-C40  1.388(6) 
C39-H39  0.95 
C40-C41  1.387(5) 
C40-H40  0.95 
C41-N2  1.364(5) 
C42-C43  1.325(5) 
C42-H42  0.95 
C43-C44  1.491(5) 
C43-C45  1.519(5) 
C44-H44A  0.98 
C44-H44B  0.98 
 
C44-H44C  0.98 
C45-H45A  0.98 
C45-H45B  0.98 
C45-H45C  0.98 
C46-H46A  0.98 
C46-H46B  0.98 
C46-H46C  0.98 
C47-C48  1.387(5) 
C47-C55  1.408(5) 
C48-O4  1.385(4) 
C48-C52  1.392(5) 
C49-O5  1.216(4) 
C49-O4  1.375(4) 
C49-C50  1.426(6) 
C50-C51  1.346(5) 
C50-H50  0.95 
C51-C52  1.422(5) 
C51-H51  0.95 
C52-C53  1.403(5) 
C53-C54  1.371(6) 
C53-H53  0.95 
C54-C55  1.381(5) 
C54-H54  0.95 
C55-O6  1.363(4) 
C56-O6  1.424(4) 
C56-H56A  0.98 
C56-H56B  0.98 
C56-H56C  0.98 
N1-H1N  0.90(3) 










































































































































































































































Table 7.20. Anisotropic displacement parameters  (Å2x 103) for 6.49.  The anisotropic 
displacement factor exponent takes the form:  -2 2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C1 31(2)  22(2) 23(2)  1(1) 6(1)  -9(1) 
C2 36(2)  29(2) 20(2)  -2(1) 4(1)  -12(2) 
C3 34(2)  37(2) 24(2)  -6(1) 7(1)  -17(2) 
C4 30(2)  31(2) 29(2)  1(1) 8(1)  -14(2) 
C5 29(2)  25(2) 31(2)  -2(1) 12(1)  -11(1) 
C6 28(2)  26(2) 21(2)  -3(1) 9(1)  -10(1) 
C7 29(2)  25(2) 22(2)  -2(1) 7(1)  -12(1) 
C8 34(2)  19(2) 28(2)  0(1) 7(1)  -11(1) 
C9 41(2)  26(2) 23(2)  -1(1) 2(2)  -11(2) 
C10 52(2)  30(2) 28(2)  3(2) -6(2)  -16(2) 
C11 38(2)  31(2) 42(2)  4(2) -4(2)  -8(2) 
C12 40(2)  27(2) 36(2)  -2(2) 4(2)  -8(2) 
C13 31(2)  22(2) 26(2)  1(1) 3(1)  -9(1) 
C14 34(2)  31(2) 28(2)  -5(2) 2(1)  -9(2) 
C15 38(2)  32(2) 26(2)  -4(2) 4(2)  -13(2) 
C16 38(2)  41(2) 32(2)  -3(2) 12(2)  -14(2) 
C17 40(2)  41(2) 29(2)  -11(2) 10(2)  -12(2) 
C18 29(2)  39(2) 48(2)  -3(2) 4(2)  -14(2) 
C19 25(2)  23(2) 25(2)  -1(1) 8(1)  -6(1) 
C20 22(2)  27(2) 24(2)  -2(1) 7(1)  -6(1) 
C21 28(2)  33(2) 28(2)  -9(2) 7(1)  -6(2) 
C22 38(2)  32(2) 27(2)  -10(2) 10(2)  -5(2) 
C23 30(2)  28(2) 37(2)  -10(2) 8(2)  -5(2) 
C24 22(2)  25(2) 32(2)  -4(1) 6(1)  -7(1) 
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Table 7.20 continued: 
C25 27(2)  26(2) 36(2)  -4(2) 8(1)  -9(1) 
C26 24(2)  29(2) 32(2)  -2(1) 5(1)  -6(1) 
C27 22(2)  26(2) 27(2)  -3(1) 6(1)  -5(1) 
C28 36(2)  33(2) 23(2)  2(1) 7(1)  -13(2) 
C29 25(2)  25(2) 21(2)  -5(1) 6(1)  -3(1) 
C30 34(2)  24(2) 26(2)  -1(1) 5(1)  -6(1) 
C31 39(2)  38(2) 33(2)  2(2) 3(2)  -1(2) 
C32 28(2)  39(2) 35(2)  -6(2) 8(2)  -3(2) 
C33 26(2)  37(2) 33(2)  -4(2) 9(2)  -6(2) 
C34 31(2)  29(2) 23(2)  -5(1) 8(1)  -7(2) 
C35 26(2)  22(2) 21(2)  -4(1) 6(1)  -5(1) 
C36 30(2)  25(2) 21(2)  -9(1) 10(1)  -3(1) 
C37 38(2)  26(2) 23(2)  -5(1) 5(1)  -3(2) 
C38 40(2)  38(2) 25(2)  -11(2) -1(2)  -5(2) 
C39 35(2)  39(2) 39(2)  -13(2) -4(2)  -9(2) 
C40 36(2)  29(2) 31(2)  -7(2) 4(2)  -9(2) 
C41 27(2)  31(2) 24(2)  -8(1) 6(1)  -10(2) 
C42 42(2)  24(2) 29(2)  0(1) 0(2)  -7(2) 
C43 34(2)  29(2) 27(2)  3(1) 0(2)  -8(2) 
C44 43(2)  47(3) 48(2)  -11(2) 20(2)  -14(2) 
C45 40(2)  42(2) 31(2)  4(2) 3(2)  -13(2) 
C46 27(2)  68(3) 48(2)  6(2) 2(2)  -1(2) 
C47 25(2)  25(2) 26(2)  -6(1) 9(1)  -4(1) 
C48 28(2)  32(2) 25(2)  -5(1) 12(1)  -7(2) 
C49 39(2)  37(2) 22(2)  -3(2) 13(2)  -10(2) 
C50 61(3)  34(2) 28(2)  0(2) 15(2)  -9(2) 
C51 52(3)  30(2) 32(2)  1(2) 13(2)  -7(2) 
C52 39(2)  26(2) 31(2)  -4(2) 14(2)  -8(2) 
C53 46(2)  26(2) 37(2)  -8(2) 13(2)  -6(2) 
C54 42(2)  30(2) 29(2)  -7(2) 11(2)  -4(2) 
C55 28(2)  27(2) 26(2)  -4(1) 9(1)  -9(1) 
C56 50(2)  28(2) 23(2)  -5(1) 8(2)  -9(2) 
N1 33(2)  29(2) 22(1)  -5(1) 7(1)  -9(1) 
N2 27(2)  24(1) 23(1)  -4(1) 8(1)  -7(1) 
O1 32(1)  28(1) 21(1)  -3(1) 9(1)  -10(1) 
 302 
Table 7.20 continued: 
O2 38(2)  34(1) 24(1)  -4(1) 12(1)  -10(1) 
O3 36(1)  26(1) 22(1)  -1(1) 7(1)  -12(1) 
O4 34(1)  29(1) 22(1)  -4(1) 10(1)  -7(1) 
O5 47(2)  35(1) 22(1)  -6(1) 11(1)  -8(1) 




Table 7.21. Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 6.49. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H2 2977 7868 3702 34 
H3A 1414 6813 3844 36 
H3B 1999 6261 4706 36 
H5 858 8849 5499 33 
H6 2521 7940 6326 30 
H9 4593 7791 7035 36 
H10 6545 7155 7471 43 
H11 7928 6235 6603 45 
H12 7371 5868 5311 41 
H14 3401 5693 3505 36 
H16A 4273 8087 2801 55 
H16B 4309 7857 1851 55 
H16C 5457 7447 2421 55 
H17A 4224 5087 2343 54 
H17B 5287 5626 1945 54 
H17C 3978 5990 1572 54 
H18A -636 8502 4853 57 
H18B -493 7298 4698 57 
H18C -272 8164 3949 57 
H22 2093 10815 8582 39 
H23 2711 11849 7482 38 
H25 3379 12074 5958 35 
H26 3691 11378 4695 34 
H28A 3250 10816 3561 45 
H28B 3827 9757 3183 45 
H28C 4589 10258 3782 45 
H30 7772 8003 8546 34 
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Table 7.21 continued: 
H31A 6479 9635 9424 46 
H31B 6029 9370 8568 46 
H33 5658 7086 10350 39 
H34 7218 7391 11184 33 
H37 9333 6776 11912 35 
H38 11221 6864 12365 41 
H39 12459 7798 11531 44 
H40 11843 8681 10220 38 
H42 7963 10168 8318 38 
H44A 9164 7697 7696 68 
H44B 10160 8174 7144 68 
H44C 8898 8178 6748 68 
H45A 8845 10872 7191 57 
H45B 8808 10244 6407 57 
H45C 10023 10130 6899 57 
H46A 4133 7919 9621 75 
H46B 4522 8301 8693 75 
H46C 4127 9138 9340 75 
H50 7346 3932 13553 50 
H51 7919 3026 12445 46 
H53 8474 3046 10910 44 
H54 8664 4014 9629 40 
H56A 9430 5124 8714 50 
H56B 8682 6051 8096 50 
H56C 8108 5062 8464 50 
H1N 5400(30) 6280(30) 4230(20) 10(8) 







































































































































































Figure 7.4. View of 6.49 showing the atom labeling scheme.  Displacement ellipsoids are 
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